
<html lang="en"     class="pb-page"  data-request-id="5e0cb2c3-5f7e-4ca2-b498-5fbfb3165674"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01524"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor" /></meta><meta name="dc.Creator" content="Yu  Lei" /></meta><meta name="dc.Creator" content="Bing  Zhang" /></meta><meta name="dc.Creator" content="Dan  Liu" /></meta><meta name="dc.Creator" content="Jian  Zhao" /></meta><meta name="dc.Creator" content="Xiwen  Dai" /></meta><meta name="dc.Creator" content="Jun  Gao" /></meta><meta name="dc.Creator" content="Qing  Mao" /></meta><meta name="dc.Creator" content="Yao  Feng" /></meta><meta name="dc.Creator" content="Jiaxing  Zhao" /></meta><meta name="dc.Creator" content="Fengwei  Lin" /></meta><meta name="dc.Creator" content="Yulin  Duan" /></meta><meta name="dc.Creator" content="Yan  Zhang" /></meta><meta name="dc.Creator" content="Ziyang  Bao" /></meta><meta name="dc.Creator" content="Yuwei  Yang" /></meta><meta name="dc.Creator" content="Yanhua  Mou" /></meta><meta name="dc.Creator" content="Shaojie  Wang" /></meta><meta name="dc.Description" content="ADP-mediated platelet aggregation is signaled through G protein-coupled receptors P2Y1 and P2Y12 on the platelet. The clinical effectiveness of inhibiting P2Y12 has been well established, and precl..." /></meta><meta name="Description" content="ADP-mediated platelet aggregation is signaled through G protein-coupled receptors P2Y1 and P2Y12 on the platelet. The clinical effectiveness of inhibiting P2Y12 has been well established, and precl..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 12, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01524" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01524" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01524" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01524" /></link>
        
    
    

<title>Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01524" /></meta><meta property="og:title" content="Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0018.jpeg" /></meta><meta property="og:description" content="ADP-mediated platelet aggregation is signaled through G protein-coupled receptors P2Y1 and P2Y12 on the platelet. The clinical effectiveness of inhibiting P2Y12 has been well established, and preclinical studies indicated that the inhibition of P2Y1 could provide equivalent antithrombotic efficacy as P2Y12 antagonists and reduce bleeding risks. On the basis of the 2-phenyl-1H-imidazole scaffold of our previously reported xanthine oxidase inhibitor WSJ-557, we first achieved the transition from the xanthine oxidase inhibitors to dual-target antagonists against P2Y1 and P2Y12. We described the structure–activity relationships of the 2-phenyl-1H-imidazole compounds, which led to the identification of the most potent antiplatelet agents, 24w and 25w, both showing a rapid onset of action in pharmacokinetic study. Furthermore, the rat model suggested that 24w demonstrated a wider therapeutic window than ticagrelor, displaying equivalent and dose-dependent antithrombotic efficacy with lower blood loss compared to ticagrelor at same oral dose. These results supported that 24w and 25w could be promising drug candidates." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01524"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01524">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01524&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01524&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01524&amp;href=/doi/10.1021/acs.jmedchem.0c01524" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15752-15772</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01372" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01528" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y<sub>1</sub> and P2Y<sub>12</sub> as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yu Lei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Lei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Lei">Yu Lei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bing Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bing Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bing++Zhang">Bing Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4427-8771" title="Orcid link">http://orcid.org/0000-0002-4427-8771</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dan Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dan Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shenyang Hinewy Pharmaceutical Technology Co., Ltd., 41 Liutang Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Liu">Dan Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Zhao">Jian Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiwen Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiwen Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiwen++Dai">Xiwen Dai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Gao">Jun Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qing Mao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qing Mao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qing++Mao">Qing Mao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yao Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yao Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yao++Feng">Yao Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiaxing Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiaxing Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiaxing++Zhao">Jiaxing Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fengwei Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengwei Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengwei++Lin">Fengwei Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yulin Duan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yulin Duan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yulin++Duan">Yulin Duan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Zhang">Yan Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ziyang Bao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ziyang Bao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ziyang++Bao">Ziyang Bao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuwei Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuwei Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuwei++Yang">Yuwei Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanhua Mou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanhua Mou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a1ccd4fec9d4c0fecbcbe1d2c8cfc08fc2cecc"><span class="__cf_email__" data-cfemail="c4a9b19bacb1a59baeae84b7adaaa5eaa7aba9">[email protected]</span></a>. Tel: 024-23986339. Fax: 024-23986339.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanhua++Mou">Yanhua Mou</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shaojie Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaojie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7c0b1d121b0f141d131615193c0f050c140952191809521f12"><span class="__cf_email__" data-cfemail="f582949b92869d949a9f9c90b5868c859d80db909180db969b">[email protected]</span></a>. Tel: (+86)24-23986421. Fax: (+86)24-23986421.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaojie++Wang">Shaojie Wang</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01524&amp;href=/doi/10.1021%2Facs.jmedchem.0c01524" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15752–15772</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 12, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 September 2020</li><li><span class="item_label"><b>Published</b> online</span>12 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01524" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01524</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15752%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYu%2BLei%252C%2BBing%2BZhang%252C%2BDan%2BLiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01524%26title%3DSwitching%2Ba%2BXanthine%2BOxidase%2BInhibitor%2Bto%2Ba%2BDual-Target%2BAntagonist%2Bof%2BP2Y1%2Band%2BP2Y12%2Bas%2Ban%2BOral%2BAntiplatelet%2BAgent%2Bwith%2Ba%2BWider%2BTherapeutic%2BWindow%2Bin%2BRats%2Bthan%2BTicagrelor%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15772%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01524"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">936</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01524" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y1 and P2Y12 as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Lei&quot;},{&quot;first_name&quot;:&quot;Bing&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Xiwen&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Qing&quot;,&quot;last_name&quot;:&quot;Mao&quot;},{&quot;first_name&quot;:&quot;Yao&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Jiaxing&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Fengwei&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Yulin&quot;,&quot;last_name&quot;:&quot;Duan&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ziyang&quot;,&quot;last_name&quot;:&quot;Bao&quot;},{&quot;first_name&quot;:&quot;Yuwei&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Yanhua&quot;,&quot;last_name&quot;:&quot;Mou&quot;},{&quot;first_name&quot;:&quot;Shaojie&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15752-15772&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01524&quot;},&quot;abstract&quot;:&quot;ADP-mediated platelet aggregation is signaled through G protein-coupled receptors P2Y1 and P2Y12 on the platelet. The clinical effectiveness of inhibiting P2Y12 has been well established, and preclinical studies indicated that the inhibition of P2Y1 could provide equivalent antithrombotic efficacy as P2Y12 antagonists and reduce bleeding risks. On the basis of the 2-phenyl-1H-imidazole scaffold of our previously reported xanthine oxidase inhibitor WSJ-557, we first achieved the transition from the xanthine oxidase inhibitors to dual-target antagonists against P2Y1 and P2Y12. We described the structure–activity relationships of the 2-phenyl-1H-imidazole compounds, which led to the identification of the most potent antiplatelet agents, 24w and 25w, both showing a rapid onset of action in pharmacokinetic study. Furthermore, the rat model suggested that 24w demonstrated a wider therapeutic window than ticagrelor, displaying equivalent and dose-dependent antithrombotic efficacy with lower blood loss compared to ti&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01524&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01524" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01524&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01524" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01524&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01524" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01524&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01524&amp;href=/doi/10.1021/acs.jmedchem.0c01524" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01524" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01524" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01524%26sid%3Dliteratum%253Aachs%26pmid%3D33307675%26genre%3Darticle%26aulast%3DLei%26date%3D2020%26atitle%3DSwitching%2Ba%2BXanthine%2BOxidase%2BInhibitor%2Bto%2Ba%2BDual-Target%2BAntagonist%2Bof%2BP2Y1%2Band%2BP2Y12%2Bas%2Ban%2BOral%2BAntiplatelet%2BAgent%2Bwith%2Ba%2BWider%2BTherapeutic%2BWindow%2Bin%2BRats%2Bthan%2BTicagrelor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15752%26epage%3D15772%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">ADP-mediated platelet aggregation is signaled through G protein-coupled receptors P2Y<sub>1</sub> and P2Y<sub>12</sub> on the platelet. The clinical effectiveness of inhibiting P2Y<sub>12</sub> has been well established, and preclinical studies indicated that the inhibition of P2Y<sub>1</sub> could provide equivalent antithrombotic efficacy as P2Y<sub>12</sub> antagonists and reduce bleeding risks. On the basis of the 2-phenyl-1<i>H</i>-imidazole scaffold of our previously reported xanthine oxidase inhibitor <b>WSJ-557</b>, we first achieved the transition from the xanthine oxidase inhibitors to dual-target antagonists against P2Y<sub>1</sub> and P2Y<sub>12</sub>. We described the structure–activity relationships of the 2-phenyl-1<i>H</i>-imidazole compounds, which led to the identification of the most potent antiplatelet agents, <b>24w</b> and <b>25w</b>, both showing a rapid onset of action in pharmacokinetic study. Furthermore, the rat model suggested that <b>24w</b> demonstrated a wider therapeutic window than ticagrelor, displaying equivalent and dose-dependent antithrombotic efficacy with lower blood loss compared to ticagrelor at same oral dose. These results supported that <b>24w</b> and <b>25w</b> could be promising drug candidates.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Inroduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04342" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04342" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute coronary syndromes (ACSs), including unstable angina and acute myocardial infarction (AMI), are life-threatening thrombotic disorders, which have been the most common causes of morbidity and mortality over the past decade worldwide in cardiovascular patients.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Platelets display a major role in these thrombotic complications. They adhere to the subendothelial matrix following endothelial damage due to the rupture of an atherosclerotic plaque and then aggregate to cause thrombus formation.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8 ref9 ref10">(4−)</a> This activation process involves several platelet-activating agonists, such as adenosine diphosphate (ADP), thrombin, and thromboxane A<sub>2</sub>.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Among them, ADP is a key mediator of activation as well as the aggregation of platelets. It could bind to two purinergic receptors P2Y<sub>1</sub> and P2Y<sub>12</sub>, which both further activate glycoprotein IIb/IIIa on platelets and lead to sustained platelet aggregation as well as thrombus growth.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8">(4−8)</a> Specifically, P2Y<sub>12</sub> is mainly expressed on the membrane of human thrombocytes, and the binding of ADP to the P2Y<sub>12</sub> receptor results in a reduction of cAMP (cyclic adenosine monophosphate) levels, which is required to amplify and sustain the responses leading to a stable thrombus formation.<a onclick="showRef(event, 'ref6 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref6 ref11 ref12 ref13 ref14 ref15 ref16">(6,11−16)</a> The inhibition of platelet aggregation targeting the P2Y<sub>12</sub> receptor has been recognized as an important element in the short-term treatment as well as for the long-term prevention of thrombotic events in patients with ACS.<a onclick="showRef(event, 'ref2 ref11 ref12 ref13 ref14 ref16'); return false;" href="javascript:void(0);" class="ref ref2 ref11 ref12 ref13 ref14 ref16">(2,11−14,16)</a> P2Y<sub>1</sub> is ubiquitously expressed, and mobilizes the transitory increases in intracellular free Ca<sup>2+</sup> ions leading to platelet shape changes in response to ADP.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16−19)</a> It is reported that the inhibition of P2Y<sub>1</sub> could provide an equivalent antithrombotic efficacy to P2Y<sub>12</sub> in terms of blocking aggregation and reducing thrombus weight, whereas P2Y<sub>1</sub> antagonists may offer safety advantages in terms of a reduced bleeding liability.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> This demonstrates that the P2Y<sub>1</sub> receptor could also represent a promising target for the development of new antiplatelet therapies.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> Therefore, specifically inhibiting either of the two receptors or inhibiting both P2Y<sub>1</sub> and P2Y<sub>12</sub> could halt ADP-induced platelet aggregation for the treatment of arterial thrombosis and related diseases.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a></div><div class="NLM_p">P2Y<sub>12</sub> receptor antagonists can be broadly classified into two classes on the basis of their chemical structures, namely, thienopyridines and nonthienopyridines.<a onclick="showRef(event, 'ref16 ref25'); return false;" href="javascript:void(0);" class="ref ref16 ref25">(16,25)</a> The thienopyridine drugs, such as ticlopidine<a onclick="showRef(event, 'ref16 ref25'); return false;" href="javascript:void(0);" class="ref ref16 ref25">(16,25)</a> (<b>1</b>, approved in 1978, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), clopidogrel<a onclick="showRef(event, 'ref2 ref26'); return false;" href="javascript:void(0);" class="ref ref2 ref26">(2,26)</a> (<b>2</b>, approved in 1997, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and prasugrel<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (<b>3</b>, approved in 2009, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), are irreversible oral P2Y<sub>12</sub> receptor prodrugs and have proved to be successful in reducing the morbidity and mortality for cardiovascular patients.<a onclick="showRef(event, 'ref2 ref16 ref28'); return false;" href="javascript:void(0);" class="ref ref2 ref16 ref28">(2,16,28)</a> In fact, the dual antiplatelet therapy of clopidogrel and acetylsalicylic acid has long been the gold standard of treatment.<a onclick="showRef(event, 'ref16 ref29'); return false;" href="javascript:void(0);" class="ref ref16 ref29">(16,29)</a> However, they all require hepatic metabolic bioactivation for their active metabolites to covalently bind to the P2Y<sub>12</sub> receptor, which results in a slow onset of their pharmacological action.<a onclick="showRef(event, 'ref2 ref16 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref2 ref16 ref30 ref31">(2,16,30,31)</a> This leads to the development of several reversible nonthienopyridine P2Y<sub>12</sub> receptor antagonists based on the nucleotide scaffold, such as ticagrelor<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> (<b>5</b>, approved in 2011, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and cangrelor<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> (<b>6</b>, approved in 2015, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Ticagrelor<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was the first drug developed and is administered orally. It reversibly binds the P2Y<sub>12</sub> receptor and has a faster onset of action than clopidogrel, but it has been shown to increase the rate of nonprocedure-related bleeding compared to clopidogrel.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> Cangrelor<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is another nucleotide-derived reversible P2Y<sub>12</sub> antagonist with a rapid onset of action. However, it must be administered by a continuous intravenous infusion and is only used at the time of percutaneous coronary intervention (PCI) in patients not preloaded with an oral P2Y<sub>12</sub> receptor antagonist.<a onclick="showRef(event, 'ref2 ref16'); return false;" href="javascript:void(0);" class="ref ref2 ref16">(2,16)</a> Consequently, there is still room for improvement in currently approved oral antiplatelet agents due to the drawbacks of slow onset of action and high bleeding risk.<a onclick="showRef(event, 'ref14 ref16 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref14 ref16 ref35 ref36">(14,16,35,36)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structures of P2Y<sub>12</sub> antagonists: ticlopidine (<b>1</b>), clopidogrel (<b>2</b>), prasugrel (<b>3</b>), vicagrel (<b>4</b>), ticagrelor (<b>5</b>), cangrelor (<b>6</b>), AZD1283 (<b>7</b>), elinogrel (<b>8</b>), selatogrel (<b>9</b>), BX048 (<b>10</b>), SAR216471 (<b>11</b>), and PSB-0739 (<b>12</b>). (B) Structures of P2Y<sub>1</sub> antagonists: MRS2179 (<b>13</b>), MRS2500 (<b>14</b>), MRS2279 (<b>15</b>), BPTU (<b>16</b>), and 4-aryl-7-hydroxylindoline derivative (<b>17</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, AZD1283<a onclick="showRef(event, 'ref25 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref25 ref37 ref38">(25,37,38)</a> (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and elinogrel<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), based on the ethyl 6-aminonicotinate acyl sulfonamide and quinazoline-2,4-dione scaffolds, respectively, both showed potent antithrombotic efficacy and reduced bleeding effects in animal models.<a onclick="showRef(event, 'ref11 ref40'); return false;" href="javascript:void(0);" class="ref ref11 ref40">(11,40)</a> Unfortunately, they were discontinued in clinical trials due to low metabolic stability and elevated liver transaminases.<a onclick="showRef(event, 'ref11 ref39'); return false;" href="javascript:void(0);" class="ref ref11 ref39">(11,39)</a> Apart from these, other P2Y<sub>12</sub> receptor antagonists based on various chemical scaffolds, including BX048<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> (<b>10</b>, 7-methylquinoline-2-carboxamide derivative, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), SAR216471<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> (<b>11</b>, indole derivative, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and PSB-0739<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> (<b>12</b>, anthraquinone derivative, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), are reported to exhibit more effective platelet inhibition, but they are still in preclinical research.<a onclick="showRef(event, 'ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45 ref46">(43−46)</a> These facts indicate that the P2Y<sub>12</sub> antagonists distinct from the thienopyridine and nucleotide chemical scaffolds have received extensive attention and will hopefully minimize these disadvantages of currently available drugs.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Furthermore, two novel P2Y<sub>12</sub> receptor antagonists are currently in phase II clinical development: vicagrel<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and selatogrel<a onclick="showRef(event, 'ref36 ref48'); return false;" href="javascript:void(0);" class="ref ref36 ref48">(36,48)</a> (<b>9</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Vicagrel (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), an irreversible thienopyridine oral P2Y<sub>12</sub> receptor antagonist, may show stronger platelet inhibition and a faster onset of action compared to clopidogrel. However, it still retains the same activation mechanism as prasugrel.<a onclick="showRef(event, 'ref2 ref16 ref47'); return false;" href="javascript:void(0);" class="ref ref2 ref16 ref47">(2,16,47)</a> Selatogrel (2-phenylpyrimidine-4-carboxamide derivative, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) could be rapidly absorbed and shows a potentially lower risk of bleeding. However, it is only developed for subcutaneous not oral administration.<a onclick="showRef(event, 'ref36 ref48'); return false;" href="javascript:void(0);" class="ref ref36 ref48">(36,48)</a> Besides, P2Y<sub>1</sub> antagonists, such as MRS2179<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (<b>13</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), MRS2500<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), MRS2279<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> (<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), BPTU<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and 4-aryl-7-hydroxylindoline derivative (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), are in preclinical development. Therefore, it is still necessary to explore an oral antiplatelet agent targeting P2Y<sub>1</sub> and P2Y<sub>12</sub> for the treatment of ACS on the basis of new chemical scaffolds to overcome the drawbacks of these clinical drugs and achieve a fast onset of action with less bleeding risk.<a onclick="showRef(event, 'ref11 ref14 ref16 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref11 ref14 ref16 ref35 ref36">(11,14,16,35,36)</a></div><div class="NLM_p">In our previous reports of the nonpurine xanthine oxidase (XO) inhibitor, <b>WSJ-557</b> (2-(3-cyano-4-isobutoxyphenyl)-1-hydroxy-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) demonstrated a stronger XO inhibitory potency (IC<sub>50</sub> = 0.003 μM for XO) than that of febuxostat (IC<sub>50</sub> = 0.01 μM for XO).<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> The remarkable XO inhibitory potency of <b>WSJ-557</b> encouraged us to investigate its pharmacokinetic (PK) profiles to further assess its development potential.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In this procedure, it was found that <b>WSJ-557</b> could delay blood coagulation, which drove us to investigate its action mechanism. The subsequent antiplatelet aggregation assay induced by ADP showed that the compound could display an apparent antiplatelet potency (IC<sub>50</sub> = 15.727 μM).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and structural modification of novel antiplatelet agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These interesting results suggested that the <b>WSJ-557</b> with a 2-phenyl-1<i>H</i>-imidazole scaffold could be considered as an initial compound for the development of P2Y<sub>1</sub> and P2Y<sub>12</sub> dual antagonists.</div><div class="NLM_p last">We described the procedure for switching the XO inhibitor <b>WSJ-557</b> to dual-target antagonists of P2Y<sub>1</sub> and P2Y<sub>12</sub> through structure–activity relationships (SAR) investigation of the 2-phenyl-1<i>H</i>-imidazole compounds, which led to the identification of compounds <b>24w</b> and <b>25w</b> as the most potential antiplatelet agents in ADP-induced rabbit platelet-rich plasma (rPRP) aggregation test <i>in vitro</i> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). P2Y<sub>1</sub> and P2Y<sub>12</sub> binding assays were also performed to investigate the effect of compound <b>25w</b> on platelet P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors by the flow cytometric assay. Moreover, the probable binding models of the target compounds <b>24w</b> and <b>25w</b> with P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors were explored by molecular modeling. Additionally, metabolic stability, pharmacokinetic profile, and acute toxicity studies were performed to support the pharmacological characterization of the most potent compounds <b>24w</b> and <b>25w</b>. Lastly, the compound <b>24w</b> was further evaluated in a rat ferric chloride model as well as a rat-tail-bleeding model to investigate its antithrombotic effect and bleeding risk, respectively. These results obtained from the investigations supported that <b>24w</b> and <b>25w</b> could be promising drug candidates for the treatment of arterial thrombosis and related diseases.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The key intermediate ethyl 2-hydroxyimino-3-oxobutanoate <b>20</b> was obtained by nitrosation of the commercially available ethyl 3-oxobutanoate <b>19</b> with sodium nitrite in acetic acid.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Commercially available benzaldehyde derivatives were cyclized with the key intermediate <b>20</b> to give compounds <b>21a</b>–<b>d</b>, which were further alkylated with iodomethane in <i>N</i>,<i>N</i>-dimethylformamide in the presence of anhydrous potassium carbonate to provide target compounds <b>22a</b>–<b>d</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaNO<sub>2</sub>, CH<sub>3</sub>COOH, 0–5 °C; (b) Benzaldehyde derivatives, CH<sub>3</sub>COOH/CH<sub>3</sub>COONH<sub>4</sub>, 50 °C; (c) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C.</p></p></figure><div class="NLM_p">Then, the 1-hydroxyl moiety of compound <b>21a</b> was removed with chlorotrimethylsilane and sodium iodide by refluxing in acetonitrile to provide compound <b>23</b>,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> which was further alkylated with iodomethane or 1-bromo-2-methylpropane in <i>N</i>,<i>N</i>-dimethylformamide in the presence of anhydrous potassium carbonate and potassium iodide to provide compounds <b>24a</b> and <b>24b</b>.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Compounds <b>24c</b>–<b>y</b> were prepared through the alkylation reaction of the compound <b>21a</b> with appropriate alkyl halides in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> and KI, which were hydrolyzed using an aqueous solution of lithium hydroxide to afford the compounds <b>25a</b>, <b>25d</b>, <b>25k</b>, <b>25s</b>, and <b>25w</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The structures were elucidated by high-resolution mass spectrometry (HRMS), infared (IR), proton nuclear magnetic resonance (<sup>1</sup>H NMR), and <sup>13</sup>C NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_002.pdf" class="ext-link">Supporting Information</a>). All spectral data were in accordance with the assumed structures.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Me<sub>3</sub>SiCl, NaI, CH<sub>3</sub>CN, reflux; (b) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C; (c) RX, K<sub>2</sub>CO<sub>3</sub>, KI, N<sub>2</sub>, DMF, 0–50 °C; (d) LiOH, THF, H<sub>2</sub>O, 50 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Discovery of Lead Compound <b>22a</b></h3><div class="NLM_p">Since the ethyl ester of <b>WSJ-557</b> (compound <b>18</b>) displays an equivalent antiplatelet potency (IC<sub>50</sub> = 16.825 μM), the ethyl ester group of 5-position was retained for further structural optimization for the possibility of higher bioavailability. Initially, we found that removing the 4′-isobutoxy group had no apparent effect on its antiplatelet potency (<b>21a</b> vs <b>18</b>, IC<sub>50</sub> = 17.636 and 16.825 μM, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In addition, the introduction of a small hydrophobic methyl group into the 1-hydroxy position of imidazole moiety was beneficial for remarkably increasing the antiplatelet potency (<b>21a</b> < <b>22a</b>, IC<sub>50</sub> = 17.636 and 9.134 μM, respectively). Consequently, <b>22a</b> was further examined to determine the antiplatelet influence by cyano group positions on the phenyl moiety. The corresponding <i>ortho</i>-, <i>para</i>-, and no cyano substituted derivatives were synthesized, and these compounds showed a marked decrease in inhibitory potency (<b>22b</b>, <b>22c</b>, and <b>22d</b> vs <b>22a</b>, IC<sub>50</sub> = 14.857, 13.353, > 30, and 9.134 μM, respectively), which implied that <i>meta</i>-cyano substitution was necessary for the antiplatelet potency. Moreover, removing the 1-hydroxy group led to compound <b>23</b>, which displayed a loss in antiplatelet potency (<b>23</b>, IC<sub>50</sub> > 30 μM). Therefore, on the basis of these data, the potent lead compound <b>22a</b> containing the 2-phenyl-1<i>H</i>-imidazole scaffold was selected for further optimization.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Antiplatelet Aggregation Potency of Lead Optimization on Imidazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0014.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">ADP-induced platelet aggregation ([ADP] = 2.27 μM, <i>n</i> = 3), rabbit platelet-rich plasma (rPRP).</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Identification of Compounds <b>24w</b> and <b>25w</b></h3><div class="NLM_p">The observation that introducing a methyl at the hydroxyl group at the 1-position could increase the antiplatelet potency greatly inspired us to investigate the substitution pattern at the 1-position further. First, the compounds containing methyl, isopropyl, and isopropoxy groups were synthesized. The results suggested that the antiplatelet potency of inserting alkoxy groups into the 1-position was stronger than those of corresponding alkyl groups (<b>24a</b> < <b>22a</b>, <b>24b</b> < <b>24c</b>, IC<sub>50</sub> = 22.136, 9.134, 9.259, and 6.736 μM, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Then, introducing allyloxy, ethoxyethoxy, and 2-ethoxy-2-oxoethoxy groups at the 1-position led to compounds <b>24d</b>, <b>24e</b>, and <b>24f</b>, and their antiplatelet potency was further enhanced (<b>24d, 24e</b>, and <b>24f</b> vs <b>22a</b>, IC<sub>50</sub> = 5.856, 6.247, 6.796, and 9.134 μM, respectively). For comparison, the more polar compounds <b>24g</b>, <b>24h</b>, and <b>24i</b> containing hydroxypropoxy, 2-amino-2-oxoethoxy, and 2-carboxyethyloxy groups at the 1-position were synthesized, and the results showed that compound <b>24g</b> exhibited an IC<sub>50</sub> value of 11.352 μM and the antiplatelet potency for compounds <b>24h</b> and <b>24i</b> disappeared completely. This indicated that enhancing the polarity of substituents at the 1-position was not beneficial for antiplatelet potency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Antiplatelet Aggregation Potency of Variations Around the Imidazole Moiety</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0017.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">ADP-induced platelet aggregation ([ADP] = 2.27 μM, <i>n</i> = 3), rabbit platelet-rich plasma (rPRP).</p></div></div><div></div></div><div class="NLM_p">In order to explore the antiplatelet effect of alkoxy groups at the 1-position further, the pyridin-4-ylmethoxy and benzloxy substitutions were introduced to provide compounds <b>24j</b> and <b>24k</b>, and they exhibited an apparent inhibitory potency in the platelet aggregation assay than that of compound <b>22a</b> (<b>24j</b>, <b>24k</b> vs <b>22a</b>, IC<sub>50</sub> = 6.196, 5.934, and 9.134 μM, respectively). The remarkable antiplatelet potency of compound <b>24k</b> encouraged us to tune the substituents on the phenyl moiety. First, the electron withdrawing substituents, such as fluoro and chloro substituents, were inserted at <i>ortho</i>, <i>meta</i>, and <i>para</i> positions of the benzyloxy group. Among them, the <i>para</i>-substituted derivatives showed a better antiplatelet aggregation potency compared to <i>ortho</i>- and <i>meta</i>-substituted derivatives (<b>24n</b> > <b>24l</b> > <b>24m</b>; <b>24q</b> > <b>24o</b> > <b>24p</b>, IC<sub>50</sub> = 5.879, 8.987, 22.358, 6.825, 8.705, and 19.357 μM, respectively), These results showed that the insertion of fluoro and chloro atoms at the <i>para</i> position was beneficial for improving the inhibitory potency. Consequently, the continued investigations of substituents at the <i>para</i> position of the benzyloxy group were carried out. The introduction of bromo, methyl, methoxy, methoxycarbonyl, nitro, and cyano groups into the <i>para</i> position led to compounds <b>24r</b>–<b>y</b> with IC<sub>50</sub> values of 24.590, 6.311, 6.826, 9.466, 8.754, and 4.237 μM, respectively. To our surprise, compound <b>24w</b> (IC<sub>50</sub> = 4.237 μM) with a cyano group at the <i>para</i> position displayed the most remarkable inhibitory potency, and it was comparable to that of ticagrelor (IC<sub>50</sub> = 7.213 μM). Subsequently, the corresponding <i>ortho</i> and <i>meta</i> counterparts were examined. The results showed that <b>24x</b> displayed a 2.2-fold decrease in inhibitory potency in comparison to compound <b>24w</b>, and the inhibitory potency of compound <b>24y</b> was lost (<b>24w</b> and <b>24y</b>, IC<sub>50</sub> = 9.376 and >30 μM, respectively). This showed the same inhibitory tendency as compounds with fluoro and chloro atoms substituted at benzyloxy moiety. Presumably, the cyano group substituted at the <i>para</i> position kept the 4-cyanobenzyloxy moiety in a more favorable position so that it could form better interactions with amino acid residues at the active pocket.</div><div class="NLM_p last">Lastly, to explore the inhibitory potency of the corresponding acids, compounds <b>22a</b>, <b>24d</b>, <b>24k</b>, <b>24s</b>, and <b>24w</b> were hydrolyzed to obtain compounds <b>25a</b>, <b>25d</b>, <b>25k</b>, <b>25s</b>, and <b>25w</b>, and the compounds showed equal potency in comparison to their ester counterparts. (<b>25a</b> vs <b>24a</b>; <b>25d</b> vs <b>24d</b>; <b>25k</b> vs <b>24k</b>; <b>25s</b> vs <b>24s</b>, IC<sub>50</sub> = 7.987 vs 9.134 μM; IC<sub>50</sub> = 6.350 vs 5.856 μM; IC<sub>50</sub> = 6.238 vs 5.934 μM; IC<sub>50</sub> = 6.563 vs 6.311 μM, respectively). Among them, compound <b>25w</b> (IC<sub>50</sub> = 3.875 μM), the acid of compound <b>24w</b>, displayed the same remarkable inhibitory potency as that of compound <b>24w</b>, and it was also comparable to that of ticagrelor (IC<sub>50</sub> = 7.213 μM).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> P2Y<sub>1</sub>-Mediated Cytosolic Ca<sup>2+</sup> Increases Assay</h3><div class="NLM_p">ADP activates platelets by simultaneously acting on two platelet G protein–coupled receptors P2Y<sub>1</sub> and P2Y<sub>12</sub>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, it is not clear which of the two receptors was inhibited by the test compounds to exert their antiplatelet effect. To elucidate the action mechanism of these test compounds in its antiplatelet potency, the antagonist effects of the most potent compound <b>25w</b> on platelet P2Y<sub>1</sub> were determined by measuring the P2Y<sub>1</sub>-mediated cytosolic Ca<sup>2+</sup> increase from intraplatelet stores after stimulation by ADP as previously described with minor modifications.<a onclick="showRef(event, 'ref22 ref23 ref46 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref46 ref54 ref55">(22,23,46,54,55)</a> The results are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Compound <b>25w</b> displayed a potent inhibitory effect against P2Y<sub>1</sub> on platelet with an IC<sub>50</sub> value of 2.59 μM, which was comparable to that of <b>BPTU</b> (IC<sub>50</sub> = 3.03 ± 0.63 μM), suggesting that compound <b>25w</b> exerted its antiplatelet potency mainly by inhibiting receptor P2Y<sub>1</sub> on platelet. Besides, several research studies have already demonstrated that the P2Y<sub>1</sub> antagonists could have an equivalent antithrombotic efficacy but less bleeding compared with the P2Y<sub>12</sub> antagonist clopidogrel.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Therefore, this activity evaluation of P2Y<sub>1</sub> rationalized that compound <b>24w</b> (parent compound <b>25w</b> released from prodrug <b>24w</b> in rats after oral administration) exhibited a therapeutically equivalent antithrombotic effect as that of ticagrelor at the same oral dose, with remarkably less blood loss than ticagrelor.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Potency of ADP-Induced Ca<sup>2+</sup> Increase</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±">inhibition of Ca<sup>2+</sup> rise in platelets (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25w</b></td><td class="colsep0 rowsep0" align="char" char="±">2.59 ± 0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>BPTU</b></td><td class="colsep0 rowsep0" align="char" char="±">3.03 ± 0.63</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">In diluted rPRP, <i>n</i> = 3.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> P2Y<sub>12</sub> Binding Assay</h3><div class="NLM_p">To examine the effect of compound <b>25w</b> on the platelet P2Y<sub>12</sub> receptor in response to ADP (no test of compound <b>24w</b> due to poor solubility), P2Y<sub>12</sub> binding assay was performed by measuring the P2Y<sub>12</sub>-mediated decrease in intraplatelet phosphorylated vasodilator-stimulated phosphoprotein (VASP) using a flow cytometric PLT VASP/P2Y<sub>12</sub> kit (Biocytex, Marseille, France).<a onclick="showRef(event, 'ref22 ref23 ref56 ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref56 ref57 ref58 ref59">(22,23,56−59)</a> ADP, as an agonist, activated the P2Y<sub>12</sub> receptor to trigger the reaction of VASP phosphorylation. Meanwhile, it also antagonized the P2Y<sub>12</sub> receptor to induce the decrease of VASP phosphorylation. Then, the test compounds were added to antagonize the P2Y<sub>12</sub> receptor to attenuate the antagonistic effect of ADP, resulting in the increase of VASP phosphorylation, and this protocol was used to measure the antagonistic effect of compounds.<a onclick="showRef(event, 'ref56 ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59">(56−59)</a> Thus, the percentage inhibition of prostaglandin E<sub>1</sub> (PGE<sub>1</sub>)-stimulated VASP phosphorylation was set as 100%, and no stimulation was set as 0% inhibition.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Specifically, the percentage inhibition was calculated relative to vehicle (0% inhibition) and PGE<sub>1</sub> (100% inhibition): inhibition (%) = [(MFI<sub>(PGE1)</sub> – MFI<sub>(PGE1+ADP+compound)</sub>)/(MFI<sub>(PGE1)</sub> – MFI<sub>(negative)</sub>)] × 100,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> where MFI is the mean fluorescence intensity of VASP phosphorylation.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> In the absence of ADP, P2Y<sub>12</sub>–VASP phosphorylation was performed to investigate whether compounds possessed an agonistic effect on the P2Y<sub>12</sub> receptor.</div><div class="NLM_p">As expected, PGE<sub>1</sub> is added to induce the full phosphorylation of VASP, which was set as 100%, and VASP phosphorylation in the presence of the P2Y<sub>12</sub> agonist ADP (3 μM) was significantly reduced in comparison with PGE<sub>1</sub> alone (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Furthermore, compound <b>25w</b> and ticagrelor both were able to dose dependently antagonize the ADP-induced reduction of VASP phosphorylation compared to PGE<sub>1</sub> alone, indicating that the antagonist effects of compound <b>25w</b> and ticagrelor were mediated through specifically binding to P2Y<sub>12</sub>. Among them, the antagonist potency of compound <b>25w</b> was higher than that of MRS2395, an antagonist for the P2Y<sub>12</sub> purinoceptor reported in the literature.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Nevertheless, the antagonist potency of both compound <b>25w</b> and MRS2395 was lower than that of ticagrelor (<b>ticagrelor</b> > <b>25w</b> > <b>MRS2395</b>, IC<sub>50</sub> = 5.14, 148.92, and 176–196 μM, respectively). In addition, compound <b>25w</b> and ticagrelor both could not cause a decrease of VASP phosphorylation in the absence of ADP, which was comparable to that of PGE<sub>1</sub> alone, suggesting that they did not possess P2Y<sub>12</sub> agonistic effects.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> The results above proved that compound <b>25w</b> could bind to P2Y<sub>12</sub> purinoceptor as an antagonist. Therefore, we could confirm that compound <b>25w</b> exerted its antiplatelet effect through both P2Y<sub>1</sub> and P2Y<sub>12</sub> receptors.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of ADP-induced, P2Y<sub>12</sub>-mediated decrease in VASP phosphorylation by compound <b>25w</b> or ticagrelor. PGE<sub>1</sub>-stimulated VASP phosphorylation and its attenuation by ADP in the presence and absence of the test compounds were measured by flow cytometry. The data were reported as the mean ± SD (<i>n</i> = 3; *<i>P</i> > 0.05, as compared to PGE<sub>1</sub> alone).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Xanthine Oxidase Inhibitory Activity</h3><div class="NLM_p last">The evaluation of the <i>in vitro</i> bovine XO inhibitory potency of compounds <b>24w</b> and <b>25w</b> was performed with febuxostat as a reference compound. The results showed that compounds <b>24w</b> and <b>25w</b> displayed no significant inhibition against XO (not active, inhibition at 10 μM < 50%), and the IC<sub>50</sub> value of febuxostat was 0.0189 μM.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Docking Studies</h3><div class="NLM_p">To explore a probable interaction model of compounds <b>24w</b> and <b>25w</b> with P2Y<sub>1</sub> and P2Y<sub>12</sub>, the molecular docking of compounds <b>24w</b> and <b>25w</b> in <b>MRS2500</b> and <b>AZD1283</b> binding pockets of proteins was performed using the Glide XP docking protocol (2016, Schrodinger Suite).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The X-ray crystal structures of the P2Y<sub>1</sub>/MRS2500 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW">4XNW</a>)<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and P2Y<sub>12</sub>/AZD1283 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ">4NTJ</a>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> used in the docking studies were obtained from the RCSB Protein Data Bank, and <b>MRS2500</b> as well as <b>AZD1283</b> were adopted as references. The proteins were prepared by removing all water molecules and adding all hydrogen atoms using Protein Preparation Wizard (2016, Schrodinger Suite).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The phosphonic acid and carboxyl groups of all compounds were calculated in dissociated forms using the LIGPREP module (2016, Schrodinger Suite).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">The binding models of compounds <b>24w</b> and <b>25w</b> were illustrated by Pymol<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). For the binding mode of P2Y<sub>1</sub>, we found that the carboxylic acid group of compound <b>25w</b> could engage in three hydrogen bonds with key residues Thr205, Tyr206, and Arg310, which was almost equivalent to the interactions formed by the phosphate group of <b>MRS2500</b>, and it could also interact with key residue Asn283 <i>via</i> two hydrogen bonds. In addition, an extra electrostatic interaction was formed between <b>25w</b> and Arg287 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C), and a π–π stacking interaction was observed between the imidazole moiety of <b>25w</b> and Tyr203. Moreover, the cyano groups on phenyl and benzyl moieties of <b>25w</b> formed new hydrogen bonds with Tyr203, Gln291, and Asn299, respectively, which was lacking in <b>MRS2500</b>. In terms of compound <b>24w</b>, the similar key hydrogen bonds with Thr205, Tyr206, Arg310, and Asn283 were also observed at the cyano group on the phenyl moiety and the N atom on the imidazole ring, and the cyano and ester carbonyl groups were able to interact with Tyr203 and Gln291 <i>via</i> two hydrogen bonds. The imidazole moiety of compound <b>24w</b> could also interact with Tyr 303 through a π–π stacking interaction. Nevertheless, compounds <b>24w</b> and <b>25w</b> both lacked hydrogen bonds formed by the other phosphate group of <b>MRS2500</b> with Lys46, Arg195, Thr201, Tyr203, and Tyr303.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of (A) <b>MRS2500</b>, (B) compound <b>24w</b>, and (C) compound <b>25w</b> in the P2Y<sub>1</sub> receptor (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW">4XNW</a>). Binding modes of (D) <b>AZD-1283</b>, (E) compound <b>24w</b>, and (F) <b>25w</b> in the P2Y<sub>12</sub> receptor (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ">4NTJ</a>). Protein is shown as a cartoon, and small molecules are shown as sticks. Hydrogen bonds, π–π stacking interactions, and electrostatic interaction are depicted by red, purple, and orange dashed lines, respectively. Residues of P2Y<sub>1</sub> and P2Y<sub>12</sub> interacting with inhibitors are depicted by green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The docking results of P2Y<sub>12</sub> showed that the cyano groups of compounds <b>24w</b> and <b>25w</b> were able to form two hydrogen bonds with the side chains of key residues Tyr109 and Gln195 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B,C), which was in agreement with the binding mode of the cyano group of <b>AZD1283</b> in the binding pocket of P2Y<sub>12</sub> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Moreover, the negatively charged carboxylic acid group of compound <b>25w</b> formed an electrostatic interaction with the positively charged side chain of Lys280, which is consistent with those observed in acidic groups such as sulfonate or carboxylic acid groups presented in anthraquinone and glutamic acid piperazine P2Y<sub>12</sub> antagonists,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> whereas the ester carbonyl group of compound <b>24w</b> only engaged in a hydrogen bond with the side chain of Lys280. Meanwhile, the phenyl ring of compounds <b>24w</b> and <b>25w</b> occupied the same region as the pyridine moiety of AZD1283 through an aromatic π–π stacking interaction with Tyr105. Moreover, compared to AZD1283, the imidazole ring of compounds <b>24w</b> and <b>25w</b> formed an additional aromatic π–π stacking interaction with Tyr105, and the 4-cyanobenzyl group further inserted into the cavity occupied by the piperidine moiety of AZD1283.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Simulated Gastric and Intestinal Fluid Stability</h3><div class="NLM_p">To characterize the <i>in vitro</i> metabolic stability of compounds <b>24w</b> and <b>25w</b>, they were incubated with simulated gastric and intestinal fluid, and the remaining percentages of compounds <b>24w</b> and <b>25w</b> after incubation are summarized in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. After a 12 h incubation period in simulated gastric fluid, approximately 90% of the parent compounds <b>24w</b> and <b>25w</b> remained intact, which suggested that they were considerably stable in simulated gastric fluid. After a 12 h incubation period in simulated intestinal fluid, compound <b>24w</b> was also stable with about 93% remaining while compound <b>25w</b> was moderately stable in simulated intestinal fluid, due to 73% of its parent compound left. These results suggested that compounds <b>24w</b> and <b>25w</b> should be stable in stomach and intestine.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A and B) Stability profiles of compounds <b>24w</b> and <b>25w</b> in simulated gastric and intestinal fluids. Each value is the mean ± SEM; <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Stability Studies in Plasma</h3><div class="NLM_p">The <i>in vitro</i> stability profiles of compounds <b>24w</b> and <b>25w</b> were further studied by incubation with both rabbit and rat plasma to observe the disappearance of the prototype and formation of the metabolite. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> showed that 12% of compound <b>24w</b> was converted to compound <b>25w</b> by 45 min in rabbit plasma. Meanwhile, in rat plasma, 43% of the compound <b>24w</b> was hydrolyzed to compound <b>25w</b> by 45 min. These results suggested that compound <b>24w</b> could be rapidly converted to compound <b>25w</b> in plasma, which is consistent with the later PK studies in rats after the oral administration of <b>24w</b>. The hydrolysis rate of compound <b>24w</b> in rat plasma was greater than that in rabbit plasma. Moreover, no significant degradation of compound <b>25w</b> was observed in these two media during the incubation period, which indicated that compound <b>25w</b> was rather stable in both rabbit and rat plasma, and compound <b>24w</b> could be used as a prodrug of <b>25w</b>.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Stability and metabolism profiles of compounds (A) <b>24w</b> and (B) <b>25w</b> in rabbit and rat plasma. Each value is the mean ± SEM; <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p">The hepatic metabolism plays a vital role in biotransformation in the majority of prodrugs, and liver microsomal metabolic stability is widely used in the research of drug metabolism.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Therefore, compounds <b>24w</b> and <b>25w</b> were further evaluated for their <i>in vitro</i> liver microsomal metabolic stability, and the data are listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. In <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,C, compound <b>24w</b> was rapidly converted to compound <b>25w</b> in both rat liver microsomes (RLMs) and human liver microsomes (HLMs), which indicated that compound <b>24w</b> could be rapidly converted into compound <b>25w</b> by hepatic metabolism and further confirmed the formation of compound <b>25w</b> in later PK studies in rats after the oral administration of <b>24w</b>. Moreover, the liver microsomal stability of compound <b>24w</b> in HLMs (<i>t</i><sub>1/2</sub> = 120.65 min, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C) was better in that in RLMs (<i>t</i><sub>1/2</sub> = 23.13 min, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), suggesting that there was a species difference of compound <b>24w</b> in both RLMs and HLMs, and compound <b>24w</b> could be converted to compound <b>25w</b> rapidly in rat liver. In addition, compound <b>25w</b> (<i>t</i><sub>1/2</sub> > 120 min in both RLMs and HLMs) was considerably stable in both RLMs and HLMs (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B,D).</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Stability profiles of compounds <b>24w</b> and <b>25w</b> obtained in both RLMs and HLMs: (A) incubation of <b>24w</b> in RLMs; (B) incubation of <b>25w</b> in RLMs; (C) incubation of <b>24w</b> in HLMs; (D) incubation of <b>25w</b> in HLMs. The data represent the mean ± SEM of three independent experiments (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Microsomal Stability of Compounds <b>24w</b> and <b>25w</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (min)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>int</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (mL/min/mg protein)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24w</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">23.13</td><td class="colsep0 rowsep0" align="char" char=".">0.060</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">120.65</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25w</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">>120</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">>120</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Microsomal protein (0.50 mg/mL), NADPH-regenerating system, [inhibitor], 0.2 μM; incubation at 37 °C.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>T</i><sub>1/2</sub>: elimination half-life.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Cl<sub>int</sub>: intrinsic body clearance.</p></div></div></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> CYP450 Inhibition Assay</h3><div class="NLM_p">CYP450-mediated drug–drug interaction is one of the important reasons for the dropout of drug candidates during new drug development.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Therefore, testing for drug–drug interaction potential of new chemical entities is essential for developing a novel drug.<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a> As a result, compounds <b>24w</b> and <b>25w</b> were selected to further evaluate their <i>in vitro</i> inhibitory potential of major CYP450 enzymes including CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in a CYP450 inhibition cocktail assay, and the results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Indeed, compound <b>25w</b> was found to show no significant inhibition against these CYP450 isoforms at 10 μM, which indicated that its IC<sub>50</sub> value against these major CYP450 isoforms was greater than 10 μM. This result implied that compound <b>25w</b> showed no apparent drug–drug interaction potential at 10 μM. However, compound <b>24w</b> exhibited a weak inhibitory potency against CYP2D6 with an inhibition of 31.69% at 10 μM, suggesting that there might be low liability for drug–drug interactions between <b>24w</b> and CYP2D6.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. CYP450 Inhibition of Compounds <b>24w</b> and <b>25w</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">inhibition at 10 μM (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">CYP1A2<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP2A6<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP2C9<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP2C19<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP2D6<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP2E1<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">CYP3A4<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24w</b></td><td class="colsep0 rowsep0" align="char" char=".">3.85</td><td class="colsep0 rowsep0" align="char" char=".">7.69</td><td class="colsep0 rowsep0" align="char" char=".">0.024</td><td class="colsep0 rowsep0" align="char" char=".">4.52</td><td class="colsep0 rowsep0" align="char" char=".">31.69</td><td class="colsep0 rowsep0" align="char" char=".">8.68</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25w</b></td><td class="colsep0 rowsep0" align="char" char=".">0.11</td><td class="colsep0 rowsep0" align="char" char=".">3.64</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">1.97</td><td class="colsep0 rowsep0" align="char" char=".">2.42</td><td class="colsep0 rowsep0" align="char" char=".">6.79</td><td class="colsep0 rowsep0" align="char" char=".">7.40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Phenacetin.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Coumarin.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Tolbutamide.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last"><i>S</i>-Mephenytoin.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Dextromethorphan,</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Chlorzoxazone.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">Nifedipine.</p></div></div></div></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Pharmacokinetic Studies</h3><div class="NLM_p">To explore the pharmacokinetic assessment of compounds <b>24w</b> and <b>25w</b>, they were further evaluated for their PK properties in Sprague-Dawley rats, as shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, and their noncompartmental PK parameters are listed in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Plasma concentration–time profiles of compounds <b>24w</b> and <b>25w</b> after administration in rats (<i>n</i> = 6). (A) Single oral administration of compounds <b>24w</b> (parent compound <b>25w</b> released from prodrug <b>24w</b>; 10 mg/kg) and <b>25w</b> (10 mg/kg). (B) Intravenous injection administration of compound <b>25w</b> (10 mg/kg). Data are presented as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Main Pharmacokinetic Parameters of Compounds <b>24w</b> and <b>25w</b> in Sprague-Dawley Rats after Administration (<i>n</i> = 6)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center">oral administration (mean ± SD; <b>24w</b>)</th><th class="colsep0 rowsep0" align="center">oral administration (mean ± SD; <b>25w</b>)</th><th class="colsep0 rowsep0" align="center">intravenous administration (mean ± SD; <b>25w</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">67.99 ± 10.72</td><td class="colsep0 rowsep0" align="left">214.05 ± 148.88</td><td class="colsep0 rowsep0" align="left">11225.0 ± 8214.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.46 ± 0.29</td><td class="colsep0 rowsep0" align="left">0.167</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">1135.08 ± 764.28</td><td class="colsep0 rowsep0" align="left">808.86 ± 382.05</td><td class="colsep0 rowsep0" align="left">3500.34 ± 1003.87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">13.83 ± 10.82</td><td class="colsep0 rowsep0" align="left">13.13 ± 15.06</td><td class="colsep0 rowsep0" align="left">4.89 ± 3.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLz (L·h<sup>–1</sup>·kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">12.40 ± 6.38</td><td class="colsep0 rowsep0" align="left">15.64 ± 8.64</td><td class="colsep0 rowsep0" align="left">3.03 ± 0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vz (L/kg)</td><td class="colsep0 rowsep0" align="left">190.56 ± 86.64</td><td class="colsep0 rowsep0" align="left">239.60 ± 183.57</td><td class="colsep0 rowsep0" align="left">21.29 ± 15.29</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last"><i>C</i><sub>max</sub>, peak plasma concentration; <i>T</i><sub>max</sub>, time to reach <i>C</i><sub>max</sub>; AUC<sub>0–∞</sub>, area under the concentration–time curve from time zero to infinity; <i>t</i><sub>1/2</sub>, elimination half-life; CLz, clearance; Vz, volume of distribution.</p></div></div></div><div class="NLM_p last">For a single oral administration of <b>24w</b> (10 mg/kg), the prototype of compound <b>24w</b> (below analytical detection limit of quantification: 10 ng/mL) was not observed in the beginning of the oral administration, while compound <b>25w</b> was immediately detected at 10 min after the oral administration of <b>24w</b> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). This suggested that the compound <b>24w</b> could be rapidly converted into the metabolite <b>25w</b>, and these results were consistent with <i>in vitro</i> plasma and liver microsomal stability. Furthermore, the average time for compounds <b>24w</b> and <b>25w</b> to reach the maximum concentration (<i>T</i><sub>max</sub>) was shorter than that of ticagrelor<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (ticagrelor > <b>24w</b> > <b>25w</b>, <i>T</i><sub>max</sub> = 4 > 0.46 > 0.167 h, respectively), indicating that they both were absorbed quickly into circulation. This might demonstrate a faster onset of action than current clinical oral P2Y<sub>12</sub> antagonists.<a onclick="showRef(event, 'ref14 ref16 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref14 ref16 ref35 ref36">(14,16,35,36)</a> Meanwhile, the half-lives (<i>t</i><sub>1/2</sub>) of compounds <b>24w</b> and <b>25w</b> were both 13 h, suggesting that they both could achieve a longer duration of action. Among them, compound <b>24w</b> displayed slightly better PK properties compared to those of <b>25w</b>, including higher plasma exposure (AUC<sub>0–∞</sub> = 1135.08 ng·h/mL) and moderate oral bioavailability (<i>F</i> = 32.4%). On the basis of its favorable pharmacokinetic profiles, compound <b>24w</b> was selected for further evaluation of its acute oral toxicity study, <i>in vivo</i> antithrombotic efficacy, and associated bleeding risk assessment in rats.</div></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Acute Oral Toxicity Study</h3><div class="NLM_p">Prior to the <i>in vivo</i> pharmacodynamics evaluation, the acute oral toxicity study of compound <b>24w</b> was carried out to investigate its preliminary toxicity profile in healthy mice according to Organization for Economic Cooperation and Development (OECD) guidelines.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The mice were carefully observed for any behavioral change and mortality after the oral administration of compound <b>24w</b> at a single dose of 2000 mg/kg. No death occurred after oral administration, and all mice in the drug administration group (male and female) grew normally compared to the mice in the control group. The body weights of these mice gradually increased during the subsequent 14 days (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), and no significant behavioral abnormalities were observed.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Body weight evolution of (A) male and (B) female mice. Each value is the mean ± SEM; <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>In Vivo</i> Antithrombotic Efficacy</h3><div class="NLM_p">On the basis of the better <i>in vitro</i> antiplatelet potency and excellent PK properties, <i>in vivo</i> antithrombotic efficacy of compound <b>24w</b> was further evaluated and ticagrelor was tested for comparison as a positive control. The thrombus weights in compound <b>24w</b> and ticagrelor groups were significantly reduced compared to that of the model group (<i>***P</i> < 0.001 for 5, 10, and 20 mg/kg of <b>24w</b> and 10 mg/kg of ticagrelor vs model; <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), indicating that this ferric chloride model in rats was successfully established,<a onclick="showRef(event, 'ref11 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref11 ref72 ref73 ref74">(11,72−74)</a> and compound <b>24w</b> as well as ticagrelor both resulted in a remarkable antithrombotic effect. Among them, the oral administration of compound <b>24w</b> demonstrated dose-dependent antithrombotic efficacy, achieving thrombus weight reductions of 22.6%, 40.7%, and 46.7% at doses of 5, 10, and 20 mg/kg, respectively. These results showed that its antithrombotic ED<sub>50</sub> was 20.8 mg/kg. Specifically, compound <b>24w</b> (10 mg/kg) resulted in a thrombus weight reduction of 40.7%, which was comparable to that of ticagrelor (39.2%) at the same 10 mg/kg dose (<sup><i>#</i></sup><i>P</i> > 0.05 for 10 mg/kg <b>24w</b> vs ticagrelor). Consequently, the results of <i>in vivo</i> antithrombotic efficacy evaluation suggested that compound <b>24w</b> could be a potentially efficacious antithrombotic agent in the treatment of thrombotic disorders.</div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of ticagrelor and compound <b>24w</b> on thrombus weight after FeCl<sub>3</sub>-induced arterial injury in anesthetized Sprague-Dawley rats at 1.5 h postdosing following the oral administration of <b>24w</b> (5, 10, and 20 mg/kg) and ticagrelor (10 mg/kg). Data are presented as the mean ± SD (<i>n</i> = 10, <i>***P</i> < 0.001 and <i>***P</i> < 0.001 vs model; <sup><i>#</i></sup><i>P</i> > 0.05 vs ticagrelor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Bleeding Risk Assessment</h3><div class="NLM_p">Since bleeding complications had largely been considered an expected complication of antiplatelet therapy for all currently approved oral P2Y<sub>12</sub> antagonists,<a onclick="showRef(event, 'ref11 ref28 ref43'); return false;" href="javascript:void(0);" class="ref ref11 ref28 ref43">(11,28,43)</a> the bleeding effect of compound <b>24w</b> was further evaluated in a rat-tail-bleeding model.<a onclick="showRef(event, 'ref11 ref44 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref72">(11,44,72)</a> In this study, the bleeding effect of compound <b>24w</b> was compared to those of ticagrelor by measuring the tail-vein-bleeding time and weights in rats after oral administration. As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, the blood loss of the vehicle-treated rats within 2 h after the tail snip amounted to 0.08 g with a bleeding time of 17.69 min, indicating that this assay was highly reproducible.<a onclick="showRef(event, 'ref44 ref72'); return false;" href="javascript:void(0);" class="ref ref44 ref72">(44,72)</a> In ticagrelor-treated rats, the total bleeding time and weight were significantly increased by 6.78-fold and 48.63-fold in comparison to the vehicle, respectively (120 vs 17.69 min, 3.89 vs 0.08 g, <i>***P</i> < 0.001 for ticagrelor group vs vehicle group). Compound <b>24w</b> only caused 1.92- and 5.00-times more than those of the vehicle group in bleeding time and weight, respectively (33.94 vs 17.69 min, 0.40 vs 0.08 g, <i>*P</i> < 0.05 for <b>24w</b> group vs vehicle group), and were 3.54- and 9.73-times less than those of ticagrelor on the bleeding time and weight, respectively (33.94 vs 120 min, 0.40 vs 3.89 g, <sup><i>###</i></sup><i>P</i> < 0.001 for <b>24w</b> group vs ticagrelor group). These results indicated that <b>24w</b> resulted in much less blood loss than ticagrelor in rats at a therapeutically equivalent antithrombotic dose of 10 mg/kg. It was observed that, at this oral dose, compound <b>24w</b> could lead to a thrombosis inhibition of 40.7%, which was comparable to that of ticagrelor (39% inhibition of thrombosis). This reduction in bleeding time and weight when compared to ticagrelor indicated that compound <b>24w</b> clearly had a wider therapeutic window than ticagrelor in a rat thrombosis model and could potentially resolve the serious concern of high bleeding risk associated with clinical oral P2Y<sub>12</sub> antagonists.<a onclick="showRef(event, 'ref14 ref16 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref14 ref16 ref35 ref36">(14,16,35,36)</a></div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0011.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of ticagrelor and compound <b>24w</b> on (A) tail-vein-bleeding weight and (B) time in anesthetized Sprague-Dawley rats at 2 h postdosing following the oral administration of <b>24w</b> (10 mg/kg) and ticagrelor (10 mg/kg). The data are presented as mean ± SD (<i>n</i> = 8, <i>*P</i> < 0.05, <i>***P</i> < 0.001 vs model group; <sup><i>###</i></sup><i>P</i> < 0.001 vs ticagrelor group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88548" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88548" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from our previously reported nonpurine XO inhibitor <b>WSJ-557</b> with an apparent antiplatelet aggregation potency (IC<sub>50</sub> = 15.727 μM), the 2-phenyl-1<i>H</i>-imidazole moiety was adopted as a new chemical scaffold for the structural optimization to lead to the identification of the most potent antiplatelet agents <b>24w</b> and <b>25w</b> (IC<sub>50</sub> = 4.237 and 3.875 μM, respectively). We completed the optimization process and SAR of the target compounds. Moreover, P2Y<sub>1</sub>-mediated cytosolic Ca<sup>2+</sup> increase indicated that compound <b>25w</b> exhibited a potent inhibitory effect for P2Y<sub>1</sub> with a IC<sub>50</sub> value of 2.59 μM, comparable with that of BPTU (IC<sub>50</sub> = 3.03 μM), and P2Y<sub>12</sub>-mediated vasodilator-stimulated phosphoprotein phosphorylation assay revealed that compound <b>25w</b> also could dose dependently antagonize P2Y<sub>12</sub> receptor, which could confirm that compound <b>25w</b> exerted its antiplatelet effect through both P2Y<sub>1</sub> and P2Y<sub>12</sub>. Molecular modeling studies revealed the binding modes of <b>24w</b> and <b>25w</b> with two receptors, P2Y<sub>1</sub> and P2Y<sub>12</sub>, which suggested that they could form hydrogen-bond interactions with key residues in active pockets. The simulated gastric and intestinal fluid stabilities indicated that they were considerably stable within 10 h, and the <i>in vitro</i> plasma and liver microsomal stability studies also showed that compound <b>24w</b> could be rapidly converted to compound <b>25w</b>. In addition, the CYP450 inhibition assay suggested that compound <b>25w</b> showed no apparent drug–drug interaction at 10 μM and there might be low liability for drug–drug interactions between <b>24w</b> and CYP2D6. Furthermore, the PK studies showed the <i>T</i><sub>max</sub> values of compounds <b>24w</b> and <b>25w</b> were 0.46 and 0.167 h, respectively, suggesting that they were both absorbed quickly into circulation, which could hopefully overcome the slow onset of action of currently approved oral P2Y<sub>12</sub> antagonists. The acute oral toxicity study of compound <b>24w</b> was evaluated in mice, and the results indicated that <b>24w</b> was nontoxic and tolerated at a dose up to 2000 mg/kg in mice. In addition, the rat ferric chloride model study suggested that compound <b>24w</b> demonstrated the dose-dependent antithrombotic efficacy and was comparable to what was observed for ticagrelor at the same oral dose (10 mg/kg). Importantly, compound <b>24w</b> showed significantly lower bleeding weight and time compared to ticagrelor at therapeutically equivalent antithrombotic dose (10 mg/kg) in a rat-tail-bleeding model, indicating that it had a clearly wider therapeutic window than ticagrelor in rats. This could potentially address the concern of high bleeding risk in clinically approved oral P2Y<sub>12</sub> antagonists. Therefore, compounds <b>24w</b> and <b>25w</b> were promising drug candidates for the treatment of arterial thrombosis and related diseases. The investigations performed in this research perfectly achieved the transition from a nonpurine imidazole XO inhibitor to dual-target P2Y<sub>1</sub> and P2Y<sub>12</sub> antagonists, which implied that other nonpurine XO inhibitors with a similar chemical structure to <b>WSJ-557</b> could also be adopted to design novel effective dual-target P2Y<sub>1</sub> and P2Y<sub>12</sub> antagonists.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16583" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16583" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p last">Compounds <b>WSJ-557</b> and <b>18</b> were prepared from our previous report,<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> and the purity of each was more than 95%. In addition, reagents and solvents were purchased from commercial sources and used without further purification. All reactions were monitored by TLC using silica gel aluminum cards (0.2 mm thickness) with 254 and 365 nm fluorescent indicators. Melting points were obtained using a YRT-3 melting apparatus and were uncorrected. <sup>1</sup>H NMR spectra were recorded on a Bruker 400 or 600 MHz spectrometer, and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 or 600 MHz spectrometer. Chemical shifts were expressed in parts per million using tetramethylsilane as an internal reference and DMSO-<i>d</i><sub>6</sub> as the solvent. Electrospray ionization-mass spectrometry (ESI-MS) data were gathered using an Agilent 1100 instrument and ESI-HRMS data were recorded in an Agilent 6540 Series quadrupole time-of-flight mass spectrometer (Q-TOF-MS) system (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_001.xlsx" class="ext-link">Supporting Information</a>).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Ethyl 2-Hydroxyimino-3-oxobutanoate (<b>20</b>)</h3><div class="NLM_p last">A solution of sodium nitrite (51.3 g, 0.74 mol) in water (102.6 mL) was added dropwise at 0–5 °C to a stirred solution of ethyl acetoacetate (80 g, 0.62 mol) in acetic acid (240 mL). Upon completion of the reaction, a mixture of DCM (500 mL) and water (250 mL) was added. The organic phase was washed with water (2 × 150 mL) and brine (150 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated to afford a crude product <b>20</b> as a yellow oil, which was used for the next reaction without further purification.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Ethyl 2-(3-Cyanophenyl)-1-hydroxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>21a</b>)</h3><div class="NLM_p last">A mixture of 3-formylbenzonitrile (30g, 0.229 mol), ethyl 2-hydroxyimino-3-oxobutanoate (43.7 g, 0.285 mol), ammonium acetate (176.3 g, 2.29 mol), and acetic acid (600 mL) was stirred at 50 °C under a nitrogen atmosphere for 24 h. The reaction mixture was cooled to room temperature and then slowly poured into cold water (2000 mL). The resulting precipitate was filtered, dried, and washed with ethyl acetate to obtain the compound <b>21a</b> as a white solid, yield: 75.5%. Purity (HPLC): 98.4%. Mp 167.7–170.2 °C. ESI-HRMS calcd. for C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 272.1030, found: 272.1057. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.28 (s, 1H), 8.39 (t, <i>J</i> = 1.7 Hz, 1H), 8.34 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.91 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.71 (t, <i>J</i> = 7.9 Hz, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 2.39 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 159.33, 142.72, 141.14, 133.16, 132.35, 131.03, 130.49, 129.77, 118.94, 118.83, 112.29, 60.53, 16.14, 14.67.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Ethyl 2-(2-Cyanophenyl)-1-hydroxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>21b</b>)</h3><div class="NLM_p last">Compound <b>21b</b> was prepared in the same manner as that described for <b>21a</b> and yielded a brown oil, which was used for the next reaction without further purification.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Ethyl 2-(4-Cyanophenyl)-1-hydroxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>21c</b>)</h3><div class="NLM_p last">Compound <b>21c</b> was prepared in the same manner as that described for <b>21a</b> to yield a white solid, yield: 72.8%. Mp 170.5–171.8 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.36 (s, 1H), 8.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.93 (d, <i>J</i> = 8.4 Hz, 2H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 2.38 (s, 3H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Ethyl 1-Hydroxy-4-methyl-2-phenyl-1<i>H</i>-imidazole-5-carboxylate (<b>21d</b>)</h3><div class="NLM_p last">Compound <b>21d</b> was prepared in the same manner as that described for <b>21a</b> to yield a white solid, yield: 83.7%. Mp 131.5–133.1 °C. ESI-MS <i>m</i>/<i>z</i>: 247.1 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.22–8.13 (m, 2H), 7.46–7.33 (m, 3H), 4.23 (q, <i>J</i> = 7.1 Hz, 2H), 2.34 (s, 3H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Ethyl 2-(3-Cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>22a</b>)</h3><div class="NLM_p last">A solution of compound <b>21a</b> (0.51 g, 2.0 mmol), anhydrous potassium carbonate (0.33g, 2.40 mmol), and iodomethane (0.33 g, 2.4 mmol) in DMF (5.4 mL) was stirred at 35 °C under a nitrogen atmosphere for 1 h. After the completion of the reaction, the reaction mixture was poured into 11 mL of water and stirred for 10 min. The precipitate was filtered and washed with water, and then, ethyl acetate (5.0 mL) was added to wash residue to yield compound <b>22a</b> as a white solid, yield: 79.3%. Purity (HPLC): 99.5%. Mp 122.4–123.5 °C. ESI-HRMS calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 285.1186, found: 286.1207. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.37–8.27 (m, 2H), 7.97 (dt, <i>J</i> = 7.6, 1.4 Hz, 1H), 7.75 (t, <i>J</i> = 7.8 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 3.98 (s, 3H), 2.40 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.68, 143.82, 140.26, 133.78, 132.14, 130.90, 130.82, 129.02, 118.70, 116.97, 112.70, 67.65, 60.84, 16.23, 14.54.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Ethyl 2-(2-Cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>22b</b>)</h3><div class="NLM_p last">Compound <b>22b</b> was prepared in the same manner as that described for <b>22a</b> to yield a yellow solid, yield: 51.4%. Purity (HPLC): 99.3%. Mp 144.2–145.6 °C. ESI-MS <i>m</i>/<i>z</i>: 286.17 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.68–7.57 (m, 3H), 7.52 (dd, <i>J</i> = 7.4, 1.4 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 3.79 (s, 3H), 2.42 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.69, 143.83, 140.26, 133.76, 132.12, 130.90, 130.81, 129.04, 118.69, 116.98, 112.71, 67.64, 60.83, 16.21, 14.53.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Ethyl 2-(4-Cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>22c</b>)</h3><div class="NLM_p last">Compound <b>22c</b> was prepared in the same manner as that described for <b>22a</b> to yield a white solid, yield: 92.4%. Purity (HPLC): 98.1%. Mp 147.3–148.5 °C. ESI-HRMS calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 286.1186, found: 286.1208. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.21 (dd, 2H), 7.99 (dd, 2H), 4.33 (q, <i>J</i> = 7.1 Hz, 2H), 3.98 (s, 3H), 2.42 (s, 3H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.67, 143.97, 140.37, 133.37, 131.94, 128.22, 118.88, 117.29, 112.53, 67.72, 60.90, 16.28, 14.55.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Ethyl 1-Methoxy-4-methyl-2-phenyl-1<i>H</i>-imidazole-5-carboxylate (<b>22d</b>)</h3><div class="NLM_p last">Compound <b>22d</b> was prepared in the same manner as that described for <b>22a</b> to yield a white solid, yield: 88.5%. Purity (HPLC): 99.8%. Mp 98.8–100.4 °C. ESI-HRMS calcd. for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup> 261.1234, found: 261.1300. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.10–7.99 (m, 2H), 7.57–7.45 (m, 3H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 3.93 (s, 3H), 2.40 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.84, 143.68, 142.27, 130.39, 129.36, 127.95, 127.72, 116.35, 67.21, 60.62, 16.28, 14.57.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Ethyl 2-(3-Cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>23</b>)</h3><div class="NLM_p last">A suspension of compound <b>21a</b> (2.6 g, 10 mmol), potassium iodide (1.16g, 10 mmol), chlorotrimethylsilane (1.63g, 15 mmol), and acetonitrile (30 mL) was stirred at 60 °C for 6 h. The reaction mixture was poured into a solution of 1 M sodium hydroxide aqueous and was stirred for 1 h. The precipitate was filtered and washed with ethyl acetate to obtain compound <b>23</b> as a white solid, yield: 77.3%. Purity (HPLC): 97.7%. Mp 209.6–210.7 °C. ESI-HRMS calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> [M – H]<sup>−</sup> 254.0935, found: 254.0959. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.35 (s, 1H), 8.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.80 (d, <i>J</i> = 7.7 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 4.80 (s, 1H), 4.25 (q, <i>J</i> = 7.1 Hz, 2H), 2.47 (s, 3H), 1.30 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.99, 144.34, 140.85, 132.04, 130.50, 130.13, 128.92, 126.99, 118.97, 112.31, 59.83, 14.86, 12.89.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Ethyl 2-(3-Cyanophenyl)-1,4-dimethyl-1<i>H</i>-imidazole-5-carboxylate (<b>24a</b>)</h3><div class="NLM_p last">A solution of compound <b>23</b> (0.51 g, 2.0 mmol), anhydrous potassium carbonate (0.33g, 2.40 mmol), and iodomethane (0.33 g, 2.4 mmol) in DMF (5.4 mL) was stirred at 35 °C under a nitrogen atmosphere for 1 h. After the completion of the reaction, the reaction mixture was poured into 11 mL of water and stirred for 10 min. The precipitate was filtered and washed with water, and then, ethyl acetate (5.0 mL) was added to wash the residue to yield compound <b>24a</b> as a white solid, yield: 76.2%. Purity (HPLC): 97.9%. Mp 137.3–138.1 °C. ESI-HRMS calcd. for C<sub>15</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 270.1237, found: 270.1250. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.13 (s, 1H), 8.07–7.91 (m, 2H), 7.73 (t, <i>J</i> = 7.8 Hz, 1H), 4.30 (q, <i>J</i> = 7.3 Hz, 2H), 3.84 (s, 3H), 2.42 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.95, 148.48, 146.87, 134.35, 133.45, 132.92, 131.23, 130.38, 120.94, 118.74, 112.32, 60.54, 35.03, 16.05, 14.65.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Ethyl 2-(3-Cyanophenyl)-1-isopropyl-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24b</b>)</h3><div class="NLM_p last">Compound <b>23</b> (0.51 g, 2.0 mmol), anhydrous potassium carbonate (0.33 g, 2.4 mmol), potassium iodide (39.84 mg, 0.24 mmol), and 2-bromopropane (295 mg, 2.4 mmol) were dissolved in DMF (5.4 mL), and the reaction mixture was stirred at 35 °C for 1 h. Then, the mixture was poured into water (11 mL) and stirred for 10 min, which was filtered and washed with ethyl acetate to provide the compound <b>24b</b> as a white solid, yield: 68.3%. Purity (HPLC): 99.2%. Mp 105.3–106.7 °C. ESI-MS <i>m</i>/<i>z</i>: 298.2 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.33–8.24 (m, 2H), 7.94 (d, <i>J</i> = 7.7 Hz, 1H), 7.73 (t, <i>J</i> = 7.8 Hz, 1H), 4.44 (hept, <i>J</i> = 6.2 Hz, 1H), 4.30 (q, <i>J</i> = 7.1 Hz, 2H), 2.41 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 1.03 (d, <i>J</i> = 6.0 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.90, 144.08, 142.05, 133.54, 132.72, 131.59, 130.54, 129.89, 118.62, 117.68, 112.39, 83.52, 60.76, 20.24, 16.32, 14.55.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Ethyl 2-(3-Cyanophenyl)-1-isopropoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24c</b>)</h3><div class="NLM_p last">A mixture of compound <b>21a</b> (0.54 g, 2.0 mmol), 2-bromopropane (295 mg, 2.4 mmol), anhydrous potassium carbonate (0.33 g, 2.4 mmol), potassium iodide (39.84 mg, 0.24 mmol), and DMF (5.4 mL) was reacted at 35 °C for 1 h under a nitrogen atmosphere. After the reaction was completed, the mixture was poured into water (11.0 mL) and stirred for 10 min. The precipitate was filtered, washed with water, and stirred for 30 min in a solution of ethyl acetate (5.0 mL), which was filtered to yield compound <b>24c</b> as a white solid, yield: 79.3%. Purity (HPLC): 99.4%. Mp 99.6–101.5 °C. ESI-HRMS calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 314.1499, found: 314.1513. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.31 (t, <i>J</i> = 1.7 Hz, 1H), 8.29 (dt, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.95 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.74 (t, <i>J</i> = 7.9 Hz, 1H), 4.44 (h, <i>J</i> = 6.2 Hz, 1H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 2.42 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H), 1.14–0.93 (m, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.93, 144.09, 142.11, 133.62, 132.78, 131.64, 130.60, 129.87, 118.66, 117.67, 112.39, 83.57, 60.81, 20.27, 16.36, 14.59.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Ethyl 1-(Allyloxy)-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24d</b>)</h3><div class="NLM_p last">Compound <b>24d</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 73.1%. Purity (HPLC): 99.6%. Mp 94.7–96.2 °C. ESI-HRMS calcd. for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 312.1343, found: 312.1361. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.34–8.32 (m, 1H), 8.31–8.27 (m, 1H), 7.97 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.79–7.72 (m, 1H), 5.95–5.76 (m, 1H), 5.41–5.25 (m, 2H), 4.66 (d, <i>J</i> = 6.4 Hz, 2H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 2.41 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.83, 143.83, 140.95, 133.69, 132.35, 131.11, 130.71, 129.33, 123.02, 118.66, 112.56, 80.69, 60.85, 16.24, 14.56.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Ethyl 2-(3-Cyanophenyl)-1-(2-ethoxyethoxy)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24e</b>)</h3><div class="NLM_p last">Compound <b>24e</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 83.2%. Purity (HPLC): 97.5%. Mp 88.6–89.4 °C. ESI-HRMS calcd. for C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 344.1605, found: 344.1619. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.46 (t, <i>J</i> = 1.7 Hz, 1H), 8.39 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.95 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.70 (t, <i>J</i> = 7.9 Hz, 1H), 4.37–4.25 (m, 4H), 3.59 (dd, <i>J</i> = 4.9, 3.2 Hz, 2H), 3.35–3.33 (m, 2H), 2.40 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H), 1.09 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.76, 143.93, 133.67, 132.57, 131.07, 130.45, 128.97, 118.76, 117.18, 112.48, 79.70, 67.18, 66.16, 60.84, 16.25, 15.30, 14.52.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Ethyl 2-(3-Cyanophenyl)-1-(2-ethoxy-2-oxoethoxy)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24f</b>)</h3><div class="NLM_p last">Compound <b>24f</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 79.8%. Purity (HPLC): 99.0%. Mp 126.3–127.7 °C. ESI-HRMS calcd. for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup> 358.1397, found: 358.1431. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.41 (s, 1H), 8.33 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.96 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.73 (t, <i>J</i> = 7.9 Hz, 1H), 4.95 (s, 2H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 4.13 (q, <i>J</i> = 7.1 Hz, 2H), 2.41 (s, 3H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H), 1.18 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.39, 158.74, 143.85, 140.75, 133.76, 132.54, 131.19, 130.58, 129.05, 118.72, 117.20, 112.51, 75.54, 61.60, 61.00, 16.26, 14.44, 14.32.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Ethyl 2-(3-Cyanophenyl)-1-(3-hydroxypropoxy)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24g</b>)</h3><div class="NLM_p last">Compound <b>24g</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 66.4%. Purity (HPLC): 95.8%. Mp 78.6–80.4 °C. ESI-HRMS calcd. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 330.1448, found: 330.1483. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.33 (t, <i>J</i> = 1.7 Hz, 1H), 8.30 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.96 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.74 (t, <i>J</i> = 7.9 Hz, 1H), 4.54 (t, <i>J</i> = 5.1 Hz, 1H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 4.15 (t, <i>J</i> = 6.5 Hz, 2H), 3.48 (q, <i>J</i> = 6.0 Hz, 2H), 2.40 (s, 3H), 1.80 (p, <i>J</i> = 6.5 Hz, 2H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.78, 143.93, 140.66, 133.71, 132.24, 131.09, 130.72, 129.10, 118.64, 117.08, 112.62, 78.14, 60.83, 57.62, 31.26, 16.22, 14.57.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Ethyl 1-(2-Amino-2-oxoethoxy)-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24h</b>)</h3><div class="NLM_p last">Compound <b>24h</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 86.7%. Purity (HPLC): 96.7%. Mp 179.6–181.2 °C. ESI-HRMS calcd. for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 329.1244, found: 329.1364. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.51 (t, <i>J</i> = 1.7 Hz, 1H), 8.38 (dt, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.95 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.72 (t, <i>J</i> = 7.9 Hz, 1H), 7.66 (s, 1H), 7.54 (s, 1H), 4.62 (s, 2H), 4.31 (q, <i>J</i> = 7.1 Hz, 2H), 2.41 (s, 3H), 1.32 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.20, 158.79, 143.89, 140.67, 133.84, 132.48, 131.19, 130.59, 128.94, 118.71, 117.15, 112.63, 77.05, 61.00, 16.23, 14.47.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-{[2-(3-Cyanophenyl)-5-(ethoxycarbonyl)-4-methyl-1<i>H</i>-imidazol-1-yl] oxy} Propanoic acid (<b>24i</b>)</h3><div class="NLM_p last">Compound <b>24i</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 75.4%. Purity (HPLC): 99.0%. Mp 142.1–143.9 °C. ESI-MS <i>m</i>/<i>z</i>: 344.2 [M + H] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.52 (s, 1H), 8.43–8.30 (m, 2H), 7.95 (d, <i>J</i> = 7.7 Hz, 1H), 7.71 (t, <i>J</i> = 7.9 Hz, 1H), 4.47–4.18 (m, 4H), 2.67 (t, <i>J</i> = 5.9 Hz, 2H), 2.41 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.77, 158.80, 143.95, 140.78, 133.80, 132.41, 131.23, 130.59, 128.94, 118.67, 117.07, 112.68, 76.00, 60.87, 33.14, 16.26, 14.58.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Ethyl 2-(3-Cyanophenyl)-4-methyl-1-(pyridin-4-ylmethoxy)-1<i>H</i>-imidazole-5-carboxylate (<b>24j</b>)</h3><div class="NLM_p last">Compound <b>24j</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 76.2%. Purity (HPLC): 99.2%. Mp 133.5–135.1 °C. ESI-HRMS calcd. for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 363.1452, found: 363.1471. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.58–8.42 (m, 2H), 8.14 (t, <i>J</i> = 1.7 Hz, 1H), 8.11 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 7.92 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.66 (t, <i>J</i> = 7.9 Hz, 1H), 7.31–7.23 (m, 2H), 5.19 (s, 2H), 4.34 (q, <i>J</i> = 7.1 Hz, 2H), 2.44 (s, 3H), 1.31 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.87, 150.26, 144.02, 141.67, 133.67, 132.49, 131.32, 130.55, 128.99, 124.24, 118.59, 116.95, 112.37, 79.87, 60.97, 16.36, 14.57.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Ethyl 1-(Benzyloxy)-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24k</b>)</h3><div class="NLM_p last">Compound <b>24k</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 94.3%. Purity (HPLC): 98.5%. Mp 124.8–126.3 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 362.1499, found: 362.1539. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.13–8.09 (m, 2H), 7.90 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.65 (td, <i>J</i> = 7.8, 0.6 Hz, 1H), 7.36–7.31 (m, 1H), 7.30–7.25 (m, 2H), 7.23–7.18 (m, 2H), 5.12 (s, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.93, 143.95, 141.46, 133.43, 132.95, 132.51, 131.21, 130.57, 130.35, 129.86, 129.17, 128.85, 118.62, 117.06, 112.25, 81.89, 60.90, 16.36, 14.63.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Ethyl 2-(3-Cyanophenyl)-1-[(2-fluorobenzyl)oxy]-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24l</b>)</h3><div class="NLM_p last">Compound <b>24l</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 83.2%. Purity (HPLC): 95.9%. Mp 135.5–136.4 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1405, found: 380.1453. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.02 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 7.86 (d, <i>J</i> = 7.7 Hz, 1H), 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 7.32 (d, <i>J</i> = 6.9 Hz, 1H), 7.15 (t, <i>J</i> = 7.1 Hz, 1H), 7.05 (t, <i>J</i> = 7.4 Hz, 1H), 6.96 (t, <i>J</i> = 9.2 Hz, 1H), 5.20 (s, 2H), 4.35 (q, <i>J</i> = 7.0 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.92, 144.05, 141.86, 133.33, 132.73, 132.65, 132.58, 131.25, 130.16, 129.03, 124.81, 124.78, 118.61, 116.96, 115.69, 115.48, 112.10, 75.22, 60.90, 16.34, 14.59.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Ethyl 2-(3-Cyanophenyl)-1-[(3-fluorobenzyl)oxy]-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24m</b>)</h3><div class="NLM_p last">Compound <b>24m</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 76.9%. Purity (HPLC): 99.7%. Mp 136.3–138.0 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1405, found: 380.1464. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.12–8.03 (m, 2H), 7.90 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.36–7.26 (m, 1H), 7.19–7.12 (m, 1H), 7.10–6.98 (m, 2H), 5.15 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.93, 144.04, 141.75, 135.30, 133.50, 133.48, 132.60, 131.30, 130.67, 130.52, 130.28, 129.75, 129.08, 129.06, 118.59, 116.94, 112.22, 80.84, 60.93, 16.36, 14.60.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Ethyl 2-(3-Cyanophenyl)-1-[(4-fluorobenzyl)oxy]-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24n</b>)</h3><div class="NLM_p last">Compound <b>24n</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 82.7%. Purity (HPLC): 98.0%. Mp 140.7–141.8 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 380.1405, found: 380.1472. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.12–8.02 (m, 2H), 7.89 (d, <i>J</i> = 7.7 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.22 (dd, <i>J</i> = 8.3, 5.5 Hz, 2H), 7.06 (t, <i>J</i> = 8.6 Hz, 2H), 5.11 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.42 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.93, 143.99, 141.64, 133.40, 133.06, 132.97, 132.51, 131.25, 130.28, 129.19, 118.60, 117.00, 115.80, 115.58, 112.18, 80.93, 60.90, 16.38, 14.62.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Ethyl 1-[(2-Chlorobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24o</b>)</h3><div class="NLM_p last">Compound <b>24o</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 76.5%. Purity (HPLC): 98.4%. Mp 124.6–125.7 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub> [M – H]<sup>−</sup> 394.1037, found: 394.0975. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.96 (s, 1H), 7.90 (d, <i>J</i> = 8.0 Hz, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 7.54 (t, <i>J</i> = 7.9 Hz, 1H), 7.28–7.21 (m, 1H), 7.21–7.14 (m, 3H), 5.24 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H).<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.94, 144.16, 142.20, 134.86, 133.37, 133.22, 132.69, 131.89, 131.46, 130.81, 130.05, 129.62, 128.97, 127.55, 118.61, 116.86, 112.01, 78.84, 60.89, 16.38, 14.58.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Ethyl 1-[(3-Chlorobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24p</b>)</h3><div class="NLM_p last">Compound <b>24p</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 83.8%. Purity (HPLC): 97.0%. Mp 118.3–119.7 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 396.1109, found: 396.1156. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.07–8.00 (m, 2H), 7.89 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.37–7.31 (m, 1H), 7.27 (t, <i>J</i> = 7.8 Hz, 1H), 7.24 (t, <i>J</i> = 1.8 Hz, 1H), 7.11 (dt, <i>J</i> = 7.5, 1.3 Hz, 1H), 5.14 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.91, 144.03, 141.69, 135.29, 133.48, 132.57, 131.27, 130.66, 130.50, 130.27, 129.74, 129.05, 116.92, 112.22, 80.82, 60.92, 16.36, 14.59.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Ethyl 1-[(4-Chlorobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24q</b>)</h3><div class="NLM_p last">Compound <b>24q</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 76.2%. Purity (HPLC): 99.6%. Mp 146.9–148.3 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 396.1109, found: 396.1170. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.07–8.02 (m, 2H), 7.89 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.69–7.58 (m, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.18 (d, <i>J</i> = 8.4 Hz, 2H), 5.12 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.91, 144.00, 134.82, 133.37, 132.49, 132.41, 131.93, 131.23, 130.24, 129.15, 128.81, 118.59, 112.18, 80.86, 60.90, 16.37, 14.61.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Ethyl 1-[(4-Bromobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24r</b>)</h3><div class="NLM_p last">Compound <b>24r</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 79.4%. Purity (HPLC): 99.7%. Mp 137.6–139.3 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 440.0604, found: 440.0653. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.08–8.00 (m, 2H), 7.90 (d, <i>J</i> = 7.7 Hz, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.42 (d, <i>J</i> = 7.9 Hz, 2H), 7.11 (d, <i>J</i> = 7.9 Hz, 2H), 5.12 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.88, 143.99, 141.57, 133.34, 132.63, 132.44, 132.28, 131.75, 131.20, 130.22, 129.12, 123.54, 118.58, 112.19, 80.91, 60.90, 16.37, 14.60.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Ethyl 2-(3-Cyanophenyl)-4-methyl-1-[(4-methylbenzyl)oxy]-1<i>H</i>-imidazole-5-carboxylate (<b>24s</b>)</h3><div class="NLM_p last">Compound <b>24s</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 81.3%. Purity (HPLC): 99.2%. Mp 119.4–120.7 °C. ESI-HRMS calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 376.1656, found: 376.1745. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.07–8.01 (m, 2H), 7.89 (dt, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.05–6.98 (m, 4H), 5.06 (s, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 2.26 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.93, 143.97, 141.66, 139.54, 133.27, 132.56, 131.16, 130.64, 130.14, 129.88, 129.33, 129.21, 118.64, 116.97, 112.08, 81.75, 60.86, 21.24, 16.36, 14.62.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Ethyl 2-(3-Cyanophenyl)-1-[(4-methoxybenzyl)oxy]-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24t</b>)</h3><div class="NLM_p last">Compound <b>24t</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 74.2%. Purity (HPLC): 99.3%. Mp 99.2–101.3 °C. ESI-HRMS calcd. for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup> 392.1605, found: 392.1635. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.09–8.00 (m, 2H), 7.87 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.69–7.57 (m, 1H), 7.10–7.00 (m, 2H), 6.80–6.67 (m, 2H), 5.04 (s, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 3.72 (s, 3H), 2.42 (s, 3H), 1.36 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.64, 158.96, 143.99, 141.78, 133.26, 132.53, 132.35, 131.21, 130.15, 129.27, 124.83, 118.65, 116.96, 114.11, 112.07, 81.62, 60.85, 55.59, 16.39, 14.64.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Ethyl 2-(3-Cyanophenyl)-1-{[4-(methoxycarbonyl)benzyl]oxy}-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24u</b>)</h3><div class="NLM_p last">Compound <b>24u</b> was prepared in the same manner as as that described for <b>24c</b> to yield a white solid, yield: 85.2%. Purity (HPLC): 97.4%. Mp 167.5–169.4 °C. ESI-HRMS calcd. for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup> 420.1554, found: 420.1676. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.05 (dt, <i>J</i> = 8.1, 1.4 Hz, 1H), 8.01 (t, <i>J</i> = 1.6 Hz, 1H), 7.88 (dt, <i>J</i> = 7.8, 1.3 Hz, 1H), 7.81 (d, <i>J</i> = 8.3 Hz, 2H), 7.62 (t, <i>J</i> = 7.9 Hz, 1H), 7.33 (d, <i>J</i> = 8.2 Hz, 2H), 5.21 (s, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.14, 158.91, 144.04, 141.62, 137.99, 133.42, 132.58, 131.28, 130.79, 130.64, 130.32, 129.54, 129.09, 118.51, 116.96, 112.23, 80.98, 60.94, 52.71, 16.36, 14.60.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Ethyl 2-(3-Cyanophenyl)-4-methyl-1-[(4-nitrobenzyl)oxy]-1<i>H</i>-imidazole-5-carboxylate (<b>24v</b>)</h3><div class="NLM_p last">Compound <b>24v</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid: 78.9%. Purity (HPLC): 98.1%. Mp 159.8–160.6 °C. ESI-HRMS calcd. for C<sub>21</sub>H<sub>18</sub>N<sub>4</sub>O<sub>5</sub> [M + H]<sup>+</sup> 407.1350, found: 407.1398. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.09 (d, <i>J</i> = 8.6 Hz, 2H), 8.07–8.00 (m, 2H), 7.89 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.49 (d, <i>J</i> = 8.6 Hz, 2H), 5.29 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.44 (s, 3H), 1.34 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.90, 148.31, 144.05, 141.55, 140.35, 133.51, 132.55, 131.48, 131.36, 130.37, 129.05, 123.80, 116.93, 112.25, 80.26, 60.97, 16.37, 14.59.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Ethyl 1-[(4-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24w</b>)</h3><div class="NLM_p last">Compound <b>24w</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid: 81.6%. Purity (HPLC): 99.6%. Mp 174.4–176.3 °C. ESI-HRMS calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 387.1452, found: 387.1540. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.10–7.98 (m, 2H), 7.90 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.41 (d, <i>J</i> = 8.2 Hz, 2H), 5.23 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.44 (s, 3H), 1.33 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.89, 144.02, 141.55, 138.34, 133.52, 132.69, 132.53, 131.33, 131.11, 130.37, 129.06, 118.76, 118.54, 116.95, 112.49, 112.26, 80.69, 60.95, 16.37, 14.59.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Ethyl 1-[(2-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24x</b>)</h3><div class="NLM_p last">Compound <b>24x</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 73.9%. Purity (HPLC): 99.7%. Mp 186.8–188.4 °C. ESI-HRMS calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 387.1452, found: 387.1481. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.91–7.79 (m, 3H), 7.62–7.52 (m, 2H), 7.56–7.46 (m, 1H), 7.42 (td, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 5.32 (s, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 2.43 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.94, 144.29, 142.20,135.74, 133.45, 133.35, 133.21, 132.74, 132.50, 131.51, 130.77, 130.21, 128.94, 118.54, 116.98, 116.85, 113.50, 112.20, 79.22, 60.94, 16.38, 14.59.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Ethyl 1-[(3-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylate (<b>24y</b>)</h3><div class="NLM_p last">Compound <b>24y</b> was prepared in the same manner as that described for <b>24c</b> to yield a white solid, yield: 76.8%. Purity (HPLC): 99.1%. Mp 172.3–173.7 °C. ESI-HRMS calcd. for C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 387.1452, found: 387.1466. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.07–7.98 (m, 2H), 7.89 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.75 (dt, <i>J</i> = 7.1, 1.7 Hz, 1H), 7.67–7.59 (m, 2H), 7.53–7.41 (m, 2H), 5.21 (s, 2H), 4.36 (q, <i>J</i> = 7.1 Hz, 2H), 2.44 (s, 3H), 1.35 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.92, 144.08, 141.72, 135.23, 134.59, 134.28, 133.53, 133.40, 132.61, 131.35, 130.34, 130.05, 129.05, 118.55, 116.93, 112.22, 111.81, 80.40, 60.95, 16.38, 14.59.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-(3-Cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid (<b>25a</b>)</h3><div class="NLM_p last">A mixture of ethyl 2-(3-cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylate <b>22a</b> (2.9 mmol), 1 M LiOH aqueous (11 mL), THF (5 mL), and ethanol (5 mL) was stirred at 50 °C for 6 h. The solvent was concentrated in a vacuum, and the residue was acidified with dilute hydrochloric acid to pH 1. The resulting precipitate was filtered, dried, and recrystallized with a mixture of methanol and ethyl acetate (2:1)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> to yield the corresponding 2-(3-cyanophenyl)-1-methoxy-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid <b>25a</b> as a white solid, yield: 91.2%. Purity (HPLC): 95.5%. Mp 203.7–205.3 °C. ESI-HRMS calcd. for C<sub>13</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub> [M – H]<sup>−</sup> 256.0801, found: 256.0725. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.12 (s, 1H), 8.36–8.29 (m, 2H), 7.99–7.93 (m, 1H), 7.75 (t, <i>J</i> = 7.8 Hz, 1H), 3.97 (s, 3H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.19, 143.51, 140.01, 133.65, 132.12, 130.86, 130.81, 129.23, 118.75, 117.59, 112.67, 67.59, 16.21.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 1-(Allyloxy)-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid (<b>25d</b>)</h3><div class="NLM_p last">Compound <b>25d</b> was prepared in the same manner as that described for <b>25a</b> to yield a white solid, yield: 91.5%. Purity (HPLC): 97.9%. Mp 176.6–178.2 °C. ESI-HRMS calcd. for C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub> [M – H]<sup>−</sup> 282.0957, found: 282.0882. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.15 (s, 1H), 8.33 (t, <i>J</i> = 1.7 Hz, 1H), 8.30 (dt, <i>J</i> = 7.9, 1.4 Hz, 1H), 7.95 (dt, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.74 (t, <i>J</i> = 7.9 Hz, 1H), 5.83 (ddt, <i>J</i> = 16.9, 10.3, 6.5 Hz, 1H), 5.40–5.26 (m, 2H), 4.67 (d, <i>J</i> = 6.5 Hz, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.30, 143.44, 140.76, 133.55, 132.35, 131.08, 130.88, 130.69, 129.55, 122.93, 118.72, 117.96, 112.52, 80.61, 16.25.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 1-(Benzyloxy)-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid (<b>25k</b>)</h3><div class="NLM_p last">Compound <b>25k</b> was prepared in the same manneras that described for <b>25a</b> to yield a white solid, yield: 90.2%. Purity (HPLC): 95.7%. Mp 195.3–197.4 °C. ESI-HRMS calcd. for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> [M – H]<sup>−</sup> 332.1041, found: 332.1003. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.22 (s, 1H), 8.15–8.08 (m, 2H), 7.89 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.69–7.60 (m, 1H), 7.37–7.30 (m, 1H), 7.31–7.24 (m, 2H), 7.24–7.18 (m, 2H), 5.13 (s, 2H), 2.43 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.43, 143.65, 141.15, 133.27, 133.06, 132.45, 131.13, 130.61, 130.32, 129.82, 129.37, 128.84, 118.67, 117.65, 112.21, 81.72, 16.31.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 2-(3-Cyanophenyl)-4-methyl-1-((4-methyl benzyl) oxy)-1<i>H</i>-imidazole-5-carboxylic acid (<b>25s</b>)</h3><div class="NLM_p last">Compound <b>25s</b> was prepared in the same manner as that described for <b>25a</b> to yield a white solid, yield: 81.2%. Purity (HPLC): 95.1%. Mp 168.2–169.8 °C. ESI-HRMS calcd. for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub> [M – H]<sup>−</sup> 346.1264, found: 346.1191. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.10–8.01 (m, 2H), 7.88 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.63 (t, <i>J</i> = 7.9 Hz, 1H), 7.03 (d, 4H), 5.08 (s, 2H), 2.43 (s, 3H), 2.26 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.82, 160.39, 143.68, 141.45, 139.51, 133.17, 132.56, 131.14, 130.67, 130.14, 130.00, 129.32, 118.69, 117.51, 112.04, 81.62, 21.25, 16.28.</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 1-[(4-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1<i>H</i>-imidazole-5-carboxylic acid (<b>25w</b>)</h3><div class="NLM_p last">Compound <b>25w</b> was prepared in the same manner as that described for <b>25a</b> to yield a white solid, yield: 92.4%. Purity (HPLC): 99.6%. Mp 201.5–202.3 °C. ESI-HRMS calcd. for C<sub>20</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub> [M – H]<sup>−</sup> 357.1066, found: 357.0983. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.17 (s, 1H), 8.09–8.00 (m, 2H), 7.88 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.71 (d, <i>J</i> = 8.1 Hz, 2H), 7.62 (t, <i>J</i> = 7.8 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 2H), 5.23 (s, 2H), 2.42 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.35, 143.76, 141.22, 138.42, 133.34, 132.66, 132.44, 131.22, 131.10, 130.31, 129.23, 118.77, 118.57, 117.47, 112.46, 112.22, 80.56, 16.31.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> ADP-Induced Rabbit PRP Aggregation Assay</h3><div class="NLM_p">All target compounds were evaluated for their antiplatelet potency in ADP-induced rabbit platelet-rich plasma (rPRP) aggregation.<a onclick="showRef(event, 'ref11 ref22 ref23 ref44 ref56 ref75'); return false;" href="javascript:void(0);" class="ref ref11 ref22 ref23 ref44 ref56 ref75">(11,22,23,44,56,75)</a></div><div id="sec4_42_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Preparation of Platelet-Rich Plasma (PRP)</h4><div class="NLM_p last">Blood was drawn from a rabbit carotid into a new tube containing 3.8% sodium citrate. The platelet-rich plasma (PRP) was obtained by centrifugation of the blood at 800 rpm for 10 min at room temperature, and the supernatant was carefully transferred to a fresh tube. Then, the remaining blood was again centrifuged at 3000 rpm for 10 min to prepare platelet-poor plasma (PPP), which was carefully transferred into a new tube.</div></div><div id="sec4_42_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Rabbit Platelet Aggregation 96-Well Assay</h4><div class="NLM_p last">The rabbit platelet aggregation assay was performed in 96-well plates (COSTAR 3599) using a microplate reader.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In brief, PRP was added into a prewarmed 96-well microplate at 37 °C. Then, 15 μL of the test compounds at a 10× final concentration in NaCl was mixed with 135 μL of fresh PRP and incubated for 5 min. Following that incubation period, 15 μL of ADP (25 μM) was added to the reaction mix, leading to a final concentration of 2.27 μM ADP. The plates were then transferred to the microplate reader, and their absorbance was monitored every 1 min at 655 nm up to 6 min. The IC<sub>50</sub> was further calculated on the basis of the aggregation of platelets (<i>n</i> = 3).</div></div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> P2Y<sub>1</sub>-Mediated Cytosolic Ca<sup>2+</sup> Increase Assay on PRP</h3><div class="NLM_p last">The ADP-dependent, P2Y<sub>1</sub>-mediated increase in platelet cytosolic Ca<sup>2+</sup> was measured by detecting changes in FLUO-4 fluorescence using a previously described method with minor modifications.<a onclick="showRef(event, 'ref22 ref23 ref46 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref46 ref54 ref55">(22,23,46,54,55)</a> PRP was prepared as stated above, and it was added to HEPES–saline buffer (1:8 dilutions; 10 mM HEPES, 0.15 M NaCl, pH 7.4). Diluted PRP (70 μL, 8-fold) was incubated with 5 μM FLUO-4 AM (10 μL) in the presence of 0.02 U/mL apyrase (10 μL) and 10 μM indomethacin (10 μL) at 30 °C for 30 min. Then, 10 μL of the vehicle or the tested compounds at various concentrations was added into the mixture, which was incubated at 30 °C for 5 min. This mixture (110 μL) was added to 430 μL of HEPES–saline buffer, and the mixture was analyzed by a flow cytometer (BD FACSCalibur). After obtaining a 30 s baseline recording, the acquisition was paused, and then, 60 μL of ADP (5 μM final concentration) was quickly added, the mixture was mixed, and the acquisition resumed (total pause time less than 10 s). FLUO-4 fluorescence was monitored for 3 min. Fluo-4 fluorescence was plotted vs time, and the mean fluo-4 fluorescence of the baseline 30 s interval and of the 10 s poststimulant intervals were calculated. The cytosolic Ca<sup>2+</sup> increase was calculated as the raise of the maximal poststimulant fluo-4 fluorescence over the baseline fluo-4 fluorescence. The percentage inhibition was calculated relative to ADP + vehicle (0% inhibition) and vehicle alone (100% inhibition): inhibition (%) = [(cytosolic Ca<sup>2+</sup> increase <sub>(ADP)</sub> – cytosolic Ca<sup>2+</sup> increase <sub>(ADP+compound)</sub>)/(cytosolic Ca<sup>2+</sup> increase <sub>(ADP)</sub> – cytosolic Ca<sup>2+</sup> increase <sub>(Black)</sub>)] × 100.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> P2Y<sub>12</sub>-Mediated Vasodilator-Stimulated Phosphoprotein (VASP) Phosphorylation Assay</h3><div class="NLM_p last">This assay was measured by flow cytometry using a kit (BioCytex, Marseilles, France) according to the manufacturer’s recommendations. First, 2 μL of the test compound solution or model (HEPES–saline) was added to each set of assay tubes, followed by 9 μL of PGE<sub>1</sub> or 9 μL of PGE<sub>1</sub>/ADP.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Next, the citrated human whole blood was added to each tube and incubated for 10 min at room temperature.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Lastly, the samples were fixed, permeabilized, and labeled with a fluorescently conjugated monoclonal antibody (clone 16C2) directed against the serine 239 phosphorylated form of VASP, and CD61 was used as a platelet identifier.<a onclick="showRef(event, 'ref23 ref56'); return false;" href="javascript:void(0);" class="ref ref23 ref56">(23,56)</a> The analysis was performed in a flow cytometer (BD FACSCalibur). The PGE<sub>1</sub>-stimulated condition showed maximum VASP phosphorylation, and HEPES–saline buffer and ticagrelor were added as a control (no inhibition) and positive control, respectively. Furthermore, the agonist effects of the test compounds were checked using PGE<sub>1</sub> alone without ADP on samples.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> The MFI was the mean fluorescence intensity of VASP phosphorylation,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and inhibition (%) = [(MFI<sub>(PGE1)</sub> – MFI<sub>(PGE1+ADP+compound)</sub>)/(MFI<sub>(PGE1)</sub> – MFI<sub>(Negative)</sub>)] × 100.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Xanthine Oxidase Inhibitory Activity</h3><div class="NLM_p last">The XO inhibitory potency with xanthine as the substrate was assayed spectrophotometrically by measuring uric acid formation at 295 nm at 25 °C according to the procedure previously reported by us<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> with modifications. Febuxostat was used as a reference. XO (Sigma, X4875) was suspended in a buffer (0.1 M sodium pyrophosphate and 0.3 mM Na<sub>2</sub>EDTA buffer, pH 8.3). The buffer (67 mL), enzyme solution (50/L, 40 μL), and sample (53 μL) or blank solution (the buffer) were added to 96-well plates (COSTAR 3599) and incubated at 25 °C for 15 min. Then, the mixture was added with substrate xanthine (40 μL, 500 μM) to the plates to a total volume of 200 μL, which was further scanned to measure the absorbance change immediately at 295 nm and at 30 s intervals for 2 min. All the tests were performed in triplicate. Compounds presenting inhibitory effects over 50% at a concentration of 10 μM were further tested at a wide range of concentrations to calculate their IC<sub>50</sub> values using SPSS 20.0 software (SPSS Inc., Chicago, IL).</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Docking Studies</h3><div class="NLM_p last">Molecular docking studies were performed using GLIDE (2016, Schrödinger Suite).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The crystal structures of P2Y<sub>1</sub> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW">4XNW</a>)<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and P2Y<sub>12</sub> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ">4NTJ</a>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> were retrieved from the RCSB Protein Data Bank, which was further prepared using the Protein Preparation Wizard tool implemented in the Schrödinger suite by adding all hydrogen atoms as well as the missed side chains of residues and deleting all bound water. The ligands were built within Maestro BUILD (2016, Schrödinger Suite) and prepared by the LIGPREP module (2016, Schrödinger Suite).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The tautomeric forms of ligands, which include the keto and enol forms of ligands, were generated at a physiological pH (7.0 ± 2.0).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The Glide Grid was built using an inner box of dimensions 14 × 14 × 14 Å<sup>3</sup> around the centroid of the ligand, assuming that the ligands to be docked were of a size similar to that of the cocrystallized ligand. This docking methodology has been validated by extracting the crystallographic bound ligand and redocking it with the Glide module using extra precision (SP). Different docking poses of ligands were generated and analyzed for interpretation of the final results. Pymol<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> was used for graphic display.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Simulated Gastric and Intestinal Fluid Stability<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a></h3><div class="NLM_p last">Incubations of tested compounds were performed at a concentration of 10 μM in simulated gastric and intestinal fluids. Then, these reaction solutions were kept at 37 °C and sampled hourly for 12 h. An aliquot (50 μL) of the mixtures was terminated hourly by the addition of 200 μL of ice-cold acetonitrile containing an internal standard (compound <b>24c</b>). After immediate mixing, extracts were centrifuged at 12 000 rpm for 10 min at 4 °C, and the supernatants were analyzed by HPLC.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Stability Studies in Plasma<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a></h3><div class="NLM_p last">The plasma stability and metabolism of compounds <b>24w</b> and <b>25w</b> (initial concentration: 10 μM) were incubated in rabbit and rat plasma, respectively, and were placed in a water bath shaker at 37 °C. Reactions were terminated following 0, 5, 15, 30, and 45 min by ice-cold acetonitrile containing an internal standard (compound <b>24c</b>). After immediate mixing, the extracts were centrifuged at 12 000 rpm for 10 min at 4 °C, and the supernatants were analyzed by HPLC.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Stability Studies in Liver Microsomes<a onclick="showRef(event, 'ref80 ref81 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82 ref83">(80−83)</a></h3><div class="NLM_p last">The assay was performed using RLMs and HLMs, which were purchased from the Research Institute for Liver Diseases (Shanghai, China). The compounds (final concentration of 0.2 μM in 0.1% DMSO) were incubated with liver microsomes (0.50 mg/mL in 0.1 M PBS buffer (pH 7.4), 3.2 mM MgCl<sub>2</sub>, and reduced nicotinamide adenine dinucleotide phosphate (NADPH, 1 mM)) at 37 °C. The reactions were stopped by transferring 50 μL of the reaction solutions into 200 μL of ice-cooled methanol containing 0.03 μM internal standard (compound <b>24c</b>) at 0, 10, 20, 30, 60, and 90 min. Then, the mixtures were vortex-mixed for 1 min and centrifuged at 12 000 rpm for 10 min, and supernatants were analyzed by LC–MS/MS.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> CYP450 Inhibition Cocktail Assay<a onclick="showRef(event, 'ref68 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70">(68−70)</a></h3><div class="NLM_p last">The incubation mixture containing HLMs (final concentration: 0.5 mg/mL), MgCl<sub>2</sub> (final concentration: 3.2 mM), compounds <b>24w</b> or <b>25w</b> (final concentration: 10 μM), and specific CYP substrates in 0.1 M PBS buffer (pH 7.4) was preincubated for 5 min at 37 °C. Then, this reaction was initiated by the addition of NADPH solution (1 mM). The total content of organic solvent was maintained at <3%. The specific CYP substrates used in this cocktail assay included phenacetin, coumarin, tolbutamide, <i>S</i>-mephenytoin, dextromethorphan, chlorzoxazone, and testosterone (as probe substrates for enzymes of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, respectively). After a 120 min incubation at 37 °C, the reactions were quenched by the addition of cooled methanol with a mixture of internal standard (2-chloro-5-methoxyaniline hydrochloride, 0.5 μM). The mixture was vortex-mixed for 1 min and centrifuged at 12 000 rpm for 10 min, and the supernatants were used for a simultaneous analysis of the probe substrate metabolites (acetaminophen, 7-hydroxycoumarin, 4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, 6-hydroxychlorzoxazone, and 6β-hydroxytestosterone) and internal standard by LC–MS/MS.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Rat Pharmacokinetic Studies<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></h3><div class="NLM_p">Eighteen male Sprague-Dawley rats (300–320 g; Number of Approval from Ethics Committee: SYPU-IACUC-2019-9-23-201) were purchased from the Animal Center of Shenyang Pharmaceutical University (Shenyang, China). Animal maintenance and treatment met the protocols approved by the Ethics Review Committee for Animal Experimentation of Shenyang Pharmaceutical University. The rats had free access to food and water and were maintained on a 12 h light/dark cycle in a temperature- and humidity-controlled room for 1 week.<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a></div><div class="NLM_p last">A total of 18 Sprague-Dawley rats were randomly distributed into three experimental groups (<i>n</i> = 6 in each group). The oral groups were given compounds (<b>24w</b> or <b>25w</b>) suspended in 0.5% CMC-Na at an oral dose of 10 mg/kg, and the other group received a single intravenous injection of compound <b>25w</b> dissolved in a solution (saline/PBS/NaOH aqueous) at dose of 10 mg/kg. Whole blood samples (0.3 mL) were gathered into heparinized tubes <i>via</i> the suborbital vein after oral administration at 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 8, 16, and 24 h and after the intravenous administration at 0.083, 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 8, and 12 h. All blood samples were centrifuged (8000<i>g</i>, 10 min, 4 °C), and the resulting plasma samples were immediately stored at −80 °C until LC–MS analysis.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Acute Oral Toxicity Study</h3><div class="NLM_p">Healthy Kunming mice of both sexes (18–22 g; <i>n</i> = 8; Number of Approval from Ethics Committee: SYPU-IACUC-2019-5-29-202) were purchased from the Animal Center of Shenyang Pharmaceutical University (Shenyang, China). Animal maintenance and treatment met the protocols approved by the Ethics Review Committee for Animal Experimentation of Shenyang Pharmaceutical University. The mice had free access to food and water and were maintained on a 12 h light/dark cycle in a temperature- and humidity-controlled room for 1 week.<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85−87)</a></div><div class="NLM_p last">After fasting for 12 h with free access to water prior to the experiment, four groups of animals (male control group, female control group, male test group, and female test group; <i>n</i> = 8) were used for acute oral toxicity study. The control groups were treated with the 0.5% CMC-Na, and the test groups were treated with a single dose (2000 mg/kg) of the test compound <b>24w</b>, which was suspended in a 0.5% CMC-Na solution. All treatments were intragastrically administered immediately after 12 h of fasting. The mice were observed continuously for any signs and symptoms of toxicity, and body weights of these mice were monitored every day over the 14 day period after treatment.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a></div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Rat FeCl<sub>3</sub> Thrombosis Model</h3><div class="NLM_p last">The FeCl<sub>3</sub>-induced arterial thrombosis was instigated according to the previously described method with minor modifications.<a onclick="showRef(event, 'ref11 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref11 ref72 ref73">(11,72,73)</a> Male Sprague-Dawley rats (300–320 g, <i>n</i> = 10; Number of Approval from Ethics Committee: SYPU-IACUC-2019-9-23-201) were purchased from the Animal Center of Shenyang Pharmaceutical University (Shenyang, China). Animal maintenance and treatment met the protocols approved by the Ethics Review Committee for Animal Experimentation of Shenyang Pharmaceutical University. The rats had free access to food and water and were maintained on a 12 h light/dark cycle in a temperature- and humidity-controlled room for 1 week.<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85−87)</a> Solutions of compound <b>24w</b>, ticagrelor, or model suspended in 0.5% CMC-Na were administered once a day for 7 consecutive days (including the last day) as a single oral dose of 10 mg/kg. Rats were anesthetized with urethane (1.25 g/kg, i.p.) and then placed on a heating pad to maintain body temperature. Through a median incision of the ventral side in the neck, a 1.5 cm long portion of the left carotid artery of rats was exposed <i>via</i> blunt dissection and carefully dissected clear of the vagus nerve and surrounding tissue. Then, this left carotid artery was put on a piece of plastic membrane (1.0 × 1.5 cm<sup>2</sup>) to protect surrounding tissues.<a onclick="showRef(event, 'ref11 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref72">(11,72)</a> A total of 1.5 h after drug administration, a strip of filter paper (0.8 × 1.0 cm<sup>2</sup>) saturated with 20% FeCl<sub>3</sub> in water was placed on the anterior of the carotid artery to induce thrombosis formation.<a onclick="showRef(event, 'ref11 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref72">(11,72)</a> Subsequently, the plastic membrane and filter paper were removed 2 h after drug administration and the right artery was cut immediately, gently blotted dry, and weighed.<a onclick="showRef(event, 'ref11 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref72">(11,72)</a> The entire thrombosis was then scraped from artery, and the vessel wall was reweighed; the wet weight of thrombosis was obtained by subtraction.<a onclick="showRef(event, 'ref11 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref72">(11,72)</a></div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Rat Blood Loss Model</h3><div class="NLM_p last">The rat blood loss model was performed as described previously with minor modifications.<a onclick="showRef(event, 'ref11 ref44 ref48 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref48 ref72">(11,44,48,72)</a> Male Sprague-Dawley rats (300–320 g, <i>n</i> = 8; Number of Approval from Ethics Committee: SYPU-IACUC-2019-9-23-201) were purchased from the Animal Center of Shenyang Pharmaceutical University (Shenyang, China). Animal maintenance and treatment met the protocols approved by the Ethics Review Committee for Animal Experimentation of Shenyang Pharmaceutical University. The rats had free access to food and water and were maintained on a 12 h light/dark cycle in a temperature- and humidity-controlled room for 1 week. Compound <b>24w</b> and ticagrelor in 0.5% CMC-Na solution were administered by oral gavage at the 10 mg/kg dose. At 0.5 h after administration, the rats were anesthetized with urethane (1.25 kg, i.p.) and placed on a 37 °C heating pad to maintain body temperature with their tails straightened.<a onclick="showRef(event, 'ref11 ref44 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref72">(11,44,72)</a> Then, 1.5 h after administration, rat tails were transected 4 mm from the tip with a scalpel blade and immediately immersed in a 20 mL graduated cylinder filled with 12 mL of saline held at 37 °C.<a onclick="showRef(event, 'ref11 ref44 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref72">(11,44,72)</a> The observation period was stopped when no additional bloodstains were observed in a period of 30 seconds, and the bleeding time (including those of rebleeding) was recorded within 2 h.<a onclick="showRef(event, 'ref11 ref44 ref72'); return false;" href="javascript:void(0);" class="ref ref11 ref44 ref72">(11,44,72)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01524" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01524?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01524</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Worksheet of molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_001.xlsx" class="ext-link">XLSX</a>)</p></li><li><p class="inline">Figures of HPLC spectra, <sup>1</sup>H and <sup>13</sup>C NMR spectra, HRMS spectra, and MS spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_001.xlsx">jm0c01524_si_001.xlsx (12.12 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_002.pdf">jm0c01524_si_002.pdf (6.89 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01524" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83125" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83125" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanhua Mou</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, 103 Culture Road, Shenhe District, Shenyang 110016, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#acc1d9f3c4d9cdf3c6c6ecdfc5c2cd82cfc3c1"><span class="__cf_email__" data-cfemail="a5c8d0facdd0c4facfcfe5d6cccbc48bc6cac8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaojie Wang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a8dfc9c6cfdbc0c9c7c2c1cde8dbd1d8c0dd86cdccdd86cbc6"><span class="__cf_email__" data-cfemail="a8dfc9c6cfdbc0c9c7c2c1cde8dbd1d8c0dd86cdccdd86cbc6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Lei</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4427-8771" title="Orcid link">http://orcid.org/0000-0002-4427-8771</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Liu</span> - <span class="hlFld-Affiliation affiliation">Shenyang
Hinewy Pharmaceutical Technology Co., Ltd., 41 Liutang Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Zhao</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, 103 Culture Road, Shenhe District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiwen Dai</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Gao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qing Mao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yao Feng</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiaxing Zhao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengwei Lin</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulin Duan</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Shenyang Pharmaceutical
University, 103 Culture Road, Shenhe District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziyang Bao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuwei Yang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Structure-Based Drugs Design & Discovery of Ministry
of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe
District, Shenyang 110016, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.L. and B.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6395-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Wei Zhang, Yanli Diao, and Jingyi Sun for their technical support in animal experiments.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACS</td><td class="NLM_def"><p class="first last">acute coronary syndromes</p></td></tr><tr><td class="NLM_term">AMI</td><td class="NLM_def"><p class="first last">acute myocardial infarction</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine diphosphate</p></td></tr><tr><td class="NLM_term">PCI</td><td class="NLM_def"><p class="first last">percutaneous coronary intervention</p></td></tr><tr><td class="NLM_term">XO</td><td class="NLM_def"><p class="first last">xanthine oxidase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">rPRP</td><td class="NLM_def"><p class="first last">rabbit platelet-rich plasma</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">VASP</td><td class="NLM_def"><p class="first last">vasodilator-stimulated phosphoprotein</p></td></tr><tr><td class="NLM_term">PGE<sub>1</sub></td><td class="NLM_def"><p class="first last">prostaglandin E<sub>1</sub></p></td></tr><tr><td class="NLM_term">MFI</td><td class="NLM_def"><p class="first last">mean fluorescence intensity</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">protein data bank</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">HLMs</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">RLMs</td><td class="NLM_def"><p class="first last">rat liver microsomes</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic body clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">peak plasma concentration</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to reach <i>C</i><sub>max</sub></p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">elimination half-life</p></td></tr><tr><td class="NLM_term">AUC<sub>0–∞</sub></td><td class="NLM_def"><p class="first last">area under the concentration–time curve</p></td></tr><tr><td class="NLM_term">CLz</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">Vz</td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">absolute oral bioavailability</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">NaNO<sub>2</sub></td><td class="NLM_def"><p class="first last">sodium nitrite</p></td></tr><tr><td class="NLM_term">Me<sub>3</sub>SiCl</td><td class="NLM_def"><p class="first last">chlorotrimethylsilane</p></td></tr><tr><td class="NLM_term">NaI</td><td class="NLM_def"><p class="first last">sodium iodide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">K<sub>2</sub>CO<sub>3</sub></td><td class="NLM_def"><p class="first last">potassium carbonate</p></td></tr><tr><td class="NLM_term">KI</td><td class="NLM_def"><p class="first last">potassium iodide</p></td></tr><tr><td class="NLM_term">LiOH</td><td class="NLM_def"><p class="first last">lithuium hydroxide</p></td></tr><tr><td class="NLM_term">Me<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">dimethyl sulfate</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 88 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.2165/11630960-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2165%2F11630960-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=22489610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=305-318&author=R.+Teng&title=Pharmacokinetic%2C+pharmacodynamic+and+pharmacogenetic+profile+of+the+oral+antiplatelet+agent+ticagrelor&doi=10.2165%2F11630960-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor</span></div><div class="casAuthors">Teng, Renli</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">305-318</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Acute coronary syndromes (ACS) remain life-threatening disorders assocd. with high morbidity and mortality, despite advances in treatment over the last decade.  ADP-induced platelet activation via P2Y12 receptors plays a pivotal role in the pathophysiol. of ACS.  The current std. of treatment involves dual antiplatelet therapy with aspirin (acetylsalicylic acid) and the thienopyridine clopidogrel.  Numerous studies and wide use in clin. practice have established the value of this approach in the treatment of ACS.  However, clopidogrel treatment has a no. of limitations, including a delayed onset of action due to the need for metabolic activation, variable and reduced antiplatelet effects in patients with certain genotypes, and prolonged recovery of platelet function due to irreversible P2Y12 receptor binding.  Prasugrel, a new thienopyridine, has demonstrated more consistent inhibition of platelet aggregation (IPA) than clopidogrel, although this thienopyridine also requires metabolic activation and treatment is assocd. with a significantly increased risk of life-threatening and fatal bleeding.  The recently approved oral antiplatelet agent ticagrelor has the potential to overcome some of the limitations of current therapy due to its unique pharmacokinetic and pharmacodynamic profiles.  It is a member of a new chem. class, the cyclopentyltriazolopyrimidines, and is a potent P2Y12 receptor antagonist.  Ticagrelor is rapidly absorbed, with a median time to max. concn. of 1.3-2.0 h.  Ticagrelor does not require metabolic activation to an active form and binds rapidly and reversibly to the P2Y12 receptor.  As well as exerting effects via platelet P2Y12 receptors, ticagrelor may confer addnl. benefits via inhibition of non-platelet P2Y12 receptors.  The pharmacokinetic profile of ticagrelor is not significantly affected by age, gender or administration with food, nor by prior treatment with, or responsiveness to, clopidogrel.  Ticagrelor is primarily metabolized via the cytochrome P 450 (CYP) 3A4 enzyme, rapidly produces plasma concn.-dependent IPA that is greater and more consistent than that obsd. with clopidogrel, and can also enhance platelet inhibition and overcome non-responsiveness in patients previously treated with clopidogrel.  Importantly, the pharmacodynamic characteristics of ticagrelor are not influenced by CYP2C19 and ABCB1 genotypes.  This article summarizes our current knowledge regarding the pharmacokinetic, pharmacodynamic and pharmacogenetic profile of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYS2MSD8qCM7Vg90H21EOLACvtfcHk0lgwsf65l6TSDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVylur0%253D&md5=4af21d7ff762a3b62eafdd3b656b1e84</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2165%2F11630960-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11630960-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26atitle%3DPharmacokinetic%252C%2520pharmacodynamic%2520and%2520pharmacogenetic%2520profile%2520of%2520the%2520oral%2520antiplatelet%2520agent%2520ticagrelor%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D305%26epage%3D318%26doi%3D10.2165%2F11630960-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemanse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of approved and investigational P2Y<sub>12</sub> receptor antagonists</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00864-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs40262-020-00864-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=32056160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1ynu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=545-566&author=U.+Schillingauthor=J.+Dingemanseauthor=M.+Ufer&title=Pharmacokinetics+and+pharmacodynamics+of+approved+and+investigational+P2Y12+receptor+antagonists&doi=10.1007%2Fs40262-020-00864-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists</span></div><div class="casAuthors">Schilling, Uta; Dingemanse, Jasper; Ufer, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">545-566</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Coronary artery disease remains the major cause of mortality worldwide.  Antiplatelet drugs such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for the prevention of thrombotic events in patients with coronary artery disease.  Clopidogrel has long been the gold std. but has major pharmacol. limitations such as a slow onset and long duration of effect, as well as weak platelet inhibition with high inter-individual pharmacokinetic and pharmacodynamic variability.  There has been a strong need to develop potent P2Y12 receptor antagonists with more favorable pharmacol. properties.  Prasugrel and ticagrelor are more potent and have a faster onset of action; however, they have shown an increased bleeding risk compared with clopidogrel.  Cangrelor is highly potent and has a very rapid onset and offset of effect; however, its indication is limited to P2Y12 antagonist-naive patients undergoing percutaneous coronary intervention.  Two novel P2Y12 receptor antagonists are currently in clin. development, namely vicagrel and selatogrel.  Vicagrel is an analog of clopidogrel with enhanced and more efficient formation of its active metabolite.  Selatogrel is characterized by a rapid onset of action following s.c. administration and developed for early treatment of a suspected acute myocardial infarction.  This review article describes the clin. pharmacol. profile of marketed P2Y12 receptor antagonists and those under development focusing on pharmacokinetic, pharmacodynamic, and drug-drug interaction liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4yrAPCq26rVg90H21EOLACvtfcHk0lg9zhHH97bxrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1ynu7o%253D&md5=c4944e0c916d6a6fb3b418af35465273</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00864-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00864-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchilling%26aufirst%3DU.%26aulast%3DDingemanse%26aufirst%3DJ.%26aulast%3DUfer%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520approved%2520and%2520investigational%2520P2Y12%2520receptor%2520antagonists%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D545%26epage%3D566%26doi%3D10.1007%2Fs40262-020-00864-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016</span>. <i>Lancet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)32152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2FS0140-6736%2817%2932152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28919116" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1151-1210&author=M.+Naghavi&title=Global%2C+regional%2C+and+national+age-sex+specific+mortality+for+264+causes+of+death%2C+1980%E2%80%932016%3A+a+systematic+analysis+for+the+global+burden+of+disease+study+2016&doi=10.1016%2FS0140-6736%2817%2932152-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2932152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252932152-9%26sid%3Dliteratum%253Aachs%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520age-sex%2520specific%2520mortality%2520for%2520264%2520causes%2520of%2520death%252C%25201980%25E2%2580%25932016%253A%2520a%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202016%26jtitle%3DLancet.%26date%3D2017%26volume%3D390%26spage%3D1151%26epage%3D1210%26doi%3D10.1016%2FS0140-6736%2817%2932152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollopeter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jantzen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, P. B.</span></span> <span> </span><span class="NLM_article-title">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1038/35051599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.+M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.+B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+of+the+platelet+ADP+receptor+targeted+by+antithrombotic+drugs&doi=10.1038%2F35051599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0lg9zhHH97bxrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.%2BM.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.%2BB.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520of%2520the%2520platelet%2520ADP%2520receptor%2520targeted%2520by%2520antithrombotic%2520drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207%26doi%3D10.1038%2F35051599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbracchio, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeynaems, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, G. A.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fpr.58.3.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=16968944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=281-341&author=M.+P.+Abbracchioauthor=G.+Burnstockauthor=J.+M.+Boeynaemsauthor=E.+A.+Barnardauthor=J.+L.+Boyerauthor=C.+Kennedyauthor=G.+E.+Knightauthor=M.+Fumagalliauthor=C.+Gachetauthor=K.+A.+Jacobsonauthor=G.+A.+Weisman&title=International+Union+of+Pharmacology+LVIII%3A+update+on+the+P2Y+G+protein-coupled+nucleotide+receptors%3A+from+molecular+mechanisms+and+pathophysiology+to+therapy&doi=10.1124%2Fpr.58.3.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy</span></div><div class="casAuthors">Abbracchio, Maria P.; Burnstock, Geoffrey; Boeynaems, Jean-Marie; Barnard, Eric A.; Boyer, Jose L.; Kennedy, Charles; Knight, Gillian E.; Fumagalli, Marta; Gachet, Christian; Jacobson, Kenneth A.; Weisman, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-341</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  There have been many advances in our knowledge about different aspects of P2Y receptor signaling since the last review published by our International Union of Pharmacol. subcommittee.  More receptor subtypes have been cloned and characterized and most orphan receptors deorphanized, so that it is now possible to provide a basis for a future subdivision of P2Y receptor subtypes.  More is known about the functional elements of the P2Y receptor mols. and the signaling pathways involved, including interactions with ion channels.  There have been substantial developments in the design of selective agonists and antagonists to some of the P2Y receptor subtypes.  There are new findings about the mechanisms underlying nucleotide release and ectoenzymic nucleotide breakdown.  Interactions between P2Y receptors and receptors to other signaling mols. have been explored as well as P2Y-mediated control of gene transcription.  The distribution and roles of P2Y receptor subtypes in many different cell types are better understood and P2Y receptor-related compds. are being explored for therapeutic purposes.  These and other advances are discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-m5Cf-JzaLVg90H21EOLACvtfcHk0lgAOzggipi0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLbF&md5=b302ee34857a5f45d740e4f2e962ed42</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.3%26sid%3Dliteratum%253Aachs%26aulast%3DAbbracchio%26aufirst%3DM.%2BP.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DBoeynaems%26aufirst%3DJ.%2BM.%26aulast%3DBarnard%26aufirst%3DE.%2BA.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DKennedy%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DG.%2BE.%26aulast%3DFumagalli%26aufirst%3DM.%26aulast%3DGachet%26aufirst%3DC.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DWeisman%26aufirst%3DG.%2BA.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology%2520LVIII%253A%2520update%2520on%2520the%2520P2Y%2520G%2520protein-coupled%2520nucleotide%2520receptors%253A%2520from%2520molecular%2520mechanisms%2520and%2520pathophysiology%2520to%2520therapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D281%26epage%3D341%26doi%3D10.1124%2Fpr.58.3.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsam, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunapuli, S. P.</span></span> <span> </span><span class="NLM_article-title">Central role of the P2Y<sub>12</sub> receptor in platelet activation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1172/JCI20986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1172%2FJCI20986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=14755328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation&doi=10.1172%2FJCI20986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Central role of the P2Y12 receptor in platelet activation</span></div><div class="casAuthors">Dorsam, Robert T.; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Platelet activation occurs in response to vessel injury and is important for the arrest of bleeding.  Platelet activation during disease states leads to vascular occlusion and ischemic damage.  The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y12 receptor antagonists that have proven therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjFviIpPpTLVg90H21EOLACvtfcHk0lgAOzggipi0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D&md5=a0a6e94419e76fe78d2cef969ece6274</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI20986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI20986%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345%26doi%3D10.1172%2FJCI20986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span> <span> </span><span class="NLM_article-title">Antiplatelet drugs: which targets for which treatments?</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">S313</span>– <span class="NLM_lpage">S322</span>, <span class="refDoi"> DOI: 10.1111/jth.12947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fjth.12947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26149041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOitLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=S313-S322&author=C.+Gachet&title=Antiplatelet+drugs%3A+which+targets+for+which+treatments%3F&doi=10.1111%2Fjth.12947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet drugs: which targets for which treatments?</span></div><div class="casAuthors">Gachet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S313-S322</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : The current std. care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous intervention.  In very high-risk patients, glycoprotein (GP) IIb/IIIa antagonists may also be used.  Secondary prevention of ischemic events requires dual antiplatelet therapy for several months followed by lifelong low-dose aspirin.  The duration of treatment and the drugs to combine nevertheless remain matters of debate and the focus of ongoing research.  Despite great progress, there is still room for improved efficacy and this could involve new targets for both antiplatelet drugs (like the thrombin receptor PAR1) and anticoagulants.  However, improved efficacy is offset by an increased risk of bleeding.  Stroke patients are still waiting for better treatment, their bleeding risk being particularly high.  New targets including the collagen receptor, glycoprotein VI (GPVI), and the GPIb-von Willebrand factor axis, governing platelet interaction with the diseased vessel wall, should enable us to complete the armamentarium of antiplatelet drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFJF4DC8OarVg90H21EOLACvtfcHk0lgAOzggipi0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOitLnP&md5=8bdce97c2472085d403bdd1263bc3141</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fjth.12947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12947%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DAntiplatelet%2520drugs%253A%2520which%2520targets%2520for%2520which%2520treatments%253F%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2015%26volume%3D13%26spage%3DS313%26epage%3DS322%26doi%3D10.1111%2Fjth.12947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel and ticlopidine: P2Y<sub>12</sub> adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1055/s-2005-869523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1055%2Fs-2005-869523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=15852221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=174-183&author=P.+Saviauthor=J.+M.+Herbert&title=Clopidogrel+and+ticlopidine%3A+P2Y12+adenosine+diphosphate-receptor+antagonists+for+the+prevention+of+atherothrombosis&doi=10.1055%2Fs-2005-869523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span></div><div class="casAuthors">Savi, Pierre; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Ticlopidine and clopidogrel belong to the same chem. family of thienopyridine ADP (ADP)-receptor antagonists.  They have shown their efficacy as platelet antiaggregant and antithrombotic agents in many animal models, both ex vivo and in vivo.  Although ticlopidine was discovered more than 30 years ago, it was only recently that the mechanism of action of ADP-receptor antagonists was characterized in detail.  Ticlopidine and clopidogrel both behave in vivo as specific antagonists of P2Y12, one of the ADP receptors on platelets.  Metabolic steps that involve cytochrome P 450-dependent pathways are required to generate the active metabolite responsible for this in vivo activity.  The active moiety is a reactive thiol deriv. that targets P2Y12 on platelets.  The interaction is irreversible, accounting for the observation that platelets are definitely antiaggregated, even if no active metabolite is detectable in plasma.  The interaction is specific for P2Y12; other purinoceptors such as P2Y1 and P2Y13 are spared.  This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase.  Platelet aggregation is affected not only when triggered by ADP but also by aggregation inducers when used at concns. requiring released ADP as an amplifier.  The efficacy and safety of clopidogrel has been established in several large, randomized, controlled trials.  The clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE) trial demonstrated the superiority of clopidogrel over acetylsalicylic acid (ASA) in patients at risk of ischemic events, including ischemic stroke, myocardial infarction (MI), and peripheral arterial disease.  The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial showed a sustained, incremental benefit when clopidogrel was added to std. therapy (including ASA) in patients with unstable angina and non-Q-wave MI.  The clopidogrel for the redn. of events during observation (CREDO) trial demonstrated the benefit of continuing clopidogrel (plus ASA) for 12 mo, as opposed to 1 mo, after percutaneous coronary intervention.  The proven efficacy of clopidogrel, coupled with its favorable safety and tolerability profile, has prompted its evaluation in an extensive, ongoing clin. trial program that will help to further characterize the benefit of clopidogrel in patients with a range of atherothrombotic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0RPp6l6_G_LVg90H21EOLACvtfcHk0lgAOzggipi0NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D&md5=e33ff9017bb1a345b8fb7f769af03a5b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869523%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26atitle%3DClopidogrel%2520and%2520ticlopidine%253A%2520P2Y12%2520adenosine%2520diphosphate-receptor%2520antagonists%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2005%26volume%3D31%26spage%3D174%26epage%3D183%26doi%3D10.1055%2Fs-2005-869523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palczewski, K.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanism of P2Y<sub>1</sub> receptor activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10331</span>– <span class="NLM_lpage">10335</span>, <span class="refDoi"> DOI: 10.1002/anie.201605147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fanie.201605147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10331-10335&author=S.+Yuanauthor=H.+C.+Chanauthor=H.+Vogelauthor=S.+Filipekauthor=R.+C.+Stevensauthor=K.+Palczewski&title=The+molecular+mechanism+of+P2Y1+receptor+activation&doi=10.1002%2Fanie.201605147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Mechanism of P2Y1 Receptor Activation</span></div><div class="casAuthors">Yuan, Shuguang; Chan, H. C. Stephen; Vogel, Horst; Filipek, Slawomir; Stevens, Raymond C.; Palczewski, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10331-10335</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human purinergic G protein-coupled receptor P2Y1 (P2Y1R) is activated by ADP (ADP) to induce platelet activation and thereby serves as an important antithrombotic drug target.  Crystal structures of P2Y1R revealed that one ligand (MRS2500) binds to the extracellular vestibule of this GPCR, whereas another (BPTU) occupies the surface between transmembrane (TM) helixes TM2 and TM3.  We introduced a total of 20 μs all-atom long-timescale mol. dynamic (MD) simulations to inquire why two mols. in completely different locations both serve as antagonists while ADP activates the receptor.  Our results indicate that BPTU acts as an antagonist by stabilizing extracellular helix bundles leading to an increase of the lipid order, whereas MRS2500 blocks signaling by occupying the ligand binding site.  Both antagonists stabilize an ionic lock within the receptor.  However, binding of ADP breaks this ionic lock, forming a continuous water channel that leads to P2Y1R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttSpukVGbybVg90H21EOLACvtfcHk0ljK01tJhPeg4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjurjE&md5=bee2945509055a868dc8e686a9199cea</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605147%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DVogel%26aufirst%3DH.%26aulast%3DFilipek%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DPalczewski%26aufirst%3DK.%26atitle%3DThe%2520molecular%2520mechanism%2520of%2520P2Y1%2520receptor%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10331%26epage%3D10335%26doi%3D10.1002%2Fanie.201605147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. D.</span></span> <span> </span><span class="NLM_article-title">The P2Y<sub>1</sub> purinergic receptor expressed by enteric neurones in guinea-pig intestine</span>. <i>Neurogastroenterol. Motil.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2982.2005.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fj.1365-2982.2005.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=16553587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BD287msF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=316-323&author=N.+Gaoauthor=H.+Z.+Huauthor=M.+X.+Zhuauthor=X.+Fangauthor=S.+Liuauthor=C.+Gaoauthor=J.+D.+Wood&title=The+P2Y1+purinergic+receptor+expressed+by+enteric+neurones+in+guinea-pig+intestine&doi=10.1111%2Fj.1365-2982.2005.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The P2Y purinergic receptor expressed by enteric neurones in guinea-pig intestine</span></div><div class="casAuthors">Gao N; Hu H-Z; Zhu M X; Fang X; Liu S; Gao C; Wood J D</div><div class="citationInfo"><span class="NLM_cas:title">Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-23</span>
        ISSN:<span class="NLM_cas:issn">1350-1925</span>.
    </div><div class="casAbstract">Electrophysiological recording methods provided evidence for presynaptic release of ATP from enteric neurones and postganglionic sympathetic fibres in the enteric nervous system (ENS) of guinea-pig intestine (J Physiol Lond 2003; 550: 493-504).  The released ATP acted at postsynaptic P2Y(1) receptors to evoke slow synaptic excitation in neurones in the submucosal division of the ENS.  Here, we report the cloning and characterization of the P2Y(1) receptor, which was found in the guinea-pig submucosal layer.  A 1178 bp cDNA clone was isolated from guinea-pig submucosal RNA by reverse transcription polymerase chain reaction (RT-PCR).  The cDNA contained an open-reading frame of 1119 bp, encoding a 373 amino acid polypeptide of the same length and with 95% identity to the human P2Y(1) receptor.  Stable expression of the guinea-pig cDNA in human embryonic kidney (HEK)293 cells was accompanied by a marked increase in sensitivity for elevation of free intracellular calcium evoked by ATP or related nucleotides.  The potency order for ATP and its analogues was: 2-methio-adenosine diphosphate > 2-methio-adenosine triphosphate > ADP > ATP-gamma-S > ATP.  The selective P2Y(1) receptor antagonist, MRS2179, was a competitive antagonist for the receptor with a pA(2) value of 6.5.  The results add to existing evidence for expression of a functional P2Y(1) purinergic receptor in neurones of the submucosal division of the ENS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlB49fIEjg1AMthz5_Rx5rfW6udTcc2eY2Cdmn8IaHorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287msF2jtw%253D%253D&md5=2f7f5d3ff69fa8fa55c1206e840b03f4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2982.2005.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2982.2005.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DH.%2BZ.%26aulast%3DZhu%26aufirst%3DM.%2BX.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520P2Y1%2520purinergic%2520receptor%2520expressed%2520by%2520enteric%2520neurones%2520in%2520guinea-pig%2520intestine%26jtitle%3DNeurogastroenterol.%2520Motil.%26date%3D2006%26volume%3D18%26spage%3D316%26epage%3D323%26doi%3D10.1111%2Fj.1365-2982.2005.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of P2Y<sub>12</sub> antagonist ethyl 6-(4-((benzylsulfonyl) carbamoyl) piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) led to the discovery of an oral antiplatelet agent with improved druglike properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3088</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01971</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01971" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3088-3106&author=D.+Kongauthor=T.+Xueauthor=B.+Guoauthor=J.+Chengauthor=S.+Liuauthor=J.+Weiauthor=Z.+Luauthor=H.+Liuauthor=G.+Gongauthor=T.+Lanauthor=W.+Huauthor=Y.+Yang&title=Optimization+of+P2Y12+antagonist+ethyl+6-%284-%28%28benzylsulfonyl%29+carbamoyl%29+piperidin-1-yl%29-5-cyano-2-methylnicotinate+%28AZD1283%29+led+to+the+discovery+of+an+oral+antiplatelet+agent+with+improved+druglike+properties&doi=10.1021%2Facs.jmedchem.8b01971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties</span></div><div class="casAuthors">Kong, Deyu; Xue, Tao; Guo, Bin; Cheng, Jianjun; Liu, Shunyin; Wei, Jianhai; Lu, Zhengyu; Liu, Haoran; Gong, Guoqing; Lan, Tian; Hu, Wenhao; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3088-3106</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis.  Based on the scaffold of a known P2Y12 antagonist AZD1283 (I), a series of novel bicyclic pyridine derivs. were designed and synthesized.  The cyclization of the ester substituent on the pyridine ring to the ortho-Me group led to lactone analogs of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies.  The metabolic stability was further enhanced by adding a 4-Me substituent to the piperidinyl moiety.  Compd. II displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model.  Moreover, II showed a safety profile that was superior to what was obsd. for clopidogrel in a rat tail-bleeding model.  These results support the further evaluation of compd. II as a promising drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aElj92vWULVg90H21EOLACvtfcHk0ljg9VGP6h7D6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D&md5=40577f34468ef13d6eea4a7a76dcaab8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520P2Y12%2520antagonist%2520ethyl%25206-%25284-%2528%2528benzylsulfonyl%2529%2520carbamoyl%2529%2520piperidin-1-yl%2529-5-cyano-2-methylnicotinate%2520%2528AZD1283%2529%2520led%2520to%2520the%2520discovery%2520of%2520an%2520oral%2520antiplatelet%2520agent%2520with%2520improved%2520druglike%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3088%26epage%3D3106%26doi%3D10.1021%2Facs.jmedchem.8b01971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span> <span> </span><span class="NLM_article-title">New P2Y<sub>12</sub> inhibitors</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.109.853069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FCIRCULATIONAHA.109.853069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=20048234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FgsFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=171-179&author=M.+Cattaneo&title=New+P2Y12+inhibitors&doi=10.1161%2FCIRCULATIONAHA.109.853069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New P2Y(12) inhibitors</span></div><div class="casAuthors">Cattaneo Marco</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0GBsuDbTwFA8IxFYvehhofW6udTcc2eY1Kgv9Xaaxa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FgsFeqtA%253D%253D&md5=99123172771709d92cd16565407578e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.109.853069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.109.853069%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DNew%2520P2Y12%2520inhibitors%26jtitle%3DCirculation%26date%3D2010%26volume%3D121%26spage%3D171%26epage%3D179%26doi%3D10.1161%2FCIRCULATIONAHA.109.853069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span> <span> </span><span class="NLM_article-title">Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1080/00498250802650077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F00498250802650077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19280520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1ansrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=218-226&author=K.+Hagiharaauthor=M.+Kazuiauthor=H.+Ikenagaauthor=T.+Nanbaauthor=K.+Fusegawaauthor=M.+Takahashiauthor=A.+Kuriharaauthor=O.+Okazakiauthor=N.+A.+Faridauthor=T.+Ikeda&title=Comparison+of+formation+of+thiolactones+and+active+metabolites+of+prasugrel+and+clopidogrel+in+rats+and+dogs&doi=10.1080%2F00498250802650077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs</span></div><div class="casAuthors">Hagihara, K.; Kazui, M.; Ikenaga, H.; Nanba, T.; Fusegawa, K.; Takahashi, M.; Kurihara, A.; Okazaki, O.; Farid, N. A.; Ikeda, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">218-226</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Prasugrel and clopidogrel are antiplatelet prodrugs that are converted to their resp. active metabolites through thiolactone intermediates.  Prasugrel is rapidly hydrolyzed by esterases to its thiolactone intermediate, while clopidogrel is oxidized by cytochrome P 450 (CYP) isoforms to its thiolactone.  The conversion of both thiolactones to the active metabolites is CYP mediated.  This study compared the efficiency, in vivo, of the formation of prasugrel and clopidogrel thiolactones and their active metabolites.  The areas under the plasma concn. vs. time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg-1) and clopidogrel (0.77 mg kg-1) were 15.8 ± 15.9 ng h ml-1 and 0.113 ± 0.226 ng h ml-1, resp., in rats, and 454 ± 104 ng h ml-1 and 23.3 ± 4.3 ng h ml-1, resp., in dogs, indicating efficient hydrolysis of prasugrel and little metab. of clopidogrel to their thiolactones in the intestine.  The relative bioavailability of the active metabolites of prasugrel and clopidogrel calcd. by the ratio of active metabolite AUC (produg oral administration/active metabolite i.v. administration) were 25% and 7%, resp., in rats, and 25% and 10%, resp., in dogs.  Single intraduodenal administration of prasugrel showed complete conversion of prasugrel, resulting in high concns. of the thiolactone and active metabolite of prasugrel in rat portal vein plasma, which demonstrates that these products are generated in the intestine during the absorption process.  In conclusion, the extent of in vivo formation of the thiolactone and the active metabolite of prasugrel was greater than for clopidogrel's thiolactone and active metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLQN2zKY2K7Vg90H21EOLACvtfcHk0ljg9VGP6h7D6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1ansrs%253D&md5=4d0a538528cfbcfc5ff2efe04b219357</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F00498250802650077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250802650077%26sid%3Dliteratum%253Aachs%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DIkenaga%26aufirst%3DH.%26aulast%3DNanba%26aufirst%3DT.%26aulast%3DFusegawa%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520formation%2520of%2520thiolactones%2520and%2520active%2520metabolites%2520of%2520prasugrel%2520and%2520clopidogrel%2520in%2520rats%2520and%2520dogs%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D218%26epage%3D226%26doi%3D10.1080%2F00498250802650077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span> <span> </span><span class="NLM_article-title">Do we need a new P2Y<sub>12</sub> receptor antagonist?</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3141</span>– <span class="NLM_lpage">3143</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehz862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehz862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31845967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BB3MbgvF2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3141-3143&author=J.+S.+Hulotauthor=G.+Montalescot&title=Do+we+need+a+new+P2Y12+receptor+antagonist%3F&doi=10.1093%2Feurheartj%2Fehz862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Do we need a new P2Y12 receptor antagonist?</span></div><div class="casAuthors">Hulot Jean-Sebastien; Hulot Jean-Sebastien; Montalescot Gilles</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3141-3143</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwh9NXgmMTbTEC-75aqa5AfW6udTcc2eZQmwckx88_brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbgvF2ltA%253D%253D&md5=435a884caf2b66a512a1185af6b02e05</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehz862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehz862%26sid%3Dliteratum%253Aachs%26aulast%3DHulot%26aufirst%3DJ.%2BS.%26aulast%3DMontalescot%26aufirst%3DG.%26atitle%3DDo%2520we%2520need%2520a%2520new%2520P2Y12%2520receptor%2520antagonist%253F%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2020%26volume%3D41%26spage%3D3141%26epage%3D3143%26doi%3D10.1093%2Feurheartj%2Fehz862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugidachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, A.</span></span> <span> </span><span class="NLM_article-title">A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1111/bph.12108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fbph.12108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23347039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFalu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=82-89&author=A.+Sugidachiauthor=K.+Ohnoauthor=T.+Ogawaauthor=J.+Jakubowskiauthor=M.+Hashimotoauthor=A.+Tomizawa&title=A+comparison+of+the+pharmacological+profiles+of+prasugrel+and+ticagrelor+assessed+by+platelet+aggregation%2C+thrombus+formation+and+haemostasis+in+rats&doi=10.1111%2Fbph.12108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats</span></div><div class="casAuthors">Sugidachi, A.; Ohno, K.; Ogawa, T.; Jakubowski, J. A.; Hashimoto, M.; Tomizawa, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-89</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Prasugrel is a third-generation thienopyridine prodrug and ticagrelor is a non-competitive P2Y12 receptor antagonist.  In their phase 3 studies, both agents reduced rates of ischemic events relative to treatment with clopidogrel.  Exptl. Approach: The pharmacodynamic profile of anti-platelet effects of prasugrel was compared with that of ticagrelor in rats.  Key Results: The active metabolite of prasugrel was less potent than ticagrelor and its active metabolite on platelet aggregation in vitro.  In contrast, prasugrel was a more potent antiplatelet agent than ticagrelor on ex vivo platelet aggregation: their ED50 values at peak for ADP 20 μmol·L-1 were 1.9 and 8.0 mg·kg-1, resp.  Prasugrel's inhibition of platelet aggregation was maintained for up to 24 h after administration, but ticagrelor's duration of action was substantially shorter.  Prasugrel and ticagrelor significantly inhibited thrombus formation with ED50 values of 1.8 and 7.7 mg·kg-1, resp.  Both agents also prolonged bleeding times (ED200 values of 3.0 and 13 mg·kg-1 resp.) suggesting that at equiv. levels of inhibition of platelet aggregation, the agents would show comparable antithrombotic activity with similar bleeding risk.  Platelet transfusion significantly increased blood platelet nos. similarly in prasugrel- and ticagrelor-treated rats.  In the prasugrel-treated group, platelet transfusion caused significant shortening of bleeding time, while in the ticagrelor-treated group, platelet transfusion showed no influence on bleeding time under the exptl. conditions employed.  Conclusions and Implications: Prasugrel and ticagrelor showed several differences in their pharmacol. profiles and these disparities may reflect their differing reversibility and/or pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz2iCKDkyB3rVg90H21EOLACvtfcHk0lj7BMBSjTairA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFalu7k%253D&md5=f6f5c96c8789109fe06f5c47d6f4147c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fbph.12108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12108%26sid%3Dliteratum%253Aachs%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DJakubowski%26aufirst%3DJ.%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DTomizawa%26aufirst%3DA.%26atitle%3DA%2520comparison%2520of%2520the%2520pharmacological%2520profiles%2520of%2520prasugrel%2520and%2520ticagrelor%2520assessed%2520by%2520platelet%2520aggregation%252C%2520thrombus%2520formation%2520and%2520haemostasis%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D82%26epage%3D89%26doi%3D10.1111%2Fbph.12108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic P2Y<sub>12</sub> receptor antagonists: recent developments in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.drudis.2018.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30291899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=325-333&author=Y.+Baqiauthor=C.+E.+Muller&title=Antithrombotic+P2Y12+receptor+antagonists%3A+recent+developments+in+drug+discovery&doi=10.1016%2Fj.drudis.2018.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery</span></div><div class="casAuthors">Baqi, Younis; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">325-333</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family.  The P2Y12 receptor is highly expressed on blood platelets and in the brain.  Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clin. as antithrombotic drugs.  Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivs.  Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTJdgZbKZDrVg90H21EOLACvtfcHk0lj7BMBSjTairA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGltrbI&md5=a6e3009e8275f5039d30830a493db529</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3DAntithrombotic%2520P2Y12%2520receptor%2520antagonists%253A%2520recent%2520developments%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D325%26epage%3D333%26doi%3D10.1016%2Fj.drudis.2018.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podda, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zighetti, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span> <span> </span><span class="NLM_article-title">Effects of 5′-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2763</span>– <span class="NLM_lpage">2766</span>, <span class="refDoi"> DOI: 10.1021/jm0493562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2763-2766&author=G.+Cristalliauthor=G.+M.+Poddaauthor=S.+Costanziauthor=C.+Lambertucciauthor=A.+Lecchiauthor=S.+Vittoriauthor=R.+Volpiniauthor=M.+L.+Zighettiauthor=M.+Cattaneo&title=Effects+of+5%E2%80%B2-phosphate+derivatives+of+2-hexynyl+adenosine+and+2-phenylethynyl+adenosine+on+responses+of+human+platelets+mediated+by+P2Y+receptors&doi=10.1021%2Fjm0493562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of 5'-Phosphate Derivatives of 2-Hexynyl Adenosine and 2-Phenylethynyl Adenosine on Responses of Human Platelets Mediated by P2Y Receptors</span></div><div class="casAuthors">Cristalli, Gloria; Podda, Gian Marco; Costanzi, Stefano; Lambertucci, Catia; Lecchi, Anna; Vittori, Sauro; Volpini, Rosaria; Zighetti, Maddalena L.; Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2763-2766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Newly synthesized mono-, di-, and triphosphate of 2-alkynyl adenosines showed very different behavior in human platelet P2Y receptor models, according to the different alkynyl chains.  In fact, 2-hexynyladenosine di- (5) and triphosphate (7) induced platelet shape change and aggregation and inhibited PGE1-induced increase in platelet cAMP.  On the contrary, the corresponding 2-phenylethynyladenosine di- (6) and triphosphate (8) did not induce platelet shape change or aggregation, but inhibited platelet aggregation induced by ADP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPU81zM8NTLbVg90H21EOLACvtfcHk0lik91V-f-msIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlSitrk%253D&md5=0948d48df9f4cf59984b94424a8ec5ff</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0493562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493562%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DPodda%26aufirst%3DG.%2BM.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DLambertucci%26aufirst%3DC.%26aulast%3DLecchi%26aufirst%3DA.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DVolpini%26aufirst%3DR.%26aulast%3DZighetti%26aufirst%3DM.%2BL.%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DEffects%2520of%25205%25E2%2580%25B2-phosphate%2520derivatives%2520of%25202-hexynyl%2520adenosine%2520and%25202-phenylethynyl%2520adenosine%2520on%2520responses%2520of%2520human%2520platelets%2520mediated%2520by%2520P2Y%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2763%26epage%3D2766%26doi%3D10.1021%2Fjm0493562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruel, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibeault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Heureux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spronk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiebert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouthillier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnur, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1′-neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y<sub>1</sub> antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9275</span>– <span class="NLM_lpage">9295</span>, <span class="refDoi"> DOI: 10.1021/jm4013906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4013906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9275-9295&author=J.+X.+Qiaoauthor=T.+C.+Wangauthor=W.+R.+Ruelauthor=C.+Thibeaultauthor=A.+L%E2%80%99Heureuxauthor=W.+A.+Schumacherauthor=S.+A.+Spronkauthor=S.+Hiebertauthor=G.+Bouthillierauthor=J.+Lloydauthor=Z.+Piauthor=D.+M.+Schnurauthor=L.+M.+Abellauthor=J.+Huaauthor=L.+A.+Priceauthor=E.+Liuauthor=Q.+Wuauthor=T.+E.+Steinbacherauthor=J.+S.+Bostwickauthor=M.+Changauthor=J.+Zhengauthor=Q.+Gaoauthor=B.+Maauthor=P.+A.+McDonnellauthor=C.+S.+Huangauthor=R.+Rehfussauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Conformationally+constrained+ortho-anilino+diaryl+ureas%3A+discovery+of+1-%282-%281%E2%80%B2-neopentylspiro%5Bindoline-3%2C4%E2%80%B2-piperidine%5D-1-yl%29phenyl%29-3-%284-%28trifluoromethoxy%29phenyl%29urea%2C+a+potent%2C+selective%2C+and+bioavailable+P2Y1+antagonist&doi=10.1021%2Fjm4013906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1 (2-(1'-Neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist</span></div><div class="casAuthors">Qiao, Jennifer X.; Wang, Tammy C.; Ruel, Rejean; Thibeault, Carl; Lheureux, Alexandre; Schumacher, William A.; Spronk, Steven A.; Hiebert, Sheldon; Bouthillier, Gilles; Lloyd, John; Pi, Zulan; Schnur, Dora M.; Abell, Lynn M.; Hua, Ji; Price, Laura A.; Liu, Eddie; Wu, Qimin; Steinbacher, Thomas E.; Bostwick, Jeffrey S.; Chang, Ming; Zheng, Joanna; Gao, Qi; Ma, Baoqing; McDonnell, Patricia A.; Huang, Christine S.; Rehfuss, Robert; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9275-9295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities.  In this article, we describe the structural modification of the tert-Bu phenoxy portion of lead compd. 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas.  In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-mol. P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats.  Homol. modeling and rat PK/PD studies on benchmark compd. 3l will also be presented.  Compd. 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBqH7TKoyjrVg90H21EOLACvtfcHk0lik91V-f-msIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7%252FL&md5=6037e3a59bde92e280e9a8d5b5d8300e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm4013906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4013906%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DRuel%26aufirst%3DW.%2BR.%26aulast%3DThibeault%26aufirst%3DC.%26aulast%3DL%25E2%2580%2599Heureux%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DSpronk%26aufirst%3DS.%2BA.%26aulast%3DHiebert%26aufirst%3DS.%26aulast%3DBouthillier%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DPi%26aufirst%3DZ.%26aulast%3DSchnur%26aufirst%3DD.%2BM.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DSteinbacher%26aufirst%3DT.%2BE.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMcDonnell%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DConformationally%2520constrained%2520ortho-anilino%2520diaryl%2520ureas%253A%2520discovery%2520of%25201-%25282-%25281%25E2%2580%25B2-neopentylspiro%255Bindoline-3%252C4%25E2%2580%25B2-piperidine%255D-1-yl%2529phenyl%2529-3-%25284-%2528trifluoromethoxy%2529phenyl%2529urea%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520bioavailable%2520P2Y1%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9275%26epage%3D9295%26doi%3D10.1021%2Fjm4013906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-aryl-7-hydroxyindoline based P2Y<sub>1</sub> antagonists as novel antiplatelet agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6150</span>– <span class="NLM_lpage">6164</span>, <span class="refDoi"> DOI: 10.1021/jm5006226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslent7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6150-6164&author=W.+Yangauthor=Y.+Wangauthor=A.+Laiauthor=J.+X.+Qiaoauthor=T.+C.+Wangauthor=J.+Huaauthor=L.+A.+Priceauthor=H.+Shenauthor=X.+Chenauthor=P.+Wongauthor=E.+Crainauthor=C.+Watsonauthor=C.+S.+Huangauthor=D.+A.+Seiffertauthor=R.+Rehfussauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+4-aryl-7-hydroxyindoline+based+P2Y1+antagonists+as+novel+antiplatelet+agents&doi=10.1021%2Fjm5006226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y1 Antagonists as Novel Antiplatelet Agents</span></div><div class="casAuthors">Yang, Wu; Wang, Yufeng; Lai, Amy; Qiao, Jennifer X.; Wang, Tammy C.; Hua, Ji; Price, Laura A.; Shen, Hong; Chen, Xue-qing; Wong, Pancras; Crain, Earl; Watson, Carol; Huang, Christine S.; Seiffert, Dietmar A.; Rehfuss, Robert; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6150-6164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ADP (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y12 and P2Y1.  Blocking P2Y12 receptor is a clin. well-validated strategy for antithrombotic therapy.  P2Y1 antagonists have been shown to have the potential to provide equiv. antithrombotic efficacy as P2Y12 inhibitors with reduced bleeding in preclin. animal models.  Th have previously reported the discovery of a potent and orally bioavailable P2Y1 antagonist, I.  This paper describes further optimization of I by introducing 4-aryl groups at the hydroxylindoline in two series.  In the neutral series, II was identified with excellent potency and desirable pharmacokinetic (PK) profile.  It also demonstrated similar antithrombotic efficacy with less bleeding compared with the known P2Y12 antagonist prasugrel in rabbit efficacy/bleeding models.  In the basic series, III (BMS-884775) was discovered with an improved PK and liability profile over I.  These results support P2Y1 antagonism as a promising new antiplatelet target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTxYWbBi9B6bVg90H21EOLACvtfcHk0liNgMVfZnfeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslent7k%253D&md5=bc2143cbd324258322e140d77cc0e564</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm5006226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006226%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DCrain%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25204-aryl-7-hydroxyindoline%2520based%2520P2Y1%2520antagonists%2520as%2520novel%2520antiplatelet%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6150%26epage%3D6164%26doi%3D10.1021%2Fjm5006226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span> <span> </span><span class="NLM_article-title">A platelet target for venous thrombosis? P2Y<sub>1</sub> deletion or antagonism protects mice from vena cava thrombosis</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1007/s11239-012-0745-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs11239-012-0745-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=22588534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=199-207&author=J.+E.+Birdauthor=X.+Wangauthor=P.+L.+Smithauthor=F.+Barberaauthor=C.+Huangauthor=W.+A.+Schumacher&title=A+platelet+target+for+venous+thrombosis%3F+P2Y1+deletion+or+antagonism+protects+mice+from+vena+cava+thrombosis&doi=10.1007%2Fs11239-012-0745-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis</span></div><div class="casAuthors">Bird, J. Eileen; Wang, Xinkang; Smith, Patricia L.; Barbera, Frank; Huang, Christine; Schumacher, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-207</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A role for platelets in the pathogenesis of venous thrombosis was suggested by clin. and preclin. studies.  However, examn. of the platelet receptor, P2Y1, in this area has been limited.  The goal of the current study was to examine effects of P2Y1 deletion, or selective antagonism with MRS2500, in oxidative venous thrombosis in mice.  The P2Y12 antagonist, clopidogrel, was included as a ref. agent.  Anesthetized C57BL/6 or genetically modified mice underwent 3.5 or 5 % FeCl3-induced vena cava thrombosis.  Pharmacokinetic properties of MRS2500 were defined for dose selection.  Platelet aggregation and renal or tail bleeding times (BT) were measured to put antithrombotic effects into perspective.  P2Y1 deletion significantly reduced (p < 0.001) venous thrombus wt. by 74 % in 3.5 % FeCl3 injury compared to P2Y1+/+ littermates.  MRS2500 (2 mg/kg, i.v.) significantly decreased (p < 0.001) thrombus wt. 64 % in C57BL/6 mice.  In the more severe 5 % FeCl3-induced injury model, thrombus wt. significantly (p < 0.001) decreased 68 % in P2Y1-/- mice vs. P2Y1+/+ mice, and MRS2500 (2 mg/kg) was also beneficial (54 % decrease, p < 0.01).  Renal BT doubled in P2Y1-/- vs. P2Y1+/+ mice, and increased threefold with MRS2500 compared to vehicle.  Tail BT was markedly prolonged in P2Y1-/- mice (7.9X) and in C57BL/6 mice given MRS2500.  The current study demonstrates that P2Y1 deletion or antagonism significantly reduced venous thrombosis in mice, suggesting that P2Y1 receptors play a role in the pathogenesis of venous thrombosis, at least in this species.  However as with many antithrombotic agents the benefit comes at the potential price of an increase in provoked bleeding times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzzjvsbFdOPbVg90H21EOLACvtfcHk0liNgMVfZnfeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhsbnO&md5=7bba9afd96fdd0022ff3c52f7fdcf629</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11239-012-0745-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-012-0745-3%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DP.%2BL.%26aulast%3DBarbera%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26atitle%3DA%2520platelet%2520target%2520for%2520venous%2520thrombosis%253F%2520P2Y1%2520deletion%2520or%2520antagonism%2520protects%2520mice%2520from%2520vena%2520cava%2520thrombosis%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2012%26volume%3D34%26spage%3D199%26epage%3D207%26doi%3D10.1007%2Fs11239-012-0745-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turdi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpin, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnur, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogletree, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y<sub>1</sub> antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/jm301708u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301708u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVeqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1704-1714&author=H.+Chaoauthor=H.+Turdiauthor=T.+F.+Herpinauthor=J.+Y.+Robergeauthor=Y.+Liuauthor=D.+M.+Schnurauthor=M.+A.+Possauthor=R.+Rehfussauthor=J.+Huaauthor=Q.+Wuauthor=L.+A.+Priceauthor=L.+M.+Abellauthor=W.+A.+Schumacherauthor=J.+S.+Bostwickauthor=T.+E.+Steinbacherauthor=A.+B.+Stewartauthor=M.+L.+Ogletreeauthor=C.+S.+Huangauthor=M.+Changauthor=A.+M.+Cacaceauthor=M.+J.+Arcuriauthor=D.+Celaniauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=Discovery+of+2-%28phenoxypyridine%29-3-phenylureas+as+small+molecule+P2Y1+antagonists&doi=10.1021%2Fjm301708u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists</span></div><div class="casAuthors">Chao, Hannguang; Turdi, Huji; Herpin, Timothy F.; Roberge, Jacques Y.; Liu, Yalei; Schnur, Dora M.; Poss, Michael A.; Rehfuss, Robert; Hua, Ji; Wu, Qimin; Price, Laura A.; Abell, Lynn M.; Schumacher, William A.; Bostwick, Jeffrey S.; Steinbacher, Thomas E.; Stewart, Anne B.; Ogletree, Martin L.; Huang, Christine S.; Chang, Ming; Cacace, Angela M.; Arcuri, Maredith J.; Celani, Deborah; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1704-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP-driven platelet activation.  The clin. effectiveness of P2Y12 blockade is well established.  Recent preclin. data suggest that P2Y1 and P2Y12 inhibition provide equiv. antithrombotic efficacy, while targeting P2Y1 has the potential for reduced bleeding liability.  In this account, the discovery of a 2-(phenoxypyridine)-3-phenylurea chemotype that inhibited ADP-mediated platelet aggregation in human blood samples is described.  Optimization of this series led to the identification of compd. 16, 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-4-(trifluoromethoxy)phenylurea, which demonstrated a 68 ± 7% thrombus wt. redn. in an established rat arterial thrombosis model (10 mg/kg plus 10 mg/kg/h) while only prolonging cuticle and mesenteric bleeding times by 3.3- and 3.1-fold, resp., in provoked rat bleeding time models.  These results suggest that a P2Y1 antagonist could potentially provide a safe and efficacious antithrombotic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKfYw47aTGrVg90H21EOLACvtfcHk0liNgMVfZnfeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVeqtbY%253D&md5=daa6e91e9700dde4054ff65096abac03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm301708u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301708u%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DH.%26aulast%3DTurdi%26aufirst%3DH.%26aulast%3DHerpin%26aufirst%3DT.%2BF.%26aulast%3DRoberge%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSchnur%26aufirst%3DD.%2BM.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DSteinbacher%26aufirst%3DT.%2BE.%26aulast%3DStewart%26aufirst%3DA.%2BB.%26aulast%3DOgletree%26aufirst%3DM.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DArcuri%26aufirst%3DM.%2BJ.%26aulast%3DCelani%26aufirst%3DD.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%25202-%2528phenoxypyridine%2529-3-phenylureas%2520as%2520small%2520molecule%2520P2Y1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1704%26epage%3D1714%26doi%3D10.1021%2Fjm301708u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berny-Lang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremmel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">New highly active antiplatelet agents with dual specificity for platelet P2Y<sub>1</sub> and P2Y<sub>12</sub> adenosine diphosphate receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2015.10.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26588064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=204-218&author=I.+B.+Yanachkovauthor=H.+Changauthor=M.+I.+Yanachkovaauthor=E.+J.+Dixauthor=M.+A.+Berny-Langauthor=T.+Gremmelauthor=A.+D.+Michelsonauthor=G.+E.+Wrightauthor=A.+L.+Frelinger&title=New+highly+active+antiplatelet+agents+with+dual+specificity+for+platelet+P2Y1+and+P2Y12+adenosine+diphosphate+receptors&doi=10.1016%2Fj.ejmech.2015.10.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors</span></div><div class="casAuthors">Yanachkov, Ivan B.; Chang, Hung; Yanachkova, Milka I.; Dix, Edward J.; Berny-Lang, Michelle A.; Gremmel, Thomas; Michelson, Alan D.; Wright, George E.; Frelinger, Andrew L. III</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-218</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently approved platelet ADP (ADP) receptor antagonists target only the platelet P2Y12 receptor.  Moreover, esp. in patients with acute coronary syndromes, there is a strong need for rapidly acting and reversible antiplatelet agents in order to minimize the risk of thrombotic events and bleeding complications.  In this study, a series of new P1,P4-di(adenosine-5') tetraphosphate (Ap4A) derivs. with modifications in the base and in the tetraphosphate chain were synthesized and evaluated with respect to their effects on platelet aggregation and function of the platelet P2Y1, P2Y12, and P2X1 receptors.  The resulting structure-activity relationships were used to design Ap4A analogs which inhibit human platelet aggregation by simultaneously antagonizing both P2Y1 and P2Y12 platelet receptors.  Unlike Ap4A, the analogs do not activate platelet P2X1 receptors.  Furthermore, the new compds. exhibit fast onset and offset of action and are significantly more stable than Ap4A to degrdn. in plasma, thus presenting a new promising class of antiplatelet agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_vhot2YyELVg90H21EOLACvtfcHk0liFMIaphjrDfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqtbzF&md5=5b83c2b5ca9e2fb3a36b51515a620766</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkova%26aufirst%3DM.%2BI.%26aulast%3DDix%26aufirst%3DE.%2BJ.%26aulast%3DBerny-Lang%26aufirst%3DM.%2BA.%26aulast%3DGremmel%26aufirst%3DT.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DNew%2520highly%2520active%2520antiplatelet%2520agents%2520with%2520dual%2520specificity%2520for%2520platelet%2520P2Y1%2520and%2520P2Y12%2520adenosine%2520diphosphate%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D107%26spage%3D204%26epage%3D218%26doi%3D10.1016%2Fj.ejmech.2015.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y<sub>1</sub>, P2Y<sub>12</sub> and P2X<sub>1</sub> receptors</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2009.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2009.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19945153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Oht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=159-165&author=H.+Changauthor=I.+B.+Yanachkovauthor=A.+D.+Michelsonauthor=Y.+Liauthor=M.+R.+Barnardauthor=G.+E.+Wrightauthor=A.+L.+Frelinger&title=Agonist+and+antagonist+effects+of+diadenosine+tetraphosphate%2C+a+platelet+dense+granule+constituent%2C+on+platelet+P2Y1%2C+P2Y12+and+P2X1+receptors&doi=10.1016%2Fj.thromres.2009.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors</span></div><div class="casAuthors">Chang, Hung; Yanachkov, Ivan B.; Michelson, Alan D.; Li, You Fu; Barnard, M. R.; Wright, George E.; Frelinger, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Diadenosine 5',5'''-P1,P4- tetraphosphate (Ap4A) is stored in platelet dense granules, but its effects on platelet function are not well understood.  We examd. the effects of Ap4A on platelet purinergic receptors P2Y1, P2Y12 and P2X1.  Flow cytometry was used to measure the effects of Ap4A in the presence or absence of ADP on: (a) P2Y12-mediated decrease in intraplatelet phosphorylated vasodilator stimulated phosphoprotein (VASP), (b) P2Y1-mediated increase in platelet cytosolic Ca2+, and (c) P2X1-mediated intraplatelet entry of extracellular Ca2+.  ADP-stimulated platelet shape change (P2Y1-mediated) and aggregation (P2Y1- and P2Y12-mediated) were measured optically.  Ap4A inhibited 3 μM ADP-induced: (a) platelet aggregation (IC50 9.8 ± 2.8 μM), (b) P2Y1-mediated shape change, (c) P2Y1-mediated increase in platelet cytosolic Ca2+ (IC50 40.8 ± 12.3 μM), and (d) P2Y12-mediated decrease in VASP phosphorylation (IC50 > 250 μM).  In the absence of added ADP, Ap4A had agonist effects on platelet P2X1 and P2Y12, but not P2Y1, receptors.  Thus, Ap4A, a constituent of platelet dense granules, is (a) an antagonist of platelet P2Y1 and P2Y12 receptors, where it inhibits the effects of ADP, and (b) an agonist of platelet P2X1 and P2Y12 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0IHrAABtbrVg90H21EOLACvtfcHk0liFMIaphjrDfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Oht70%253D&md5=b4d48ee8845fa8646c5426250eac83f8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2009.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2009.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBarnard%26aufirst%3DM.%2BR.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DAgonist%2520and%2520antagonist%2520effects%2520of%2520diadenosine%2520tetraphosphate%252C%2520a%2520platelet%2520dense%2520granule%2520constituent%252C%2520on%2520platelet%2520P2Y1%252C%2520P2Y12%2520and%2520P2X1%2520receptors%26jtitle%3DThromb.%2520Res.%26date%3D2010%26volume%3D125%26spage%3D159%26epage%3D165%26doi%3D10.1016%2Fj.thromres.2009.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gremmel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undyala, V. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przyklenk, K.</span></span> <span> </span><span class="NLM_article-title">Synergistic inhibition of both P2Y<sub>1</sub> and P2Y<sub>12</sub> adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.115.306885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FATVBAHA.115.306885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26743169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=501-509&author=T.+Gremmelauthor=I.+B.+Yanachkovauthor=M.+I.+Yanachkovaauthor=G.+E.+Wrightauthor=J.+Widerauthor=V.+V.+R.+Undyalaauthor=A.+D.+Michelsonauthor=A.+L.+Frelingerauthor=K.+Przyklenk&title=Synergistic+inhibition+of+both+P2Y1+and+P2Y12+adenosine+diphosphate+receptors+as+novel+approach+to+rapidly+attenuate+platelet-mediated+thrombosis&doi=10.1161%2FATVBAHA.115.306885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis</span></div><div class="casAuthors">Gremmel, Thomas; Yanachkov, Ivan B.; Yanachkova, Milka I.; Wright, George E.; Wider, Joseph; Undyala, Vishnu V. R.; Michelson, Alan D.; Frelinger, Andrew L., III; Przyklenk, Karin</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: Unlike currently approved ADP receptor antagonists, the new diadenosine tetraphosphate deriv. GLS-409 targets not only P2Y12 but also the second human platelet ADP receptor P2Y1 and may, therefore, be a promising antiplatelet drug candidate.  The current study is the first to investigate the in vivo antithrombotic effects of GLS-409.  APPROACH AND RESULTS-: We studied (1) the in vivo effects of GLS-409 on agonist-stimulated platelet aggregation in anesthetized rats, (2) the antithrombotic activity of GLS-409 and the assocd. effect on the bleeding time in a canine model of platelet-mediated coronary artery thrombosis, and (3) the inhibition of agonist-stimulated platelet aggregation by GLS-409 vs. selective P2Y1 and P2Y12 inhibition in vitro in samples from healthy human subjects before and 2 h after aspirin intake.  In vivo treatment with GLS-409 significantly inhibited ADP- and collagen-stimulated platelet aggregation in rats.  Further, GLS-409 attenuated cyclic flow variation, i.e., platelet-mediated thrombosis, in vivo in our canine model of unstable angina.  The improvement in coronary patency was accompanied by a nonsignificant 30% increase in bleeding time.  Of note, GLS-409 exerted its effects without affecting rat and canine hemodynamics.  Finally, in vitro treatment with GLS-409 showed effects similar to that of cangrelor and the combination of cangrelor with the selective P2Y1 inhibitor MRS 2179 on agonist-stimulated platelet aggregation in human platelet-rich plasma and whole blood before and 2 h after aspirin intake.  CONCLUSIONS-: Synergistic inhibition of both P2Y1 and P2Y12 ADP receptors by GLS-409 immediately attenuates platelet-mediated thrombosis and effectively blocks agonist-stimulated platelet aggregation irresp. of concomitant aspirin therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrooU8ELBTtFbVg90H21EOLACvtfcHk0ljsdRp4D5L9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVKls78%253D&md5=01a67cfaad749593447c6133a41d2ef4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.115.306885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.115.306885%26sid%3Dliteratum%253Aachs%26aulast%3DGremmel%26aufirst%3DT.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DYanachkova%26aufirst%3DM.%2BI.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DWider%26aufirst%3DJ.%26aulast%3DUndyala%26aufirst%3DV.%2BV.%2BR.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26aulast%3DPrzyklenk%26aufirst%3DK.%26atitle%3DSynergistic%2520inhibition%2520of%2520both%2520P2Y1%2520and%2520P2Y12%2520adenosine%2520diphosphate%2520receptors%2520as%2520novel%2520approach%2520to%2520rapidly%2520attenuate%2520platelet-mediated%2520thrombosis%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D501%26epage%3D509%26doi%3D10.1161%2FATVBAHA.115.306885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span> <span> </span><span class="NLM_article-title">State of affairs: Design and structure-activity relationships of reversible P2Y<sub>12</sub> receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2754</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bmcl.2016.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=27133596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2739-2754&author=F.+Zetterbergauthor=P.+Svensson&title=State+of+affairs%3A+Design+and+structure-activity+relationships+of+reversible+P2Y12+receptor+antagonists&doi=10.1016%2Fj.bmcl.2016.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists</span></div><div class="casAuthors">Zetterberg, Fredrik; Svensson, Peder</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2739-2754</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Myocardial infarction and stroke are the most common causes of mortality and morbidity in the developed world.  Therefore the search for antiplatelet therapy has been in focus for the last decades, in particular the search for new P2Y12R antagonists.  The first P2Y12R drug developed, clopidogrel, is a major success but there is still room for improvement with respect to bleeding profile and nonresponders.  These liabilities could be due to the fact that clopidogrel is a pro-drug and upon activation binds covalently to the receptor.  Therefore a lot of effort has gone into identifying reversible inhibitors.  One recent example is ticagrelor, which in clin. studies have been shown to be safer and even reduce rate of death from vascular events as compared head to head with clopidogrel.  The authors here review the medicinal chem. strategies used in the design of new reversible P2Y12R antagonists.  In addn., the authors also present structure based design studies based on the recently published agonist and antagonist x-ray structures of P2Y12R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTE3kxUEF_T7Vg90H21EOLACvtfcHk0ljsdRp4D5L9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCltb4%253D&md5=14dd39621a44a3c245f92352cca42b29</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DZetterberg%26aufirst%3DF.%26aulast%3DSvensson%26aufirst%3DP.%26atitle%3DState%2520of%2520affairs%253A%2520Design%2520and%2520structure-activity%2520relationships%2520of%2520reversible%2520P2Y12%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2739%26epage%3D2754%26doi%3D10.1016%2Fj.bmcl.2016.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doll, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiswell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosiborod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. Y.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehx255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehx255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28541452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFegsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=193-200&author=J.+A.+Dollauthor=S.+Liauthor=K.+Chiswellauthor=M.+T.+Roeauthor=M.+Kosiborodauthor=B.+M.+Sciricaauthor=T.+Y.+Wang&title=Clopidogrel+reloading+for+patients+with+acute+myocardial+infarction+already+on+clopidogrel+therapy&doi=10.1093%2Feurheartj%2Fehx255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel reloading for patients with acutemyocardial infarction already on clopidogrel therapy</span></div><div class="casAuthors">Doll, Jacob A.; Li, Shuang; Chiswell, Karen; Roe, Matthew T.; Kosiborod, Mikhail; Scirica, Benjamin M.; Wang, Tracy Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-200</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">1522-9645</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims We sought to det. the assocn. of clopidogrel reloading with in-hospital bleeding and mortality in contemporary practice.  Methods and results We examd. clopidogrel reloading for ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients on pre-admission clopidogrel therapy in the ACTION Registry-GWTG from 2009 to 2014.  We used inverse probability weighted propensity adjustment to compare in-hospital mortality and major bleeding risks between patients reloaded in the first 24 h with ≥300 mg of clopidogrel vs. those continued on a maintenance (<300 mg) dose.  Among the 12 366 patients on pre-admission clopidogrel therapy who were admitted with STEMI, 9369 (75.8%) received a loading dose.  Of 39 158 patients with NSTEMI, 10 144 (25.9%) were reloaded.  Reloaded patients were younger, had fewer comorbid conditions, and were more likely to be treated with primary PCI (STEMI) or an early invasive strategy (NSTEMI).  Risks of major bleeding were not significantly different between patients with and without reloading, whether presenting with STEMI (OR 0.98, 95% CI 0.85-1.13) or NSTEMI (OR 1.00, 95% CI 0.90-1.11).  Among STEMI patients, clopidogrel reloading was assocd. with lower risks of in-hospital mortality (OR 0.80, 95% CI 0.66-0.96), however no significant mortality difference was obsd. among NSTEMI patients (OR 1.13, 95% CI 0.93-1.37).  Conclusion Clopidogrel reloading occurs frequently among MI patients who are on pre-admission clopidogrel therapy, particularly among STEMI patients.  We did not observe increased bleeding or mortality risk with clopidogrel reloading, and therefore reloading could be safe for most MI patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40DX403wH6rVg90H21EOLACvtfcHk0ljsdRp4D5L9dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFegsr4%253D&md5=635b2746165aa8a0cdbbfefdac01b2b1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehx255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehx255%26sid%3Dliteratum%253Aachs%26aulast%3DDoll%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChiswell%26aufirst%3DK.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DKosiborod%26aufirst%3DM.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DWang%26aufirst%3DT.%2BY.%26atitle%3DClopidogrel%2520reloading%2520for%2520patients%2520with%2520acute%2520myocardial%2520infarction%2520already%2520on%2520clopidogrel%2520therapy%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2018%26volume%3D39%26spage%3D193%26epage%3D200%26doi%3D10.1093%2Feurheartj%2Fehx255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Prasugrel</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">449</span>, <span class="refDoi"> DOI: 10.1038/nrd2899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnrd2899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19483707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1aksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=449&author=K.+Huberauthor=U.+Yasothanauthor=B.+Hamadauthor=P.+Kirkpatrick&title=Prasugrel&doi=10.1038%2Fnrd2899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel</span></div><div class="casAuthors">Huber, Kurt; Yasothan, Uma; Hamad, Bashar; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">449-450</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Feb. 2009, the antiplatelet therapy prasugrel (Efient; Daiichi Sankyo/Eli Lilly) was granted marketing authorization by the European Commission for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing primary or delayed percutaneous coronary intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV6EsSGqEoFrVg90H21EOLACvtfcHk0lhufyx--BSJ-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1aksL8%253D&md5=fb046ab031a6358a715f7588ff2bd876</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd2899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2899%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DHamad%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPrasugrel%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D449%26doi%3D10.1038%2Fnrd2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, K.</span></span> <span> </span><span class="NLM_article-title">Current and future antiplatelet therapies: emphasis on preserving haemostasis</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnrcardio.2017.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29297508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=181-191&author=J.+D.+McFadyenauthor=M.+Schaffauthor=K.+Peter&title=Current+and+future+antiplatelet+therapies%3A+emphasis+on+preserving+haemostasis&doi=10.1038%2Fnrcardio.2017.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future antiplatelet therapies: emphasis on preserving haemostasis</span></div><div class="casAuthors">McFadyen, James D.; Schaff, Mathieu; Peter, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein IIb/IIIa inhibitors, have proved to be successful in reducing morbidity and mortality assocd. with arterial thrombosis.  These agents are, therefore, cornerstone of therapy for patients with acute coronary syndromes.  However, these drugs all carry an inherent risk of bleeding, which is assocd. with adverse cardiovascular outcomes and mortality.  Thus, potential benefits of more potent, conventional antiplatelet drugs are likely be offset by increased risk of bleeding.  Data from expts. in vivo have highlighted potentially important differences between hemostasis and thrombosis, raising prospect of developing new antiplatelet drugs that are not assocd. with bleeding.  Indeed, in preclin. studies, several novel antiplatelet therapies that seem to inhibit thrombosis while maintaining hemostasis have been identified.  These agents include inhibitors of PI3Kβ, protein disulfide-isomerase, activated GPIIb/IIIa, GPIIb/IIIa outside-in signalling, protease-activated receptors, and platelet GPVI-mediated adhesion pathways.  In this Review, we discuss how a therapeutic ceiling has been reached with existing antiplatelet drugs, whereby increased potency is offset by elevated bleeding risk.  The latest advances in our understanding of thrombus formation have informed the development of new antiplatelet drugs that are potentially safer than currently available therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlNsh2or617Vg90H21EOLACvtfcHk0lhufyx--BSJ-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGnsQ%253D%253D&md5=f7c912d36a348c83cb73df5c94b55a87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.206%26sid%3Dliteratum%253Aachs%26aulast%3DMcFadyen%26aufirst%3DJ.%2BD.%26aulast%3DSchaff%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DCurrent%2520and%2520future%2520antiplatelet%2520therapies%253A%2520emphasis%2520on%2520preserving%2520haemostasis%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D181%26epage%3D191%26doi%3D10.1038%2Fnrcardio.2017.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Columbo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambour, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linshaw, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riblet, N. B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodney, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, D. H.</span></span> <span> </span><span class="NLM_article-title">A meta-analysis of the impact of aspirin, clopidogrel, and dual antiplatelet therapy on bleeding complications in noncardiac surgery</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1097/SLA.0000000000002279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1097%2FSLA.0000000000002279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28463896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC1crjt1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2018&pages=1-10&author=J.+A.+Columboauthor=A.+J.+Lambourauthor=R.+A.+Sundlingauthor=N.+B.+Chauhanauthor=S.+Y.+Bessenauthor=D.+L.+Linshawauthor=R.+Kangauthor=N.+B.+V.+Ribletauthor=P.+P.+Goodneyauthor=D.+H.+Stone&title=A+meta-analysis+of+the+impact+of+aspirin%2C+clopidogrel%2C+and+dual+antiplatelet+therapy+on+bleeding+complications+in+noncardiac+surgery&doi=10.1097%2FSLA.0000000000002279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery</span></div><div class="casAuthors">Columbo Jesse A; Goodney Philip P; Stone David H; Columbo Jesse A; Sundling Rebecca A; Chauhan Nirali B; Bessen Sarah Y; Kang Ravinder; Riblet Natalie B V; Goodney Philip P; Columbo Jesse A; Kang Ravinder; Goodney Philip P; Columbo Jesse A; Kang Ravinder; Lambour Andrew J; Linshaw David L; Kang Ravinder</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The aim of this study was to determine the bleeding risks associated with single (aspirin) and dual (aspirin + clopidogrel) antiplatelet therapy (DAPT) versus placebo or no treatment in adults undergoing noncardiac surgery.  SUMMARY OF BACKGROUND DATA:  The impact of antiplatelet therapy on bleeding during noncardiac surgery remains controversial.  A meta-analysis was performed to examine the risk associated with single and DAPT.  METHODS:  A systematic review of antiplatelet therapy, noncardiac surgery, and perioperative bleeding was performed.  Peer-reviewed sources and meeting abstracts from relevant societies were queried.  Studies without a control group, or those that only examined patients with coronary stents, were excluded.  Primary endpoints were transfusion and reintervention for bleeding.  RESULTS:  Of 11,592 references, 46 studies met inclusion criteria.  In a meta-analysis of >30,000 patients, the relative risk (RR) of transfusion versus control was 1.14 [95% confidence interval (CI) 1.03-1.26, P = 0.009] for aspirin, and 1.33 (1.15-1.55, P = 0.001) for DAPT.  Clopidogrel had an elevated risk, but data were too heterogeneous to analyze.  The RR of bleeding requiring reintervention was not significantly higher for any agent compared to control [RR 0.96 (0.76-1.22, P = 0.76) for aspirin, 1.84 (0.87-3.87, P = 0.11) for clopidogrel, and 1.51 (0.92-2.49, P = 0.1) for DAPT].  Subanalysis of thoracic and abdominal procedures was similar.  There was no difference in RR for myocardial infarction [1.06 (0.79-1.43)], stroke [0.97 (0.71-1.33)], or mortality [0.97 (0.87-1.1)].  CONCLUSIONS:  Antiplatelet therapy at the time of noncardiac surgery confers minimal bleeding risk with no difference in thrombotic complications.  In many cases, it is safe to continue antiplatelet therapy in patients with important indications for their use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTv7p_fd1MkY_9pSBfyDvp7fW6udTcc2ebOUdBV2M_T1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjt1GhtA%253D%253D&md5=f50a6b766a572d792313c4a5dac46a9f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2FSLA.0000000000002279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSLA.0000000000002279%26sid%3Dliteratum%253Aachs%26aulast%3DColumbo%26aufirst%3DJ.%2BA.%26aulast%3DLambour%26aufirst%3DA.%2BJ.%26aulast%3DSundling%26aufirst%3DR.%2BA.%26aulast%3DChauhan%26aufirst%3DN.%2BB.%26aulast%3DBessen%26aufirst%3DS.%2BY.%26aulast%3DLinshaw%26aufirst%3DD.%2BL.%26aulast%3DKang%26aufirst%3DR.%26aulast%3DRiblet%26aufirst%3DN.%2BB.%2BV.%26aulast%3DGoodney%26aufirst%3DP.%2BP.%26aulast%3DStone%26aufirst%3DD.%2BH.%26atitle%3DA%2520meta-analysis%2520of%2520the%2520impact%2520of%2520aspirin%252C%2520clopidogrel%252C%2520and%2520dual%2520antiplatelet%2520therapy%2520on%2520bleeding%2520complications%2520in%2520noncardiac%2520surgery%26jtitle%3DAnn.%2520Surg.%26date%3D2018%26volume%3D267%26spage%3D1%26epage%3D10%26doi%3D10.1097%2FSLA.0000000000002279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Cangrelor: a review in percutaneous coronary intervention</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0445-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs40265-015-0445-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26201463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1425-1434&author=G.+M.+Keating&title=Cangrelor%3A+a+review+in+percutaneous+coronary+intervention&doi=10.1007%2Fs40265-015-0445-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor: A Review in Percutaneous Coronary Intervention</span></div><div class="casAuthors">Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1425-1434</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Cangrelor (Kengrexal, Kengreal) is an i.v. administered P2Y12 receptor inhibitor.  It is direct-acting and reversible, with a very rapid onset and offset of action.  The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of i.v. cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI).  The primary composite efficacy endpoint of death from any cause, MI, ischemia-drive revascularization or stent thrombosis in the 48 h following randomization occurred in significantly fewer cangrelor than clopidogrel recipients.  The rate of severe or life-threatening non-coronary artery bypass graft-related, GUSTO-defined bleeding at 48 h did not significantly differ between cangrelor and clopidogrel recipients.  In conclusion, i.v. cangrelor is an important new option for use in patients undergoing PCI who have not been treated with oral P2Y12 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Xn6rpGOd4LVg90H21EOLACvtfcHk0lhufyx--BSJ-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eks7jL&md5=1a421fb4f5ba89115baf569b4488b54e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0445-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0445-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DCangrelor%253A%2520a%2520review%2520in%2520percutaneous%2520coronary%2520intervention%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1425%26epage%3D1434%26doi%3D10.1007%2Fs40265-015-0445-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckland, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span> <span> </span><span class="NLM_article-title">Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y<sub>12</sub> receptors in vitro</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.3109/09537104.2015.1069809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3109%2F09537104.2015.1069809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26270719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=191-195&author=H.+M.+Judgeauthor=R.+J.+Bucklandauthor=J.+A.+Jakubowskiauthor=R.+F.+Storey&title=Cangrelor+inhibits+the+binding+of+the+active+metabolites+of+clopidogrel+and+prasugrel+to+P2Y12+receptors+in+vitro&doi=10.3109%2F09537104.2015.1069809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro</span></div><div class="casAuthors">Judge, Heather M.; Buckland, Robert J.; Jakubowski, Joseph A.; Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-195</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cangrelor is a rapid-acting, direct-binding, and reversible P2Y12 antagonist which has been studied for use during percutaneous coronary intervention (PCI) in patients with or without pretreatment with an oral P2Y12 antagonist.  As cangrelor is administered i.v., it is necessary to switch to an oral P2Y12 antagonist following PCI, such as the thienopyridines clopidogrel, and prasugrel or the non-pyridine ticagrelor.  Previous studies have suggested a neg. pharmacodynamic interaction between cangrelor and thienopyridines.  This in vitro study evaluated the receptor-level interaction between cangrelor and the active metabolite (AM) of clopidogrel or prasugrel by assessing functional P2Y12 receptor no. using a 33P-2MeSADP binding assay.  All P2Y12 antagonists studied resulted in strong P2Y12 receptor blockade (cangrelor: 93.6%; clopidogrel AM: 93.0%; prasugrel AM: 97.9%).  Adding a thienopyridine AM in the presence of cangrelor strongly reduces P2Y12 receptor blockade by the AM (clopidogrel AM: 7%, prasugrel AM: 3.2%).  The thienopyridine AMs had limited ability to compete with cangrelor for binding to P2Y12 (% P2Y12 receptor blockade after co-incubation with cangrelor 1000 nmol/L: 11.7% for clopidogrel AM 3 μmol/L; 34.1% for prasugrel AM 3 μmol/L).  In conclusion, in vitro cangrelor strongly inhibits the binding of clopidogrel and prasugrel AMs to the P2Y12 receptor, consistent with the previous observation of a neg. pharmacodynamic interaction.  Care may need to be taken to not overlap exposure to thienopyridine AMs and cangrelor in order to reduce the risk of thrombotic complications following PCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Mix2woQ5prVg90H21EOLACvtfcHk0lgxCljv50keBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gjt7Y%253D&md5=b03f6e04ddf9724f141d37a52690e784</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3109%2F09537104.2015.1069809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F09537104.2015.1069809%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DH.%2BM.%26aulast%3DBuckland%26aufirst%3DR.%2BJ.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DCangrelor%2520inhibits%2520the%2520binding%2520of%2520the%2520active%2520metabolites%2520of%2520clopidogrel%2520and%2520prasugrel%2520to%2520P2Y12%2520receptors%2520in%2520vitro%26jtitle%3DPlatelets%26date%3D2016%26volume%3D27%26spage%3D191%26epage%3D195%26doi%3D10.3109%2F09537104.2015.1069809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sfantou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekakis, J.</span></span> <span> </span><span class="NLM_article-title">Cangrelor in percutaneous coronary intervention: current status and perspectives</span>. <i>J. Cardiovasc. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1177/1074248417715004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1177%2F1074248417715004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29228817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=13-22&author=D.+Alexopoulosauthor=C.+Pappasauthor=D.+Sfantouauthor=J.+Lekakis&title=Cangrelor+in+percutaneous+coronary+intervention%3A+current+status+and+perspectives&doi=10.1177%2F1074248417715004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives</span></div><div class="casAuthors">Alexopoulos, Dimitrios; Pappas, Christos; Sfantou, Danai; Lekakis, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">JCPTFE</span>;
        ISSN:<span class="NLM_cas:issn">1074-2484</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Cangrelor is an i.v. administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action.  In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without increasing the risk of severe bleeding.  Cangrelor is currently approved by drug regulating authorities for patients undergoing percutaneous coronary intervention (PCI) without prior treatment with a P2Y12 receptor antagonist and not receiving a glycoprotein IIb/IIIa inhibitor, while its use is endorsed with a class IIb recommendation by the European Society of Cardiol. guidelines.  Several subanalyses of CHAMPION PHOENIX trial have tried to elucidate the role of cangrelor in PCI, including its usefulness during a 2-h landmark anal., impact on intraprocedural stent thrombosis, and redn. in myocardial infarction (MI) rate.  The influence of gender, geog. region, access site, and bivalirudin use on cangrelor's effects has also been reported.  In patients with ST elevation MI and in clin. scenarios of disturbed absorption of oral antiplatelet agents or in need of an i.v. agent, cangrelor may surpass oral agents' drawbacks.  Transitioning to an oral agent is mandatory following cangrelor infusion discontinuation, although ticagrelor may be administered earlier without any pharmacodynamic interaction.  Nevertheless, the clin. role of cangrelor in conjunction with administration of prasugrel or ticagrelor remains unclear.  Accruing real-life experience is expected to improve our understanding of cangrelor's role in everyday clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoST_dOw__zhLVg90H21EOLACvtfcHk0lgxCljv50keBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOgtg%253D%253D&md5=0eba04774992b402f33cc67a727f0d89</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F1074248417715004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1074248417715004%26sid%3Dliteratum%253Aachs%26aulast%3DAlexopoulos%26aufirst%3DD.%26aulast%3DPappas%26aufirst%3DC.%26aulast%3DSfantou%26aufirst%3DD.%26aulast%3DLekakis%26aufirst%3DJ.%26atitle%3DCangrelor%2520in%2520percutaneous%2520coronary%2520intervention%253A%2520current%2520status%2520and%2520perspectives%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D23%26spage%3D13%26epage%3D22%26doi%3D10.1177%2F1074248417715004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husted, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaffey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steg, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span> <span> </span><span class="NLM_article-title">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0904327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1056%2FNEJMoa0904327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19717846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1045-1057&author=L.+Wallentinauthor=R.+C.+Beckerauthor=A.+Budajauthor=C.+P.+Cannonauthor=H.+Emanuelssonauthor=C.+Heldauthor=J.+Horrowauthor=S.+Hustedauthor=S.+Jamesauthor=H.+Katusauthor=K.+W.+Mahaffeyauthor=B.+M.+Sciricaauthor=A.+Skeneauthor=P.+G.+Stegauthor=R.+F.+Storeyauthor=R.+A.+Harrington&title=Ticagrelor+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0904327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wallentin, Lars; Becker, Richard C.; Budaj, Andrej; Cannon, Christopher P.; Emanuelsson, Hakan; Held, Claes; Horrow, Jay; Husted, Steen; James, Stefan; Katus, Hugo; Mahaffey, Kenneth W.; Scirica, Benjamin M.; Skene, Allan; Steg, Philppe Gabriel; Storey, Robert F.; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1045-1057</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ticagrelor is an oral, reversible, direct-acting inhibitor of the ADP receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.  In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg. loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.  At 12 mo, the primary end point - a composite of death from vascular causes, myocardial infarction, or stroke - had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P < 0.001).  Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P = 0.005) and death from vascular causes (4.0% vs. 5.1%0/, P = 0.001) but not stroke alone (1.5% vs. 1.3%, P = 0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P < 0.001).  No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, resp.; P = 0.43), but ticagrelor was assocd. with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P = 0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.  In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTdvlM1dfTz7Vg90H21EOLACvtfcHk0ljg9Pm_PnpvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ&md5=9c215c4ceeb6dd14d406ab26e2db25d5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904327%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DEmanuelsson%26aufirst%3DH.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DHorrow%26aufirst%3DJ.%26aulast%3DHusted%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DKatus%26aufirst%3DH.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSkene%26aufirst%3DA.%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26atitle%3DTicagrelor%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1045%26epage%3D1057%26doi%3D10.1056%2FNEJMoa0904327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. H.</span></span> <span> </span><span class="NLM_article-title">Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S196535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2147%2FDDDT.S196535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30863011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=719-730&author=Z.+G.+Fanauthor=W.+L.+Zhangauthor=B.+Xuauthor=J.+Jiauthor=N.+L.+Tianauthor=S.+H.+He&title=Comparisons+between+ticagrelor+and+clopidogrel+following+percutaneous+coronary+intervention+in+patients+with+acute+coronary+syndrome%3A+a+comprehensive+meta-analysis&doi=10.2147%2FDDDT.S196535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis</span></div><div class="casAuthors">Fan, Zhong-Guo; Zhang, Wen-Ling; Xu, Bing; Ji, Jun; Tian, Nai-Liang; He, Sheng-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">719-730</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The efficacy and safety of ticagrelor following percutaneous coronary intervention for patients with acute coronary syndrome remains unclear.  This study sought to evaluate clin. outcomes of ticagrelor as part of dual-antiplatelet treatment for these patients.  Methods: PubMed, MEDLINE, Embase, and other Internet sources were searched for eligible citations.  The primary end point was major adverse cardiovascular and cerebrovascular events, consisting of cardiovascular death, myocardial infarction, and stroke.  The secondary end point was the occurrence of definite/probable stent thrombosis (ST).  The risk of bleeding was chosen to be the safety end point.  Results: Eleven clin. trials - six randomized trials and five observational trials - were finally analyzed.  A tendency toward redn. in the risk of major adverse cardiovascular and cere♂brovascular events was obsd. only with respect to ticagrelor (OR 0.83, 95% CI 0.66-1.03; P=0.091), which might have resulted from the lower risk of cardiovascular death (OR 0.78, 95% CI 0.68-0.89; P,0.001).  The overall incidence of ST differed significantly between the ticagrelor group and the clopidogrel group (OR 0.74, 95% CI 0.59-0.93; P=0.009), but the risk of bleeding, regardless of major or minor bleeding, increased significantly.  Conclusion: As part of dual-antiplatelet treatment following percutaneous coronary interven♂tion, ticagrelor significantly reduced the risk of cardiovascular death and ST in acute coronary syndrome patients, but at the cost of bleeding.  More powerful relevant randomized trials are still warranted to guide clin. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yKWYfx-sfLVg90H21EOLACvtfcHk0ljg9Pm_PnpvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7vF&md5=0ff76da8a30af0c7c9bc0535f089f04a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S196535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S196535%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DW.%2BL.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DN.%2BL.%26aulast%3DHe%26aufirst%3DS.%2BH.%26atitle%3DComparisons%2520between%2520ticagrelor%2520and%2520clopidogrel%2520following%2520percutaneous%2520coronary%2520intervention%2520in%2520patients%2520with%2520acute%2520coronary%2520syndrome%253A%2520a%2520comprehensive%2520meta-analysis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D719%26epage%3D730%26doi%3D10.2147%2FDDDT.S196535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Been, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smairat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryadevara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soffer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenni, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span> <span> </span><span class="NLM_article-title">Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1661</span>– <span class="NLM_lpage">1670</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.118.038317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FCIRCULATIONAHA.118.038317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30630341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=1661-1670&author=F.+Franchiauthor=F.+Rolliniauthor=A.+Rivasauthor=M.+Waliauthor=M.+Bricenoauthor=M.+Agarwalauthor=Z.+Shaikhauthor=A.+Nawazauthor=G.+Silvaauthor=L.+Beenauthor=R.+Smairatauthor=M.+Kaufmanauthor=A.+Pinedaauthor=S.+Suryadevaraauthor=D.+Sofferauthor=M.+M.+Zenniauthor=T.+A.+Bassauthor=D.+J.+Angiolillo&title=Platelet+inhibition+with+cangrelor+and+crushed+ticagrelor+in+patients+with+ST-segment-elevation+myocardial+infarction+undergoing+primary+percutaneous+coronary+intervention&doi=10.1161%2FCIRCULATIONAHA.118.038317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study</span></div><div class="casAuthors">Franchi, Francesco; Rollini, Fabiana; Rivas, Andrea; Wali, Mustafa; Briceno, Maryuri; Agarwal, Malhar; Shaikh, Zubair; Nawaz, Ahmed; Silva, Gabriel; Been, Latonya; Smairat, Ramez; Kaufman, Marc; Pineda, Andres M.; Suryadevara, Siva; Soffer, Daniel; Zenni, Martin M.; Bass, Theodore A.; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1661-1670</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (P-PCI).  In turn, this leads to a gap in platelet inhibition, exposing patients to an increased risk of early thrombotic complications and underscoring the need to define strategies assocd. with more effective platelet inhibition in the peri-primary percutaneous coronary intervention period.  Cangrelor is an i.v. P2Y12 inhibitor with prompt and potent antiplatelet effects.  However, to date, there are limited data on the effects of cangrelor used in combination with ticagrelor in patients undergoing primary percutaneous coronary intervention.  Moreover, questions have emerged on the potential for drug-drug interactions during the transition from cangrelor to oral P2Y12 inhibitors.  Methods: This was a prospective, randomized, double-blind, placebo-controlled pharmacodynamic study conducted in patients undergoing primary percutaneous coronary intervention (n=50) who were randomized to treatment with either cangrelor or matching placebo (bolus followed by 2-h infusion).  All patients received ticagrelor 180-mg loading dose administered as crushed tablets at the time of cangrelor/placebo bolus administration.  Pharmacodynamic analyses were performed at 8 time points.  Pharmacodynamic effects were measured as P2Y12 reaction units by VerifyNow and platelet reactivity index by vasodilator-stimulated phosphoprotein.  Results: Compared with placebo, cangrelor was assocd. with reduced P2Y12 reaction units as early as 5 min after bolus, which persisted during the entire duration of drug infusion, including at 30 min (63 [32-93] vs. 214 [183-245]; mean difference, 152 [95% CI, 108-195]; P<0·001; primary end point).  Parallel findings were shown with platelet reactivity index.  Accordingly, high on-treatment platelet reactivity rates were reduced with cangrelor.  After discontinuation of cangrelor/placebo infusion, there were no differences in levels of platelet reactivity between groups, ruling out a drug-drug interaction when cangrelor and ticagrelor are concomitantly administered.  Conclusions: In patients undergoing primary percutaneous coronary intervention, cangrelor is an effective strategy to bridge the gap in platelet inhibition assocd. with the use of oral P2Y12 inhibition induced by ticagrelor.  Ticagrelor can be administered as a crushed formulation concomitantly with cangrelor without any apparent drug-drug interaction.  The clin. implications of these pharmacodynamic findings warrant investigation in an adequately powered clin. trial.  Clin. trial registration: URL: https://www.clinicaltrials.gov.  Unique identifier: NCT03247738.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qoeoQLDTMLVg90H21EOLACvtfcHk0ljg9Pm_PnpvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqurg%253D&md5=0c2cff05ae628e5193f1beb4df541443</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.118.038317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.118.038317%26sid%3Dliteratum%253Aachs%26aulast%3DFranchi%26aufirst%3DF.%26aulast%3DRollini%26aufirst%3DF.%26aulast%3DRivas%26aufirst%3DA.%26aulast%3DWali%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DM.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DZ.%26aulast%3DNawaz%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DG.%26aulast%3DBeen%26aufirst%3DL.%26aulast%3DSmairat%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DA.%26aulast%3DSuryadevara%26aufirst%3DS.%26aulast%3DSoffer%26aufirst%3DD.%26aulast%3DZenni%26aufirst%3DM.%2BM.%26aulast%3DBass%26aufirst%3DT.%2BA.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DPlatelet%2520inhibition%2520with%2520cangrelor%2520and%2520crushed%2520ticagrelor%2520in%2520patients%2520with%2520ST-segment-elevation%2520myocardial%2520infarction%2520undergoing%2520primary%2520percutaneous%2520coronary%2520intervention%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26spage%3D1661%26epage%3D1670%26doi%3D10.1161%2FCIRCULATIONAHA.118.038317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangas, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenoux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorog, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hmissi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunadian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanguay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Harst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Hof, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y<sub>12</sub> receptor antagonist, in patients with chronic coronary syndromes</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3132</span>– <span class="NLM_lpage">3140</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehz807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehz807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31994703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FlslyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3132-3140&author=R.+F.+Storeyauthor=P.+A.+Gurbelauthor=J.+Ten+Bergauthor=C.+Bernaudauthor=G.+D.+Dangasauthor=J.+M.+Frenouxauthor=D.+A.+Gorogauthor=A.+Hmissiauthor=V.+Kunadianauthor=S.+K.+Jamesauthor=J.+F.+Tanguayauthor=H.+Tranauthor=D.+Trenkauthor=M.+Uferauthor=P.+Van+der+Harstauthor=A.+W.+J.+Van%E2%80%99t+Hofauthor=D.+J.+Angiolillo&title=Pharmacodynamics%2C+pharmacokinetics%2C+and+safety+of+single-dose+subcutaneous+administration+of+selatogrel%2C+a+novel+P2Y12+receptor+antagonist%2C+in+patients+with+chronic+coronary+syndromes&doi=10.1093%2Feurheartj%2Fehz807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes</span></div><div class="casAuthors">Storey Robert F; Gurbel Paul A; Tran Henry; Ten Berg Jurrien; Bernaud Corine; Frenoux Jean-Marie; Hmissi Abdel; Ufer Mike; Dangas George D; Gorog Diana A; Gorog Diana A; Kunadian Vijay; Kunadian Vijay; James Stefan K; Tanguay Jean-Francois; Trenk Dietmar; Van der Harst Pim; Van't Hof Arnoud W J; Van't Hof Arnoud W J; Van't Hof Arnoud W J; Angiolillo Dominick J</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3132-3140</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS).  METHODS AND RESULTS:  In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966).  Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA).  Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU) <100 at 30 min post-dose and lasting ≥3 h.  At 30 min post-dose, 89% of patients were responders to selatogrel 8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001).  PRU values (mean ± standard deviation) were 10 ± 25 (8 mg), 4 ± 10 (16 mg), and 163 ± 73 (placebo) at 15 min and remained <100 up to 8 h for both doses, returning to pre-dose or near pre-dose levels by 24 h post-dose.  LTA data showed similarly rapid and potent inhibition of platelet aggregation.  Selatogrel plasma concentrations peaked ∼30 min post-dose.  Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence interval: 4-11%).  CONCLUSIONS:  Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y12 inhibition sustained for ≥8 h and reversible within 24 h.  Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwheMBIhRNxWmbXvSEQle5fW6udTcc2eYOMTsLG0A0DLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FlslyqtQ%253D%253D&md5=95a03009fe056694da10b11315458623</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehz807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehz807%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DTen%2BBerg%26aufirst%3DJ.%26aulast%3DBernaud%26aufirst%3DC.%26aulast%3DDangas%26aufirst%3DG.%2BD.%26aulast%3DFrenoux%26aufirst%3DJ.%2BM.%26aulast%3DGorog%26aufirst%3DD.%2BA.%26aulast%3DHmissi%26aufirst%3DA.%26aulast%3DKunadian%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DS.%2BK.%26aulast%3DTanguay%26aufirst%3DJ.%2BF.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DTrenk%26aufirst%3DD.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DVan%2Bder%2BHarst%26aufirst%3DP.%26aulast%3DVan%25E2%2580%2599t%2BHof%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520single-dose%2520subcutaneous%2520administration%2520of%2520selatogrel%252C%2520a%2520novel%2520P2Y12%2520receptor%2520antagonist%252C%2520in%2520patients%2520with%2520chronic%2520coronary%2520syndromes%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2020%26volume%3D41%26spage%3D3132%26epage%3D3140%26doi%3D10.1093%2Feurheartj%2Fehz807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groneberg, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y<sub>12</sub> receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2013.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23747805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFemtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=360-375&author=P.+Bachauthor=J.+Bostr%C3%B6mauthor=K.+Brickmannauthor=J.+J.+J.+van+Giezenauthor=R.+D.+Gronebergauthor=D.+M.+Harveyauthor=M.+O%E2%80%99Sullivanauthor=F.+Zetterberg&title=Synthesis%2C+structure%E2%80%93property+relationships+and+pharmacokinetic+evaluation+of+ethyl+6-aminonicotinate+sulfonylureas+as+antagonists+of+the+P2Y12+receptor&doi=10.1016%2Fj.ejmech.2013.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor</span></div><div class="casAuthors">Bach, Peter; Bostroem, Jonas; Brickmann, Kay; van Giezen, J. J. J.; Groneberg, Robert D.; Harvey, Darren M.; O'Sullivan, Michael; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">360-375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The present paper describes the development of a new series of P2Y12 receptor antagonists based on the previously reported piperazinyl urea series (IC50 binding affinity = 0.33 μM, aq. soly. <0.1 μM, microsomal CLint (HLM) ≥300 μM/min/mg).  By replacement of the urea functionality with a sulfonylurea group the authors obsd. increased affinity along with improved stability and soly. as exemplified by I (IC50 binding affinity = 0.042 μM, aq. soly. = 90 μM, microsomal CLint (HLM) = 70 μM/min/mg).  Further improvements in affinity and metabolic stability were achieved by replacing the central piperazine ring with a 3-aminoazetidine as exemplified by II (IC50 binding affinity = 0.0062 μM, aq. soly. = 83 μM, microsomal CLint (HLM) = 28 μM/min/mg).  The improved affinity obsd. in the in vitro binding assay also translated to the potency obsd. in the WPA aggregation assay (I : 19 nM and II : 9.5 nM) and the obsd. in vitro ADME properties translates to the in vivo PK properties obsd. in rat.  In addn., the authors found that the chem. stability of the sulfonylureas during prolonged storage in soln. was related to the sulfonyl urea linker and depended on the type of solvent and the substitution pattern of the sulfonyl urea functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgEnFukjBUnrVg90H21EOLACvtfcHk0lj2-UyNlF1JtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFemtb%252FK&md5=4c32c6f59c0eff04d96611a27f888af2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrickmann%26aufirst%3DK.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGroneberg%26aufirst%3DR.%2BD.%26aulast%3DHarvey%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593property%2520relationships%2520and%2520pharmacokinetic%2520evaluation%2520of%2520ethyl%25206-aminonicotinate%2520sulfonylureas%2520as%2520antagonists%2520of%2520the%2520P2Y12%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D360%26epage%3D375%26doi%3D10.1016%2Fj.ejmech.2013.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachrisson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y<sub>12</sub> receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7015</span>– <span class="NLM_lpage">7024</span>, <span class="refDoi"> DOI: 10.1021/jm400820m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400820m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7015-7024&author=P.+Bachauthor=T.+Antonssonauthor=R.+Bylundauthor=J.+A.+Bjorkmanauthor=K.+Osterlundauthor=F.+Giordanettoauthor=J.+J.+van+Giezenauthor=S.+M.+Andersenauthor=H.+Zachrissonauthor=F.+Zetterberg&title=Lead+optimization+of+ethyl+6-aminonicotinate+acyl+sulfonamides+as+antagonists+of+the+P2Y12+receptor.+separation+of+the+antithrombotic+effect+and+bleeding+for+candidate+drug+AZD1283&doi=10.1021%2Fjm400820m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span></div><div class="casAuthors">Bach, Peter; Antonsson, Thomas; Bylund, Ruth; Bjoerkman, Jan-Arne; Oesterlund, Krister; Giordanetto, Fabrizio; van Giezen, J. J. J.; Andersen, Soeren M.; Zachrisson, Helen; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7015-7024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationships of Et 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented.  Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay.  Evaluation of PK parameters in vivo in dog for six compds. showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines.  In a modified Folts model in dog, both piperidine (I) and azetidine (II) dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, resp.  The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for I and II, resp.  Thus, the therapeutic index (TI) was ≥10 for both compds.  On the basis of these data, compd. I was progressed into human clin. trials as candidate drug AZD1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmCuB-1CBurVg90H21EOLACvtfcHk0ljC0Tmy0dBUIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP&md5=3810ed67647a776b9ad8bdb165f715e7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400820m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400820m%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DAntonsson%26aufirst%3DT.%26aulast%3DBylund%26aufirst%3DR.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26aulast%3DOsterlund%26aufirst%3DK.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DLead%2520optimization%2520of%2520ethyl%25206-aminonicotinate%2520acyl%2520sulfonamides%2520as%2520antagonists%2520of%2520the%2520P2Y12%2520receptor.%2520separation%2520of%2520the%2520antithrombotic%2520effect%2520and%2520bleeding%2520for%2520candidate%2520drug%2520AZD1283%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7015%26epage%3D7024%26doi%3D10.1021%2Fjm400820m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafeedheen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliden, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel antiplatelet agents in cardiovascular medicine</span>. <i>Curr. Treat Options Cardiovasc Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s11936-015-0383-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs11936-015-0383-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1-15&author=R.+Rafeedheenauthor=K.+P.+Blidenauthor=F.+Liuauthor=U.+S.+Tantryauthor=P.+A.+Gurbel&title=Novel+antiplatelet+agents+in+cardiovascular+medicine&doi=10.1007%2Fs11936-015-0383-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs11936-015-0383-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11936-015-0383-0%26sid%3Dliteratum%253Aachs%26aulast%3DRafeedheen%26aufirst%3DR.%26aulast%3DBliden%26aufirst%3DK.%2BP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520antiplatelet%2520agents%2520in%2520cardiovascular%2520medicine%26jtitle%3DCurr.%2520Treat%2520Options%2520Cardiovasc%2520Med.%26date%3D2015%26volume%3D17%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs11936-015-0383-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGuzman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, P. B.</span></span> <span> </span><span class="NLM_article-title">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.178574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fjpet.110.178574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21447613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=22-30&author=P.+Andreauthor=F.+DeGuzmanauthor=H.+Haberstock-Debicauthor=S.+Millsauthor=Y.+Pakauthor=M.+Inagakiauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=Thienopyridines%2C+but+not+elinogrel%2C+result+in+off-target+effects+at+the+vessel+wall+that+contribute+to+bleeding&doi=10.1124%2Fjpet.110.178574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span></div><div class="casAuthors">Andre, Patrick; DeGuzman, Francis; Haberstock-Debic, Helena; Mills, Scott; Pak, Yvonne; Inagaki, Mayuko; Pandey, Anjali; Hollenbach, Stanley; Phillips, David R.; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. studies with clopidogrel or prasugrel show that although increased inhibition of P2Y12 and platelet function improves efficacy, bleeding is also increased.  Other preclin. and clin. studies have suggested a greater therapeutic index (TI) with reversible inhibitors and disproportionate effects of thienopyridines on bleeding at high doses.  We used multiple in vivo (FeCl3-induced arterial thrombosis in mesenteric arteries, blood loss after tail transsection, and platelet deposition and wound closure time in a micropuncture model in mesenteric veins) and ex vivo (light transmittance aggregometry, prothrombin time, and activated partial thromboplastin time) mouse models to (1) compare the TI of clopidogrel, prasugrel, and elinogrel, a reversible, competitive antagonist, with that in P2Y12(-/-) mice and (2) det. whether the bleeding consequences of the thienopyridines are attributed only to the inhibition of P2Y12.  Data indicated greater (elinogrel) and decreased (thienopyridines) TI compared with that in P2Y12(-/-) mice.  The impaired TI assocd. with the thienopyridines was not attributed to non-P2Y12 activities on platelet function or coagulation but was related to a direct effect at the vessel wall (inhibition of vascular tone).  Further anal. showed that the prasugrel off-target effect was dose- and time-dependent and of a reversible nature.  In conclusion, the TI of thienopyridines in the mouse may be decreased by P2Y12-independent off-target effects at the vessel wall, whereas that of elinogrel may be enhanced by the reversible, competitive nature of the antiplatelet agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4BcD1er_e7Vg90H21EOLACvtfcHk0lhXc_I1oOLO8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D&md5=b2cd05a85e0988416608e5b2af2ea976</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178574%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DThienopyridines%252C%2520but%2520not%2520elinogrel%252C%2520result%2520in%2520off-target%2520effects%2520at%2520the%2520vessel%2520wall%2520that%2520contribute%2520to%2520bleeding%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D22%26epage%3D30%26doi%3D10.1124%2Fjpet.110.178574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morser, J.</span></span> <span> </span><span class="NLM_article-title">Novel P2Y<sub>12</sub> adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18495218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=523-532&author=J.+Bryantauthor=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=L.+Kentauthor=S.+Schirmauthor=J.+L.+Tsengauthor=B.+Subramanyamauthor=B.+Buckmanauthor=I.+Islamauthor=S.+Yuanauthor=M.+E.+Sullivanauthor=M.+Sniderauthor=J.+Morser&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28I%29%3A+in+vitro+effects+on+platelets&doi=10.1016%2Fj.thromres.2008.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets</span></div><div class="casAuthors">Bryant, Judi; Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Kent, Lorraine; Schirm, Sabine; Tseng, Jih-Lie; Subramanyam, Babu; Buckman, Brad; Islam, Imadul; Yuan, Shendong; Sullivan, Mark E.; Snider, Mike; Morser, John</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the effects of two novel P2Y12 receptor antagonists, BX 667 and its active metabolite BX 048, on platelets.  BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets.  Both compds. were shown to be reversible inhibitors of platelet aggregation.  BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADP.  The specificity of BX 667 and BX 048 was demonstrated against cell lines expressing P2Y1 and P2Y6 as well as against a panel of receptors and enzymes.  Taken all together these data show that both BX 048 and BX 667 are potent P2Y12 antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePdQfPdqtrbVg90H21EOLACvtfcHk0lhXc_I1oOLO8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D&md5=9667b7bdfa878d9cee94486f77c4dd9f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DSchirm%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DSnider%26aufirst%3DM.%26aulast%3DMorser%26aufirst%3DJ.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528I%2529%253A%2520in%2520vitro%2520effects%2520on%2520platelets%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D523%26epage%3D532%26doi%3D10.1016%2Fj.thromres.2008.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Post, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincelette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergona, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span> <span> </span><span class="NLM_article-title">Novel P2Y<sub>12</sub> adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18539312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=533-540&author=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=J.+Vinceletteauthor=R.+Vergonaauthor=L.+Kentauthor=J.+Bryantauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=B.+Subramanyam&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28II%29%3A+pharmacodynamic+and+pharmacokinetic+characterization&doi=10.1016%2Fj.thromres.2008.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span></div><div class="casAuthors">Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Vincelette, Jon; Vergona, Ron; Kent, Lorraine; Bryant, Judi; Sullivan, Mark E.; Dole, William P.; Morser, John; Subramanyam, Babu</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiplatelet drugs are used to prevent aberrant platelet activation in pathophysiol. conditions such as myocardial infarction and ischemic stroke.  The key role that ADP plays in this process has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of the novel P2Y12 receptor antagonists, BX 667 and BX 048.  BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50 = 97, 317 and 3000 nM resp.).  BX 667 had nominal effects on collagen-induced aggregation and weakly inhibited arachidonic acid-induced aggregation.  BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50 = 290 nM) in human blood.  BX 667 was shown to have high oral bioavailability in both dog and rat unlike BX 048.  Administration of BX 667 resulted in a rapid and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition was directly proportional to circulating plasma levels.  This report describes the PK/PD properties of BX 667 showing that it has the properties required for a potential antiplatelet therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWxENonqg7bVg90H21EOLACvtfcHk0lj0199zT3Tdgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D&md5=87826ec634199235a94b2f89553fe806</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DB.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528II%2529%253A%2520pharmacodynamic%2520and%2520pharmacokinetic%2520characterization%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D533%26epage%3D540%26doi%3D10.1016%2Fj.thromres.2008.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boldron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordes, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tissandie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yvon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badorc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseaux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneyrol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zech, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Lignon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-[6-(4-butanoyl-5-methyl-1<i>H</i>-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methyl piperazin-1-yl)-2-oxoethyl]-1<i>H</i>-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y<sub>12</sub> antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7293</span>– <span class="NLM_lpage">7316</span>, <span class="refDoi"> DOI: 10.1021/jm500588w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500588w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7293-7316&author=C.+Boldronauthor=A.+Besseauthor=M.+F.+Bordesauthor=S.+Tissandieauthor=X.+Yvonauthor=B.+Gauauthor=A.+Badorcauthor=T.+Rousseauxauthor=G.+Barreauthor=J.+Meneyrolauthor=G.+Zechauthor=M.+Nazareauthor=V.+Fosseyauthor=A.+M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=C.+Briotauthor=F.+Dolauthor=J.+P.+Heraultauthor=P.+Saviauthor=G.+Lassalleauthor=N.+Delesqueauthor=J.+M.+Herbertauthor=F.+Bono&title=N-%5B6-%284-butanoyl-5-methyl-1H-pyrazol-1-yl%29pyridazin-3-yl%5D-5-chloro-1-%5B2-%284-methyl+piperazin-1-yl%29-2-oxoethyl%5D-1H-indole-3-carboxamide+%28SAR216471%29%2C+a+novel+intravenous+and+oral%2C+reversible%2C+and+directly+acting+P2Y12+antagonist&doi=10.1021%2Fjm500588w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist</span></div><div class="casAuthors">Boldron, Christophe; Besse, Angelina; Bordes, Marie-Francoise; Tissandie, Stephanie; Yvon, Xavier; Gau, Benjamin; Badorc, Alain; Rousseaux, Tristan; Barre, Guillaume; Meneyrol, Jerome; Zech, Gernot; Nazare, Marc; Fossey, Valerie; Pflieger, Anne-Marie; Bonnet-Lignon, Sandrine; Millet, Laurence; Briot, Christophe; Dol, Frederique; Herault, Jean-Pascal; Savi, Pierre; Lassalle, Gilbert; Delesque, Nathalie; Herbert, Jean-Marc; Bono, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7293-7316</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the search of a potential backup for clopidogrel, the authors have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists.  Starting from a hit with low micromolar binding activity, the authors report here the main steps of the optimization process leading to the identification of the preclin. candidate SAR216471, I.  It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature.  I displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGUVg5pZdW1rVg90H21EOLACvtfcHk0lj0199zT3Tdgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git7fO&md5=b6eeb28566a300c4aadb6575bdd28607</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm500588w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500588w%26sid%3Dliteratum%253Aachs%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBordes%26aufirst%3DM.%2BF.%26aulast%3DTissandie%26aufirst%3DS.%26aulast%3DYvon%26aufirst%3DX.%26aulast%3DGau%26aufirst%3DB.%26aulast%3DBadorc%26aufirst%3DA.%26aulast%3DRousseaux%26aufirst%3DT.%26aulast%3DBarre%26aufirst%3DG.%26aulast%3DMeneyrol%26aufirst%3DJ.%26aulast%3DZech%26aufirst%3DG.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DFossey%26aufirst%3DV.%26aulast%3DPflieger%26aufirst%3DA.%2BM.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DBriot%26aufirst%3DC.%26aulast%3DDol%26aufirst%3DF.%26aulast%3DHerault%26aufirst%3DJ.%2BP.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DN-%255B6-%25284-butanoyl-5-methyl-1H-pyrazol-1-yl%2529pyridazin-3-yl%255D-5-chloro-1-%255B2-%25284-methyl%2520piperazin-1-yl%2529-2-oxoethyl%255D-1H-indole-3-carboxamide%2520%2528SAR216471%2529%252C%2520a%2520novel%2520intravenous%2520and%2520oral%252C%2520reversible%252C%2520and%2520directly%2520acting%2520P2Y12%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7293%26epage%3D7316%26doi%3D10.1021%2Fjm500588w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delesque-Touchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Lignon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span> <span> </span><span class="NLM_article-title">SAR216471, an alternative to the use of currently available P2Y<sub>12</sub> receptor inhibitors?</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2014.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2014.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=25064036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1WjsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=693-703&author=N.+Delesque-Touchardauthor=A.+M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=V.+Salelauthor=C.+Boldronauthor=G.+Lassalleauthor=J.+M.+Herbertauthor=P.+Saviauthor=F.+Bono&title=SAR216471%2C+an+alternative+to+the+use+of+currently+available+P2Y12+receptor+inhibitors%3F&doi=10.1016%2Fj.thromres.2014.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?</span></div><div class="casAuthors">Delesque-Touchard, N.; Pflieger, A. M.; Bonnet-Lignon, S.; Millet, L.; Salel, V.; Boldron, C.; Lassalle, G.; Herbert, J. M.; Savi, P.; Bono, F.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-703</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  P2Y12 antagonism is a key therapeutic strategy in the management and prevention of arterial thrombosis.  The objective of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of SAR216471, a novel P2Y12 receptor antagonist.  SAR216471 blocks the binding of 2MeSADP to P2Y12 receptors in vitro (IC50 = 17 nM).  This inhibition was shown to be reversible.  It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50 = 108 and 62 nM, resp.).  It also inhibited platelet aggregation when blood was exposed to collagen or thromboxane A2.  Its high selectivity was demonstrated against a large panel of receptors, enzymes, and ion channels.  Despite its moderate bioavailability in rats, oral administration of SAR216471 resulted in a fast, potent, and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition were directly proportional to its circulating plasma levels.  Pre-clin. study of SAR216471 in a rat shunt thrombosis model demonstrated a dose-dependent antithrombotic activity after oral administration (ED50 = 6.7 mg/kg).  By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, resp.  Finally, the anti-hemostatic effect of SAR216471 and its competitors was investigated in a rat tail bleeding model, revealing a favorable safety profile of SAR216471.  Together, these findings have established a reliable antiplatelet profile of SAR216471, and support its potential use in clin. practice as an alternative to currently available P2Y12 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKEact9v22yrVg90H21EOLACvtfcHk0li-3JfoInXNfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1WjsrzI&md5=f628876c891ea3f6bcde187c1f2427bc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2014.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2014.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DPflieger%26aufirst%3DA.%2BM.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DSalel%26aufirst%3DV.%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DSAR216471%252C%2520an%2520alternative%2520to%2520the%2520use%2520of%2520currently%2520available%2520P2Y12%2520receptor%2520inhibitors%253F%26jtitle%3DThromb.%2520Res.%26date%3D2014%26volume%3D134%26spage%3D693%26epage%3D703%26doi%3D10.1016%2Fj.thromres.2014.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atzler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GläNzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y<sub>12</sub> receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3784</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1021/jm9003297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9003297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlelsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3784-3793&author=Y.+Baqiauthor=K.+Atzlerauthor=M.+K%C3%B6seauthor=M.+Gl%C3%A4Nzelauthor=C.+E.+M%C3%BCller&title=High-affinity%2C+non-nucleotide-derived+competitive+antagonists+of+platelet+P2Y12+receptors&doi=10.1021%2Fjm9003297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y12 Receptors</span></div><div class="casAuthors">Baqi, Younis; Atzler, Kerstin; Kose, Meryem; Glanzel, Markus; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3784-3793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anthraquinone derivs. related to the moderately potent, nonselective P2Y12 receptor antagonist reactive blue 2 were synthesized and optimized with respect to P2Y12 receptor affinity.  These new anthraquinone derivs. were prepd. via copper(0)-catalyzed Ullmann coupling reaction of 1-amino-4-bromoanthraquinone derivs. with anilines in phosphate buffer under microwave irradn.  The most potent compds. I (R1 = SO3Na and CO2H) exhibited Ki values of 24.9 nM and 21.0 nM resp.  1-Amino-2-sulfonato-4-anilinoanthraquinone derivs. appeared to be noncytotoxic, as shown for selected derivs. at two human cell lines (melanoma and astrocytoma).  Compds. I (R1 = SO3Na and CO2H) represent new lead structures for the development of antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNFMcZdKXubVg90H21EOLACvtfcHk0li-3JfoInXNfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlelsbo%253D&md5=59607a39ed17589cd2c3a36628cbcde7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm9003297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9003297%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DAtzler%26aufirst%3DK.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DGl%25C3%25A4Nzel%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DHigh-affinity%252C%2520non-nucleotide-derived%2520competitive%2520antagonists%2520of%2520platelet%2520P2Y12%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3784%26epage%3D3793%26doi%3D10.1021%2Fjm9003297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morena, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kugelgen, I.</span></span> <span> </span><span class="NLM_article-title">Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y<sub>12</sub> receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.156687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fjpet.109.156687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19690189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=648-655&author=K.+Hoffmannauthor=Y.+Baqiauthor=M.+S.+Morenaauthor=M.+Glanzelauthor=C.+E.+Mullerauthor=I.+von+Kugelgen&title=Interaction+of+new%2C+very+potent+non-nucleotide+antagonists+with+Arg256+of+the+human+platelet+P2Y12+receptor&doi=10.1124%2Fjpet.109.156687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor</span></div><div class="casAuthors">Hoffmann, Kristina; Baqi, Younis; Morena, Maria Sol; Glaenzel, Markus; Mueller, Christa E.; von Kuegelgen, Ivar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The P2Y12 receptor plays a crucial role in platelet aggregation.  In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the mol. interaction.  Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells.  The cellular cAMP prodn. was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs.  2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approx. 1 nM.  The anthraquinone deriv. reactive blue 2 used at increasing concns. shifted the concn.-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4).  Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8.  In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased.  The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA.  In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3).  In summary, the results demonstrate that PSB-0739 is the most potent competitive non-nucleotide antagonist at the human P2Y12 receptor described so far.  The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y12 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAK7tsHlBv2LVg90H21EOLACvtfcHk0lhwb_Dfn3io0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu73F&md5=91c4a53c07bb3087d47fc194dbed13c6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.156687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.156687%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DMorena%26aufirst%3DM.%2BS.%26aulast%3DGlanzel%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3Dvon%2BKugelgen%26aufirst%3DI.%26atitle%3DInteraction%2520of%2520new%252C%2520very%2520potent%2520non-nucleotide%2520antagonists%2520with%2520Arg256%2520of%2520the%2520human%2520platelet%2520P2Y12%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D648%26epage%3D655%26doi%3D10.1124%2Fjpet.109.156687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3342</span>– <span class="NLM_lpage">3352</span>, <span class="refDoi"> DOI: 10.1021/jm300038c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300038c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFemtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3342-3352&author=J.+Shanauthor=B.+Zhangauthor=Y.+Zhuauthor=B.+Jiaoauthor=W.+Zhengauthor=X.+Qiauthor=Y.+Gongauthor=F.+Yuanauthor=F.+Lvauthor=H.+Sun&title=Overcoming+clopidogrel+resistance%3A+discovery+of+vicagrel+as+a+highly+potent+and+orally+bioavailable+antiplatelet+agent&doi=10.1021%2Fjm300038c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet Agent</span></div><div class="casAuthors">Shan, Jiaqi; Zhang, Boyu; Zhu, Yaoqiu; Jiao, Bo; Zheng, Weiyi; Qi, Xiaowei; Gong, Yanchun; Yuan, Fang; Lv, Fusheng; Sun, Hongbin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3342-3352</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of optically active 2-hydroxytetrahydrothienopyridine derivs. were designed and synthesized as prodrugs of clopidogrel thiolactone in order to overcome clopidogrel resistance.  The final compds. were evaluated for their inhibitory effect on ADP-induced platelet aggregation in rats.  Compd. 9a was selected for further in vitro and in vivo metab. studies, since its potency was comparable to that of prasugrel and was much higher than that of clopidogrel.  Preliminary pharmacokinetic study results showed that the bioavailability of clopidogrel thiolactone generated from 9a was 6-fold higher than that generated from clopidogrel, implying a much lower clin. ED for 9a in comparison with clopidogrel.  In summary, 9a (vicagrel, I) holds great promise as a more potent and a safer antiplatelet agent that might have the following advantages over clopidogrel: (1) no drug resistance for CYP2C19 poor metabolizers; (2) lower dose-related toxicity due to a much lower ED; (3) faster onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjnY3RFwYKpbVg90H21EOLACvtfcHk0lhwb_Dfn3io0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFemtLo%253D&md5=de26cb85b78ffed42eb877f74d1b43b7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm300038c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300038c%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJiao%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DF.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DOvercoming%2520clopidogrel%2520resistance%253A%2520discovery%2520of%2520vicagrel%2520as%2520a%2520highly%2520potent%2520and%2520orally%2520bioavailable%2520antiplatelet%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3342%26epage%3D3352%26doi%3D10.1021%2Fjm300038c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, M. A.</span></span> <span> </span><span class="NLM_article-title">4-((R)-2-{[6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl] amino}- 3-phosphonopropionyl) piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y<sub>12</sub> receptor antagonist with a wider therapeutic window in the rat than clopidogrel</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9133</span>– <span class="NLM_lpage">9153</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyktbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9133-9153&author=E.+Caroffauthor=F.+Hublerauthor=E.+Meyerauthor=D.+Rennebergauthor=C.+Gnerreauthor=A.+Treiberauthor=M.+Reyauthor=P.+Hessauthor=B.+Steinerauthor=K.+Hilpertauthor=M.+A.+Riederer&title=4-%28%28R%29-2-%7B%5B6-%28%28S%29-3-methoxypyrrolidin-1-yl%29-2-phenylpyrimidine-4-carbonyl%5D+amino%7D-+3-phosphonopropionyl%29+piperazine-1-carboxylic+acid+butyl+ester+%28ACT-246475%29+and+its+prodrug+%28ACT-281959%29%2C+a+novel+P2Y12+receptor+antagonist+with+a+wider+therapeutic+window+in+the+rat+than+clopidogrel&doi=10.1021%2Facs.jmedchem.5b00933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel</span></div><div class="casAuthors">Caroff, Eva; Hubler, Francis; Meyer, Emmanuel; Renneberg, Dorte; Gnerre, Carmela; Treiber, Alexander; Rey, Markus; Hess, Patrick; Steiner, Beat; Hilpert, Kurt; Riederer, Markus A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9133-9153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent posthoc analyses of several clin. trials with P2Y12 antagonists showed the need for new mols. being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding.  The authors have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y12 antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma.  Herein the authors present the optimization steps that led to the discovery of clin. candidate ACT-246475 I.  The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent mols. of the program.  In addn., low in vivo clearance in rat and dog was achieved for the first time.  Since the bioavailability of I was low in rat and dog, the authors developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug ACT-281959, II.  Compd. I showed efficacy in the rat ferric chloride thrombosis model when administered i.v. as parent or orally as its prodrug 45.  Moreover, I displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroPF59EdlX8LVg90H21EOLACvtfcHk0lg9VimZwg7j6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyktbnI&md5=ee08c3b17c78295e847003159aa5eaed</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00933%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26aulast%3DHubler%26aufirst%3DF.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3DRenneberg%26aufirst%3DD.%26aulast%3DGnerre%26aufirst%3DC.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DRiederer%26aufirst%3DM.%2BA.%26atitle%3D4-%2528%2528R%2529-2-%257B%255B6-%2528%2528S%2529-3-methoxypyrrolidin-1-yl%2529-2-phenylpyrimidine-4-carbonyl%255D%2520amino%257D-%25203-phosphonopropionyl%2529%2520piperazine-1-carboxylic%2520acid%2520butyl%2520ester%2520%2528ACT-246475%2529%2520and%2520its%2520prodrug%2520%2528ACT-281959%2529%252C%2520a%2520novel%2520P2Y12%2520receptor%2520antagonist%2520with%2520a%2520wider%2520therapeutic%2520window%2520in%2520the%2520rat%2520than%2520clopidogrel%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9133%26epage%3D9153%26doi%3D10.1021%2Facs.jmedchem.5b00933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, S. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Fernandes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savio, L. E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, F. G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho-Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. L. M.</span></span> <span> </span><span class="NLM_article-title">Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y<sub>1</sub> receptors</span>. <i>Vasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.vph.2016.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.vph.2016.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26924460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12gt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=66-72&author=S.+D.+S.+Oliveiraauthor=N.+F.+Oliveiraauthor=J.+R.+Meyer-Fernandesauthor=L.+E.+B.+Savioauthor=F.+G.+I.+Ornelasauthor=Z.+S.+Ferreiraauthor=R.+Coutinho-Silvaauthor=C.+L.+M.+Silva&title=Increased+expression+of+NTPDases+2+and+3+in+mesenteric+endothelial+cells+during+schistosomiasis+favors+leukocyte+adhesion+through+P2Y1+receptors&doi=10.1016%2Fj.vph.2016.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y1 receptors</span></div><div class="casAuthors">Oliveira, Suellen Darc Santos; Oliveira, Nathalia F.; Meyer-Fernandes, Jose R.; Savio, Luiz Eduardo Baggio; Ornelas, Flavia G. I.; Ferreira, Zulma S.; Coutinho-Silva, Robson; Silva, Claudia Lucia Martins</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-72</span>CODEN:
                <span class="NLM_cas:coden">VPAHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1537-1891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Schistosomiasis is caused by an intravascular parasite and linked to phenotypic changes in endothelial cells that favor inflammation.  Endothelial cells express P2Y1 receptors (P2Y1R), and their activation by ADP favors leukocyte adhesion to the endothelial monolayer.  We aimed to evaluate the influence of schistosomiasis upon endothelial purinergic signaling-mediated leukocyte adhesion.  Mesenteric endothelial cells and mononuclear cells from control and Schistosoma mansoni-infected mice were used in co-culture.  P2Y1R levels were similar in both groups.  Basal leukocyte adhesion was higher in the infected than in the control group; leukocyte adhesion increased after treatment with the P2Y1R agonist 2-MeSATP in both groups, though it only marginally increased in the infected group.  Pre-incubation with the selective P2Y1R antagonist MRS2179 (0.3 μM) prevented the agonist effect.  However, in the infected group it also reduced the basal leukocyte adhesion, suggesting endothelial cell pre-activation.  The endothelial expressions of NTPDases 2 and 3 were significantly increased in the infected group, increasing extracellular ATP hydrolysis and ADP formation by endothelial cells.  Therefore, mesenteric endothelial cells are primed by schistosomiasis to a pro-inflammatory phenotype characterized by an increased expression of NTPDases 2 and 3, favoring ADP accumulation and mononuclear cell adhesion, possibly contributing to mesenteric inflammation and schistosomiasis morbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-atbvubuHSbVg90H21EOLACvtfcHk0lg9VimZwg7j6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12gt7w%253D&md5=08d524f4c68abfb8532963fbd33079fd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.vph.2016.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vph.2016.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DOliveira%26aufirst%3DS.%2BD.%2BS.%26aulast%3DOliveira%26aufirst%3DN.%2BF.%26aulast%3DMeyer-Fernandes%26aufirst%3DJ.%2BR.%26aulast%3DSavio%26aufirst%3DL.%2BE.%2BB.%26aulast%3DOrnelas%26aufirst%3DF.%2BG.%2BI.%26aulast%3DFerreira%26aufirst%3DZ.%2BS.%26aulast%3DCoutinho-Silva%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DC.%2BL.%2BM.%26atitle%3DIncreased%2520expression%2520of%2520NTPDases%25202%2520and%25203%2520in%2520mesenteric%2520endothelial%2520cells%2520during%2520schistosomiasis%2520favors%2520leukocyte%2520adhesion%2520through%2520P2Y1%2520receptors%26jtitle%3DVasc.%2520Pharmacol.%26date%3D2016%26volume%3D82%26spage%3D66%26epage%3D72%26doi%3D10.1016%2Fj.vph.2016.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y<sub>1</sub> receptor antagonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fsj.bjp.0704673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=11959804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlels74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=2004-2010&author=J.+L.+Boyerauthor=M.+Adamsauthor=R.+G.+Raviauthor=K.+A.+Jacobsonauthor=T.+K.+Harden&title=2-Chloro-N6-methyl-%28N%29-methanocarba-2%E2%80%B2-deoxyadenosine-3%E2%80%B2%2C5%E2%80%B2-bisphosphate+is+a+selective+high+affinity+P2Y1+receptor+antagonist&doi=10.1038%2Fsj.bjp.0704673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">2-chloro N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y1 receptor antagonist</span></div><div class="casAuthors">Boyer, Jose L.; Adams, Mary; Ravi, R. Gnana; Jacobson, Kenneth A.; Harden, T. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2004-2010</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We reported previously that bisphosphate derivs. of adenosine are antagonists of the P2Y1 receptor and that modification of the ribose in these analogs is tolerated in the P2Y1 receptor binding pharmacophore.  Here we delineate the pharmacol. activity of one such non-nucleotide mol., 2-chloro N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate (MRS2279), in which the ribose is replaced by a cyclopentane ring constrained in the (N)-conformation by a cyclopropane moiety.  MRS2279 antagonized 2MeSADP-stimulated inositol phosphate formation in turkey erythrocyte membranes with competitive kinetics (pKB = 7.75).  High affinity competitive antagonism by MRS2279 was also obsd. at the human P2Y1 receptor (pKB = 8.10) stably expressed in 1321N1 human astrocytoma cells.  Antagonism was specific for the P2Y1 receptor since MRS2279 had no effect on activation of the human P2Y2, P2Y4, P2Y6, or P2Y11 receptors by their cognate agonists.  MRS2279 also did not block the capacity of ADP to act through the Gi/adenylyl cyclase linked P2Y receptor of platelets to inhibit cAMP accumulation.  In contrast, the P2Y1 receptor is known to be obligatory in the process of ADP-induced platelet aggregation, and MRS2279 competitively inhibited ADP-promoted platelet aggregation with an apparent affinity (pKB = 8.05) similar to that obsd. at the human P2Y1 receptor heterologously expressed in 1321N1 cells.  Taken together these results illustrate selective high affinity antagonism of the P2Y1 receptor by a non-nucleotide mol. that should prove useful for pharmacol. delineation of this receptor in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5daZS3WWovrVg90H21EOLACvtfcHk0lhMVqMrmNFeFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlels74%253D&md5=c961b239774ebec55d3c467a1cbbd241</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704673%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DRavi%26aufirst%3DR.%2BG.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26atitle%3D2-Chloro-N6-methyl-%2528N%2529-methanocarba-2%25E2%2580%25B2-deoxyadenosine-3%25E2%2580%25B2%252C5%25E2%2580%25B2-bisphosphate%2520is%2520a%2520selective%2520high%2520affinity%2520P2Y1%2520receptor%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D2004%26epage%3D2010%26doi%3D10.1038%2Fsj.bjp.0704673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1<i>H</i>-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2015.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26363870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=343-353&author=S.+Chenauthor=T.+Zhangauthor=J.+Wangauthor=F.+Wangauthor=H.+Niuauthor=C.+Wuauthor=S.+Wang&title=Synthesis+and+evaluation+of+1-hydroxy%2Fmethoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic+acid+derivatives+as+non-purine+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2015.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors</span></div><div class="casAuthors">Chen, Shaolei; Zhang, Tingjian; Wang, Jian; Wang, Fangyang; Niu, Handong; Wu, Chunfu; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-353</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Xanthine oxidase is a key enzyme that catalyzes hypoxanthine and xanthine to uric acid, whose overprodn. leads to the gout-causing hyperuricemia.  In this study, a series of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivs. was synthesized and evaluated for their inhibitory potency against xanthine oxidase.  The 1-hydroxyl substituted derivs. showed excellent inhibitory potency with IC50 values ranging from 0.003 μM to 1.2 μM, with compds. I [R = n-Bu] (IC50 = 0.003 μM), I [R = sec-Bu] (IC50 = 0.003 μM), and I [R = iso-Bu] (IC50 = 0.006 μM) manifesting the most potent xanthine oxidase inhibitory potency that were comparable with that of Febuxostat (IC50 = 0.01 μM).  Lineweaver-Burk plot anal. revealed that representative compd. I [R = iso-Bu] acted as a mixed-type inhibitor for xanthine oxidase.  The basis of significant inhibition of xanthine oxidase by compd. I [R = iso-Bu] was rationalized by its mol. docking into the active site of xanthine dehydrogenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_tKiu3i8ErVg90H21EOLACvtfcHk0lhMVqMrmNFeFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsbjF&md5=c8a19d841a0ec5e515095db8a96b19f9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25201-hydroxy%252Fmethoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic%2520acid%2520derivatives%2520as%2520non-purine%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D343%26epage%3D353%26doi%3D10.1016%2Fj.ejmech.2015.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS</span>. <i>J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1113</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.jchromb.2019.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.jchromb.2019.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30901732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1113&publication_year=2019&pages=77-83&author=D.+Zhangauthor=T.+Yangauthor=J.+Lin&title=A+novel+xanthine+oxidase+inhibitor+WSJ-557+study+on+pharmacokinetics+and+tissue+distribution+in+rats+by+UPLC-MS%2FMS&doi=10.1016%2Fj.jchromb.2019.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS</span></div><div class="casAuthors">Zhang, Donghu; Yang, Tian; Lin, Jianyang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-83</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a novel non-purine xanthine oxidase inhibitor, WSJ-557 is a potential drug for gout.  To det. the WSJ-557 concn. in plasma and various tissues of rats, a fast and sensitive method was first established by the ultra-performance liq. chromatog.-tandem mass spectrometry (UPLC-MS/MS) in this paper.  The liq.-liq. extn. of Et acetate was adopted for the sample prepn., and carbamazepine was taken as the internal std.  In the process of chromatog. sepn., MRM transitions for WSJ-557 and carbamazepine (internal std., IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.  The great linearity of WSJ-557 in all bio-samples was found in the corresponding concn. range (r > 0.99).  The intra- and inter-day precision (RSD%) were below 9.5% in various tissues and plasma, whose accuracy (RE%) was within ±9.2%.  This method was resoundingly employed to the WSJ-557 study on rat pharmacokinetics and tissue distribution after the i.v. administration and oral administration.  The av. abs. bioavailability (F) of WSJ-557 was 6.48%.  The highest distribution level of gastric and intestinal tissues indicated that WSJ-557 was first absorbed in the stomach and intestine.  Moreover, this anal. method provides a significant approach for the further development and investigation of WSJ-557.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjy6BdV4z1bVg90H21EOLACvtfcHk0lhOZGk39Kgyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1eht70%253D&md5=8344a518cdc3add4ca3b1033ce2770b0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2019.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2019.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DA%2520novel%2520xanthine%2520oxidase%2520inhibitor%2520WSJ-557%2520study%2520on%2520pharmacokinetics%2520and%2520tissue%2520distribution%2520in%2520rats%2520by%2520UPLC-MS%252FMS%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2019%26volume%3D1113%26spage%3D77%26epage%3D83%26doi%3D10.1016%2Fj.jchromb.2019.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. J.</span></span> <span> </span><span class="NLM_article-title">Compound with Xanthine Oxidase Inhibitory Activity and Salt Thereof, Preparation Method and Usage for the Same</span>. Patent <span class="NLM_patent">WO 2014023104A1</span>, Feb 13, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+J.+Wang&title=Compound+with+Xanthine+Oxidase+Inhibitory+Activity+and+Salt+Thereof%2C+Preparation+Method+and+Usage+for+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BJ.%26atitle%3DCompound%2520with%2520Xanthine%2520Oxidase%2520Inhibitory%2520Activity%2520and%2520Salt%2520Thereof%252C%2520Preparation%2520Method%2520and%2520Usage%2520for%2520the%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aungraheeta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundell, S. J.</span></span> <span> </span><span class="NLM_article-title">Inverse agonism at the P2Y<sub>12</sub> receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2717</span>– <span class="NLM_lpage">2728</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1182%2Fblood-2016-03-707844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=27694321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2717-2728&author=R.+Aungraheetaauthor=A.+Conibearauthor=M.+Butlerauthor=E.+Kellyauthor=S.+Nylanderauthor=A.+Mumfordauthor=S.+J.+Mundell&title=Inverse+agonism+at+the+P2Y12+receptor+and+ENT1+transporter+blockade+contribute+to+platelet+inhibition+by+ticagrelor&doi=10.1182%2Fblood-2016-03-707844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor</span></div><div class="casAuthors">Aungraheeta, Riyaad; Conibear, Alexandra; Butler, Mark; Kelly, Eamonn; Nylander, Sven; Mumford, Andrew; Mundell, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2717-2728</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis.  Here, we sought to further characterize its mol. mechanism of action.  Initial studies showed that ticagrelor promoted a greater inhibition of ADP (ADP) -induced Ca2+ release in washed platelets vs other P2Y12R antagonists.  This addnl. effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors.  This contributed to an increase in basal cyclic adenosine monophosphate (cAMP) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P).  In addn., ticagrelor increased platelet cAMP and VASP-P in the absence of ADP in an adenosine receptor-independent manner.  We hypothesized that this increase originated from a direct effect on basal agonist-independent P2Y12R signaling, and this was validated in 1321N1 cells stably transfected with humanP2Y12R.  In these cells, ticagrelor blocked the constitutive agonist-independent activity of the P2Y12R, limiting basalGi-coupled signaling and thereby increasing cAMP levels.  These data suggest that ticagrelor has the pharmacol. profile of an inverse agonist.  Based on our results showing insurmountable inhibition of ADP-induced Ca2+ release and forskolin-induced cAMP, the mode of antagonism of ticagrelor also appears noncompetitive, at least functionally.  In summary, our studies describe 2 novel modes of action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12Rthat contribute to its effective inhibition of platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE62NVOLgembVg90H21EOLACvtfcHk0lhOZGk39Kgyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWgsLY%253D&md5=5d3c979c05bb10ad9424f13a661a55fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707844%26sid%3Dliteratum%253Aachs%26aulast%3DAungraheeta%26aufirst%3DR.%26aulast%3DConibear%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DMumford%26aufirst%3DA.%26aulast%3DMundell%26aufirst%3DS.%2BJ.%26atitle%3DInverse%2520agonism%2520at%2520the%2520P2Y12%2520receptor%2520and%2520ENT1%2520transporter%2520blockade%2520contribute%2520to%2520platelet%2520inhibition%2520by%2520ticagrelor%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2717%26epage%3D2728%26doi%3D10.1182%2Fblood-2016-03-707844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Antiaggregatory activity in human platelets of potent antagonists of the P2Y<sub>1</sub> receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bcp.2004.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=15476670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot12ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=1995-2002&author=M.+Cattaneoauthor=A.+Lecchiauthor=M.+Ohnoauthor=B.+V.+Joshiauthor=P.+Besadaauthor=S.+Tchilibonauthor=R.+Lombardiauthor=N.+Bischofbergerauthor=T.+K.+Hardenauthor=K.+A.+Jacobson&title=Antiaggregatory+activity+in+human+platelets+of+potent+antagonists+of+the+P2Y1+receptor&doi=10.1016%2Fj.bcp.2004.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor</span></div><div class="casAuthors">Cattaneo, Marco; Lecchi, Anna; Ohno, Michihiro; Joshi, Bhalchandra V.; Besada, Pedro; Tchilibon, Susanna; Lombardi, Rossana; Bischofberger, Norbert; Harden, T. Kendall; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1995-2002</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Activation of the P2Y1 nucleotide receptor in platelets by ADP causes changes in shape and aggregation, mediated by activation of phospholipase C (PLC).  Recently, MRS2500 (2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate) was introduced as a highly potent and selective antagonist for this receptor.  We have studied the actions of MRS2500 in human platelets and compared these effects with the effects of two acyclic nucleotide analogs, a bisphosphate MRS2298 and a bisphosphonate deriv. MRS2496, which act as P2Y1 receptor antagonists, although less potently than MRS2500.  Improved synthetic methods for MRS2500 and MRS2496 were devised.  The bisphosphonate is predicted to be more stable in general in biol. systems than phosphate antagonists due to the non-hydrolyzable C-P bond.  MRS2500 inhibited the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM.  MRS2298 and MRS2496 also both inhibited the ADP-induced aggregation of human platelets with IC50 values of 62.8 nM and 1.5 μM, resp.  A similar order of potency was obsd. for the three antagonists in binding to the recombinant human P2Y1 receptor and in inhibition of ADP-induced shape change and ADP-induced rise in intracellular Ca2+.  No substantial antagonism of the pathway linked to the inhibition of cAMP was obsd. for the nucleotide derivs., indicating no interaction of these three P2Y1 receptor antagonists with the proaggregatory P2Y12 receptor, which is also activated by ADP.  Thus, all three of the bisphosphate derivs. are highly selective antagonists of the platelet P2Y1 receptor, and MRS2500 is the most potent such antagonist yet reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQU9krQWJwpbVg90H21EOLACvtfcHk0lhOZGk39Kgyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot12ntro%253D&md5=23ea4e4a3600f0b2fe89efa651028cb9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26aulast%3DLecchi%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DB.%2BV.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DTchilibon%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DR.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DAntiaggregatory%2520activity%2520in%2520human%2520platelets%2520of%2520potent%2520antagonists%2520of%2520the%2520P2Y1%2520receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D1995%26epage%3D2002%26doi%3D10.1016%2Fj.bcp.2004.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Modified diadenosine tetraphosphates with dual specificity for P2Y<sub>1</sub> and P2Y<sub>12</sub> are potent antagonists of ADP-induced platelet activation</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2573</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1111/jth.12035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fjth.12035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23083103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2573-2580&author=H.+Changauthor=I.+B.+Yanachkovauthor=E.+J.+Dixauthor=Y.+F.+Liauthor=M.+R.+Barnardauthor=G.+E.+Wrightauthor=A.+D.+Michelsonauthor=A.+L.+Frelinger&title=Modified+diadenosine+tetraphosphates+with+dual+specificity+for+P2Y1+and+P2Y12+are+potent+antagonists+of+ADP-induced+platelet+activation&doi=10.1111%2Fjth.12035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation</span></div><div class="casAuthors">Chang, H.; Yanachkov, I. B.; Dix, E. J.; Li, Y. F.; Barnard, M. R.; Wright, G. E.; Michelson, A. D.; Frelinger, A. L., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2573-2580</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Diadenosine 5',5'"-P1,P4-tetraphosphate (Ap4A), a natural compd. stored in platelet dense granules, inhibits ADP-induced platelet aggregation.  Ap4A inhibits the platelet ADP receptors P2Y1 and P2Y12, is a partial agonist of P2Y12, and is a full agonist of the platelet ATP-gated ion channel P2X1.  Modification of the Ap4A tetraphosphate backbone enhances inhibition of ADP-induced platelet aggregation.  However, the effects of these Ap4A analogs on human platelet P2Y1, P2Y12 and P2X1 are unclear.  Objective: To det. the agonist and antagonist activities of diadenosine tetraphosphate analogs towards P2Y1, P2Y12, and P2X1.  Methods: We synthesized the following Ap4A analogs: P1,P4-dithiotetraphosphate; P2,P3-chloromethylenetetraphosphate; P1-thio-P2,P3-chloromethylenetetraphosphate; and P1,P4-dithio-P2,P3-chloromethylenetetraphosphate.  We then measured the effects of these analogs on: (i) ADP-induced platelet aggregation; (ii) P2Y1-mediated changes in cytosolic Ca2+; (iii) P2Y12-mediated changes in vasodilator-stimulated phosphoprotein phosphorylation; and (iv) P2X1-mediated entry of extracellular Ca2+.  Results: Ap4A analogs with modifications in the phosphate backbone inhibited both P2Y1 and P2Y12, and showed no agonist activity towards these receptors.  The dithio modification increased inhibition of P2Y1, P2Y12, and platelet aggregation, whereas the chloromethylene modification increased inhibition of P2Y12 and platelet aggregation, but decreased P2Y1 inhibition.  Combining the dithio and chloromethylene modifications increased P2Y1 and P2Y12 inhibition.  As compared with Ap4A, each modification decreased agonist activity towards P2X1, and the dual modification completely eliminated P2X1 agonist activity.  Conclusions: As compared with Ap4A, tetraphosphate backbone analogs of Ap4A have diminished activity towards P2X1 but inhibit both P2Y1 and P2Y12 and, with greater potency, inhibit ADP-induced platelet aggregation.  Thus, diadenosine tetraphosphate analogs with dual receptor selectivity may have potential as antiplatelet drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbETpMYCHXLVg90H21EOLACvtfcHk0lirBnill_7ZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtrY%253D&md5=13580b821cc2907fc183d381499da177</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjth.12035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12035%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DDix%26aufirst%3DE.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DBarnard%26aufirst%3DM.%2BR.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DModified%2520diadenosine%2520tetraphosphates%2520with%2520dual%2520specificity%2520for%2520P2Y1%2520and%2520P2Y12%2520are%2520potent%2520antagonists%2520of%2520ADP-induced%2520platelet%2520activation%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26spage%3D2573%26epage%3D2580%26doi%3D10.1111%2Fjth.12035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bmc.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28789912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yrs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5260-5267&author=D.+Singhauthor=O.+Silakari&title=Facile+alkylation+of+4-nitrobenzotriazole+and+its+platelet+aggregation+inhibitory+activity&doi=10.1016%2Fj.bmc.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity</span></div><div class="casAuthors">Singh, Dhandeep; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5260-5267</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors explored the facile alkylation of 4-nitrobenzotriazole under basic conditions and the synthesized derivs. were tested for their potential ADP induced platelet aggregation inhibition activity in comparison with std. drug ticagrelor (selective P2Y12 inhibitor).  The nitro group at 4-position is highly activating toward alkylation reactions (under strong basic conditions) and resulted in formation of degrdn. product like 3-nitrobenzene-1,2-diamine which make isolation of alkyl products very difficult.  The authors optimized the reaction under mild basic condition (potassium carbonate and DMF) which is devoid of any degrdn. product.  This is perhaps the first report of 4-nitrobenzotriazole derivs. possessing platelet aggregation inhibitory activity.  Generally activity increases with increase in length of alkyl chain and 1-alkyl positional isomers were found to be more potent than 2-alkyl isomers.  The benzoyl deriv. was found to be the most potent [compd. 22; (4-Nitro-1H-benzotriazol-1-yl)(phenyl)methanone; IC50 = 0.65±0.10 mM] which may be attributed to electroneg. oxygen atom and arom. ring.  Benzyl derivs. [compd. 20; 1-Benzyl-4-nitro-1H-benzotriazole; IC50 = 0.81±0.08 mM, compd. 21; 2-Benzyl-4-nitro-2H-benzotriazole; IC50 = 0.82±0.19 mM] and sulfonyl deriv. [compd. 23; 1-[(4-Methylphenyl)sulfonyl]-4-nitro-1H-benzotriazole; IC50 = 0.82±0.19 mM] are also found to be highly active.  Furthermore, all compds. possess P2Y12 binding affinity as confirmed by VASP/P2Y12 phosphorylation assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUQufzw-dv7LVg90H21EOLACvtfcHk0lirBnill_7ZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yrs77I&md5=0e72f9746600693c22b3095ccf5a7deb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DFacile%2520alkylation%2520of%25204-nitrobenzotriazole%2520and%2520its%2520platelet%2520aggregation%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5260%26epage%3D5267%26doi%3D10.1016%2Fj.bmc.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bijak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelenberger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saluk-Bijak, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of flavonolignans on the P2Y<sub>12</sub> pathway in blood platelets</span>. <i>Molecules.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">374</span>, <span class="refDoi"> DOI: 10.3390/molecules23020374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3390%2Fmolecules23020374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=374&author=M.+Bijakauthor=R.+Szelenbergerauthor=A.+Dziedzicauthor=J.+Saluk-Bijak&title=Inhibitory+effect+of+flavonolignans+on+the+P2Y12+pathway+in+blood+platelets&doi=10.3390%2Fmolecules23020374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of Flavonolignans on the P2Y12 pathway in blood platelets</span></div><div class="casAuthors">Bijak, Michal; Szelenberger, Rafal; Dziedzic, Angela; Saluk-Bijak, Joanna</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374/1-374/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">ADP (ADP) is the major platelet agonist, which is important in the shape changes, stability, and growth of the thrombus.  Platelet activation by ADP is assocd. with the G protein-coupled receptors P2Y1 and P2Y12.  The pharmacol. blockade of the P2Y12 receptor significantly reduces the risk of peripheral artery disease, myocardial infarction, ischemic stroke, and vascular death.  Recent studies demonstrated the inhibition of ADP-induced blood platelet activation by three major compds. of the flavonolignans group: silybin, silychristin, and silydianin.  For this reason, the aim of the current work was to verify the effects of silybin, silychristin, and silydianin on ADP-induced physiol. platelets responses, as well as mechanisms of P2Y12-dependent intracellular signal transduction.  We evaluated the effect of tested flavonolignans on ADP-induced blood platelets' aggregation in platelet-rich plasma (PRP) (using light transmission aggregometry), adhesion to fibrinogen (using the static method), and the secretion of PF-4 (using the ELISA method).  Addnl., using the double labeled flow cytometry method, we estd. platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation.  We demonstrated a dose-dependent redn. of blood platelets' ability to perform ADP-induced aggregation, adhere to fibrinogen, and secrete PF-4 in samples treated with flavonolignans.  Addnl., we obsd. that all of the tested flavonolignans were able to increase VASP phosphorylation in blood platelets samples, which is correlated with P2Y12 receptor inhibition.  All of these analyses show that silychristin and silybin have the strongest inhibitory effect on blood platelet activation by ADP, while silydianin also inhibits the ADP pathway, but to a lesser extent.  The results obtained in this study clearly demonstrate that silybin, silychristin, and silydianin have inhibitory properties against the P2Y12 receptor and block ADP-induced blood platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LW1Q82jl_LVg90H21EOLACvtfcHk0lirBnill_7ZKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqsrzP&md5=8fc3ebdb50353a8944be9125f430e033</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23020374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23020374%26sid%3Dliteratum%253Aachs%26aulast%3DBijak%26aufirst%3DM.%26aulast%3DSzelenberger%26aufirst%3DR.%26aulast%3DDziedzic%26aufirst%3DA.%26aulast%3DSaluk-Bijak%26aufirst%3DJ.%26atitle%3DInhibitory%2520effect%2520of%2520flavonolignans%2520on%2520the%2520P2Y12%2520pathway%2520in%2520blood%2520platelets%26jtitle%3DMolecules.%26date%3D2018%26volume%3D23%26spage%3D374%26doi%3D10.3390%2Fmolecules23020374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lortie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudreault, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J. F.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19128824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvV2nurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=869-873&author=E.+Lortieauthor=F.+Girardauthor=D.+Boudreaultauthor=M.+Ruelauthor=S.+Mansourauthor=N.+Blaisauthor=J.+F.+Hardy&title=Clopidogrel+induces+an+acute+hemostatic+deficit+and+increases+intra+abdominal+bleeding+in+rabbits&doi=10.1016%2Fj.thromres.2008.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits</span></div><div class="casAuthors">Lortie, Elise; Girard, Francois; Boudreault, Daniel; Ruel, Monique; Mansour, Saad; Blais, Normand; Hardy, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clopidogrel, a potent antiplatelet drug, increases hemorrhagic adverse events when its use is continued ≤ 5 days before cardiac surgery but data are lacking in non-cardiac surgery.  We sought to det. the dose of clopidogrel which has a maximal antiplatelet and hemorrhagic effect in a rabbit model of non-cardiac surgery.  Twenty-four rabbits were divided into 3 groups according to the dose of clopidogrel administered (5, 10, and 20 mg.kg- 1).  Baseline measurement of platelet aggregation induced with ADP, platelet reactivity index (PRI) of the VASP-phosphorylation assay and hematol. variables were obtained the day before the expt.  Two hours after clopidogrel administration, the same variables were measured, along with intra abdominal bleeding following standardized hepato-splenic lesions.  Platelet aggregation was inhibited in a dose-dependent manner: 46% with 5 mg.kg- 1 and 93% with 20 mg.kg- 1 of clopidogrel.  PRI was reduced by 61 with 5 mg.kg- 1 of clopidogrel and by 92 and 94% with 10 mg.kg- 1 and 20 mg.kg- 1 resp.  Percentage redn. of platelet aggregation was pos. correlated with the percentage redn. of PRI (r = 0.69; CI95, 0.40 to 0.86).  Bleeding from hepato-splenic lesions was more important in the 10 and 20 mg.kg- 1 groups compared to the 5 mg.kg- 1 group.  Higher doses of clopidogrel are assocd. with a more profound inhibition of platelet aggregation and PRI and increased blood losses following standardized hepato-splenic lesions.  We conclude that our animal model demonstrates clopidogrel's propensity to increase intra abdominal bleeding after standardized hepato-splenic lesions and may help develop blood sparing strategies for patients undergoing surgery while on clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ6_41XfEMirVg90H21EOLACvtfcHk0lgpsl-QBQqx3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvV2nurk%253D&md5=c219c6bfd9095ed9383f23a9deb24cab</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DLortie%26aufirst%3DE.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DBoudreault%26aufirst%3DD.%26aulast%3DRuel%26aufirst%3DM.%26aulast%3DMansour%26aufirst%3DS.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DHardy%26aufirst%3DJ.%2BF.%26atitle%3DClopidogrel%2520induces%2520an%2520acute%2520hemostatic%2520deficit%2520and%2520increases%2520intra%2520abdominal%2520bleeding%2520in%2520rabbits%26jtitle%3DThromb.%2520Res.%26date%3D2009%26volume%3D123%26spage%3D869%26epage%3D873%26doi%3D10.1016%2Fj.thromres.2008.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Söderlund, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asztély, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berggren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellheim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romlin, B. S.</span></span> <span> </span><span class="NLM_article-title">In vitro anti-platelet potency of ticagrelor in blood samples from infants and children</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2015.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2015.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26210892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FmsV2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=620-624&author=F.+S%C3%B6derlundauthor=A.-K.+Aszt%C3%A9lyauthor=A.+Jeppssonauthor=S.+Nylanderauthor=A.+Berggrenauthor=K.+Nelanderauthor=A.+Castellheimauthor=B.+S.+Romlin&title=In+vitro+anti-platelet+potency+of+ticagrelor+in+blood+samples+from+infants+and+children&doi=10.1016%2Fj.thromres.2015.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro anti-platelet potency of ticagrelor in blood samples from infants and children</span></div><div class="casAuthors">Soderlund Fredrik; Asztely Anna-Karin; Nylander Sven; Berggren Anders; Nelander Karin; Jeppsson Anders; Castellheim Albert; Romlin Birgitta S</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">620-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Ticagrelor, a novel platelet inhibitor acting on the ADP-dependent P2Y12 receptor, is currently approved for treating adults with acute coronary syndrome.  The effect of ticagrelor in children has not been explored.  As a first step, we here evaluate if the in vitro anti-platelet potency of ticagrelor in blood samples from children of different age is different as compared with in blood samples from adults.  MATERIALS AND METHODS:  Blood samples from 36 healthy children grouped by age (0-2 months, n=6; 2-6 months, n=6; 6months-2years, n=6; 2-6 years, n=10; 6-12 years, n=8) and 13 adults were collected for in vitro analysis using vasodilator stimulated phosphoprotein phosphorylation (VASP) assay in whole blood and ADP-induced light transmission aggregometry (LTA) in platelet rich plasma.  Ticagrelor (0.01 - 10μmol/L) was added in vitro and its potency was assessed by calculating the concentration that provided 50% inhibition of the maximum response (IC50).  RESULTS:  The in vitro potency of ticagrelor in blood from adults and in blood from children of any age group were comparable, both when analyzed with LTA and with VASP.  CONCLUSIONS:  These in vitro results are consistent with the hypothesis that ticagrelor would achieve a comparable anti-platelet effect in children of different ages as in adults at equal plasma exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2vWkaw12dnpI8NvIb08rbfW6udTcc2eYrsQaaBkizBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FmsV2hsg%253D%253D&md5=3cc5492667e0ed0d7c1518c79792f9fa</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2015.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2015.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6derlund%26aufirst%3DF.%26aulast%3DAszt%25C3%25A9ly%26aufirst%3DA.-K.%26aulast%3DJeppsson%26aufirst%3DA.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DBerggren%26aufirst%3DA.%26aulast%3DNelander%26aufirst%3DK.%26aulast%3DCastellheim%26aufirst%3DA.%26aulast%3DRomlin%26aufirst%3DB.%2BS.%26atitle%3DIn%2520vitro%2520anti-platelet%2520potency%2520of%2520ticagrelor%2520in%2520blood%2520samples%2520from%2520infants%2520and%2520children%26jtitle%3DThromb.%2520Res.%26date%3D2015%26volume%3D136%26spage%3D620%26epage%3D624%26doi%3D10.1016%2Fj.thromres.2015.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay-moine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulard, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of ELISA-based VASP assay with whole blood samples from several animal species, and compatibility with various platelet antagonists</span>. <i>BIOCYTEX.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>, <span class="refDoi"> DOI: 10.13140/RG.2.2.10221.69609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.13140%2FRG.2.2.10221.69609" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Bourguetauthor=D.+Boulay-moineauthor=S.+Mietauthor=M.+Moulard&title=Evaluation+of+ELISA-based+VASP+assay+with+whole+blood+samples+from+several+animal+species%2C+and+compatibility+with+various+platelet+antagonists&doi=10.13140%2FRG.2.2.10221.69609"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.13140%2FRG.2.2.10221.69609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.13140%252FRG.2.2.10221.69609%26sid%3Dliteratum%253Aachs%26aulast%3DBourguet%26aufirst%3DN.%26aulast%3DBoulay-moine%26aufirst%3DD.%26aulast%3DMiet%26aufirst%3DS.%26aulast%3DMoulard%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520ELISA-based%2520VASP%2520assay%2520with%2520whole%2520blood%2520samples%2520from%2520several%2520animal%2520species%252C%2520and%2520compatibility%2520with%2520various%2520platelet%2520antagonists%26jtitle%3DBIOCYTEX.%26date%3D2011%26doi%3D10.13140%2FRG.2.2.10221.69609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span> <i>Glide</i>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Glide%3B+Schrodinger%2C+LLC%3A+New+York%2C+NY%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchrodinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span> <span> </span><span class="NLM_article-title">Two disparate ligand-binding sites in the human P2Y<sub>1</sub> receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/nature14287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnature14287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=25822790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFekt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=317-321&author=D.+Zhangauthor=Z.-G.+Gaoauthor=K.+Zhangauthor=E.+Kiselevauthor=S.+Craneauthor=J.+Wangauthor=S.+Paolettaauthor=C.+Yiauthor=L.+Maauthor=W.+Zhangauthor=G.+W.+Hanauthor=H.+Liuauthor=V.+Cherezovauthor=V.+Katritchauthor=H.+Jiangauthor=R.+C.+Stevensauthor=K.+A.+Jacobsonauthor=Q.+Zhaoauthor=B.+Wu&title=Two+disparate+ligand-binding+sites+in+the+human+P2Y1+receptor&doi=10.1038%2Fnature14287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Two disparate ligand-binding sites in the human P2Y1 receptor</span></div><div class="casAuthors">Zhang, Dandan; Gao, Zhan-Guo; Zhang, Kaihua; Kiselev, Evgeny; Crane, Steven; Wang, Jiang; Paoletta, Silvia; Yi, Cuiying; Ma, Limin; Zhang, Wenru; Han, Gye Won; Liu, Hong; Cherezov, Vadim; Katritch, Vsevolod; Jiang, Hualiang; Stevens, Raymond C.; Jacobson, Kenneth A.; Zhao, Qiang; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">520</span>
        (<span class="NLM_cas:issue">7547</span>),
    <span class="NLM_cas:pages">317-321</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to ADP, the P2Y1 receptor (P2Y1R) facilitates platelet aggregation, and thus serves as an important antithrombotic drug target.  Here we report the crystal structures of the human P2Y1R in complex with a nucleotide antagonist MRS2500 at 2.7 Å resoln., and with a non-nucleotide antagonist BPTU at 2.2 Å resoln.  The structures reveal two distinct ligand-binding sites, providing at. details of P2Y1R's unique ligand-binding modes.  MRS2500 recognizes a binding site within the seven transmembrane bundle of P2Y1R, which is different in shape and location from the nucleotide binding site in the previously detd. structure of P2Y12R, representative of another P2YR subfamily.  BPTU binds to an allosteric pocket on the external receptor interface with the lipid bilayer, making it the first structurally characterized selective G-protein-coupled receptor (GPCR) ligand located entirely outside of the helical bundle.  These high-resoln. insights into P2Y1R should enable discovery of new orthosteric and allosteric antithrombotic drugs with reduced adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE4fFTJwyarVg90H21EOLACvtfcHk0lg23c6sbS1U5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFekt7Y%253D&md5=fb29b394fbf9497f63833c05364460b3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnature14287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14287%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DB.%26atitle%3DTwo%2520disparate%2520ligand-binding%2520sites%2520in%2520the%2520human%2520P2Y1%2520receptor%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D317%26epage%3D321%26doi%3D10.1038%2Fnature14287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenalti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Structure of the human P2Y<sub>12</sub> receptor in complex with an antithrombotic drug</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1038/nature13083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnature13083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=24670650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=115-118&author=K.+Zhangauthor=J.+Zhangauthor=Z.+G.+Gaoauthor=D.+Zhangauthor=L.+Zhuauthor=G.+W.+Hanauthor=S.+M.+Mossauthor=S.+Paolettaauthor=E.+Kiselevauthor=W.+Luauthor=G.+Fenaltiauthor=W.+Zhangauthor=C.+E.+Mullerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Structure+of+the+human+P2Y12+receptor+in+complex+with+an+antithrombotic+drug&doi=10.1038%2Fnature13083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span></div><div class="casAuthors">Zhang, Kaihua; Zhang, Jin; Gao, Zhan-Guo; Zhang, Dandan; Zhu, Lan; Han, Gye Won; Moss, Steven M.; Paoletta, Silvia; Kiselev, Evgeny; Lu, Weizhen; Fenalti, Gustavo; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides.  There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.  Their ligands are generally charged mols. with relatively low bioavailability and stability in vivo, which limits the authors' understanding of this receptor family.  P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R-including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analog ticagrelor (Brilinta) that acts directly on the receptor-have been approved for the prevention of stroke and myocardial infarction.  However, limitations of these drugs (for example, a very long half-life of clopidogrel action and a characteristic adverse effect profile of ticagrelor) suggest that there is an unfulfilled medical need for developing a new generation of P2Y12R inhibitors.  Here the authors report the 2.6 Å resoln. crystal structure of human P2Y12R in complex with a non-nucleotide reversible antagonist, AZD1283.  The structure reveals a distinct straight conformation of helix V, which sets P2Y12R apart from all other known class A GPCR structures.  With AZD1283 bound, the highly conserved disulfide bridge in GPCRs between helix III and extracellular loop 2 is not obsd. and appears to be dynamic.  Along with the details of the AZD1283-binding site, anal. of the extracellular interface reveals an adjacent ligand-binding region and suggests that both pockets could be required for dinucleotide binding.  The structure provides essential insights for the development of improved P2Y12R ligands and allosteric modulators as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY06VN4D76bVg90H21EOLACvtfcHk0liNCdp3UZQEMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D&md5=539bb91325c547737bc98baf59f3ff26</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature13083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13083%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DMoss%26aufirst%3DS.%2BM.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520P2Y12%2520receptor%2520in%2520complex%2520with%2520an%2520antithrombotic%2520drug%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature13083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span> <i>The PyMOL Molecular Graphics System</i>, version <span class="NLM_edition">1.5.0.3</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbadin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kugelgen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassburger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Modeling ligand recognition at the P2Y<sub>12</sub> receptor in light of X-ray structural information</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1007/s10822-015-9858-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs10822-015-9858-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26194851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=737-756&author=S.+Paolettaauthor=D.+Sabbadinauthor=I.+von+Kugelgenauthor=S.+Hinzauthor=V.+Katritchauthor=K.+Hoffmannauthor=A.+Abdelrahmanauthor=J.+Strassburgerauthor=Y.+Baqiauthor=Q.+Zhaoauthor=R.+C.+Stevensauthor=S.+Moroauthor=C.+E.+Mullerauthor=K.+A.+Jacobson&title=Modeling+ligand+recognition+at+the+P2Y12+receptor+in+light+of+X-ray+structural+information&doi=10.1007%2Fs10822-015-9858-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span></div><div class="casAuthors">Paoletta, Silvia; Sabbadin, Davide; von Kugelgen, Ivar; Hinz, Sonja; Katritch, Vsevolod; Hoffmann, Kristina; Abdelrahman, Aliaa; Strassburger, Jens; Baqi, Younis; Zhao, Qiang; Stevens, Raymond C.; Moro, Stefano; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery.  Its recently solved, highly divergent crystallog. structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition.  Therefore, we performed extensive mol. modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported.  Various nucleotide derivs. docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6.  Supervised mol. dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites.  Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R.  Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets.  Thus, our structure-based approach consistently rationalized the main structure-activity relationships within each ligand class, giving useful information for designing improved ligands.  Graphical Abstr.: [Figure not available: see full text.].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QHrDrSpB57Vg90H21EOLACvtfcHk0liNCdp3UZQEMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J&md5=f6d2128d8067de9a9e0aed5dd1a375d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9858-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9858-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DSabbadin%26aufirst%3DD.%26aulast%3Dvon%2BKugelgen%26aufirst%3DI.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DStrassburger%26aufirst%3DJ.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DModeling%2520ligand%2520recognition%2520at%2520the%2520P2Y12%2520receptor%2520in%2520light%2520of%2520X-ray%2520structural%2520information%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D737%26epage%3D756%26doi%3D10.1007%2Fs10822-015-9858-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miners, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> drug metabolism using liver microsomes</span>. <i>Curr. Protoc Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1002/cpph.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fcpph.9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2016&pages=1-24&author=K.+M.+Knightsauthor=D.+M.+Stresserauthor=J.+O.+Minersauthor=C.+L.+Crespi&title=In+vitro+drug+metabolism+using+liver+microsomes&doi=10.1002%2Fcpph.9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcpph.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpph.9%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DK.%2BM.%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DIn%2520vitro%2520drug%2520metabolism%2520using%2520liver%2520microsomes%26jtitle%3DCurr.%2520Protoc%2520Pharmacol.%26date%3D2016%26volume%3D74%26spage%3D1%26epage%3D24%26doi%3D10.1002%2Fcpph.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. H.</span></span> <span> </span><span class="NLM_article-title">Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/bdd.2174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fbdd.2174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30730576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=101-111&author=H.+J.+Kimauthor=H.+Leeauthor=H.+K.+Jiauthor=T.+Leeauthor=K.+H.+Liu&title=Screening+of+ten+cytochrome+P450+enzyme+activities+with+12+probe+substrates+in+human+liver+microsomes+using+cocktail+incubation+and+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fbdd.2174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Kim, Hyun-Ji; Lee, Hyunyoung; Ji, Hyeon-Kyeong; Lee, Taeho; Liu, Kwang-Hyeon</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">101-111</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">In this study, an assay was designed to evaluate drug interactions with 10 major human cytochrome P 450 (P 450) enzymes incubated in liver microsomes, involving 12 probe substrates with two cocktail incubation sets used in a single liq. chromatog.-tandem mass spectrometry run.  The P 450 substrate compn. in each cocktail set was optimized to minimize solvent effects and mutual drug interactions among substrates as follows: cocktail A was composed of phenacetin for CYP1A2, bupropion for CYP2B6, amodiaquine for CYP2C8, diclofenac for CYP2C9, S-mephenytoin for CYP2C19, and dextromethorphan for CYP2D6; cocktail B was composed of coumarin for CYP2A6, chlorzoxazone for CYP2E1, astemizole for CYP2J2, and midazolam, nifedipine, and testosterone for CYP3A.  Multiple probe substrates were used for CYP3A owing to the multiple substrate-binding sites and substrate-dependent inhibition.  After incubation in human liver microsomes, each incubation mixt. was pooled and all probe metabolites were simultaneously analyzed in a single LC-MS/MS run.  Polarity switching was used to acquire the neg.-ion mode for hydroxychlorzoxazone and pos.-ion mode for the remaining analytes.  The method was validated by comparing inhibition data obtained from incubation of each individual probe substrate alone and with the substrate cocktails.  The half-maximal inhibitory concn. values obtained from the cocktail and individual incubations were well correlated and in agreement with previously reported values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWQt2lI2WtrVg90H21EOLACvtfcHk0li8VvuD06onHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVWjsr8%253D&md5=eac65e5423eb84a58a4ad4ff901a527b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2174%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DH.%2BK.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DK.%2BH.%26atitle%3DScreening%2520of%2520ten%2520cytochrome%2520P450%2520enzyme%2520activities%2520with%252012%2520probe%2520substrates%2520in%2520human%2520liver%2520microsomes%2520using%2520cocktail%2520incubation%2520and%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2019%26volume%3D40%26spage%3D101%26epage%3D111%26doi%3D10.1002%2Fbdd.2174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargill, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandeneau, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patten, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of human cyp3aa in vitro by azamulin and evidence that inhibition is irreversible</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1124/dmd.32.1.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.32.1.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=14709627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFWqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=105-112&author=D.+M.+Stresserauthor=M.+I.+Broudyauthor=T.+Hoauthor=C.+E.+Cargillauthor=A.+P.+Blanchardauthor=R.+Sharmaauthor=A.+A.+Dandeneauauthor=J.+J.+Goodwinauthor=S.+D.+Turnerauthor=J.+C.+L.+Erveauthor=C.+J.+Pattenauthor=S.+S.+Dehalauthor=C.+L.+Crespi&title=Highly+selective+inhibition+of+human+cyp3aa+in+vitro+by+azamulin+and+evidence+that+inhibition+is+irreversible&doi=10.1124%2Fdmd.32.1.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible</span></div><div class="casAuthors">Stresser, David M.; Broudy, Marc I.; Ho, Thuy; Cargill, Catherine E.; Blanchard, Andrew P.; Sharma, Raman; Dandeneau, Andre A.; Goodwin, Joseph J.; Turner, Stephanie D.; Erve, John C. L.; Patten, Christopher J.; Dehal, Shangara S.; Crespi, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole deriv. of the pleuromutilin class of anti-infectives.  The authors tested the inhibition potency of azamulin toward 18 cytochromes P 450 using human liver microsomes or microsomes from insect cells expressing single isoforms.  In a competitive inhibition model, IC50 values for CYP3A (0.03-0.24 μM) were at least 100-fold lower than all other non-CYP3A enzymes except CYP2J2 (∼50-fold lower).  The IC50 value with heterologously expressed CYP3A4 was 15-fold and 13-fold less than those of CYP3A5 and CYP3A7, resp.  The ref. inhibitor ketoconazole was less selective and exhibited potent inhibition (IC50 values <10 μM) for CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP4F2, and CYP4F12.  Inhibition of CYP3A by azamulin appeared sigmoidal and well behaved with the substrates 7-benzyloxy-4-trifluoromethylcoumarin, testosterone, and midazolam.  Preincubation of 4.8 μM azamulin in the presence of NADPH for 10 min inhibited ∼95% of testosterone 6β-hydroxylase activity compared with preincubation in the absence of NADPH.  Catalytic activities of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were unaffected by similar expts.  Incubation of azamulin with heterologously expressed CYP3A4 yielded a type I binding spectrum with a spectral dissocn. const. of 3.5 μM, whereas no interaction was found with CYP2D6.  Azamulin exhibited good chem. stability when stored in acetonitrile for up to 12 days.  Aq. soly. was found to be >300 μM.  Azamulin represents an important new chem. tool for use in characterizing the contribution of CYP3A to the metab. of xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxpHyX0lmJULVg90H21EOLACvtfcHk0li8VvuD06onHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFWqs7o%253D&md5=a6119b5808418a555a9abe3353508be0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.1.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.1.105%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCargill%26aufirst%3DC.%2BE.%26aulast%3DBlanchard%26aufirst%3DA.%2BP.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DGoodwin%26aufirst%3DJ.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26aulast%3DPatten%26aufirst%3DC.%2BJ.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520human%2520cyp3aa%2520in%2520vitro%2520by%2520azamulin%2520and%2520evidence%2520that%2520inhibition%2520is%2520irreversible%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D105%26epage%3D112%26doi%3D10.1124%2Fdmd.32.1.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. J.</span></span> <span> </span><span class="NLM_article-title">The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S151660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2147%2FDDDT.S151660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29343943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1SmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=57-65&author=N.+Chenauthor=X.+Y.+Yangauthor=C.+E.+Guoauthor=X.+N.+Biauthor=J.+H.+Chenauthor=H.+Y.+Chenauthor=H.+P.+Liauthor=H.+Y.+Linauthor=Y.+J.+Zhang&title=The+oral+bioavailability%2C+excretion+and+cytochrome+P450+inhibition+properties+of+epiberberine%3A+an+in+vivo+and+in+vitro+evaluation&doi=10.2147%2FDDDT.S151660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation</span></div><div class="casAuthors">Chen, Ning; Yang, Xiao-yan; Guo, Chang-e; Bi, Xin-ning; Chen, Jian-hua; Chen, Hong-ying; Li, Hong-pin; Lin, Hong-ying; Zhang, Yu-jie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Epiberberine (EPI) is a novel and potentially effective therapeutic and preventive agent for diabetes and cardiovascular disease.  To evaluate its potential value for drug development, a specific, sensitive and robust high-performance liq. chromatog.-tandem mass spectrometry assay for the detn. of EPI in rat biol. samples was established.  This assay was used to study the pharmacokinetics, bioavailability and excretion of EPI in rats after oral administration.  In addn., a cocktail method was used to compare the inhibition characteristics of EPI on cytochrome P 450 (CYP450) isoforms in human liver microsomes (HLMs) and rat liver microsomes (RLMs).  The results demonstrated that EPI was rapidly absorbed and metabolized after oral administration (10, 54 or 81 mg/kg) in rats, with Tmax of 0.37-0.42 h and T1/2 of 0.49-2.73 h.  The Cmax and area under the curve values for EPI increased proportionally with the dose, and the oral abs. bioavailability was 14.46%.  EPI was excreted mainly in bile and feces, and after its oral administration to rats, EPI was eliminated predominantly by the kidneys.  A comparison of the current half-maximal inhibitory concn. and Ki values revealed that EPI demonstrated an obvious inhibitory effect on CYP2C9 and CYP2D6.  Furthermore, its effect was stronger in HLM than in RLM, more likely to be a result of noncompetitive inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocsnqYGEveF7Vg90H21EOLACvtfcHk0lhgVDxFz8ryOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1SmtLw%253D&md5=8944d97a4036c32cf31ea04662325855</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S151660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S151660%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DC.%2BE.%26aulast%3DBi%26aufirst%3DX.%2BN.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DH.%2BP.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26atitle%3DThe%2520oral%2520bioavailability%252C%2520excretion%2520and%2520cytochrome%2520P450%2520inhibition%2520properties%2520of%2520epiberberine%253A%2520an%2520in%2520vivo%2520and%2520in%2520vitro%2520evaluation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D57%26epage%3D65%26doi%3D10.2147%2FDDDT.S151660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span> <i>The Hershberger Guideline, Performance-Based Test: OECD guideline
for the testing of chemicals</i>. <span class="NLM_year">2001</span>;  <span class="NLM_volume">601</span>,  <span class="NLM_fpage">858</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Hershberger+Guideline%2C+Performance-Based+Test%3A+OECD+guideline%0Afor+the+testing+of+chemicals.+2001%3B+601%2C+858."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Hershberger%2520Guideline%252C%2520Performance-Based%2520Test%253A%2520OECD%2520guideline%250Afor%2520the%2520testing%2520of%2520chemicals%26date%3D2001%26volume%3D601%26spage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100(R) and Multiplate (R) whole blood aggregometer <i>in vitro</i>, <i>ex vivo</i> and FeCl<sub>3</sub>-induced thrombosis models <i>in vivo</i></span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2011.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2011.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21420150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFWntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=565-570&author=C.+W.+Kimauthor=J.+W.+Yunauthor=I.+H.+Baeauthor=Y.+H.+Parkauthor=Y.+S.+Jeongauthor=J.+W.+Parkauthor=J.+H.+Chungauthor=Y.+H.+Parkauthor=K.+M.+Lim&title=Evaluation+of+anti-platelet+and+anti-thrombotic+effects+of+cilostazol+with+PFA-100%28R%29+and+Multiplate+%28R%29+whole+blood+aggregometer+in+vitro%2C+ex+vivo+and+FeCl3-induced+thrombosis+models+in+vivo&doi=10.1016%2Fj.thromres.2011.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100 and Multiplate whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo</span></div><div class="casAuthors">Kim, Chae-Wook; Yun, Jun-Won; Bae, Il-Hong; Park, Yang-Hui; Jeong, Yeon-Su; Park, Jin-Woo; Chung, Jin-Ho; Park, Young-Ho; Lim, Kyung-Min</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate and PFA-100 in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without potential issues of species differences.  In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 μM while it showed a highly sensitive and all-or-none type inhibition response from 25 μM in PFA-100.  Interestingly, cilostazol manifested anti-thrombotic effects in vivo at much lower plasma concns. than the effective concns. measured in ex vivo or in vitro aggregation tests using PFA-100 or Multiplate.  In addn., the tail bleeding time measurement demonstrated that rats have lower sensitivity to the anti-platelet effects of cilostazol than mice.  These results suggest that the detailed comparative evaluation of whole blood aggregometer assays with anti-thrombotic effects in vivo should be preceded before the application of these methods for the pharmacodynamic studies of anti-thrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5s_LLoldIy7Vg90H21EOLACvtfcHk0lhgVDxFz8ryOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFWntLY%253D&md5=bd2f7369f0aca7ccf58b381976fd37de</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2011.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2011.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DYun%26aufirst%3DJ.%2BW.%26aulast%3DBae%26aufirst%3DI.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DK.%2BM.%26atitle%3DEvaluation%2520of%2520anti-platelet%2520and%2520anti-thrombotic%2520effects%2520of%2520cilostazol%2520with%2520PFA-100%2528R%2529%2520and%2520Multiplate%2520%2528R%2529%2520whole%2520blood%2520aggregometer%2520in%2520vitro%252C%2520ex%2520vivo%2520and%2520FeCl3-induced%2520thrombosis%2520models%2520in%2520vivo%26jtitle%3DThromb.%2520Res.%26date%3D2011%26volume%3D127%26spage%3D565%26epage%3D570%26doi%3D10.1016%2Fj.thromres.2011.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Effects of modified Je-Ho-Tang on ferric chloride-induced thrombosis in a rat model and of peripheral circulatory disturbance in a mouse model</span>. <i>Han'guk Eungyong Sangmyong Hwahakhoeji</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.3839/jksabc.2010.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3839%2Fjksabc.2010.128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=842-846&author=S.+K.+Kim&title=Effects+of+modified+Je-Ho-Tang+on+ferric+chloride-induced+thrombosis+in+a+rat+model+and+of+peripheral+circulatory+disturbance+in+a+mouse+model&doi=10.3839%2Fjksabc.2010.128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3839%2Fjksabc.2010.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3839%252Fjksabc.2010.128%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DEffects%2520of%2520modified%2520Je-Ho-Tang%2520on%2520ferric%2520chloride-induced%2520thrombosis%2520in%2520a%2520rat%2520model%2520and%2520of%2520peripheral%2520circulatory%2520disturbance%2520in%2520a%2520mouse%2520model%26jtitle%3DHan%2527guk%2520Eungyong%2520Sangmyong%2520Hwahakhoeji%26date%3D2010%26volume%3D53%26spage%3D842%26epage%3D846%26doi%3D10.3839%2Fjksabc.2010.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazenave, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangin, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms underlying FeCl<sub>3</sub>-induced arterial thrombosis</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2011.04218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fj.1538-7836.2011.04218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21261806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1egu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=779-789&author=A.+Ecklyauthor=B.+Hechlerauthor=M.+Freundauthor=M.+Zerrauthor=J.+P.+Cazenaveauthor=F.+Lanzaauthor=P.+H.+Manginauthor=C.+Gachet&title=Mechanisms+underlying+FeCl3-induced+arterial+thrombosis&doi=10.1111%2Fj.1538-7836.2011.04218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying FeCl3-induced arterial thrombosis</span></div><div class="casAuthors">Eckly, A.; Hechler, B.; Freund, M.; Zerr, M.; Cazenave, J.-P.; Lanza, F.; Mangin, P. H.; Gachet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779-789</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The FeCl3-induced vascular injury model is widely used to study thrombogenesis in vivo, but the processes leading to vascular injury and thrombosis are poorly defined.  The aim of our study was to better characterize the mechanisms of FeCl3-induced vascular injury and thrombus formation, in order to evaluate the pathophysiol. relevance of this model.  FeCl3 was applied at different concns. (from 7.5% to 20%) and for different time periods (up to 5 min) to mouse carotid or mesenteric arteries.  Under all the conditions tested, ultrastructural anal. revealed that FeCl3 diffused through the vessel wall, resulting in endothelial ceil denudation without exposure of the inner layers.  Hence, only the basement membrane components were exposed to circulating blood cells and might have contributed to thrombus formation.  Shortly after FeCl3 application, numerous ferric ion-filled spherical bodies appeared on the endothelial cells.  Interestingly, platelets could adhere to these spheres and form aggregates.  Immunogold labeling revealed important amts. of tissue factor at their surface, suggesting that these spheres may play a role in thrombin generation.  In vitro expts. indicated that FeCl3 altered the ability of adhesive proteins, including collagen, fibrinogen and von Willebrand factor, to support platelet adhesion.  Finally, real-time intravital microscopy showed no protection against thrombosis in GPVI-immunodepleted and β1 -/- mice, suggesting that GPVI and β1 integrins, known to be involved in initial platelet adhesion and activation, do not play a crit. role in FeCl3-induced thrombus formation.  This model should be used cautiously, in particular to study the earliest stage of thrombus formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJr5Ut17tn7Vg90H21EOLACvtfcHk0lhblVZLqjVKaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1egu7k%253D&md5=6ad7142cce2152f9b3a90dda1e66680b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2011.04218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2011.04218.x%26sid%3Dliteratum%253Aachs%26aulast%3DEckly%26aufirst%3DA.%26aulast%3DHechler%26aufirst%3DB.%26aulast%3DFreund%26aufirst%3DM.%26aulast%3DZerr%26aufirst%3DM.%26aulast%3DCazenave%26aufirst%3DJ.%2BP.%26aulast%3DLanza%26aufirst%3DF.%26aulast%3DMangin%26aufirst%3DP.%2BH.%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DMechanisms%2520underlying%2520FeCl3-induced%2520arterial%2520thrombosis%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2011%26volume%3D9%26spage%3D779%26epage%3D789%26doi%3D10.1111%2Fj.1538-7836.2011.04218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, T. D.</span></span> <span> </span><span class="NLM_article-title">96-well plate-based aggregometry</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1080/09537104.2018.1445838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F09537104.2018.1445838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29543546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=650-655&author=M.+V.+Chanauthor=P.+C.+Armstrongauthor=T.+D.+Warner&title=96-well+plate-based+aggregometry&doi=10.1080%2F09537104.2018.1445838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A 96-well plate-based aggregometry</span></div><div class="casAuthors">Chan, Melissa V.; Armstrong, Paul C.; Warner, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  While there are many bench and bedside tests to assess platelet reactivity, ex vivo light transmission aggregometry (LTA) remains the gold std.  LTA, however, is expensive, time-consuming and requires dedicated equipment and staff, making it impractical in many situations.  In addn., there is significant variability between data generated at different testing sites meaning that tests often need to be repeated if a patient is transferred to the care of a different hospital.  As such, there is clearly an unmet need for standardization of platelet testing.  Using the principles of LTA, aggregometry can be conducted in 96-well plates with readings being made in a std. plate reader.  This approach allows for the assessment of multiple concns. of agonists, since the vol. of platelets required for each test is significantly lower than for LTA.  Furthermore, the lyophilization of a set panel of agonists to a 96-well plate to produce a stable assay substrate allows the prodn. of portable, standardized plates that can be used to generate reproducible tests at multiple sites.  In this review, we will discuss the methods and uses of 96-well plate aggregometry for both research and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUOBsH2ipg7Vg90H21EOLACvtfcHk0ljIK5s64hbxzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslamtbo%253D&md5=b366c6d06e85ffd89bb79d1e3785d6f6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F09537104.2018.1445838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09537104.2018.1445838%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DM.%2BV.%26aulast%3DArmstrong%26aufirst%3DP.%2BC.%26aulast%3DWarner%26aufirst%3DT.%2BD.%26atitle%3D96-well%2520plate-based%2520aggregometry%26jtitle%3DPlatelets%26date%3D2018%26volume%3D29%26spage%3D650%26epage%3D655%26doi%3D10.1080%2F09537104.2018.1445838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Megías, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedroche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yust, M. d. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girón-Calle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millán, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vioque, J.</span></span> <span> </span><span class="NLM_article-title">Stability of sunflower protein hydrolysates in simulated gastric and intestinal fluids and Caco-2 cell extracts</span>. <i>LWT - Food Science and Technology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.lwt.2009.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.lwt.2009.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=1496-1500&author=C.+Meg%C3%ADasauthor=J.+Pedrocheauthor=M.+d.+M.+Yustauthor=M.+Alaizauthor=J.+Gir%C3%B3n-Calleauthor=F.+Mill%C3%A1nauthor=J.+Vioque&title=Stability+of+sunflower+protein+hydrolysates+in+simulated+gastric+and+intestinal+fluids+and+Caco-2+cell+extracts&doi=10.1016%2Fj.lwt.2009.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Stability of sunflower protein hydrolysates in simulated gastric and intestinal fluids and Caco-2 cell extracts</span></div><div class="casAuthors">Megias, Cristina; Pedroche, Justo; Yust, Maria del Mar; Alaiz, Manuel; Giron-Calle, Julio; Millan, Francisco; Vioque, Javier</div><div class="citationInfo"><span class="NLM_cas:title">LWT--Food Science and Technology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1496-1500</span>CODEN:
                <span class="NLM_cas:coden">LSTWB3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The in vitro stability of bioactive properties in sunflower protein hydrolyzates and purified peptides was studied by using simulated gastric fluid, simulated intestinal fluid, and Caco-2 cells exts.  Protein hydrolyzates that inhibit the angiotensin converting enzyme and copper chelating peptides produced by hydrolysis with the microbial protease alcalase were partially resistant to incubation with simulated gastric and intestinal fluids.  These hydrolyzates and others produced by hydrolysis using pepsin plus pancreatin were also partially resistant to incubation with Caco-2 cells exts.  In addn., the ACE inhibitory peptide FVNPQAGS that is generated by extensive hydrolysis using pepsin and pancreatin, was found to be resistant to hydrolysis by Caco-2 cells exts.  These results suggest that stability in the digestive tract should not be a problem for the bioavailability of these bioactive peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSI5pwRfCrs7Vg90H21EOLACvtfcHk0ljIK5s64hbxzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFajurY%253D&md5=f065438320b19d3339384eb7a723ed03</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lwt.2009.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lwt.2009.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DMeg%25C3%25ADas%26aufirst%3DC.%26aulast%3DPedroche%26aufirst%3DJ.%26aulast%3DYust%26aufirst%3DM.%2Bd.%2BM.%26aulast%3DAlaiz%26aufirst%3DM.%26aulast%3DGir%25C3%25B3n-Calle%26aufirst%3DJ.%26aulast%3DMill%25C3%25A1n%26aufirst%3DF.%26aulast%3DVioque%26aufirst%3DJ.%26atitle%3DStability%2520of%2520sunflower%2520protein%2520hydrolysates%2520in%2520simulated%2520gastric%2520and%2520intestinal%2520fluids%2520and%2520Caco-2%2520cell%2520extracts%26jtitle%3DLWT%2520-%2520Food%2520Science%2520and%2520Technology%26date%3D2009%26volume%3D42%26spage%3D1496%26epage%3D1500%26doi%3D10.1016%2Fj.lwt.2009.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konotop, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafiah, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2017.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28258034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Ojsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=240-247&author=A.+B.+Petersenauthor=N.+S.+Andersenauthor=G.+Konotopauthor=N.+H.+Hanafiahauthor=M.+S.+Raabauthor=A.+Kramerauthor=M.+H.+Clausen&title=Synthesis+and+formulation+studies+of+griseofulvin+analogues+with+improved+solubility+and+metabolic+stability&doi=10.1016%2Fj.ejmech.2017.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability</span></div><div class="casAuthors">Petersen, Asger B.; Andersen, Nikolaj S.; Konotop, Gleb; Hanafiah, Nur Hafzan Md.; Raab, Marc S.; Kramer, Alwin; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-247</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Griseofulvin I (R = Me) is an important antifungal agent that has recently received attention due to its antiproliferative activity in mammalian cancer cells.  Comprehensive SAR studies have led to the identification of 2'-benzyloxy griseofulvin I (R = CH2Ph) (II), a more potent analog with low micromolar anticancer potency in vitro.  Analog II was also shown to retard tumor growth through inhibition of centrosomal clustering in murine xenograft models of colon cancer and multiple myeloma.  However, similar to griseofulvin, compd. II exhibited poor metabolic stability and aq. soly.  In order to improve the poor pharmacokinetic properties, 11 griseofulvin analogs were synthesized and evaluated for biol. activity and physiol. stabilities including SGF, plasma, and metabolic stability.  Finally, the most promising compds. were investigated in respect to thermodn. soly. and formulation studies.  The 2'-benzylamine analog I (R = NHCH2Ph) (III) proved to be the most promising compd. with low μM in vitro anticancer potency, a 200-fold increase in PBS soly. over compd. II, and with improved metabolic stability.  Furthermore, this analog proved compatible with formulations suitable for both oral and i.v. administration.  Finally, 2'-benzylamine analog III was confirmed to induce G2/M cell cycle arrest in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VVdH4LbX6LVg90H21EOLACvtfcHk0ljIK5s64hbxzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Ojsbc%253D&md5=e60d91f73ddad3fc2bd14318220647bd</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DA.%2BB.%26aulast%3DAndersen%26aufirst%3DN.%2BS.%26aulast%3DKonotop%26aufirst%3DG.%26aulast%3DHanafiah%26aufirst%3DN.%2BH.%26aulast%3DRaab%26aufirst%3DM.%2BS.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520formulation%2520studies%2520of%2520griseofulvin%2520analogues%2520with%2520improved%2520solubility%2520and%2520metabolic%2520stability%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D130%26spage%3D240%26epage%3D247%26doi%3D10.1016%2Fj.ejmech.2017.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konsoula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+vitro+plasma+stability%2C+permeability+and+solubility+of+mercaptoacetamide+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0lgLzSHAkKs1vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520plasma%2520stability%252C%2520permeability%2520and%2520solubility%2520of%2520mercaptoacetamide%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent muscarinic M<sub>3</sub> receptor antagonists with proper plasma stability by structural recombination of marketed M<sub>3</sub> antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fcmdc.201700189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28741876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1173-1182&author=Z.+Xiangauthor=J.+Liuauthor=H.+Sunauthor=X.+Wen&title=Discovery+of+novel+potent+muscarinic+M3+receptor+antagonists+with+proper+plasma+stability+by+structural+recombination+of+marketed+M3+antagonists&doi=10.1002%2Fcmdc.201700189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists</span></div><div class="casAuthors">Xiang, Zuojuan; Liu, Jun; Sun, Hongbin; Wen, Xiaoan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The marketed long-acting M3 antagonists for treatment of chronic obstructive pulmonary disease have inappropriate plasma stability (either overstable or excessively unstable), which causes substantial systemic exposure or poor patient compliance.  To discover novel M3 antagonists with proper plasma stability, the authors synthesized and biol. evaluated a series of chiral quaternary ammonium salts of pyrrolidinol esters, which were designed by structural recombination of the marketed M3 antagonists.  As a result, two novel potent M3 antagonists, (R/S)-3-[2-hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromides ( (R)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide: Ki = 0.16 nM, IC50=0.38 nM, t1/2=9.34 min;(S)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide: Ki = 0.32 nM, IC50=1.01 nM, t1/2=19.2 min) with proper plasma stability were identified, which (particularly(R)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide) hold great promise as clin. drug candidates to overcome the drawbacks caused by the inappropriate stability of the currently marketed M3 antagonists.  In addn., structure-activity relation studies revealed that the R configuration of the pyrrolidinyl C3 atom was clearly better than the S configuration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_UQZ9hNnXgbVg90H21EOLACvtfcHk0lgLzSHAkKs1vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WnsrbF&md5=fa9d4bc1e809975fc978f13c31fa21f5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700189%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520proper%2520plasma%2520stability%2520by%2520structural%2520recombination%2520of%2520marketed%2520M3%2520antagonists%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1173%26epage%3D1182%26doi%3D10.1002%2Fcmdc.201700189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">607</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.014100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.106.014100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=17237157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVOntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=607-613&author=G.+Linauthor=J.+Tangauthor=X.+Q.+Liuauthor=Y.+Jiangauthor=J.+Zheng&title=Deacetylclivorine%3A+a+gender-selective+metabolite+of+clivorine+formed+in+female+Sprague-Dawley+rat+liver+microsomes&doi=10.1124%2Fdmd.106.014100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes</span></div><div class="casAuthors">Lin, Ge; Tang, Jun; Liu, Xiao Quan; Jiang, Yan; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-613</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clivorine, a naturally occurring pyrrolizidine alkaloid, causes liver toxicity via its metabolic activation to generate toxic metabolite (pyrrolic ester).  Female Sprague-Dawley (SD) rats are reported to be less susceptible to clivorine intoxication than male SD rats.  However, the biochem. mechanism causing such gender difference is largely unknown.  The present study investigated hepatic microsomal metab. of clivorine in female rats to delineate the mechanism of the gender difference.  Two pathways, which directly metabolize clivorine, were obsd.  First, the metabolic activation to produce the toxic pyrrolic ester followed by formations of bound pyrroles, dehydroretronecine, 7-glutathionyldehydroretronecine, and clivoric acid were found in female rats, and CYP3A1/2 isoenzymes were identified to catalyze the metabolic activation.  Compared with male rats (∼21%), the metabolic activation in female rats was significantly lower (∼4%) possibly because of significantly lower CYP3A1/2 levels expressed in female rats.  Second, a direct hydrolysis to generate the novel female rat-specific metabolite deacetylclivorine was shown as the predominant pathway (∼16% clivorine metab.) in female rat liver microsomes and was detd. to be mediated by microsomal hydrolase A.  Furthermore, when the metabolic activation was completely inhibited by ketoconazole, the amt. of deacetylclivorine formed in a 1-h incubation significantly increased from 19.44 ± 3.00 to 54.87 ± 9.30 nmol/mg protein, suggesting that the two pathways compete with each other.  Therefore, the lower susceptibility of female SD rats to clivorine intoxication is suggested to be caused by the significantly higher extent of the direct hydrolysis and a lower degree of the metabolic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3E9gSwN7m7Vg90H21EOLACvtfcHk0lgLzSHAkKs1vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVOntL0%253D&md5=eb5d9b18b16200a68c5982ea5ae52725</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.014100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.014100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DDeacetylclivorine%253A%2520a%2520gender-selective%2520metabolite%2520of%2520clivorine%2520formed%2520in%2520female%2520Sprague-Dawley%2520rat%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D607%26epage%3D613%26doi%3D10.1124%2Fdmd.106.014100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of epoxide-derived metabolite(s) of benzbromarone</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">607</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.066803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.115.066803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26792818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC28nivVCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=607-615&author=K.+Wangauthor=H.+Wangauthor=Y.+Pengauthor=J.+Zheng&title=Identification+of+epoxide-derived+metabolite%28s%29+of+benzbromarone&doi=10.1124%2Fdmd.115.066803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Epoxide-Derived Metabolite(s) of Benzbromarone</span></div><div class="casAuthors">Wang Kai; Wang Hui; Peng Ying; Zheng Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Benzbromarone (BBR) is a benzofuran derivative that has been quite useful for the treatment of gout; however, it was withdrawn from European markets in 2003 because of reported serious incidents of drug-induced liver injury.  BBR-induced hepatotoxicity has been suggested to be associated with the formation of a quinone intermediate.  The present study reported epoxide-derived intermediate(s) of BBR.  An N-acetylcysteine (NAC) conjugate derived from epoxide metabolite(s) was detected in both microsomal incubations of BBR and urine samples of mice treated with BBR.  The NAC conjugate was identified as 6-NAC BBR.  Ketoconazole suppressed the bioactivation of BBR to the epoxide intermediate(s), and the CYP3A subfamily was the primary enzyme responsible for the formation of the epoxide(s).  The present study provided new information on metabolic activation of BBR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTewHRhiyuvaOWhZTslLrfffW6udTcc2eYOEKTZEToxy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nivVCnsg%253D%253D&md5=b1854ab5e77d14aa084f243674150221</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.066803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.066803%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520epoxide-derived%2520metabolite%2528s%2529%2520of%2520benzbromarone%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D607%26epage%3D615%26doi%3D10.1124%2Fdmd.115.066803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhonker, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleightholm, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span> <span> </span><span class="NLM_article-title">Bioanalytical method development and validation of moxidectin in plasma by LC-MS/MS: Application to in vitro metabolism</span>. <i>Biomed. Chromatogr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">e4389</span>, <span class="refDoi"> DOI: 10.1002/bmc.4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fbmc.4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30238696" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=e4389&author=Y.+S.+Chhonkerauthor=R.+L.+Sleightholmauthor=D.+J.+Murry&title=Bioanalytical+method+development+and+validation+of+moxidectin+in+plasma+by+LC-MS%2FMS%3A+Application+to+in+vitro+metabolism&doi=10.1002%2Fbmc.4389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fbmc.4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.4389%26sid%3Dliteratum%253Aachs%26aulast%3DChhonker%26aufirst%3DY.%2BS.%26aulast%3DSleightholm%26aufirst%3DR.%2BL.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26atitle%3DBioanalytical%2520method%2520development%2520and%2520validation%2520of%2520moxidectin%2520in%2520plasma%2520by%2520LC-MS%252FMS%253A%2520Application%2520to%2520in%2520vitro%2520metabolism%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2019%26volume%3D33%26spage%3De4389%26doi%3D10.1002%2Fbmc.4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, H. H.</span></span> <span> </span><span class="NLM_article-title">Determination of microsome and hepatocyte scaling factors for <i>in vitro</i>/<i>in vivo</i> extrapolation in the rat and dog</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1080/00498250802491662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F00498250802491662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18988082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=1386-1398&author=R.+Smithauthor=R.+D.+Jonesauthor=P.+G.+Ballardauthor=H.+H.+Griffiths&title=Determination+of+microsome+and+hepatocyte+scaling+factors+for+in+vitro%2Fin+vivo+extrapolation+in+the+rat+and+dog&doi=10.1080%2F00498250802491662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog</span></div><div class="casAuthors">Smith, R.; Jones, R. D. O.; Ballard, P. G.; Griffiths, H. H.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1386-1398</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In vivo clearance predictions from in vitro assays require scaling factors to relate the concns. of hepatocytes or microsomal protein to the intact liver.  The aims were to measure the variability in scaling factors for Wistar rat and beagle dog for which the literature is particularly scarce and det. any sex differences.  Scaling factors were detd. by comparing the cytochrome P 450 (P 450) content in hepatocytes or microsomes against the P 450 content of fresh liver homogenate.  The use of fresh homogenate is recommended as freezing can increase contamination and affect the P 450 assay.  Meangeo hepatic microsomal concns. in Wistar rats were 61 mg/g liver (95% confidence interval (CI); 47-75 mg/g liver) and in beagle dogs 55 mg/g liver (95% CI = 48-62 mg/g liver).  Meangeo hepatocellularity was 163 × 106 cells/g liver for Wistar rats (95% CI = 127-199 × 106 cells/g liver) and 169 × 106 cells/g liver (95% CI = 131-207 × 106 cells/g liver) for beagle dogs.  The data generated in this study indicate a consistency in scaling factors between rat and dog.  No sex differences were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUaQwY_CMkBbVg90H21EOLACvtfcHk0liZYcPuc1EFOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlens7vM&md5=67f11c3d42fd45eda1787bd1f9f3e045</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1080%2F00498250802491662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250802491662%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DBallard%26aufirst%3DP.%2BG.%26aulast%3DGriffiths%26aufirst%3DH.%2BH.%26atitle%3DDetermination%2520of%2520microsome%2520and%2520hepatocyte%2520scaling%2520factors%2520for%2520in%2520vitro%252Fin%2520vivo%2520extrapolation%2520in%2520the%2520rat%2520and%2520dog%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D1386%26epage%3D1398%26doi%3D10.1080%2F00498250802491662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cunha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winokur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.jpba.2019.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30981954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1CktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=111-117&author=T.+Bachauthor=S.+Baeauthor=R.+D%E2%80%99Cunhaauthor=P.+Winokurauthor=G.+An&title=Development+and+validation+of+a+simple%2C+fast%2C+and+sensitive+LC%2FMS%2FMS+method+for+the+quantification+of+oxfendazole+in+human+plasma+and+its+application+to+clinical+pharmacokinetic+study&doi=10.1016%2Fj.jpba.2019.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study</span></div><div class="casAuthors">Bach, Thanh; Bae, SoHyun; D'Cunha, Ronilda; Winokur, Patricia; An, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-117</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The most popular std. treatments for soil transmitted helminths in humans including mebendazole, albendazole, levamisole, and pyrantel pamoate, show greatly variable efficacy against different species of parasites and have unfavorable pharmacokinetic characteristics, such as short half-life.  The transition of oxfendazole, a potent broad-spectrum anthelmintic with long half-life, from veterinary medicine to human use has been considered as a promising approach.  However, anal. methods for the quant. detection of oxfendazole in human matrix are very limited and lack sensitivity.  In this study, we have developed a high-performance liq. chromatog.-tandem mass spectrometry (LC/MS/MS) method for the quantification of oxfendazole in human plasma using albendazole as an internal std.  The established method was fully validated with lower limit of quantitation (LLOQ) of 0.5 ng/mL and linearity in the range of 0.5-1000 ng/mL; intra-day and inter-day accuracies ranged from 2.6 to 9.5% for 3 quality control levels (1.5 ng/mL, 75 ng/mL, and 750 ng/mL) and LLOQ; intra-day and inter-day precision was ≤13.6% for quality controls and ≤15.1% for LLOQ; matrix factor and extn. recovery were consistent with coeff. of variation of less than 15.0%.  Other parameters including matrix selectivity, injection carryover, reinjection reproducibility, hemolysis effect, interference of analyte with internal std., diln. integrity, freeze/thaw stability, whole blood stability, and stock soln. stability were also validated and met the acceptance criteria.  The assay was successfully applied to quantify oxfendazole plasma concn. in healthy adult volunteers after the administration of multiple oral doses of oxfendazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqMUvHjkcf6bVg90H21EOLACvtfcHk0liz7gwILKW_zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1CktLw%253D&md5=3f3d8f717de606ca435e1886f0074ff9</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DT.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Cunha%26aufirst%3DR.%26aulast%3DWinokur%26aufirst%3DP.%26aulast%3DAn%26aufirst%3DG.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520simple%252C%2520fast%252C%2520and%2520sensitive%2520LC%252FMS%252FMS%2520method%2520for%2520the%2520quantification%2520of%2520oxfendazole%2520in%2520human%2520plasma%2520and%2520its%2520application%2520to%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D171%26spage%3D111%26epage%3D117%26doi%3D10.1016%2Fj.jpba.2019.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano) phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111558</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2019.07.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31369933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsV2jurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111558&author=Q.+Maoauthor=X.+Daiauthor=G.+Xuauthor=Y.+Suauthor=B.+Zhangauthor=D.+Liuauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+2-%284-alkoxy-3-cyano%29+phenyl-6-oxo-1%2C6-dihydropyrimidine-5-carboxylic+acid+derivatives+as+novel+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2019.07.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors</span></div><div class="casAuthors">Mao, Qing; Dai, Xiwen; Xu, Gaoyang; Su, Yu; Zhang, Bing; Liu, Dan; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111558pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-(4-alkoxy-3-cyano)phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivs. I [R = O, NH; R1 = i-Pr, allyl, Bn, etc.; R2 = H, Me] was synthesized as novel xanthine oxidase (XO) inhibitors.  These compds. exhibited remarkable in vitro XO inhibitory potency with IC50 values ranging from 0.0181 μM to 0.5677 μM.  Specifically, compds. I [R = NH; R1 = (CH2)2CH(CH3)2, 2-methylallyl], with IC50 values of 0.0240 μM and 0.0181 μM, resp., emerged as the most potent XO inhibitors and their potencies were comparable to that of febuxostat.  Structure-activity relationship anal. revealed that the Me group at 4-position of pyrimidine ring could damage the potency and the XO inhibitory potency was maintained when carbonyl group was changed to an imino group.  Lineweaver-Burk plot anal. revealed that the representative compd. I [R = NH; R1 = (CH2)2CH(CH3)2] acted as a mixed-type inhibitor.  A potassium oxonate induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of compd. I [R = NH; R1 = (CH2)2CH(CH3)2] and the results showed that compd. I [R = NH; R1 = (CH2)2CH(CH3)2] (5 mg/kg) was able to significantly lower the serum uric acid level.  Furthermore, in acute oral toxicity study, no sign of toxicity was obsd. when the mice were administered with a single 2000 mg/kg oral dose of compd. I [R = NH; R1 = (CH2)2CH(CH3)2].  These results suggested that compd. I [R = NH; R1 = (CH2)2CH(CH3)2] was a potent and promising uric acid-lowing agent for the treatment of hyperuricemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCwRnSfm0CarVg90H21EOLACvtfcHk0liz7gwILKW_zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsV2jurvF&md5=f31a2b4edf5bcbbb98ecc0d01d2628fb</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.061%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25202-%25284-alkoxy-3-cyano%2529%2520phenyl-6-oxo-1%252C6-dihydropyrimidine-5-carboxylic%2520acid%2520derivatives%2520as%2520novel%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111558%26doi%3D10.1016%2Fj.ejmech.2019.07.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1<i>H</i>-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111559</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2019.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31376568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111559&author=B.+Zhangauthor=X.+Daiauthor=Z.+Baoauthor=Q.+Maoauthor=Y.+Duanauthor=Y.+Yangauthor=S.+Wang&title=Targeting+the+subpocket+in+xanthine+oxidase%3A+Design%2C+synthesis%2C+and+biological+evaluation+of+2-%5B4-alkoxy-3-%281H-tetrazol-1-yl%29+phenyl%5D-6-oxo-1%2C6-dihydropyrimidine-5-carboxylic+acid+derivatives&doi=10.1016%2Fj.ejmech.2019.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives</span></div><div class="casAuthors">Zhang, Bing; Dai, Xiwen; Bao, Ziyang; Mao, Qing; Duan, Yulin; Yang, Yuwei; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111559</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-[4-alkoxy-3-(1H-tetrazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivs. I (R =H, Me, Bn, etc.) with a tetrazole group targeting subpocket of the xanthine oxidase active site were designed, synthesized and they were further evaluated for their inhibitory potency against xanthine oxidase in vitro.  All the tested compds. exhibited an apparent xanthine oxidase inhibitory potency, with IC50 values ranging from 0.0288μM to 0.629μM and the structure-activity relationship results revealed that the hydrophobic group at the 4'-position was indispensable for the inhibitory potency in vitro against xanthine oxidase.  Compd. I (R = 3-chlorobenzyl) emerged as the most potent xanthine oxidase inhibitor, with an IC50 value of 0.0288μM, which was comparable to febuxostat (IC50 = 0.0236μM) and a Lineweaver-Burk plot revealed of this compd. acted as a mixed-type inhibitor for xanthine oxidase.  Mol. modeling studies were performed to gain insights into the binding mode of this compd. with xanthine oxidase which suggested that the tetrazole group of the Ph unit was accommodated in the subpocket, as expected.  A potassium oxonate-induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of the above compd. and the result demonstrated that it could effectively reduce serum uric acid levels at an oral dose of 5 mg/kg, acute oral toxicity study in mice indicated that it was nontoxic and tolerated at a dose up to 2000 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriD45HSf08k7Vg90H21EOLACvtfcHk0liETOfjhBgQgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3J&md5=933c7ce340b133a645f853c5ea12fd48</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520subpocket%2520in%2520xanthine%2520oxidase%253A%2520Design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-%255B4-alkoxy-3-%25281H-tetrazol-1-yl%2529%2520phenyl%255D-6-oxo-1%252C6-dihydropyrimidine-5-carboxylic%2520acid%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111559%26doi%3D10.1016%2Fj.ejmech.2019.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1<i>H</i>-indole-3-carbonitriles as novel xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112077</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2020.112077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=32014678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112077&author=J.+Gaoauthor=X.+Liuauthor=B.+Zhangauthor=Q.+Maoauthor=Z.+Zhangauthor=Q.+Zouauthor=X.+Daiauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+1-alkyl-5%2F6-%285-oxo-4%2C5-dihydro-1%2C2%2C4-oxadiazol-3-yl%29-1H-indole-3-carbonitriles+as+novel+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2020.112077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors</span></div><div class="casAuthors">Gao, Jun; Liu, Xuegui; Zhang, Bing; Mao, Qing; Zhang, Zhuo; Zou, Qian; Dai, Xiwen; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112077pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Xanthine oxidase (XO) has emerged as an important target for the treatment of hyperuricemia and gout.  In this study, to obtain novel nonpurine XO inhibitors, a series of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles I (R = H, iso-Bu, cyclopentyl, benzyl, etc.; R1 = R2 = H, 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) was designed using a bioisosteric replacement strategy and synthesized through a five-step procedure with good yields.  Thereafter, the in vitro XO inhibitory potencies of these compds. were evaluated by spectrophotometry, showing inhibitory profiles in the micromolar/submicromolar range.  Particularly, compd. I (R = cyclopentyl; R1 = 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) (A) emerged as the strongest XO inhibitor, with an IC50 value of 0.36μM, which was approx. 21-fold more potent than the pos. control allopurinol.  Addnl., the structure-activity relationships revealed that the 5-oxo-4,5-dihydro-1,2,4-oxadiazole moiety linked at the 5-position of the indole scaffold was more preferable than the 6-position for the XO inhibitory potency.  Enzyme kinetic studies indicated that compd. A acted as a mixed-type XO inhibitor.  Moreover, mol. modeling studies were performed on compd. A to gain insights into its binding modes with XO.  The results showed that the 5-oxo-4,5-dihydro-1,2,4-oxadiazole moiety could interact with Arg880 and Thr1010 in the innermost part of the active pocket through hydrogen bonds, while the cyano group could form hydrogen bonds with Asn768 and Lys771 in the subpocket.  Furthermore, the in vivo hypouricemic effect of compd. I (R = cyclopentyl) was further investigated in a hyperuricemia rat model induced by potassium oxonate.  The results suggested that compd. I (R = cyclopentyl) could effectively reduce serum uric acid levels at an oral dose of 10 mg/kg.  Therefore, compd. I (R = cyclopentyl) could be a promising lead compd. for the treatment of hyperuricemia and gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9xCCOk7_kbVg90H21EOLACvtfcHk0liETOfjhBgQgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOgtrs%253D&md5=c5f3c2deb1cc0249eff200dcae09eae0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112077%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201-alkyl-5%252F6-%25285-oxo-4%252C5-dihydro-1%252C2%252C4-oxadiazol-3-yl%2529-1H-indole-3-carbonitriles%2520as%2520novel%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112077%26doi%3D10.1016%2Fj.ejmech.2020.112077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuser, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalloum, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4810</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnt12ru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4790-4810&author=L.+Sunauthor=A.+Dickauthor=M.+E.+Meuserauthor=T.+Huangauthor=W.+A.+Zalloumauthor=C.+H.+Chenauthor=S.+Cherukupalliauthor=S.+Xuauthor=X.+Dingauthor=P.+Gaoauthor=D.+Kangauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=S.+Cocklinauthor=K.+H.+Leeauthor=X.+Liuauthor=P.+Zhan&title=Design%2C+synthesis%2C+and+mechanism+study+of+benzenesulfonamide-containing+phenylalanine+derivatives+as+novel+HIV-1+capsid+inhibitors+with+improved+antiviral+activities&doi=10.1021%2Facs.jmedchem.0c00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities</span></div><div class="casAuthors">Sun, Lin; Dick, Alexej; Meuser, Megan E.; Huang, Tianguang; Zalloum, Waleed A.; Chen, Chin-Ho; Cherukupalli, Srinivasulu; Xu, Shujing; Ding, Xiao; Gao, Ping; Kang, Dongwei; De Clercq, Erik; Pannecouque, Christophe; Cocklin, Simon; Lee, Kuo-Hsiung; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4790-4810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory).  Herein, we report the design and synthesis of three series of benzenesulfonamide-contg. phenylalanine derivs. obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors.  Structure-activity relationship studies of these compds. led to the identification of new phenylalanine derivs. with a piperazinone moiety, represented by compd. (I), which exhibited anti-HIV-1NL4-3 activity 5.78-fold better than PF-74.  Interestingly, I also showed anti-HIV-2ROD activity (EC50 = 31 nΜ), with almost 120 times increased potency over PF-74.  However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focused on the mechanism of action of our compds. in the context of HIV-1.  SPR studies on representative compds. confirmed CA as the binding target.  The action stage detn. assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile.  The early-stage inhibitory activity of compd. I was 6.25 times more potent as compared to PF-74, but appears to work via accelerating capsid core assembly rather than stabilization.  However, the mechanism by which they exert their antiviral activity in the late-stage appears to be the same as PF-74 with less infectious HIV-1 virions are produced in their presence as judged p24 content studies.  MD simulations provided the key rationale for the promising antiviral potency of I.  Addnl., I exhibited modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity.  These studies provide insights and serves as a starting point for subsequent medicinal chem. efforts in optimizing these promising HIV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKdnsc-Iy-LVg90H21EOLACvtfcHk0lghPpLd_WT9fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnt12ru7s%253D&md5=77a89a34489fc04cbe4c29b5bdb4b396</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00015%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DA.%26aulast%3DMeuser%26aufirst%3DM.%2BE.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DZalloum%26aufirst%3DW.%2BA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520mechanism%2520study%2520of%2520benzenesulfonamide-containing%2520phenylalanine%2520derivatives%2520as%2520novel%2520HIV-1%2520capsid%2520inhibitors%2520with%2520improved%2520antiviral%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4790%26epage%3D4810%26doi%3D10.1021%2Facs.jmedchem.0c00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoqing  Guo</span>, <span class="hlFld-ContribAuthor ">Qin  Li</span>, <span class="hlFld-ContribAuthor ">Shulan  Pi</span>, <span class="hlFld-ContribAuthor ">Yuanpeng  Xia</span>, <span class="hlFld-ContribAuthor ">Ling  Mao</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled purinergic P2Y receptor oligomerization: Pharmacological changes and dynamic regulation. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>192 </em>, 114689. <a href="https://doi.org/10.1016/j.bcp.2021.114689" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114689</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114689%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DG%252Bprotein-coupled%252Bpurinergic%252BP2Y%252Breceptor%252Boligomerization%25253A%252BPharmacological%252Bchanges%252Band%252Bdynamic%252Bregulation%26aulast%3DGuo%26aufirst%3DXiaoqing%26date%3D2021%26volume%3D192%26spage%3D114689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Lei</span>, <span class="hlFld-ContribAuthor ">Bing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiwen  Dai</span>, <span class="hlFld-ContribAuthor ">Yulin  Duan</span>, <span class="hlFld-ContribAuthor ">Qing  Mao</span>, <span class="hlFld-ContribAuthor ">Jun  Gao</span>, <span class="hlFld-ContribAuthor ">Yuwei  Yang</span>, <span class="hlFld-ContribAuthor ">Ziyang  Bao</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Fu</span>, <span class="hlFld-ContribAuthor ">Kunqi  Ping</span>, <span class="hlFld-ContribAuthor ">Chengda  Yan</span>, <span class="hlFld-ContribAuthor ">Yanhua  Mou</span>, <span class="hlFld-ContribAuthor ">Shaojie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113437. <a href="https://doi.org/10.1016/j.ejmech.2021.113437" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113437%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BFXIa%252Binhibitors%252Bwith%252B2-phenyl-1H-imidazole-5-carboxamide%252Bmoiety%252Bas%252BP1%252Bfragment%26aulast%3DLei%26aufirst%3DYu%26date%3D2021%26volume%3D220%26spage%3D113437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Wang</span>, <span class="hlFld-ContribAuthor ">Jin‐Ping  Fu</span>, <span class="hlFld-ContribAuthor ">Jia‐Hui  Mo</span>, <span class="hlFld-ContribAuthor ">Yu‐Hong  Tian</span>, <span class="hlFld-ContribAuthor ">Chun‐You  Liu</span>, <span class="hlFld-ContribAuthor ">Hai‐Tao  Tang</span>, <span class="hlFld-ContribAuthor ">Zi‐Jun  Sun</span>, <span class="hlFld-ContribAuthor ">Ying‐Ming  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Assembly of 5‐Aminoimidazoles via Palladium‐Catalysed Double Isocyanide Insertion Reaction. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (11)
                                     , 2762-2766. <a href="https://doi.org/10.1002/adsc.202100142" title="DOI URL">https://doi.org/10.1002/adsc.202100142</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100142%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DAssembly%252Bof%252B5%2525E2%252580%252590Aminoimidazoles%252Bvia%252BPalladium%2525E2%252580%252590Catalysed%252BDouble%252BIsocyanide%252BInsertion%252BReaction%26aulast%3DWang%26aufirst%3DXu%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D11%26spage%3D2762%26epage%3D2766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structures of P2Y<sub>12</sub> antagonists: ticlopidine (<b>1</b>), clopidogrel (<b>2</b>), prasugrel (<b>3</b>), vicagrel (<b>4</b>), ticagrelor (<b>5</b>), cangrelor (<b>6</b>), AZD1283 (<b>7</b>), elinogrel (<b>8</b>), selatogrel (<b>9</b>), BX048 (<b>10</b>), SAR216471 (<b>11</b>), and PSB-0739 (<b>12</b>). (B) Structures of P2Y<sub>1</sub> antagonists: MRS2179 (<b>13</b>), MRS2500 (<b>14</b>), MRS2279 (<b>15</b>), BPTU (<b>16</b>), and 4-aryl-7-hydroxylindoline derivative (<b>17</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design and structural modification of novel antiplatelet agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaNO<sub>2</sub>, CH<sub>3</sub>COOH, 0–5 °C; (b) Benzaldehyde derivatives, CH<sub>3</sub>COOH/CH<sub>3</sub>COONH<sub>4</sub>, 50 °C; (c) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Me<sub>3</sub>SiCl, NaI, CH<sub>3</sub>CN, reflux; (b) Me<sub>2</sub>SO<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DMF, 0 °C; (c) RX, K<sub>2</sub>CO<sub>3</sub>, KI, N<sub>2</sub>, DMF, 0–50 °C; (d) LiOH, THF, H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of ADP-induced, P2Y<sub>12</sub>-mediated decrease in VASP phosphorylation by compound <b>25w</b> or ticagrelor. PGE<sub>1</sub>-stimulated VASP phosphorylation and its attenuation by ADP in the presence and absence of the test compounds were measured by flow cytometry. The data were reported as the mean ± SD (<i>n</i> = 3; *<i>P</i> > 0.05, as compared to PGE<sub>1</sub> alone).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding modes of (A) <b>MRS2500</b>, (B) compound <b>24w</b>, and (C) compound <b>25w</b> in the P2Y<sub>1</sub> receptor (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW">4XNW</a>). Binding modes of (D) <b>AZD-1283</b>, (E) compound <b>24w</b>, and (F) <b>25w</b> in the P2Y<sub>12</sub> receptor (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ">4NTJ</a>). Protein is shown as a cartoon, and small molecules are shown as sticks. Hydrogen bonds, π–π stacking interactions, and electrostatic interaction are depicted by red, purple, and orange dashed lines, respectively. Residues of P2Y<sub>1</sub> and P2Y<sub>12</sub> interacting with inhibitors are depicted by green sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A and B) Stability profiles of compounds <b>24w</b> and <b>25w</b> in simulated gastric and intestinal fluids. Each value is the mean ± SEM; <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Stability and metabolism profiles of compounds (A) <b>24w</b> and (B) <b>25w</b> in rabbit and rat plasma. Each value is the mean ± SEM; <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Stability profiles of compounds <b>24w</b> and <b>25w</b> obtained in both RLMs and HLMs: (A) incubation of <b>24w</b> in RLMs; (B) incubation of <b>25w</b> in RLMs; (C) incubation of <b>24w</b> in HLMs; (D) incubation of <b>25w</b> in HLMs. The data represent the mean ± SEM of three independent experiments (<i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Plasma concentration–time profiles of compounds <b>24w</b> and <b>25w</b> after administration in rats (<i>n</i> = 6). (A) Single oral administration of compounds <b>24w</b> (parent compound <b>25w</b> released from prodrug <b>24w</b>; 10 mg/kg) and <b>25w</b> (10 mg/kg). (B) Intravenous injection administration of compound <b>25w</b> (10 mg/kg). Data are presented as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Body weight evolution of (A) male and (B) female mice. Each value is the mean ± SEM; <i>n</i> = 8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of ticagrelor and compound <b>24w</b> on thrombus weight after FeCl<sub>3</sub>-induced arterial injury in anesthetized Sprague-Dawley rats at 1.5 h postdosing following the oral administration of <b>24w</b> (5, 10, and 20 mg/kg) and ticagrelor (10 mg/kg). Data are presented as the mean ± SD (<i>n</i> = 10, <i>***P</i> < 0.001 and <i>***P</i> < 0.001 vs model; <sup><i>#</i></sup><i>P</i> > 0.05 vs ticagrelor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/medium/jm0c01524_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0011.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effects of ticagrelor and compound <b>24w</b> on (A) tail-vein-bleeding weight and (B) time in anesthetized Sprague-Dawley rats at 2 h postdosing following the oral administration of <b>24w</b> (10 mg/kg) and ticagrelor (10 mg/kg). The data are presented as mean ± SD (<i>n</i> = 8, <i>*P</i> < 0.05, <i>***P</i> < 0.001 vs model group; <sup><i>###</i></sup><i>P</i> < 0.001 vs ticagrelor group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01524/20201218/images/large/jm0c01524_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01524&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33203" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33203" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 88 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">318</span>, <span class="refDoi"> DOI: 10.2165/11630960-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2165%2F11630960-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=22489610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XovVylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=305-318&author=R.+Teng&title=Pharmacokinetic%2C+pharmacodynamic+and+pharmacogenetic+profile+of+the+oral+antiplatelet+agent+ticagrelor&doi=10.2165%2F11630960-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor</span></div><div class="casAuthors">Teng, Renli</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">305-318</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis Data Information BV</span>)
        </div><div class="casAbstract">A review.  Acute coronary syndromes (ACS) remain life-threatening disorders assocd. with high morbidity and mortality, despite advances in treatment over the last decade.  ADP-induced platelet activation via P2Y12 receptors plays a pivotal role in the pathophysiol. of ACS.  The current std. of treatment involves dual antiplatelet therapy with aspirin (acetylsalicylic acid) and the thienopyridine clopidogrel.  Numerous studies and wide use in clin. practice have established the value of this approach in the treatment of ACS.  However, clopidogrel treatment has a no. of limitations, including a delayed onset of action due to the need for metabolic activation, variable and reduced antiplatelet effects in patients with certain genotypes, and prolonged recovery of platelet function due to irreversible P2Y12 receptor binding.  Prasugrel, a new thienopyridine, has demonstrated more consistent inhibition of platelet aggregation (IPA) than clopidogrel, although this thienopyridine also requires metabolic activation and treatment is assocd. with a significantly increased risk of life-threatening and fatal bleeding.  The recently approved oral antiplatelet agent ticagrelor has the potential to overcome some of the limitations of current therapy due to its unique pharmacokinetic and pharmacodynamic profiles.  It is a member of a new chem. class, the cyclopentyltriazolopyrimidines, and is a potent P2Y12 receptor antagonist.  Ticagrelor is rapidly absorbed, with a median time to max. concn. of 1.3-2.0 h.  Ticagrelor does not require metabolic activation to an active form and binds rapidly and reversibly to the P2Y12 receptor.  As well as exerting effects via platelet P2Y12 receptors, ticagrelor may confer addnl. benefits via inhibition of non-platelet P2Y12 receptors.  The pharmacokinetic profile of ticagrelor is not significantly affected by age, gender or administration with food, nor by prior treatment with, or responsiveness to, clopidogrel.  Ticagrelor is primarily metabolized via the cytochrome P 450 (CYP) 3A4 enzyme, rapidly produces plasma concn.-dependent IPA that is greater and more consistent than that obsd. with clopidogrel, and can also enhance platelet inhibition and overcome non-responsiveness in patients previously treated with clopidogrel.  Importantly, the pharmacodynamic characteristics of ticagrelor are not influenced by CYP2C19 and ABCB1 genotypes.  This article summarizes our current knowledge regarding the pharmacokinetic, pharmacodynamic and pharmacogenetic profile of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYS2MSD8qCM7Vg90H21EOLACvtfcHk0lg0-Nk7iHH32w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovVylur0%253D&md5=4af21d7ff762a3b62eafdd3b656b1e84</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2165%2F11630960-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11630960-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DR.%26atitle%3DPharmacokinetic%252C%2520pharmacodynamic%2520and%2520pharmacogenetic%2520profile%2520of%2520the%2520oral%2520antiplatelet%2520agent%2520ticagrelor%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D305%26epage%3D318%26doi%3D10.2165%2F11630960-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schilling, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingemanse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and pharmacodynamics of approved and investigational P2Y<sub>12</sub> receptor antagonists</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00864-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs40262-020-00864-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=32056160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1ynu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=545-566&author=U.+Schillingauthor=J.+Dingemanseauthor=M.+Ufer&title=Pharmacokinetics+and+pharmacodynamics+of+approved+and+investigational+P2Y12+receptor+antagonists&doi=10.1007%2Fs40262-020-00864-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists</span></div><div class="casAuthors">Schilling, Uta; Dingemanse, Jasper; Ufer, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">545-566</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Coronary artery disease remains the major cause of mortality worldwide.  Antiplatelet drugs such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for the prevention of thrombotic events in patients with coronary artery disease.  Clopidogrel has long been the gold std. but has major pharmacol. limitations such as a slow onset and long duration of effect, as well as weak platelet inhibition with high inter-individual pharmacokinetic and pharmacodynamic variability.  There has been a strong need to develop potent P2Y12 receptor antagonists with more favorable pharmacol. properties.  Prasugrel and ticagrelor are more potent and have a faster onset of action; however, they have shown an increased bleeding risk compared with clopidogrel.  Cangrelor is highly potent and has a very rapid onset and offset of effect; however, its indication is limited to P2Y12 antagonist-naive patients undergoing percutaneous coronary intervention.  Two novel P2Y12 receptor antagonists are currently in clin. development, namely vicagrel and selatogrel.  Vicagrel is an analog of clopidogrel with enhanced and more efficient formation of its active metabolite.  Selatogrel is characterized by a rapid onset of action following s.c. administration and developed for early treatment of a suspected acute myocardial infarction.  This review article describes the clin. pharmacol. profile of marketed P2Y12 receptor antagonists and those under development focusing on pharmacokinetic, pharmacodynamic, and drug-drug interaction liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob4yrAPCq26rVg90H21EOLACvtfcHk0lg0-Nk7iHH32w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1ynu7o%253D&md5=c4944e0c916d6a6fb3b418af35465273</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00864-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00864-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchilling%26aufirst%3DU.%26aulast%3DDingemanse%26aufirst%3DJ.%26aulast%3DUfer%26aufirst%3DM.%26atitle%3DPharmacokinetics%2520and%2520pharmacodynamics%2520of%2520approved%2520and%2520investigational%2520P2Y12%2520receptor%2520antagonists%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D545%26epage%3D566%26doi%3D10.1007%2Fs40262-020-00864-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016</span>. <i>Lancet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">1151</span>– <span class="NLM_lpage">1210</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)32152-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2FS0140-6736%2817%2932152-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28919116" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=1151-1210&author=M.+Naghavi&title=Global%2C+regional%2C+and+national+age-sex+specific+mortality+for+264+causes+of+death%2C+1980%E2%80%932016%3A+a+systematic+analysis+for+the+global+burden+of+disease+study+2016&doi=10.1016%2FS0140-6736%2817%2932152-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2932152-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252932152-9%26sid%3Dliteratum%253Aachs%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520age-sex%2520specific%2520mortality%2520for%2520264%2520causes%2520of%2520death%252C%25201980%25E2%2580%25932016%253A%2520a%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202016%26jtitle%3DLancet.%26date%3D2017%26volume%3D390%26spage%3D1151%26epage%3D1210%26doi%3D10.1016%2FS0140-6736%2817%2932152-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollopeter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jantzen, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">England, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramakrishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurden, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurden, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, P. B.</span></span> <span> </span><span class="NLM_article-title">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>409</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1038/35051599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2F35051599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=11196645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=409&publication_year=2001&pages=202-207&author=G.+Hollopeterauthor=H.+M.+Jantzenauthor=D.+Vincentauthor=G.+Liauthor=L.+Englandauthor=V.+Ramakrishnanauthor=R.+B.+Yangauthor=P.+Nurdenauthor=A.+Nurdenauthor=D.+Juliusauthor=P.+B.+Conley&title=Identification+of+the+platelet+ADP+receptor+targeted+by+antithrombotic+drugs&doi=10.1038%2F35051599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the platelet ADP receptor targeted by antithrombotic drugs</span></div><div class="casAuthors">Hollopeter, Gunther; Jantzen, Hans-Michiel; Vincent, Diana; Li, Georgia; England, Laura; Ramakrishnan, Vanitha; Yang, Ruey-Bing; Nurden, Paquita; Nurden, Alan; Julius, David; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">409</span>
        (<span class="NLM_cas:issue">6817</span>),
    <span class="NLM_cas:pages">202-207</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Platelets have a crucial role in the maintenance of normal hemostasis, and perturbations of this system can lead to pathol. thrombus formation and vascular occlusion, resulting in stroke; myocardial infarction and unstable angina.  ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb-IIIa and subsequent binding of fibrinogen.  ADP is also secreted from platelets on activation, providing pos. feedback that potentiates the actions of many platelet activators.  ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes.  The P2Y1 receptor couples to Gq and. mobilizes intracellular calcium ions to mediate platelet shape change and aggregation.  The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi.  The mol. identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel and AR-C66096. Here the authors describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder has a defect in this gene.  Cloning of the P2Y12 receptor should facilitate the development- of better antiplatelet agents to treat cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbNuDi2tNS7bVg90H21EOLACvtfcHk0ljLIORRJxx1YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlvFSktQ%253D%253D&md5=fe30017f0d3bd9aacb4ad3bd6189c5d9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35051599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35051599%26sid%3Dliteratum%253Aachs%26aulast%3DHollopeter%26aufirst%3DG.%26aulast%3DJantzen%26aufirst%3DH.%2BM.%26aulast%3DVincent%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DEngland%26aufirst%3DL.%26aulast%3DRamakrishnan%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DR.%2BB.%26aulast%3DNurden%26aufirst%3DP.%26aulast%3DNurden%26aufirst%3DA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DIdentification%2520of%2520the%2520platelet%2520ADP%2520receptor%2520targeted%2520by%2520antithrombotic%2520drugs%26jtitle%3DNature%26date%3D2001%26volume%3D409%26spage%3D202%26epage%3D207%26doi%3D10.1038%2F35051599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbracchio, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnstock, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeynaems, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fumagalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisman, G. A.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fpr.58.3.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=16968944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=281-341&author=M.+P.+Abbracchioauthor=G.+Burnstockauthor=J.+M.+Boeynaemsauthor=E.+A.+Barnardauthor=J.+L.+Boyerauthor=C.+Kennedyauthor=G.+E.+Knightauthor=M.+Fumagalliauthor=C.+Gachetauthor=K.+A.+Jacobsonauthor=G.+A.+Weisman&title=International+Union+of+Pharmacology+LVIII%3A+update+on+the+P2Y+G+protein-coupled+nucleotide+receptors%3A+from+molecular+mechanisms+and+pathophysiology+to+therapy&doi=10.1124%2Fpr.58.3.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy</span></div><div class="casAuthors">Abbracchio, Maria P.; Burnstock, Geoffrey; Boeynaems, Jean-Marie; Barnard, Eric A.; Boyer, Jose L.; Kennedy, Charles; Knight, Gillian E.; Fumagalli, Marta; Gachet, Christian; Jacobson, Kenneth A.; Weisman, Gary A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">281-341</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  There have been many advances in our knowledge about different aspects of P2Y receptor signaling since the last review published by our International Union of Pharmacol. subcommittee.  More receptor subtypes have been cloned and characterized and most orphan receptors deorphanized, so that it is now possible to provide a basis for a future subdivision of P2Y receptor subtypes.  More is known about the functional elements of the P2Y receptor mols. and the signaling pathways involved, including interactions with ion channels.  There have been substantial developments in the design of selective agonists and antagonists to some of the P2Y receptor subtypes.  There are new findings about the mechanisms underlying nucleotide release and ectoenzymic nucleotide breakdown.  Interactions between P2Y receptors and receptors to other signaling mols. have been explored as well as P2Y-mediated control of gene transcription.  The distribution and roles of P2Y receptor subtypes in many different cell types are better understood and P2Y receptor-related compds. are being explored for therapeutic purposes.  These and other advances are discussed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3-m5Cf-JzaLVg90H21EOLACvtfcHk0ljLIORRJxx1YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLbF&md5=b302ee34857a5f45d740e4f2e962ed42</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.3%26sid%3Dliteratum%253Aachs%26aulast%3DAbbracchio%26aufirst%3DM.%2BP.%26aulast%3DBurnstock%26aufirst%3DG.%26aulast%3DBoeynaems%26aufirst%3DJ.%2BM.%26aulast%3DBarnard%26aufirst%3DE.%2BA.%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DKennedy%26aufirst%3DC.%26aulast%3DKnight%26aufirst%3DG.%2BE.%26aulast%3DFumagalli%26aufirst%3DM.%26aulast%3DGachet%26aufirst%3DC.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DWeisman%26aufirst%3DG.%2BA.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology%2520LVIII%253A%2520update%2520on%2520the%2520P2Y%2520G%2520protein-coupled%2520nucleotide%2520receptors%253A%2520from%2520molecular%2520mechanisms%2520and%2520pathophysiology%2520to%2520therapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D281%26epage%3D341%26doi%3D10.1124%2Fpr.58.3.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorsam, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunapuli, S. P.</span></span> <span> </span><span class="NLM_article-title">Central role of the P2Y<sub>12</sub> receptor in platelet activation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1172/JCI20986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1172%2FJCI20986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=14755328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2004&pages=340-345&author=R.+T.+Dorsamauthor=S.+P.+Kunapuli&title=Central+role+of+the+P2Y12+receptor+in+platelet+activation&doi=10.1172%2FJCI20986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Central role of the P2Y12 receptor in platelet activation</span></div><div class="casAuthors">Dorsam, Robert T.; Kunapuli, Satya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Platelet activation occurs in response to vessel injury and is important for the arrest of bleeding.  Platelet activation during disease states leads to vascular occlusion and ischemic damage.  The P2Y12 receptor, activated by ADP, plays a central role in platelet activation and is the target of P2Y12 receptor antagonists that have proven therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNjFviIpPpTLVg90H21EOLACvtfcHk0ljLIORRJxx1YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFSlsrs%253D&md5=a0a6e94419e76fe78d2cef969ece6274</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2FJCI20986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI20986%26sid%3Dliteratum%253Aachs%26aulast%3DDorsam%26aufirst%3DR.%2BT.%26aulast%3DKunapuli%26aufirst%3DS.%2BP.%26atitle%3DCentral%2520role%2520of%2520the%2520P2Y12%2520receptor%2520in%2520platelet%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D113%26spage%3D340%26epage%3D345%26doi%3D10.1172%2FJCI20986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span> <span> </span><span class="NLM_article-title">Antiplatelet drugs: which targets for which treatments?</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">S313</span>– <span class="NLM_lpage">S322</span>, <span class="refDoi"> DOI: 10.1111/jth.12947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fjth.12947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26149041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOitLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=S313-S322&author=C.+Gachet&title=Antiplatelet+drugs%3A+which+targets+for+which+treatments%3F&doi=10.1111%2Fjth.12947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antiplatelet drugs: which targets for which treatments?</span></div><div class="casAuthors">Gachet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S313-S322</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : The current std. care for acute coronary syndromes is dual antiplatelet therapy combining the COX1 inhibitor aspirin with a drug targeting the P2Y12 receptor, together with anticoagulation during and after early revascularization by percutaneous intervention.  In very high-risk patients, glycoprotein (GP) IIb/IIIa antagonists may also be used.  Secondary prevention of ischemic events requires dual antiplatelet therapy for several months followed by lifelong low-dose aspirin.  The duration of treatment and the drugs to combine nevertheless remain matters of debate and the focus of ongoing research.  Despite great progress, there is still room for improved efficacy and this could involve new targets for both antiplatelet drugs (like the thrombin receptor PAR1) and anticoagulants.  However, improved efficacy is offset by an increased risk of bleeding.  Stroke patients are still waiting for better treatment, their bleeding risk being particularly high.  New targets including the collagen receptor, glycoprotein VI (GPVI), and the GPIb-von Willebrand factor axis, governing platelet interaction with the diseased vessel wall, should enable us to complete the armamentarium of antiplatelet drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFJF4DC8OarVg90H21EOLACvtfcHk0lgR1sG8r5SKgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOitLnP&md5=8bdce97c2472085d403bdd1263bc3141</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fjth.12947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12947%26sid%3Dliteratum%253Aachs%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DAntiplatelet%2520drugs%253A%2520which%2520targets%2520for%2520which%2520treatments%253F%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2015%26volume%3D13%26spage%3DS313%26epage%3DS322%26doi%3D10.1111%2Fjth.12947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel and ticlopidine: P2Y<sub>12</sub> adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span>. <i>Semin. Thromb. Hemostasis</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1055/s-2005-869523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1055%2Fs-2005-869523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=15852221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2005&pages=174-183&author=P.+Saviauthor=J.+M.+Herbert&title=Clopidogrel+and+ticlopidine%3A+P2Y12+adenosine+diphosphate-receptor+antagonists+for+the+prevention+of+atherothrombosis&doi=10.1055%2Fs-2005-869523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis</span></div><div class="casAuthors">Savi, Pierre; Herbert, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Thrombosis and Hemostasis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">STHMBV</span>;
        ISSN:<span class="NLM_cas:issn">0094-6176</span>.
    
            (<span class="NLM_cas:orgname">Thieme Medical Publishers, Inc.</span>)
        </div><div class="casAbstract">A review.  Ticlopidine and clopidogrel belong to the same chem. family of thienopyridine ADP (ADP)-receptor antagonists.  They have shown their efficacy as platelet antiaggregant and antithrombotic agents in many animal models, both ex vivo and in vivo.  Although ticlopidine was discovered more than 30 years ago, it was only recently that the mechanism of action of ADP-receptor antagonists was characterized in detail.  Ticlopidine and clopidogrel both behave in vivo as specific antagonists of P2Y12, one of the ADP receptors on platelets.  Metabolic steps that involve cytochrome P 450-dependent pathways are required to generate the active metabolite responsible for this in vivo activity.  The active moiety is a reactive thiol deriv. that targets P2Y12 on platelets.  The interaction is irreversible, accounting for the observation that platelets are definitely antiaggregated, even if no active metabolite is detectable in plasma.  The interaction is specific for P2Y12; other purinoceptors such as P2Y1 and P2Y13 are spared.  This results in inhibition of the binding of the P2Y12 agonist 2-methylthio-ADP and the ADP-induced downregulation of adenylyl cyclase.  Platelet aggregation is affected not only when triggered by ADP but also by aggregation inducers when used at concns. requiring released ADP as an amplifier.  The efficacy and safety of clopidogrel has been established in several large, randomized, controlled trials.  The clopidogrel vs. aspirin in patients at risk of ischemic events (CAPRIE) trial demonstrated the superiority of clopidogrel over acetylsalicylic acid (ASA) in patients at risk of ischemic events, including ischemic stroke, myocardial infarction (MI), and peripheral arterial disease.  The clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial showed a sustained, incremental benefit when clopidogrel was added to std. therapy (including ASA) in patients with unstable angina and non-Q-wave MI.  The clopidogrel for the redn. of events during observation (CREDO) trial demonstrated the benefit of continuing clopidogrel (plus ASA) for 12 mo, as opposed to 1 mo, after percutaneous coronary intervention.  The proven efficacy of clopidogrel, coupled with its favorable safety and tolerability profile, has prompted its evaluation in an extensive, ongoing clin. trial program that will help to further characterize the benefit of clopidogrel in patients with a range of atherothrombotic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0RPp6l6_G_LVg90H21EOLACvtfcHk0lgR1sG8r5SKgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvVSnurc%253D&md5=e33ff9017bb1a345b8fb7f769af03a5b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869523%26sid%3Dliteratum%253Aachs%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26atitle%3DClopidogrel%2520and%2520ticlopidine%253A%2520P2Y12%2520adenosine%2520diphosphate-receptor%2520antagonists%2520for%2520the%2520prevention%2520of%2520atherothrombosis%26jtitle%3DSemin.%2520Thromb.%2520Hemostasis%26date%3D2005%26volume%3D31%26spage%3D174%26epage%3D183%26doi%3D10.1055%2Fs-2005-869523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palczewski, K.</span></span> <span> </span><span class="NLM_article-title">The molecular mechanism of P2Y<sub>1</sub> receptor activation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10331</span>– <span class="NLM_lpage">10335</span>, <span class="refDoi"> DOI: 10.1002/anie.201605147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fanie.201605147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1GjurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10331-10335&author=S.+Yuanauthor=H.+C.+Chanauthor=H.+Vogelauthor=S.+Filipekauthor=R.+C.+Stevensauthor=K.+Palczewski&title=The+molecular+mechanism+of+P2Y1+receptor+activation&doi=10.1002%2Fanie.201605147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Mechanism of P2Y1 Receptor Activation</span></div><div class="casAuthors">Yuan, Shuguang; Chan, H. C. Stephen; Vogel, Horst; Filipek, Slawomir; Stevens, Raymond C.; Palczewski, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">10331-10335</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human purinergic G protein-coupled receptor P2Y1 (P2Y1R) is activated by ADP (ADP) to induce platelet activation and thereby serves as an important antithrombotic drug target.  Crystal structures of P2Y1R revealed that one ligand (MRS2500) binds to the extracellular vestibule of this GPCR, whereas another (BPTU) occupies the surface between transmembrane (TM) helixes TM2 and TM3.  We introduced a total of 20 μs all-atom long-timescale mol. dynamic (MD) simulations to inquire why two mols. in completely different locations both serve as antagonists while ADP activates the receptor.  Our results indicate that BPTU acts as an antagonist by stabilizing extracellular helix bundles leading to an increase of the lipid order, whereas MRS2500 blocks signaling by occupying the ligand binding site.  Both antagonists stabilize an ionic lock within the receptor.  However, binding of ADP breaks this ionic lock, forming a continuous water channel that leads to P2Y1R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrttSpukVGbybVg90H21EOLACvtfcHk0lgR1sG8r5SKgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1GjurjE&md5=bee2945509055a868dc8e686a9199cea</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605147%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DH.%2BC.%26aulast%3DVogel%26aufirst%3DH.%26aulast%3DFilipek%26aufirst%3DS.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DPalczewski%26aufirst%3DK.%26atitle%3DThe%2520molecular%2520mechanism%2520of%2520P2Y1%2520receptor%2520activation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10331%26epage%3D10335%26doi%3D10.1002%2Fanie.201605147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. D.</span></span> <span> </span><span class="NLM_article-title">The P2Y<sub>1</sub> purinergic receptor expressed by enteric neurones in guinea-pig intestine</span>. <i>Neurogastroenterol. Motil.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2982.2005.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fj.1365-2982.2005.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=16553587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BD287msF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2006&pages=316-323&author=N.+Gaoauthor=H.+Z.+Huauthor=M.+X.+Zhuauthor=X.+Fangauthor=S.+Liuauthor=C.+Gaoauthor=J.+D.+Wood&title=The+P2Y1+purinergic+receptor+expressed+by+enteric+neurones+in+guinea-pig+intestine&doi=10.1111%2Fj.1365-2982.2005.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The P2Y purinergic receptor expressed by enteric neurones in guinea-pig intestine</span></div><div class="casAuthors">Gao N; Hu H-Z; Zhu M X; Fang X; Liu S; Gao C; Wood J D</div><div class="citationInfo"><span class="NLM_cas:title">Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-23</span>
        ISSN:<span class="NLM_cas:issn">1350-1925</span>.
    </div><div class="casAbstract">Electrophysiological recording methods provided evidence for presynaptic release of ATP from enteric neurones and postganglionic sympathetic fibres in the enteric nervous system (ENS) of guinea-pig intestine (J Physiol Lond 2003; 550: 493-504).  The released ATP acted at postsynaptic P2Y(1) receptors to evoke slow synaptic excitation in neurones in the submucosal division of the ENS.  Here, we report the cloning and characterization of the P2Y(1) receptor, which was found in the guinea-pig submucosal layer.  A 1178 bp cDNA clone was isolated from guinea-pig submucosal RNA by reverse transcription polymerase chain reaction (RT-PCR).  The cDNA contained an open-reading frame of 1119 bp, encoding a 373 amino acid polypeptide of the same length and with 95% identity to the human P2Y(1) receptor.  Stable expression of the guinea-pig cDNA in human embryonic kidney (HEK)293 cells was accompanied by a marked increase in sensitivity for elevation of free intracellular calcium evoked by ATP or related nucleotides.  The potency order for ATP and its analogues was: 2-methio-adenosine diphosphate > 2-methio-adenosine triphosphate > ADP > ATP-gamma-S > ATP.  The selective P2Y(1) receptor antagonist, MRS2179, was a competitive antagonist for the receptor with a pA(2) value of 6.5.  The results add to existing evidence for expression of a functional P2Y(1) purinergic receptor in neurones of the submucosal division of the ENS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlB49fIEjg1AMthz5_Rx5rfW6udTcc2eZAnuDw-oR0Kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287msF2jtw%253D%253D&md5=2f7f5d3ff69fa8fa55c1206e840b03f4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2982.2005.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2982.2005.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DH.%2BZ.%26aulast%3DZhu%26aufirst%3DM.%2BX.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520P2Y1%2520purinergic%2520receptor%2520expressed%2520by%2520enteric%2520neurones%2520in%2520guinea-pig%2520intestine%26jtitle%3DNeurogastroenterol.%2520Motil.%26date%3D2006%26volume%3D18%26spage%3D316%26epage%3D323%26doi%3D10.1111%2Fj.1365-2982.2005.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of P2Y<sub>12</sub> antagonist ethyl 6-(4-((benzylsulfonyl) carbamoyl) piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) led to the discovery of an oral antiplatelet agent with improved druglike properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3088</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01971</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01971" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3088-3106&author=D.+Kongauthor=T.+Xueauthor=B.+Guoauthor=J.+Chengauthor=S.+Liuauthor=J.+Weiauthor=Z.+Luauthor=H.+Liuauthor=G.+Gongauthor=T.+Lanauthor=W.+Huauthor=Y.+Yang&title=Optimization+of+P2Y12+antagonist+ethyl+6-%284-%28%28benzylsulfonyl%29+carbamoyl%29+piperidin-1-yl%29-5-cyano-2-methylnicotinate+%28AZD1283%29+led+to+the+discovery+of+an+oral+antiplatelet+agent+with+improved+druglike+properties&doi=10.1021%2Facs.jmedchem.8b01971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties</span></div><div class="casAuthors">Kong, Deyu; Xue, Tao; Guo, Bin; Cheng, Jianjun; Liu, Shunyin; Wei, Jianhai; Lu, Zhengyu; Liu, Haoran; Gong, Guoqing; Lan, Tian; Hu, Wenhao; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3088-3106</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis.  Based on the scaffold of a known P2Y12 antagonist AZD1283 (I), a series of novel bicyclic pyridine derivs. were designed and synthesized.  The cyclization of the ester substituent on the pyridine ring to the ortho-Me group led to lactone analogs of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies.  The metabolic stability was further enhanced by adding a 4-Me substituent to the piperidinyl moiety.  Compd. II displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model.  Moreover, II showed a safety profile that was superior to what was obsd. for clopidogrel in a rat tail-bleeding model.  These results support the further evaluation of compd. II as a promising drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aElj92vWULVg90H21EOLACvtfcHk0lgZoBR1OMtnOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D&md5=40577f34468ef13d6eea4a7a76dcaab8</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520P2Y12%2520antagonist%2520ethyl%25206-%25284-%2528%2528benzylsulfonyl%2529%2520carbamoyl%2529%2520piperidin-1-yl%2529-5-cyano-2-methylnicotinate%2520%2528AZD1283%2529%2520led%2520to%2520the%2520discovery%2520of%2520an%2520oral%2520antiplatelet%2520agent%2520with%2520improved%2520druglike%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3088%26epage%3D3106%26doi%3D10.1021%2Facs.jmedchem.8b01971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span> <span> </span><span class="NLM_article-title">New P2Y<sub>12</sub> inhibitors</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.109.853069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FCIRCULATIONAHA.109.853069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=20048234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FgsFeqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2010&pages=171-179&author=M.+Cattaneo&title=New+P2Y12+inhibitors&doi=10.1161%2FCIRCULATIONAHA.109.853069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New P2Y(12) inhibitors</span></div><div class="casAuthors">Cattaneo Marco</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0GBsuDbTwFA8IxFYvehhofW6udTcc2eZAnuDw-oR0Kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FgsFeqtA%253D%253D&md5=99123172771709d92cd16565407578e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.109.853069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.109.853069%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DNew%2520P2Y12%2520inhibitors%26jtitle%3DCirculation%26date%3D2010%26volume%3D121%26spage%3D171%26epage%3D179%26doi%3D10.1161%2FCIRCULATIONAHA.109.853069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusegawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farid, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, T.</span></span> <span> </span><span class="NLM_article-title">Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">218</span>– <span class="NLM_lpage">226</span>, <span class="refDoi"> DOI: 10.1080/00498250802650077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F00498250802650077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19280520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXos1ansrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=218-226&author=K.+Hagiharaauthor=M.+Kazuiauthor=H.+Ikenagaauthor=T.+Nanbaauthor=K.+Fusegawaauthor=M.+Takahashiauthor=A.+Kuriharaauthor=O.+Okazakiauthor=N.+A.+Faridauthor=T.+Ikeda&title=Comparison+of+formation+of+thiolactones+and+active+metabolites+of+prasugrel+and+clopidogrel+in+rats+and+dogs&doi=10.1080%2F00498250802650077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs</span></div><div class="casAuthors">Hagihara, K.; Kazui, M.; Ikenaga, H.; Nanba, T.; Fusegawa, K.; Takahashi, M.; Kurihara, A.; Okazaki, O.; Farid, N. A.; Ikeda, T.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">218-226</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Prasugrel and clopidogrel are antiplatelet prodrugs that are converted to their resp. active metabolites through thiolactone intermediates.  Prasugrel is rapidly hydrolyzed by esterases to its thiolactone intermediate, while clopidogrel is oxidized by cytochrome P 450 (CYP) isoforms to its thiolactone.  The conversion of both thiolactones to the active metabolites is CYP mediated.  This study compared the efficiency, in vivo, of the formation of prasugrel and clopidogrel thiolactones and their active metabolites.  The areas under the plasma concn. vs. time curve (AUC) of the thiolactone intermediates in the portal vein plasma after an oral dose of prasugrel (1 mg kg-1) and clopidogrel (0.77 mg kg-1) were 15.8 ± 15.9 ng h ml-1 and 0.113 ± 0.226 ng h ml-1, resp., in rats, and 454 ± 104 ng h ml-1 and 23.3 ± 4.3 ng h ml-1, resp., in dogs, indicating efficient hydrolysis of prasugrel and little metab. of clopidogrel to their thiolactones in the intestine.  The relative bioavailability of the active metabolites of prasugrel and clopidogrel calcd. by the ratio of active metabolite AUC (produg oral administration/active metabolite i.v. administration) were 25% and 7%, resp., in rats, and 25% and 10%, resp., in dogs.  Single intraduodenal administration of prasugrel showed complete conversion of prasugrel, resulting in high concns. of the thiolactone and active metabolite of prasugrel in rat portal vein plasma, which demonstrates that these products are generated in the intestine during the absorption process.  In conclusion, the extent of in vivo formation of the thiolactone and the active metabolite of prasugrel was greater than for clopidogrel's thiolactone and active metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLQN2zKY2K7Vg90H21EOLACvtfcHk0ljH3FN_NynTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXos1ansrs%253D&md5=4d0a538528cfbcfc5ff2efe04b219357</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F00498250802650077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250802650077%26sid%3Dliteratum%253Aachs%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DKazui%26aufirst%3DM.%26aulast%3DIkenaga%26aufirst%3DH.%26aulast%3DNanba%26aufirst%3DT.%26aulast%3DFusegawa%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DOkazaki%26aufirst%3DO.%26aulast%3DFarid%26aufirst%3DN.%2BA.%26aulast%3DIkeda%26aufirst%3DT.%26atitle%3DComparison%2520of%2520formation%2520of%2520thiolactones%2520and%2520active%2520metabolites%2520of%2520prasugrel%2520and%2520clopidogrel%2520in%2520rats%2520and%2520dogs%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D218%26epage%3D226%26doi%3D10.1080%2F00498250802650077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalescot, G.</span></span> <span> </span><span class="NLM_article-title">Do we need a new P2Y<sub>12</sub> receptor antagonist?</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3141</span>– <span class="NLM_lpage">3143</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehz862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehz862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31845967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BB3MbgvF2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3141-3143&author=J.+S.+Hulotauthor=G.+Montalescot&title=Do+we+need+a+new+P2Y12+receptor+antagonist%3F&doi=10.1093%2Feurheartj%2Fehz862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Do we need a new P2Y12 receptor antagonist?</span></div><div class="casAuthors">Hulot Jean-Sebastien; Hulot Jean-Sebastien; Montalescot Gilles</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3141-3143</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwh9NXgmMTbTEC-75aqa5AfW6udTcc2ea5TjfiEgM_G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbgvF2ltA%253D%253D&md5=435a884caf2b66a512a1185af6b02e05</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehz862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehz862%26sid%3Dliteratum%253Aachs%26aulast%3DHulot%26aufirst%3DJ.%2BS.%26aulast%3DMontalescot%26aufirst%3DG.%26atitle%3DDo%2520we%2520need%2520a%2520new%2520P2Y12%2520receptor%2520antagonist%253F%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2020%26volume%3D41%26spage%3D3141%26epage%3D3143%26doi%3D10.1093%2Feurheartj%2Fehz862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugidachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizawa, A.</span></span> <span> </span><span class="NLM_article-title">A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1111/bph.12108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fbph.12108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23347039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtFalu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=82-89&author=A.+Sugidachiauthor=K.+Ohnoauthor=T.+Ogawaauthor=J.+Jakubowskiauthor=M.+Hashimotoauthor=A.+Tomizawa&title=A+comparison+of+the+pharmacological+profiles+of+prasugrel+and+ticagrelor+assessed+by+platelet+aggregation%2C+thrombus+formation+and+haemostasis+in+rats&doi=10.1111%2Fbph.12108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats</span></div><div class="casAuthors">Sugidachi, A.; Ohno, K.; Ogawa, T.; Jakubowski, J. A.; Hashimoto, M.; Tomizawa, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-89</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: Prasugrel is a third-generation thienopyridine prodrug and ticagrelor is a non-competitive P2Y12 receptor antagonist.  In their phase 3 studies, both agents reduced rates of ischemic events relative to treatment with clopidogrel.  Exptl. Approach: The pharmacodynamic profile of anti-platelet effects of prasugrel was compared with that of ticagrelor in rats.  Key Results: The active metabolite of prasugrel was less potent than ticagrelor and its active metabolite on platelet aggregation in vitro.  In contrast, prasugrel was a more potent antiplatelet agent than ticagrelor on ex vivo platelet aggregation: their ED50 values at peak for ADP 20 μmol·L-1 were 1.9 and 8.0 mg·kg-1, resp.  Prasugrel's inhibition of platelet aggregation was maintained for up to 24 h after administration, but ticagrelor's duration of action was substantially shorter.  Prasugrel and ticagrelor significantly inhibited thrombus formation with ED50 values of 1.8 and 7.7 mg·kg-1, resp.  Both agents also prolonged bleeding times (ED200 values of 3.0 and 13 mg·kg-1 resp.) suggesting that at equiv. levels of inhibition of platelet aggregation, the agents would show comparable antithrombotic activity with similar bleeding risk.  Platelet transfusion significantly increased blood platelet nos. similarly in prasugrel- and ticagrelor-treated rats.  In the prasugrel-treated group, platelet transfusion caused significant shortening of bleeding time, while in the ticagrelor-treated group, platelet transfusion showed no influence on bleeding time under the exptl. conditions employed.  Conclusions and Implications: Prasugrel and ticagrelor showed several differences in their pharmacol. profiles and these disparities may reflect their differing reversibility and/or pharmacokinetic profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz2iCKDkyB3rVg90H21EOLACvtfcHk0ljH3FN_NynTNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtFalu7k%253D&md5=f6f5c96c8789109fe06f5c47d6f4147c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fbph.12108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12108%26sid%3Dliteratum%253Aachs%26aulast%3DSugidachi%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DJakubowski%26aufirst%3DJ.%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DTomizawa%26aufirst%3DA.%26atitle%3DA%2520comparison%2520of%2520the%2520pharmacological%2520profiles%2520of%2520prasugrel%2520and%2520ticagrelor%2520assessed%2520by%2520platelet%2520aggregation%252C%2520thrombus%2520formation%2520and%2520haemostasis%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D169%26spage%3D82%26epage%3D89%26doi%3D10.1111%2Fbph.12108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span> <span> </span><span class="NLM_article-title">Antithrombotic P2Y<sub>12</sub> receptor antagonists: recent developments in drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2018.09.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.drudis.2018.09.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30291899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGltrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=325-333&author=Y.+Baqiauthor=C.+E.+Muller&title=Antithrombotic+P2Y12+receptor+antagonists%3A+recent+developments+in+drug+discovery&doi=10.1016%2Fj.drudis.2018.09.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery</span></div><div class="casAuthors">Baqi, Younis; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">325-333</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family.  The P2Y12 receptor is highly expressed on blood platelets and in the brain.  Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clin. as antithrombotic drugs.  Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivs.  Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTJdgZbKZDrVg90H21EOLACvtfcHk0ljdQrPusqqp4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGltrbI&md5=a6e3009e8275f5039d30830a493db529</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2018.09.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2018.09.021%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26atitle%3DAntithrombotic%2520P2Y12%2520receptor%2520antagonists%253A%2520recent%2520developments%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26spage%3D325%26epage%3D333%26doi%3D10.1016%2Fj.drudis.2018.09.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cristalli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podda, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zighetti, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span> <span> </span><span class="NLM_article-title">Effects of 5′-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2763</span>– <span class="NLM_lpage">2766</span>, <span class="refDoi"> DOI: 10.1021/jm0493562</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0493562" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2763-2766&author=G.+Cristalliauthor=G.+M.+Poddaauthor=S.+Costanziauthor=C.+Lambertucciauthor=A.+Lecchiauthor=S.+Vittoriauthor=R.+Volpiniauthor=M.+L.+Zighettiauthor=M.+Cattaneo&title=Effects+of+5%E2%80%B2-phosphate+derivatives+of+2-hexynyl+adenosine+and+2-phenylethynyl+adenosine+on+responses+of+human+platelets+mediated+by+P2Y+receptors&doi=10.1021%2Fjm0493562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of 5'-Phosphate Derivatives of 2-Hexynyl Adenosine and 2-Phenylethynyl Adenosine on Responses of Human Platelets Mediated by P2Y Receptors</span></div><div class="casAuthors">Cristalli, Gloria; Podda, Gian Marco; Costanzi, Stefano; Lambertucci, Catia; Lecchi, Anna; Vittori, Sauro; Volpini, Rosaria; Zighetti, Maddalena L.; Cattaneo, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2763-2766</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Newly synthesized mono-, di-, and triphosphate of 2-alkynyl adenosines showed very different behavior in human platelet P2Y receptor models, according to the different alkynyl chains.  In fact, 2-hexynyladenosine di- (5) and triphosphate (7) induced platelet shape change and aggregation and inhibited PGE1-induced increase in platelet cAMP.  On the contrary, the corresponding 2-phenylethynyladenosine di- (6) and triphosphate (8) did not induce platelet shape change or aggregation, but inhibited platelet aggregation induced by ADP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPU81zM8NTLbVg90H21EOLACvtfcHk0ljdQrPusqqp4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlSitrk%253D&md5=0948d48df9f4cf59984b94424a8ec5ff</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm0493562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0493562%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DPodda%26aufirst%3DG.%2BM.%26aulast%3DCostanzi%26aufirst%3DS.%26aulast%3DLambertucci%26aufirst%3DC.%26aulast%3DLecchi%26aufirst%3DA.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DVolpini%26aufirst%3DR.%26aulast%3DZighetti%26aufirst%3DM.%2BL.%26aulast%3DCattaneo%26aufirst%3DM.%26atitle%3DEffects%2520of%25205%25E2%2580%25B2-phosphate%2520derivatives%2520of%25202-hexynyl%2520adenosine%2520and%25202-phenylethynyl%2520adenosine%2520on%2520responses%2520of%2520human%2520platelets%2520mediated%2520by%2520P2Y%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2763%26epage%3D2766%26doi%3D10.1021%2Fjm0493562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruel, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibeault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">L’Heureux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spronk, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiebert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouthillier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnur, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1′-neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y<sub>1</sub> antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9275</span>– <span class="NLM_lpage">9295</span>, <span class="refDoi"> DOI: 10.1021/jm4013906</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4013906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9275-9295&author=J.+X.+Qiaoauthor=T.+C.+Wangauthor=W.+R.+Ruelauthor=C.+Thibeaultauthor=A.+L%E2%80%99Heureuxauthor=W.+A.+Schumacherauthor=S.+A.+Spronkauthor=S.+Hiebertauthor=G.+Bouthillierauthor=J.+Lloydauthor=Z.+Piauthor=D.+M.+Schnurauthor=L.+M.+Abellauthor=J.+Huaauthor=L.+A.+Priceauthor=E.+Liuauthor=Q.+Wuauthor=T.+E.+Steinbacherauthor=J.+S.+Bostwickauthor=M.+Changauthor=J.+Zhengauthor=Q.+Gaoauthor=B.+Maauthor=P.+A.+McDonnellauthor=C.+S.+Huangauthor=R.+Rehfussauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Conformationally+constrained+ortho-anilino+diaryl+ureas%3A+discovery+of+1-%282-%281%E2%80%B2-neopentylspiro%5Bindoline-3%2C4%E2%80%B2-piperidine%5D-1-yl%29phenyl%29-3-%284-%28trifluoromethoxy%29phenyl%29urea%2C+a+potent%2C+selective%2C+and+bioavailable+P2Y1+antagonist&doi=10.1021%2Fjm4013906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1 (2-(1'-Neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist</span></div><div class="casAuthors">Qiao, Jennifer X.; Wang, Tammy C.; Ruel, Rejean; Thibeault, Carl; Lheureux, Alexandre; Schumacher, William A.; Spronk, Steven A.; Hiebert, Sheldon; Bouthillier, Gilles; Lloyd, John; Pi, Zulan; Schnur, Dora M.; Abell, Lynn M.; Hua, Ji; Price, Laura A.; Liu, Eddie; Wu, Qimin; Steinbacher, Thomas E.; Bostwick, Jeffrey S.; Chang, Ming; Zheng, Joanna; Gao, Qi; Ma, Baoqing; McDonnell, Patricia A.; Huang, Christine S.; Rehfuss, Robert; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9275-9295</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities.  In this article, we describe the structural modification of the tert-Bu phenoxy portion of lead compd. 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas.  In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-mol. P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats.  Homol. modeling and rat PK/PD studies on benchmark compd. 3l will also be presented.  Compd. 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonBqH7TKoyjrVg90H21EOLACvtfcHk0ljdQrPusqqp4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1yls7%252FL&md5=6037e3a59bde92e280e9a8d5b5d8300e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm4013906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4013906%26sid%3Dliteratum%253Aachs%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DRuel%26aufirst%3DW.%2BR.%26aulast%3DThibeault%26aufirst%3DC.%26aulast%3DL%25E2%2580%2599Heureux%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DSpronk%26aufirst%3DS.%2BA.%26aulast%3DHiebert%26aufirst%3DS.%26aulast%3DBouthillier%26aufirst%3DG.%26aulast%3DLloyd%26aufirst%3DJ.%26aulast%3DPi%26aufirst%3DZ.%26aulast%3DSchnur%26aufirst%3DD.%2BM.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DSteinbacher%26aufirst%3DT.%2BE.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DMcDonnell%26aufirst%3DP.%2BA.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DConformationally%2520constrained%2520ortho-anilino%2520diaryl%2520ureas%253A%2520discovery%2520of%25201-%25282-%25281%25E2%2580%25B2-neopentylspiro%255Bindoline-3%252C4%25E2%2580%25B2-piperidine%255D-1-yl%2529phenyl%2529-3-%25284-%2528trifluoromethoxy%2529phenyl%2529urea%252C%2520a%2520potent%252C%2520selective%252C%2520and%2520bioavailable%2520P2Y1%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9275%26epage%3D9295%26doi%3D10.1021%2Fjm4013906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiffert, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-aryl-7-hydroxyindoline based P2Y<sub>1</sub> antagonists as novel antiplatelet agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6150</span>– <span class="NLM_lpage">6164</span>, <span class="refDoi"> DOI: 10.1021/jm5006226</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006226" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslent7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6150-6164&author=W.+Yangauthor=Y.+Wangauthor=A.+Laiauthor=J.+X.+Qiaoauthor=T.+C.+Wangauthor=J.+Huaauthor=L.+A.+Priceauthor=H.+Shenauthor=X.+Chenauthor=P.+Wongauthor=E.+Crainauthor=C.+Watsonauthor=C.+S.+Huangauthor=D.+A.+Seiffertauthor=R.+Rehfussauthor=R.+R.+Wexlerauthor=P.+Y.+S.+Lam&title=Discovery+of+4-aryl-7-hydroxyindoline+based+P2Y1+antagonists+as+novel+antiplatelet+agents&doi=10.1021%2Fjm5006226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y1 Antagonists as Novel Antiplatelet Agents</span></div><div class="casAuthors">Yang, Wu; Wang, Yufeng; Lai, Amy; Qiao, Jennifer X.; Wang, Tammy C.; Hua, Ji; Price, Laura A.; Shen, Hong; Chen, Xue-qing; Wong, Pancras; Crain, Earl; Watson, Carol; Huang, Christine S.; Seiffert, Dietmar A.; Rehfuss, Robert; Wexler, Ruth R.; Lam, Patrick Y. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6150-6164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">ADP (ADP)-mediated platelet aggregation is signaled through two distinct G protein-coupled receptors (GPCR) on the platelet surface: P2Y12 and P2Y1.  Blocking P2Y12 receptor is a clin. well-validated strategy for antithrombotic therapy.  P2Y1 antagonists have been shown to have the potential to provide equiv. antithrombotic efficacy as P2Y12 inhibitors with reduced bleeding in preclin. animal models.  Th have previously reported the discovery of a potent and orally bioavailable P2Y1 antagonist, I.  This paper describes further optimization of I by introducing 4-aryl groups at the hydroxylindoline in two series.  In the neutral series, II was identified with excellent potency and desirable pharmacokinetic (PK) profile.  It also demonstrated similar antithrombotic efficacy with less bleeding compared with the known P2Y12 antagonist prasugrel in rabbit efficacy/bleeding models.  In the basic series, III (BMS-884775) was discovered with an improved PK and liability profile over I.  These results support P2Y1 antagonism as a promising new antiplatelet target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTxYWbBi9B6bVg90H21EOLACvtfcHk0lgPSwQ5iEVing"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslent7k%253D&md5=bc2143cbd324258322e140d77cc0e564</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm5006226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006226%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DQiao%26aufirst%3DJ.%2BX.%26aulast%3DWang%26aufirst%3DT.%2BC.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DCrain%26aufirst%3DE.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DSeiffert%26aufirst%3DD.%2BA.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BS.%26atitle%3DDiscovery%2520of%25204-aryl-7-hydroxyindoline%2520based%2520P2Y1%2520antagonists%2520as%2520novel%2520antiplatelet%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6150%26epage%3D6164%26doi%3D10.1021%2Fjm5006226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bird, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span> <span> </span><span class="NLM_article-title">A platelet target for venous thrombosis? P2Y<sub>1</sub> deletion or antagonism protects mice from vena cava thrombosis</span>. <i>J. Thromb. Thrombolysis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1007/s11239-012-0745-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs11239-012-0745-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=22588534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhsbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=199-207&author=J.+E.+Birdauthor=X.+Wangauthor=P.+L.+Smithauthor=F.+Barberaauthor=C.+Huangauthor=W.+A.+Schumacher&title=A+platelet+target+for+venous+thrombosis%3F+P2Y1+deletion+or+antagonism+protects+mice+from+vena+cava+thrombosis&doi=10.1007%2Fs11239-012-0745-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis</span></div><div class="casAuthors">Bird, J. Eileen; Wang, Xinkang; Smith, Patricia L.; Barbera, Frank; Huang, Christine; Schumacher, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Thrombolysis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-207</span>CODEN:
                <span class="NLM_cas:coden">JTTHFF</span>;
        ISSN:<span class="NLM_cas:issn">0929-5305</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A role for platelets in the pathogenesis of venous thrombosis was suggested by clin. and preclin. studies.  However, examn. of the platelet receptor, P2Y1, in this area has been limited.  The goal of the current study was to examine effects of P2Y1 deletion, or selective antagonism with MRS2500, in oxidative venous thrombosis in mice.  The P2Y12 antagonist, clopidogrel, was included as a ref. agent.  Anesthetized C57BL/6 or genetically modified mice underwent 3.5 or 5 % FeCl3-induced vena cava thrombosis.  Pharmacokinetic properties of MRS2500 were defined for dose selection.  Platelet aggregation and renal or tail bleeding times (BT) were measured to put antithrombotic effects into perspective.  P2Y1 deletion significantly reduced (p < 0.001) venous thrombus wt. by 74 % in 3.5 % FeCl3 injury compared to P2Y1+/+ littermates.  MRS2500 (2 mg/kg, i.v.) significantly decreased (p < 0.001) thrombus wt. 64 % in C57BL/6 mice.  In the more severe 5 % FeCl3-induced injury model, thrombus wt. significantly (p < 0.001) decreased 68 % in P2Y1-/- mice vs. P2Y1+/+ mice, and MRS2500 (2 mg/kg) was also beneficial (54 % decrease, p < 0.01).  Renal BT doubled in P2Y1-/- vs. P2Y1+/+ mice, and increased threefold with MRS2500 compared to vehicle.  Tail BT was markedly prolonged in P2Y1-/- mice (7.9X) and in C57BL/6 mice given MRS2500.  The current study demonstrates that P2Y1 deletion or antagonism significantly reduced venous thrombosis in mice, suggesting that P2Y1 receptors play a role in the pathogenesis of venous thrombosis, at least in this species.  However as with many antithrombotic agents the benefit comes at the potential price of an increase in provoked bleeding times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzzjvsbFdOPbVg90H21EOLACvtfcHk0lgPSwQ5iEVing"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhsbnO&md5=7bba9afd96fdd0022ff3c52f7fdcf629</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11239-012-0745-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11239-012-0745-3%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DP.%2BL.%26aulast%3DBarbera%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26atitle%3DA%2520platelet%2520target%2520for%2520venous%2520thrombosis%253F%2520P2Y1%2520deletion%2520or%2520antagonism%2520protects%2520mice%2520from%2520vena%2520cava%2520thrombosis%26jtitle%3DJ.%2520Thromb.%2520Thrombolysis%26date%3D2012%26volume%3D34%26spage%3D199%26epage%3D207%26doi%3D10.1007%2Fs11239-012-0745-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turdi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herpin, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberge, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnur, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poss, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehfuss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogletree, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cacace, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wexler, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y<sub>1</sub> antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/jm301708u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301708u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVeqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1704-1714&author=H.+Chaoauthor=H.+Turdiauthor=T.+F.+Herpinauthor=J.+Y.+Robergeauthor=Y.+Liuauthor=D.+M.+Schnurauthor=M.+A.+Possauthor=R.+Rehfussauthor=J.+Huaauthor=Q.+Wuauthor=L.+A.+Priceauthor=L.+M.+Abellauthor=W.+A.+Schumacherauthor=J.+S.+Bostwickauthor=T.+E.+Steinbacherauthor=A.+B.+Stewartauthor=M.+L.+Ogletreeauthor=C.+S.+Huangauthor=M.+Changauthor=A.+M.+Cacaceauthor=M.+J.+Arcuriauthor=D.+Celaniauthor=R.+R.+Wexlerauthor=R.+M.+Lawrence&title=Discovery+of+2-%28phenoxypyridine%29-3-phenylureas+as+small+molecule+P2Y1+antagonists&doi=10.1021%2Fjm301708u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists</span></div><div class="casAuthors">Chao, Hannguang; Turdi, Huji; Herpin, Timothy F.; Roberge, Jacques Y.; Liu, Yalei; Schnur, Dora M.; Poss, Michael A.; Rehfuss, Robert; Hua, Ji; Wu, Qimin; Price, Laura A.; Abell, Lynn M.; Schumacher, William A.; Bostwick, Jeffrey S.; Steinbacher, Thomas E.; Stewart, Anne B.; Ogletree, Martin L.; Huang, Christine S.; Chang, Ming; Cacace, Angela M.; Arcuri, Maredith J.; Celani, Deborah; Wexler, Ruth R.; Lawrence, R. Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1704-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP-driven platelet activation.  The clin. effectiveness of P2Y12 blockade is well established.  Recent preclin. data suggest that P2Y1 and P2Y12 inhibition provide equiv. antithrombotic efficacy, while targeting P2Y1 has the potential for reduced bleeding liability.  In this account, the discovery of a 2-(phenoxypyridine)-3-phenylurea chemotype that inhibited ADP-mediated platelet aggregation in human blood samples is described.  Optimization of this series led to the identification of compd. 16, 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-4-(trifluoromethoxy)phenylurea, which demonstrated a 68 ± 7% thrombus wt. redn. in an established rat arterial thrombosis model (10 mg/kg plus 10 mg/kg/h) while only prolonging cuticle and mesenteric bleeding times by 3.3- and 3.1-fold, resp., in provoked rat bleeding time models.  These results suggest that a P2Y1 antagonist could potentially provide a safe and efficacious antithrombotic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKfYw47aTGrVg90H21EOLACvtfcHk0lhoQqOFh2p44g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVeqtbY%253D&md5=daa6e91e9700dde4054ff65096abac03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm301708u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301708u%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DH.%26aulast%3DTurdi%26aufirst%3DH.%26aulast%3DHerpin%26aufirst%3DT.%2BF.%26aulast%3DRoberge%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSchnur%26aufirst%3DD.%2BM.%26aulast%3DPoss%26aufirst%3DM.%2BA.%26aulast%3DRehfuss%26aufirst%3DR.%26aulast%3DHua%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DPrice%26aufirst%3DL.%2BA.%26aulast%3DAbell%26aufirst%3DL.%2BM.%26aulast%3DSchumacher%26aufirst%3DW.%2BA.%26aulast%3DBostwick%26aufirst%3DJ.%2BS.%26aulast%3DSteinbacher%26aufirst%3DT.%2BE.%26aulast%3DStewart%26aufirst%3DA.%2BB.%26aulast%3DOgletree%26aufirst%3DM.%2BL.%26aulast%3DHuang%26aufirst%3DC.%2BS.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DCacace%26aufirst%3DA.%2BM.%26aulast%3DArcuri%26aufirst%3DM.%2BJ.%26aulast%3DCelani%26aufirst%3DD.%26aulast%3DWexler%26aufirst%3DR.%2BR.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%25202-%2528phenoxypyridine%2529-3-phenylureas%2520as%2520small%2520molecule%2520P2Y1%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1704%26epage%3D1714%26doi%3D10.1021%2Fjm301708u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berny-Lang, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremmel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">New highly active antiplatelet agents with dual specificity for platelet P2Y<sub>1</sub> and P2Y<sub>12</sub> adenosine diphosphate receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.10.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2015.10.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26588064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2016&pages=204-218&author=I.+B.+Yanachkovauthor=H.+Changauthor=M.+I.+Yanachkovaauthor=E.+J.+Dixauthor=M.+A.+Berny-Langauthor=T.+Gremmelauthor=A.+D.+Michelsonauthor=G.+E.+Wrightauthor=A.+L.+Frelinger&title=New+highly+active+antiplatelet+agents+with+dual+specificity+for+platelet+P2Y1+and+P2Y12+adenosine+diphosphate+receptors&doi=10.1016%2Fj.ejmech.2015.10.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors</span></div><div class="casAuthors">Yanachkov, Ivan B.; Chang, Hung; Yanachkova, Milka I.; Dix, Edward J.; Berny-Lang, Michelle A.; Gremmel, Thomas; Michelson, Alan D.; Wright, George E.; Frelinger, Andrew L. III</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-218</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Currently approved platelet ADP (ADP) receptor antagonists target only the platelet P2Y12 receptor.  Moreover, esp. in patients with acute coronary syndromes, there is a strong need for rapidly acting and reversible antiplatelet agents in order to minimize the risk of thrombotic events and bleeding complications.  In this study, a series of new P1,P4-di(adenosine-5') tetraphosphate (Ap4A) derivs. with modifications in the base and in the tetraphosphate chain were synthesized and evaluated with respect to their effects on platelet aggregation and function of the platelet P2Y1, P2Y12, and P2X1 receptors.  The resulting structure-activity relationships were used to design Ap4A analogs which inhibit human platelet aggregation by simultaneously antagonizing both P2Y1 and P2Y12 platelet receptors.  Unlike Ap4A, the analogs do not activate platelet P2X1 receptors.  Furthermore, the new compds. exhibit fast onset and offset of action and are significantly more stable than Ap4A to degrdn. in plasma, thus presenting a new promising class of antiplatelet agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp_vhot2YyELVg90H21EOLACvtfcHk0lhoQqOFh2p44g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqtbzF&md5=5b83c2b5ca9e2fb3a36b51515a620766</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.10.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.10.055%26sid%3Dliteratum%253Aachs%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkova%26aufirst%3DM.%2BI.%26aulast%3DDix%26aufirst%3DE.%2BJ.%26aulast%3DBerny-Lang%26aufirst%3DM.%2BA.%26aulast%3DGremmel%26aufirst%3DT.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DNew%2520highly%2520active%2520antiplatelet%2520agents%2520with%2520dual%2520specificity%2520for%2520platelet%2520P2Y1%2520and%2520P2Y12%2520adenosine%2520diphosphate%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D107%26spage%3D204%26epage%3D218%26doi%3D10.1016%2Fj.ejmech.2015.10.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y<sub>1</sub>, P2Y<sub>12</sub> and P2X<sub>1</sub> receptors</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2009.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2009.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19945153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1Oht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2010&pages=159-165&author=H.+Changauthor=I.+B.+Yanachkovauthor=A.+D.+Michelsonauthor=Y.+Liauthor=M.+R.+Barnardauthor=G.+E.+Wrightauthor=A.+L.+Frelinger&title=Agonist+and+antagonist+effects+of+diadenosine+tetraphosphate%2C+a+platelet+dense+granule+constituent%2C+on+platelet+P2Y1%2C+P2Y12+and+P2X1+receptors&doi=10.1016%2Fj.thromres.2009.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors</span></div><div class="casAuthors">Chang, Hung; Yanachkov, Ivan B.; Michelson, Alan D.; Li, You Fu; Barnard, M. R.; Wright, George E.; Frelinger, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Diadenosine 5',5'''-P1,P4- tetraphosphate (Ap4A) is stored in platelet dense granules, but its effects on platelet function are not well understood.  We examd. the effects of Ap4A on platelet purinergic receptors P2Y1, P2Y12 and P2X1.  Flow cytometry was used to measure the effects of Ap4A in the presence or absence of ADP on: (a) P2Y12-mediated decrease in intraplatelet phosphorylated vasodilator stimulated phosphoprotein (VASP), (b) P2Y1-mediated increase in platelet cytosolic Ca2+, and (c) P2X1-mediated intraplatelet entry of extracellular Ca2+.  ADP-stimulated platelet shape change (P2Y1-mediated) and aggregation (P2Y1- and P2Y12-mediated) were measured optically.  Ap4A inhibited 3 μM ADP-induced: (a) platelet aggregation (IC50 9.8 ± 2.8 μM), (b) P2Y1-mediated shape change, (c) P2Y1-mediated increase in platelet cytosolic Ca2+ (IC50 40.8 ± 12.3 μM), and (d) P2Y12-mediated decrease in VASP phosphorylation (IC50 > 250 μM).  In the absence of added ADP, Ap4A had agonist effects on platelet P2X1 and P2Y12, but not P2Y1, receptors.  Thus, Ap4A, a constituent of platelet dense granules, is (a) an antagonist of platelet P2Y1 and P2Y12 receptors, where it inhibits the effects of ADP, and (b) an agonist of platelet P2X1 and P2Y12 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0IHrAABtbrVg90H21EOLACvtfcHk0lhoQqOFh2p44g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1Oht70%253D&md5=b4d48ee8845fa8646c5426250eac83f8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2009.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2009.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBarnard%26aufirst%3DM.%2BR.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DAgonist%2520and%2520antagonist%2520effects%2520of%2520diadenosine%2520tetraphosphate%252C%2520a%2520platelet%2520dense%2520granule%2520constituent%252C%2520on%2520platelet%2520P2Y1%252C%2520P2Y12%2520and%2520P2X1%2520receptors%26jtitle%3DThromb.%2520Res.%26date%3D2010%26volume%3D125%26spage%3D159%26epage%3D165%26doi%3D10.1016%2Fj.thromres.2009.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gremmel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkova, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Undyala, V. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przyklenk, K.</span></span> <span> </span><span class="NLM_article-title">Synergistic inhibition of both P2Y<sub>1</sub> and P2Y<sub>12</sub> adenosine diphosphate receptors as novel approach to rapidly attenuate platelet-mediated thrombosis</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.115.306885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FATVBAHA.115.306885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26743169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=501-509&author=T.+Gremmelauthor=I.+B.+Yanachkovauthor=M.+I.+Yanachkovaauthor=G.+E.+Wrightauthor=J.+Widerauthor=V.+V.+R.+Undyalaauthor=A.+D.+Michelsonauthor=A.+L.+Frelingerauthor=K.+Przyklenk&title=Synergistic+inhibition+of+both+P2Y1+and+P2Y12+adenosine+diphosphate+receptors+as+novel+approach+to+rapidly+attenuate+platelet-mediated+thrombosis&doi=10.1161%2FATVBAHA.115.306885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis</span></div><div class="casAuthors">Gremmel, Thomas; Yanachkov, Ivan B.; Yanachkova, Milka I.; Wright, George E.; Wider, Joseph; Undyala, Vishnu V. R.; Michelson, Alan D.; Frelinger, Andrew L., III; Przyklenk, Karin</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">501-509</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: Unlike currently approved ADP receptor antagonists, the new diadenosine tetraphosphate deriv. GLS-409 targets not only P2Y12 but also the second human platelet ADP receptor P2Y1 and may, therefore, be a promising antiplatelet drug candidate.  The current study is the first to investigate the in vivo antithrombotic effects of GLS-409.  APPROACH AND RESULTS-: We studied (1) the in vivo effects of GLS-409 on agonist-stimulated platelet aggregation in anesthetized rats, (2) the antithrombotic activity of GLS-409 and the assocd. effect on the bleeding time in a canine model of platelet-mediated coronary artery thrombosis, and (3) the inhibition of agonist-stimulated platelet aggregation by GLS-409 vs. selective P2Y1 and P2Y12 inhibition in vitro in samples from healthy human subjects before and 2 h after aspirin intake.  In vivo treatment with GLS-409 significantly inhibited ADP- and collagen-stimulated platelet aggregation in rats.  Further, GLS-409 attenuated cyclic flow variation, i.e., platelet-mediated thrombosis, in vivo in our canine model of unstable angina.  The improvement in coronary patency was accompanied by a nonsignificant 30% increase in bleeding time.  Of note, GLS-409 exerted its effects without affecting rat and canine hemodynamics.  Finally, in vitro treatment with GLS-409 showed effects similar to that of cangrelor and the combination of cangrelor with the selective P2Y1 inhibitor MRS 2179 on agonist-stimulated platelet aggregation in human platelet-rich plasma and whole blood before and 2 h after aspirin intake.  CONCLUSIONS-: Synergistic inhibition of both P2Y1 and P2Y12 ADP receptors by GLS-409 immediately attenuates platelet-mediated thrombosis and effectively blocks agonist-stimulated platelet aggregation irresp. of concomitant aspirin therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrooU8ELBTtFbVg90H21EOLACvtfcHk0ljZuZoHOK9J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtVKls78%253D&md5=01a67cfaad749593447c6133a41d2ef4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.115.306885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.115.306885%26sid%3Dliteratum%253Aachs%26aulast%3DGremmel%26aufirst%3DT.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DYanachkova%26aufirst%3DM.%2BI.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DWider%26aufirst%3DJ.%26aulast%3DUndyala%26aufirst%3DV.%2BV.%2BR.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26aulast%3DPrzyklenk%26aufirst%3DK.%26atitle%3DSynergistic%2520inhibition%2520of%2520both%2520P2Y1%2520and%2520P2Y12%2520adenosine%2520diphosphate%2520receptors%2520as%2520novel%2520approach%2520to%2520rapidly%2520attenuate%2520platelet-mediated%2520thrombosis%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D501%26epage%3D509%26doi%3D10.1161%2FATVBAHA.115.306885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, P.</span></span> <span> </span><span class="NLM_article-title">State of affairs: Design and structure-activity relationships of reversible P2Y<sub>12</sub> receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2739</span>– <span class="NLM_lpage">2754</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.04.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bmcl.2016.04.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=27133596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2739-2754&author=F.+Zetterbergauthor=P.+Svensson&title=State+of+affairs%3A+Design+and+structure-activity+relationships+of+reversible+P2Y12+receptor+antagonists&doi=10.1016%2Fj.bmcl.2016.04.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists</span></div><div class="casAuthors">Zetterberg, Fredrik; Svensson, Peder</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2739-2754</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Myocardial infarction and stroke are the most common causes of mortality and morbidity in the developed world.  Therefore the search for antiplatelet therapy has been in focus for the last decades, in particular the search for new P2Y12R antagonists.  The first P2Y12R drug developed, clopidogrel, is a major success but there is still room for improvement with respect to bleeding profile and nonresponders.  These liabilities could be due to the fact that clopidogrel is a pro-drug and upon activation binds covalently to the receptor.  Therefore a lot of effort has gone into identifying reversible inhibitors.  One recent example is ticagrelor, which in clin. studies have been shown to be safer and even reduce rate of death from vascular events as compared head to head with clopidogrel.  The authors here review the medicinal chem. strategies used in the design of new reversible P2Y12R antagonists.  In addn., the authors also present structure based design studies based on the recently published agonist and antagonist x-ray structures of P2Y12R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTE3kxUEF_T7Vg90H21EOLACvtfcHk0ljZuZoHOK9J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCltb4%253D&md5=14dd39621a44a3c245f92352cca42b29</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.04.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.04.030%26sid%3Dliteratum%253Aachs%26aulast%3DZetterberg%26aufirst%3DF.%26aulast%3DSvensson%26aufirst%3DP.%26atitle%3DState%2520of%2520affairs%253A%2520Design%2520and%2520structure-activity%2520relationships%2520of%2520reversible%2520P2Y12%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2739%26epage%3D2754%26doi%3D10.1016%2Fj.bmcl.2016.04.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doll, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiswell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosiborod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T. Y.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehx255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehx255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28541452" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFegsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=193-200&author=J.+A.+Dollauthor=S.+Liauthor=K.+Chiswellauthor=M.+T.+Roeauthor=M.+Kosiborodauthor=B.+M.+Sciricaauthor=T.+Y.+Wang&title=Clopidogrel+reloading+for+patients+with+acute+myocardial+infarction+already+on+clopidogrel+therapy&doi=10.1093%2Feurheartj%2Fehx255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel reloading for patients with acutemyocardial infarction already on clopidogrel therapy</span></div><div class="casAuthors">Doll, Jacob A.; Li, Shuang; Chiswell, Karen; Roe, Matthew T.; Kosiborod, Mikhail; Scirica, Benjamin M.; Wang, Tracy Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-200</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">1522-9645</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims We sought to det. the assocn. of clopidogrel reloading with in-hospital bleeding and mortality in contemporary practice.  Methods and results We examd. clopidogrel reloading for ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients on pre-admission clopidogrel therapy in the ACTION Registry-GWTG from 2009 to 2014.  We used inverse probability weighted propensity adjustment to compare in-hospital mortality and major bleeding risks between patients reloaded in the first 24 h with ≥300 mg of clopidogrel vs. those continued on a maintenance (<300 mg) dose.  Among the 12 366 patients on pre-admission clopidogrel therapy who were admitted with STEMI, 9369 (75.8%) received a loading dose.  Of 39 158 patients with NSTEMI, 10 144 (25.9%) were reloaded.  Reloaded patients were younger, had fewer comorbid conditions, and were more likely to be treated with primary PCI (STEMI) or an early invasive strategy (NSTEMI).  Risks of major bleeding were not significantly different between patients with and without reloading, whether presenting with STEMI (OR 0.98, 95% CI 0.85-1.13) or NSTEMI (OR 1.00, 95% CI 0.90-1.11).  Among STEMI patients, clopidogrel reloading was assocd. with lower risks of in-hospital mortality (OR 0.80, 95% CI 0.66-0.96), however no significant mortality difference was obsd. among NSTEMI patients (OR 1.13, 95% CI 0.93-1.37).  Conclusion Clopidogrel reloading occurs frequently among MI patients who are on pre-admission clopidogrel therapy, particularly among STEMI patients.  We did not observe increased bleeding or mortality risk with clopidogrel reloading, and therefore reloading could be safe for most MI patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40DX403wH6rVg90H21EOLACvtfcHk0ljZuZoHOK9J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFegsr4%253D&md5=635b2746165aa8a0cdbbfefdac01b2b1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehx255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehx255%26sid%3Dliteratum%253Aachs%26aulast%3DDoll%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChiswell%26aufirst%3DK.%26aulast%3DRoe%26aufirst%3DM.%2BT.%26aulast%3DKosiborod%26aufirst%3DM.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DWang%26aufirst%3DT.%2BY.%26atitle%3DClopidogrel%2520reloading%2520for%2520patients%2520with%2520acute%2520myocardial%2520infarction%2520already%2520on%2520clopidogrel%2520therapy%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2018%26volume%3D39%26spage%3D193%26epage%3D200%26doi%3D10.1093%2Feurheartj%2Fehx255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Prasugrel</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">449</span>, <span class="refDoi"> DOI: 10.1038/nrd2899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnrd2899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19483707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1aksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=449&author=K.+Huberauthor=U.+Yasothanauthor=B.+Hamadauthor=P.+Kirkpatrick&title=Prasugrel&doi=10.1038%2Fnrd2899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prasugrel</span></div><div class="casAuthors">Huber, Kurt; Yasothan, Uma; Hamad, Bashar; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">449-450</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In Feb. 2009, the antiplatelet therapy prasugrel (Efient; Daiichi Sankyo/Eli Lilly) was granted marketing authorization by the European Commission for the prevention of atherothrombotic events in patients with acute coronary syndromes undergoing primary or delayed percutaneous coronary intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV6EsSGqEoFrVg90H21EOLACvtfcHk0lhLOkHDooiNFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1aksL8%253D&md5=fb046ab031a6358a715f7588ff2bd876</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd2899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2899%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DHamad%26aufirst%3DB.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPrasugrel%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D449%26doi%3D10.1038%2Fnrd2899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, K.</span></span> <span> </span><span class="NLM_article-title">Current and future antiplatelet therapies: emphasis on preserving haemostasis</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2017.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnrcardio.2017.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29297508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=181-191&author=J.+D.+McFadyenauthor=M.+Schaffauthor=K.+Peter&title=Current+and+future+antiplatelet+therapies%3A+emphasis+on+preserving+haemostasis&doi=10.1038%2Fnrcardio.2017.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future antiplatelet therapies: emphasis on preserving haemostasis</span></div><div class="casAuthors">McFadyen, James D.; Schaff, Mathieu; Peter, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein IIb/IIIa inhibitors, have proved to be successful in reducing morbidity and mortality assocd. with arterial thrombosis.  These agents are, therefore, cornerstone of therapy for patients with acute coronary syndromes.  However, these drugs all carry an inherent risk of bleeding, which is assocd. with adverse cardiovascular outcomes and mortality.  Thus, potential benefits of more potent, conventional antiplatelet drugs are likely be offset by increased risk of bleeding.  Data from expts. in vivo have highlighted potentially important differences between hemostasis and thrombosis, raising prospect of developing new antiplatelet drugs that are not assocd. with bleeding.  Indeed, in preclin. studies, several novel antiplatelet therapies that seem to inhibit thrombosis while maintaining hemostasis have been identified.  These agents include inhibitors of PI3Kβ, protein disulfide-isomerase, activated GPIIb/IIIa, GPIIb/IIIa outside-in signalling, protease-activated receptors, and platelet GPVI-mediated adhesion pathways.  In this Review, we discuss how a therapeutic ceiling has been reached with existing antiplatelet drugs, whereby increased potency is offset by elevated bleeding risk.  The latest advances in our understanding of thrombus formation have informed the development of new antiplatelet drugs that are potentially safer than currently available therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlNsh2or617Vg90H21EOLACvtfcHk0lhLOkHDooiNFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGnsQ%253D%253D&md5=f7c912d36a348c83cb73df5c94b55a87</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2017.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2017.206%26sid%3Dliteratum%253Aachs%26aulast%3DMcFadyen%26aufirst%3DJ.%2BD.%26aulast%3DSchaff%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DK.%26atitle%3DCurrent%2520and%2520future%2520antiplatelet%2520therapies%253A%2520emphasis%2520on%2520preserving%2520haemostasis%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2018%26volume%3D15%26spage%3D181%26epage%3D191%26doi%3D10.1038%2Fnrcardio.2017.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Columbo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambour, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessen, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linshaw, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riblet, N. B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodney, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, D. H.</span></span> <span> </span><span class="NLM_article-title">A meta-analysis of the impact of aspirin, clopidogrel, and dual antiplatelet therapy on bleeding complications in noncardiac surgery</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1097/SLA.0000000000002279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1097%2FSLA.0000000000002279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28463896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC1crjt1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=2018&pages=1-10&author=J.+A.+Columboauthor=A.+J.+Lambourauthor=R.+A.+Sundlingauthor=N.+B.+Chauhanauthor=S.+Y.+Bessenauthor=D.+L.+Linshawauthor=R.+Kangauthor=N.+B.+V.+Ribletauthor=P.+P.+Goodneyauthor=D.+H.+Stone&title=A+meta-analysis+of+the+impact+of+aspirin%2C+clopidogrel%2C+and+dual+antiplatelet+therapy+on+bleeding+complications+in+noncardiac+surgery&doi=10.1097%2FSLA.0000000000002279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery</span></div><div class="casAuthors">Columbo Jesse A; Goodney Philip P; Stone David H; Columbo Jesse A; Sundling Rebecca A; Chauhan Nirali B; Bessen Sarah Y; Kang Ravinder; Riblet Natalie B V; Goodney Philip P; Columbo Jesse A; Kang Ravinder; Goodney Philip P; Columbo Jesse A; Kang Ravinder; Lambour Andrew J; Linshaw David L; Kang Ravinder</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The aim of this study was to determine the bleeding risks associated with single (aspirin) and dual (aspirin + clopidogrel) antiplatelet therapy (DAPT) versus placebo or no treatment in adults undergoing noncardiac surgery.  SUMMARY OF BACKGROUND DATA:  The impact of antiplatelet therapy on bleeding during noncardiac surgery remains controversial.  A meta-analysis was performed to examine the risk associated with single and DAPT.  METHODS:  A systematic review of antiplatelet therapy, noncardiac surgery, and perioperative bleeding was performed.  Peer-reviewed sources and meeting abstracts from relevant societies were queried.  Studies without a control group, or those that only examined patients with coronary stents, were excluded.  Primary endpoints were transfusion and reintervention for bleeding.  RESULTS:  Of 11,592 references, 46 studies met inclusion criteria.  In a meta-analysis of >30,000 patients, the relative risk (RR) of transfusion versus control was 1.14 [95% confidence interval (CI) 1.03-1.26, P = 0.009] for aspirin, and 1.33 (1.15-1.55, P = 0.001) for DAPT.  Clopidogrel had an elevated risk, but data were too heterogeneous to analyze.  The RR of bleeding requiring reintervention was not significantly higher for any agent compared to control [RR 0.96 (0.76-1.22, P = 0.76) for aspirin, 1.84 (0.87-3.87, P = 0.11) for clopidogrel, and 1.51 (0.92-2.49, P = 0.1) for DAPT].  Subanalysis of thoracic and abdominal procedures was similar.  There was no difference in RR for myocardial infarction [1.06 (0.79-1.43)], stroke [0.97 (0.71-1.33)], or mortality [0.97 (0.87-1.1)].  CONCLUSIONS:  Antiplatelet therapy at the time of noncardiac surgery confers minimal bleeding risk with no difference in thrombotic complications.  In many cases, it is safe to continue antiplatelet therapy in patients with important indications for their use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTv7p_fd1MkY_9pSBfyDvp7fW6udTcc2eZZn537jEY3P7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjt1GhtA%253D%253D&md5=f50a6b766a572d792313c4a5dac46a9f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2FSLA.0000000000002279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FSLA.0000000000002279%26sid%3Dliteratum%253Aachs%26aulast%3DColumbo%26aufirst%3DJ.%2BA.%26aulast%3DLambour%26aufirst%3DA.%2BJ.%26aulast%3DSundling%26aufirst%3DR.%2BA.%26aulast%3DChauhan%26aufirst%3DN.%2BB.%26aulast%3DBessen%26aufirst%3DS.%2BY.%26aulast%3DLinshaw%26aufirst%3DD.%2BL.%26aulast%3DKang%26aufirst%3DR.%26aulast%3DRiblet%26aufirst%3DN.%2BB.%2BV.%26aulast%3DGoodney%26aufirst%3DP.%2BP.%26aulast%3DStone%26aufirst%3DD.%2BH.%26atitle%3DA%2520meta-analysis%2520of%2520the%2520impact%2520of%2520aspirin%252C%2520clopidogrel%252C%2520and%2520dual%2520antiplatelet%2520therapy%2520on%2520bleeding%2520complications%2520in%2520noncardiac%2520surgery%26jtitle%3DAnn.%2520Surg.%26date%3D2018%26volume%3D267%26spage%3D1%26epage%3D10%26doi%3D10.1097%2FSLA.0000000000002279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Cangrelor: a review in percutaneous coronary intervention</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1434</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0445-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs40265-015-0445-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26201463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1425-1434&author=G.+M.+Keating&title=Cangrelor%3A+a+review+in+percutaneous+coronary+intervention&doi=10.1007%2Fs40265-015-0445-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor: A Review in Percutaneous Coronary Intervention</span></div><div class="casAuthors">Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1425-1434</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Cangrelor (Kengrexal, Kengreal) is an i.v. administered P2Y12 receptor inhibitor.  It is direct-acting and reversible, with a very rapid onset and offset of action.  The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of i.v. cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI).  The primary composite efficacy endpoint of death from any cause, MI, ischemia-drive revascularization or stent thrombosis in the 48 h following randomization occurred in significantly fewer cangrelor than clopidogrel recipients.  The rate of severe or life-threatening non-coronary artery bypass graft-related, GUSTO-defined bleeding at 48 h did not significantly differ between cangrelor and clopidogrel recipients.  In conclusion, i.v. cangrelor is an important new option for use in patients undergoing PCI who have not been treated with oral P2Y12 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Xn6rpGOd4LVg90H21EOLACvtfcHk0liylH1v_90u4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eks7jL&md5=1a421fb4f5ba89115baf569b4488b54e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0445-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0445-3%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DCangrelor%253A%2520a%2520review%2520in%2520percutaneous%2520coronary%2520intervention%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D1425%26epage%3D1434%26doi%3D10.1007%2Fs40265-015-0445-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Judge, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckland, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowski, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span> <span> </span><span class="NLM_article-title">Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y<sub>12</sub> receptors in vitro</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.3109/09537104.2015.1069809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3109%2F09537104.2015.1069809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26270719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=191-195&author=H.+M.+Judgeauthor=R.+J.+Bucklandauthor=J.+A.+Jakubowskiauthor=R.+F.+Storey&title=Cangrelor+inhibits+the+binding+of+the+active+metabolites+of+clopidogrel+and+prasugrel+to+P2Y12+receptors+in+vitro&doi=10.3109%2F09537104.2015.1069809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro</span></div><div class="casAuthors">Judge, Heather M.; Buckland, Robert J.; Jakubowski, Joseph A.; Storey, Robert F.</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-195</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cangrelor is a rapid-acting, direct-binding, and reversible P2Y12 antagonist which has been studied for use during percutaneous coronary intervention (PCI) in patients with or without pretreatment with an oral P2Y12 antagonist.  As cangrelor is administered i.v., it is necessary to switch to an oral P2Y12 antagonist following PCI, such as the thienopyridines clopidogrel, and prasugrel or the non-pyridine ticagrelor.  Previous studies have suggested a neg. pharmacodynamic interaction between cangrelor and thienopyridines.  This in vitro study evaluated the receptor-level interaction between cangrelor and the active metabolite (AM) of clopidogrel or prasugrel by assessing functional P2Y12 receptor no. using a 33P-2MeSADP binding assay.  All P2Y12 antagonists studied resulted in strong P2Y12 receptor blockade (cangrelor: 93.6%; clopidogrel AM: 93.0%; prasugrel AM: 97.9%).  Adding a thienopyridine AM in the presence of cangrelor strongly reduces P2Y12 receptor blockade by the AM (clopidogrel AM: 7%, prasugrel AM: 3.2%).  The thienopyridine AMs had limited ability to compete with cangrelor for binding to P2Y12 (% P2Y12 receptor blockade after co-incubation with cangrelor 1000 nmol/L: 11.7% for clopidogrel AM 3 μmol/L; 34.1% for prasugrel AM 3 μmol/L).  In conclusion, in vitro cangrelor strongly inhibits the binding of clopidogrel and prasugrel AMs to the P2Y12 receptor, consistent with the previous observation of a neg. pharmacodynamic interaction.  Care may need to be taken to not overlap exposure to thienopyridine AMs and cangrelor in order to reduce the risk of thrombotic complications following PCI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Mix2woQ5prVg90H21EOLACvtfcHk0liylH1v_90u4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Gjt7Y%253D&md5=b03f6e04ddf9724f141d37a52690e784</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3109%2F09537104.2015.1069809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F09537104.2015.1069809%26sid%3Dliteratum%253Aachs%26aulast%3DJudge%26aufirst%3DH.%2BM.%26aulast%3DBuckland%26aufirst%3DR.%2BJ.%26aulast%3DJakubowski%26aufirst%3DJ.%2BA.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26atitle%3DCangrelor%2520inhibits%2520the%2520binding%2520of%2520the%2520active%2520metabolites%2520of%2520clopidogrel%2520and%2520prasugrel%2520to%2520P2Y12%2520receptors%2520in%2520vitro%26jtitle%3DPlatelets%26date%3D2016%26volume%3D27%26spage%3D191%26epage%3D195%26doi%3D10.3109%2F09537104.2015.1069809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sfantou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lekakis, J.</span></span> <span> </span><span class="NLM_article-title">Cangrelor in percutaneous coronary intervention: current status and perspectives</span>. <i>J. Cardiovasc. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1177/1074248417715004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1177%2F1074248417715004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29228817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=13-22&author=D.+Alexopoulosauthor=C.+Pappasauthor=D.+Sfantouauthor=J.+Lekakis&title=Cangrelor+in+percutaneous+coronary+intervention%3A+current+status+and+perspectives&doi=10.1177%2F1074248417715004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives</span></div><div class="casAuthors">Alexopoulos, Dimitrios; Pappas, Christos; Sfantou, Danai; Lekakis, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">JCPTFE</span>;
        ISSN:<span class="NLM_cas:issn">1074-2484</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Cangrelor is an i.v. administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action.  In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without increasing the risk of severe bleeding.  Cangrelor is currently approved by drug regulating authorities for patients undergoing percutaneous coronary intervention (PCI) without prior treatment with a P2Y12 receptor antagonist and not receiving a glycoprotein IIb/IIIa inhibitor, while its use is endorsed with a class IIb recommendation by the European Society of Cardiol. guidelines.  Several subanalyses of CHAMPION PHOENIX trial have tried to elucidate the role of cangrelor in PCI, including its usefulness during a 2-h landmark anal., impact on intraprocedural stent thrombosis, and redn. in myocardial infarction (MI) rate.  The influence of gender, geog. region, access site, and bivalirudin use on cangrelor's effects has also been reported.  In patients with ST elevation MI and in clin. scenarios of disturbed absorption of oral antiplatelet agents or in need of an i.v. agent, cangrelor may surpass oral agents' drawbacks.  Transitioning to an oral agent is mandatory following cangrelor infusion discontinuation, although ticagrelor may be administered earlier without any pharmacodynamic interaction.  Nevertheless, the clin. role of cangrelor in conjunction with administration of prasugrel or ticagrelor remains unclear.  Accruing real-life experience is expected to improve our understanding of cangrelor's role in everyday clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoST_dOw__zhLVg90H21EOLACvtfcHk0liylH1v_90u4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVOgtg%253D%253D&md5=0eba04774992b402f33cc67a727f0d89</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1177%2F1074248417715004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1074248417715004%26sid%3Dliteratum%253Aachs%26aulast%3DAlexopoulos%26aufirst%3DD.%26aulast%3DPappas%26aufirst%3DC.%26aulast%3DSfantou%26aufirst%3DD.%26aulast%3DLekakis%26aufirst%3DJ.%26atitle%3DCangrelor%2520in%2520percutaneous%2520coronary%2520intervention%253A%2520current%2520status%2520and%2520perspectives%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2018%26volume%3D23%26spage%3D13%26epage%3D22%26doi%3D10.1177%2F1074248417715004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallentin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budaj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuelsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husted, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katus, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahaffey, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scirica, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steg, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, R. A.</span></span> <span> </span><span class="NLM_article-title">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">1045</span>– <span class="NLM_lpage">1057</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa0904327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1056%2FNEJMoa0904327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19717846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1045-1057&author=L.+Wallentinauthor=R.+C.+Beckerauthor=A.+Budajauthor=C.+P.+Cannonauthor=H.+Emanuelssonauthor=C.+Heldauthor=J.+Horrowauthor=S.+Hustedauthor=S.+Jamesauthor=H.+Katusauthor=K.+W.+Mahaffeyauthor=B.+M.+Sciricaauthor=A.+Skeneauthor=P.+G.+Stegauthor=R.+F.+Storeyauthor=R.+A.+Harrington&title=Ticagrelor+versus+clopidogrel+in+patients+with+acute+coronary+syndromes&doi=10.1056%2FNEJMoa0904327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor versus clopidogrel in patients with acute coronary syndromes</span></div><div class="casAuthors">Wallentin, Lars; Becker, Richard C.; Budaj, Andrej; Cannon, Christopher P.; Emanuelsson, Hakan; Held, Claes; Horrow, Jay; Husted, Steen; James, Stefan; Katus, Hugo; Mahaffey, Kenneth W.; Scirica, Benjamin M.; Skene, Allan; Steg, Philppe Gabriel; Storey, Robert F.; Harrington, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1045-1057</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ticagrelor is an oral, reversible, direct-acting inhibitor of the ADP receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.  In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg. loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation.  At 12 mo, the primary end point - a composite of death from vascular causes, myocardial infarction, or stroke - had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P < 0.001).  Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P = 0.005) and death from vascular causes (4.0% vs. 5.1%0/, P = 0.001) but not stroke alone (1.5% vs. 1.3%, P = 0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P < 0.001).  No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, resp.; P = 0.43), but ticagrelor was assocd. with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P = 0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types.  In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTdvlM1dfTz7Vg90H21EOLACvtfcHk0liylH1v_90u4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFaltL%252FJ&md5=9c215c4ceeb6dd14d406ab26e2db25d5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0904327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0904327%26sid%3Dliteratum%253Aachs%26aulast%3DWallentin%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DR.%2BC.%26aulast%3DBudaj%26aufirst%3DA.%26aulast%3DCannon%26aufirst%3DC.%2BP.%26aulast%3DEmanuelsson%26aufirst%3DH.%26aulast%3DHeld%26aufirst%3DC.%26aulast%3DHorrow%26aufirst%3DJ.%26aulast%3DHusted%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DS.%26aulast%3DKatus%26aufirst%3DH.%26aulast%3DMahaffey%26aufirst%3DK.%2BW.%26aulast%3DScirica%26aufirst%3DB.%2BM.%26aulast%3DSkene%26aufirst%3DA.%26aulast%3DSteg%26aufirst%3DP.%2BG.%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DHarrington%26aufirst%3DR.%2BA.%26atitle%3DTicagrelor%2520versus%2520clopidogrel%2520in%2520patients%2520with%2520acute%2520coronary%2520syndromes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1045%26epage%3D1057%26doi%3D10.1056%2FNEJMoa0904327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S. H.</span></span> <span> </span><span class="NLM_article-title">Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S196535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2147%2FDDDT.S196535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30863011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=719-730&author=Z.+G.+Fanauthor=W.+L.+Zhangauthor=B.+Xuauthor=J.+Jiauthor=N.+L.+Tianauthor=S.+H.+He&title=Comparisons+between+ticagrelor+and+clopidogrel+following+percutaneous+coronary+intervention+in+patients+with+acute+coronary+syndrome%3A+a+comprehensive+meta-analysis&doi=10.2147%2FDDDT.S196535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis</span></div><div class="casAuthors">Fan, Zhong-Guo; Zhang, Wen-Ling; Xu, Bing; Ji, Jun; Tian, Nai-Liang; He, Sheng-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">719-730</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The efficacy and safety of ticagrelor following percutaneous coronary intervention for patients with acute coronary syndrome remains unclear.  This study sought to evaluate clin. outcomes of ticagrelor as part of dual-antiplatelet treatment for these patients.  Methods: PubMed, MEDLINE, Embase, and other Internet sources were searched for eligible citations.  The primary end point was major adverse cardiovascular and cerebrovascular events, consisting of cardiovascular death, myocardial infarction, and stroke.  The secondary end point was the occurrence of definite/probable stent thrombosis (ST).  The risk of bleeding was chosen to be the safety end point.  Results: Eleven clin. trials - six randomized trials and five observational trials - were finally analyzed.  A tendency toward redn. in the risk of major adverse cardiovascular and cere♂brovascular events was obsd. only with respect to ticagrelor (OR 0.83, 95% CI 0.66-1.03; P=0.091), which might have resulted from the lower risk of cardiovascular death (OR 0.78, 95% CI 0.68-0.89; P,0.001).  The overall incidence of ST differed significantly between the ticagrelor group and the clopidogrel group (OR 0.74, 95% CI 0.59-0.93; P=0.009), but the risk of bleeding, regardless of major or minor bleeding, increased significantly.  Conclusion: As part of dual-antiplatelet treatment following percutaneous coronary interven♂tion, ticagrelor significantly reduced the risk of cardiovascular death and ST in acute coronary syndrome patients, but at the cost of bleeding.  More powerful relevant randomized trials are still warranted to guide clin. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2yKWYfx-sfLVg90H21EOLACvtfcHk0lgkuONE7mgqiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7vF&md5=0ff76da8a30af0c7c9bc0535f089f04a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S196535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S196535%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DW.%2BL.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DN.%2BL.%26aulast%3DHe%26aufirst%3DS.%2BH.%26atitle%3DComparisons%2520between%2520ticagrelor%2520and%2520clopidogrel%2520following%2520percutaneous%2520coronary%2520intervention%2520in%2520patients%2520with%2520acute%2520coronary%2520syndrome%253A%2520a%2520comprehensive%2520meta-analysis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D719%26epage%3D730%26doi%3D10.2147%2FDDDT.S196535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briceno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaikh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Been, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smairat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryadevara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soffer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenni, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span> <span> </span><span class="NLM_article-title">Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1661</span>– <span class="NLM_lpage">1670</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.118.038317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1161%2FCIRCULATIONAHA.118.038317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30630341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2019&pages=1661-1670&author=F.+Franchiauthor=F.+Rolliniauthor=A.+Rivasauthor=M.+Waliauthor=M.+Bricenoauthor=M.+Agarwalauthor=Z.+Shaikhauthor=A.+Nawazauthor=G.+Silvaauthor=L.+Beenauthor=R.+Smairatauthor=M.+Kaufmanauthor=A.+Pinedaauthor=S.+Suryadevaraauthor=D.+Sofferauthor=M.+M.+Zenniauthor=T.+A.+Bassauthor=D.+J.+Angiolillo&title=Platelet+inhibition+with+cangrelor+and+crushed+ticagrelor+in+patients+with+ST-segment-elevation+myocardial+infarction+undergoing+primary+percutaneous+coronary+intervention&doi=10.1161%2FCIRCULATIONAHA.118.038317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of the CANTIC Study</span></div><div class="casAuthors">Franchi, Francesco; Rollini, Fabiana; Rivas, Andrea; Wali, Mustafa; Briceno, Maryuri; Agarwal, Malhar; Shaikh, Zubair; Nawaz, Ahmed; Silva, Gabriel; Been, Latonya; Smairat, Ramez; Kaufman, Marc; Pineda, Andres M.; Suryadevara, Siva; Soffer, Daniel; Zenni, Martin M.; Bass, Theodore A.; Angiolillo, Dominick J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1661-1670</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (P-PCI).  In turn, this leads to a gap in platelet inhibition, exposing patients to an increased risk of early thrombotic complications and underscoring the need to define strategies assocd. with more effective platelet inhibition in the peri-primary percutaneous coronary intervention period.  Cangrelor is an i.v. P2Y12 inhibitor with prompt and potent antiplatelet effects.  However, to date, there are limited data on the effects of cangrelor used in combination with ticagrelor in patients undergoing primary percutaneous coronary intervention.  Moreover, questions have emerged on the potential for drug-drug interactions during the transition from cangrelor to oral P2Y12 inhibitors.  Methods: This was a prospective, randomized, double-blind, placebo-controlled pharmacodynamic study conducted in patients undergoing primary percutaneous coronary intervention (n=50) who were randomized to treatment with either cangrelor or matching placebo (bolus followed by 2-h infusion).  All patients received ticagrelor 180-mg loading dose administered as crushed tablets at the time of cangrelor/placebo bolus administration.  Pharmacodynamic analyses were performed at 8 time points.  Pharmacodynamic effects were measured as P2Y12 reaction units by VerifyNow and platelet reactivity index by vasodilator-stimulated phosphoprotein.  Results: Compared with placebo, cangrelor was assocd. with reduced P2Y12 reaction units as early as 5 min after bolus, which persisted during the entire duration of drug infusion, including at 30 min (63 [32-93] vs. 214 [183-245]; mean difference, 152 [95% CI, 108-195]; P<0·001; primary end point).  Parallel findings were shown with platelet reactivity index.  Accordingly, high on-treatment platelet reactivity rates were reduced with cangrelor.  After discontinuation of cangrelor/placebo infusion, there were no differences in levels of platelet reactivity between groups, ruling out a drug-drug interaction when cangrelor and ticagrelor are concomitantly administered.  Conclusions: In patients undergoing primary percutaneous coronary intervention, cangrelor is an effective strategy to bridge the gap in platelet inhibition assocd. with the use of oral P2Y12 inhibition induced by ticagrelor.  Ticagrelor can be administered as a crushed formulation concomitantly with cangrelor without any apparent drug-drug interaction.  The clin. implications of these pharmacodynamic findings warrant investigation in an adequately powered clin. trial.  Clin. trial registration: URL: https://www.clinicaltrials.gov.  Unique identifier: NCT03247738.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8qoeoQLDTMLVg90H21EOLACvtfcHk0lgkuONE7mgqiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqurg%253D&md5=0c2cff05ae628e5193f1beb4df541443</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.118.038317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.118.038317%26sid%3Dliteratum%253Aachs%26aulast%3DFranchi%26aufirst%3DF.%26aulast%3DRollini%26aufirst%3DF.%26aulast%3DRivas%26aufirst%3DA.%26aulast%3DWali%26aufirst%3DM.%26aulast%3DBriceno%26aufirst%3DM.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DShaikh%26aufirst%3DZ.%26aulast%3DNawaz%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DG.%26aulast%3DBeen%26aufirst%3DL.%26aulast%3DSmairat%26aufirst%3DR.%26aulast%3DKaufman%26aufirst%3DM.%26aulast%3DPineda%26aufirst%3DA.%26aulast%3DSuryadevara%26aufirst%3DS.%26aulast%3DSoffer%26aufirst%3DD.%26aulast%3DZenni%26aufirst%3DM.%2BM.%26aulast%3DBass%26aufirst%3DT.%2BA.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DPlatelet%2520inhibition%2520with%2520cangrelor%2520and%2520crushed%2520ticagrelor%2520in%2520patients%2520with%2520ST-segment-elevation%2520myocardial%2520infarction%2520undergoing%2520primary%2520percutaneous%2520coronary%2520intervention%26jtitle%3DCirculation%26date%3D2019%26volume%3D139%26spage%3D1661%26epage%3D1670%26doi%3D10.1161%2FCIRCULATIONAHA.118.038317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Storey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernaud, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangas, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenoux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorog, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hmissi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunadian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanguay, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Harst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van’t Hof, A. W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angiolillo, D. J.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y<sub>12</sub> receptor antagonist, in patients with chronic coronary syndromes</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">3132</span>– <span class="NLM_lpage">3140</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehz807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1093%2Feurheartj%2Fehz807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31994703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FlslyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=3132-3140&author=R.+F.+Storeyauthor=P.+A.+Gurbelauthor=J.+Ten+Bergauthor=C.+Bernaudauthor=G.+D.+Dangasauthor=J.+M.+Frenouxauthor=D.+A.+Gorogauthor=A.+Hmissiauthor=V.+Kunadianauthor=S.+K.+Jamesauthor=J.+F.+Tanguayauthor=H.+Tranauthor=D.+Trenkauthor=M.+Uferauthor=P.+Van+der+Harstauthor=A.+W.+J.+Van%E2%80%99t+Hofauthor=D.+J.+Angiolillo&title=Pharmacodynamics%2C+pharmacokinetics%2C+and+safety+of+single-dose+subcutaneous+administration+of+selatogrel%2C+a+novel+P2Y12+receptor+antagonist%2C+in+patients+with+chronic+coronary+syndromes&doi=10.1093%2Feurheartj%2Fehz807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes</span></div><div class="casAuthors">Storey Robert F; Gurbel Paul A; Tran Henry; Ten Berg Jurrien; Bernaud Corine; Frenoux Jean-Marie; Hmissi Abdel; Ufer Mike; Dangas George D; Gorog Diana A; Gorog Diana A; Kunadian Vijay; Kunadian Vijay; James Stefan K; Tanguay Jean-Francois; Trenk Dietmar; Van der Harst Pim; Van't Hof Arnoud W J; Van't Hof Arnoud W J; Van't Hof Arnoud W J; Angiolillo Dominick J</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">3132-3140</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  To study the pharmacodynamics and pharmacokinetics of selatogrel, a novel P2Y12 receptor antagonist for subcutaneous administration, in patients with chronic coronary syndromes (CCS).  METHODS AND RESULTS:  In this double-blind, randomized study of 345 patients with CCS on background oral antiplatelet therapy, subcutaneous selatogrel (8 mg, n = 114; or 16 mg, n = 115) was compared with placebo (n = 116) (ClinicalTrials.gov: NCT03384966).  Platelet aggregation was assessed over 24 h (VerifyNow assay) and 8 h (light transmittance aggregometry; LTA).  Pharmacodynamic responders were defined as patients having P2Y12 reaction units (PRU) <100 at 30 min post-dose and lasting ≥3 h.  At 30 min post-dose, 89% of patients were responders to selatogrel 8 mg, 90% to selatogrel 16 mg, and 16% to placebo (P < 0.0001).  PRU values (mean ± standard deviation) were 10 ± 25 (8 mg), 4 ± 10 (16 mg), and 163 ± 73 (placebo) at 15 min and remained <100 up to 8 h for both doses, returning to pre-dose or near pre-dose levels by 24 h post-dose.  LTA data showed similarly rapid and potent inhibition of platelet aggregation.  Selatogrel plasma concentrations peaked ∼30 min post-dose.  Selatogrel was safe and well-tolerated with transient dyspnoea occurring overall in 7% (16/229) of patients (95% confidence interval: 4-11%).  CONCLUSIONS:  Selatogrel was rapidly absorbed following subcutaneous administration in CCS patients, providing prompt, potent, and consistent platelet P2Y12 inhibition sustained for ≥8 h and reversible within 24 h.  Further studies of subcutaneous selatogrel are warranted in clinical scenarios where rapid platelet inhibition is desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwheMBIhRNxWmbXvSEQle5fW6udTcc2eYaLrtIIiA13rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FlslyqtQ%253D%253D&md5=95a03009fe056694da10b11315458623</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehz807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehz807%26sid%3Dliteratum%253Aachs%26aulast%3DStorey%26aufirst%3DR.%2BF.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26aulast%3DTen%2BBerg%26aufirst%3DJ.%26aulast%3DBernaud%26aufirst%3DC.%26aulast%3DDangas%26aufirst%3DG.%2BD.%26aulast%3DFrenoux%26aufirst%3DJ.%2BM.%26aulast%3DGorog%26aufirst%3DD.%2BA.%26aulast%3DHmissi%26aufirst%3DA.%26aulast%3DKunadian%26aufirst%3DV.%26aulast%3DJames%26aufirst%3DS.%2BK.%26aulast%3DTanguay%26aufirst%3DJ.%2BF.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DTrenk%26aufirst%3DD.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DVan%2Bder%2BHarst%26aufirst%3DP.%26aulast%3DVan%25E2%2580%2599t%2BHof%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DAngiolillo%26aufirst%3DD.%2BJ.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520single-dose%2520subcutaneous%2520administration%2520of%2520selatogrel%252C%2520a%2520novel%2520P2Y12%2520receptor%2520antagonist%252C%2520in%2520patients%2520with%2520chronic%2520coronary%2520syndromes%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2020%26volume%3D41%26spage%3D3132%26epage%3D3140%26doi%3D10.1093%2Feurheartj%2Fehz807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groneberg, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure–property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y<sub>12</sub> receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2013.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23747805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFemtb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=360-375&author=P.+Bachauthor=J.+Bostr%C3%B6mauthor=K.+Brickmannauthor=J.+J.+J.+van+Giezenauthor=R.+D.+Gronebergauthor=D.+M.+Harveyauthor=M.+O%E2%80%99Sullivanauthor=F.+Zetterberg&title=Synthesis%2C+structure%E2%80%93property+relationships+and+pharmacokinetic+evaluation+of+ethyl+6-aminonicotinate+sulfonylureas+as+antagonists+of+the+P2Y12+receptor&doi=10.1016%2Fj.ejmech.2013.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor</span></div><div class="casAuthors">Bach, Peter; Bostroem, Jonas; Brickmann, Kay; van Giezen, J. J. J.; Groneberg, Robert D.; Harvey, Darren M.; O'Sullivan, Michael; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">360-375</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The present paper describes the development of a new series of P2Y12 receptor antagonists based on the previously reported piperazinyl urea series (IC50 binding affinity = 0.33 μM, aq. soly. <0.1 μM, microsomal CLint (HLM) ≥300 μM/min/mg).  By replacement of the urea functionality with a sulfonylurea group the authors obsd. increased affinity along with improved stability and soly. as exemplified by I (IC50 binding affinity = 0.042 μM, aq. soly. = 90 μM, microsomal CLint (HLM) = 70 μM/min/mg).  Further improvements in affinity and metabolic stability were achieved by replacing the central piperazine ring with a 3-aminoazetidine as exemplified by II (IC50 binding affinity = 0.0062 μM, aq. soly. = 83 μM, microsomal CLint (HLM) = 28 μM/min/mg).  The improved affinity obsd. in the in vitro binding assay also translated to the potency obsd. in the WPA aggregation assay (I : 19 nM and II : 9.5 nM) and the obsd. in vitro ADME properties translates to the in vivo PK properties obsd. in rat.  In addn., the authors found that the chem. stability of the sulfonylureas during prolonged storage in soln. was related to the sulfonyl urea linker and depended on the type of solvent and the substitution pattern of the sulfonyl urea functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgEnFukjBUnrVg90H21EOLACvtfcHk0lhDm5HUjOfoEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFemtb%252FK&md5=4c32c6f59c0eff04d96611a27f888af2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26aulast%3DBrickmann%26aufirst%3DK.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%2BJ.%26aulast%3DGroneberg%26aufirst%3DR.%2BD.%26aulast%3DHarvey%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593property%2520relationships%2520and%2520pharmacokinetic%2520evaluation%2520of%2520ethyl%25206-aminonicotinate%2520sulfonylureas%2520as%2520antagonists%2520of%2520the%2520P2Y12%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D360%26epage%3D375%26doi%3D10.1016%2Fj.ejmech.2013.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bylund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterlund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordanetto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachrisson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, F.</span></span> <span> </span><span class="NLM_article-title">Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y<sub>12</sub> receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7015</span>– <span class="NLM_lpage">7024</span>, <span class="refDoi"> DOI: 10.1021/jm400820m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400820m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7015-7024&author=P.+Bachauthor=T.+Antonssonauthor=R.+Bylundauthor=J.+A.+Bjorkmanauthor=K.+Osterlundauthor=F.+Giordanettoauthor=J.+J.+van+Giezenauthor=S.+M.+Andersenauthor=H.+Zachrissonauthor=F.+Zetterberg&title=Lead+optimization+of+ethyl+6-aminonicotinate+acyl+sulfonamides+as+antagonists+of+the+P2Y12+receptor.+separation+of+the+antithrombotic+effect+and+bleeding+for+candidate+drug+AZD1283&doi=10.1021%2Fjm400820m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283</span></div><div class="casAuthors">Bach, Peter; Antonsson, Thomas; Bylund, Ruth; Bjoerkman, Jan-Arne; Oesterlund, Krister; Giordanetto, Fabrizio; van Giezen, J. J. J.; Andersen, Soeren M.; Zachrisson, Helen; Zetterberg, Fredrik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7015-7024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationships of Et 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented.  Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the potency in the residual platelet count assay.  Evaluation of PK parameters in vivo in dog for six compds. showed a 10-fold higher clearance for the azetidines than for the matched-pair piperidines.  In a modified Folts model in dog, both piperidine (I) and azetidine (II) dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, resp.  The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for I and II, resp.  Thus, the therapeutic index (TI) was ≥10 for both compds.  On the basis of these data, compd. I was progressed into human clin. trials as candidate drug AZD1283.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgmCuB-1CBurVg90H21EOLACvtfcHk0lhDm5HUjOfoEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qs7bP&md5=3810ed67647a776b9ad8bdb165f715e7</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm400820m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400820m%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DP.%26aulast%3DAntonsson%26aufirst%3DT.%26aulast%3DBylund%26aufirst%3DR.%26aulast%3DBjorkman%26aufirst%3DJ.%2BA.%26aulast%3DOsterlund%26aufirst%3DK.%26aulast%3DGiordanetto%26aufirst%3DF.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26aulast%3DAndersen%26aufirst%3DS.%2BM.%26aulast%3DZachrisson%26aufirst%3DH.%26aulast%3DZetterberg%26aufirst%3DF.%26atitle%3DLead%2520optimization%2520of%2520ethyl%25206-aminonicotinate%2520acyl%2520sulfonamides%2520as%2520antagonists%2520of%2520the%2520P2Y12%2520receptor.%2520separation%2520of%2520the%2520antithrombotic%2520effect%2520and%2520bleeding%2520for%2520candidate%2520drug%2520AZD1283%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7015%26epage%3D7024%26doi%3D10.1021%2Fjm400820m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rafeedheen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliden, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tantry, U. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurbel, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel antiplatelet agents in cardiovascular medicine</span>. <i>Curr. Treat Options Cardiovasc Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1007/s11936-015-0383-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs11936-015-0383-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1-15&author=R.+Rafeedheenauthor=K.+P.+Blidenauthor=F.+Liuauthor=U.+S.+Tantryauthor=P.+A.+Gurbel&title=Novel+antiplatelet+agents+in+cardiovascular+medicine&doi=10.1007%2Fs11936-015-0383-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2Fs11936-015-0383-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11936-015-0383-0%26sid%3Dliteratum%253Aachs%26aulast%3DRafeedheen%26aufirst%3DR.%26aulast%3DBliden%26aufirst%3DK.%2BP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DTantry%26aufirst%3DU.%2BS.%26aulast%3DGurbel%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520antiplatelet%2520agents%2520in%2520cardiovascular%2520medicine%26jtitle%3DCurr.%2520Treat%2520Options%2520Cardiovasc%2520Med.%26date%3D2015%26volume%3D17%26spage%3D1%26epage%3D15%26doi%3D10.1007%2Fs11936-015-0383-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGuzman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haberstock-Debic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbach, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, P. B.</span></span> <span> </span><span class="NLM_article-title">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1124/jpet.110.178574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fjpet.110.178574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21447613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=22-30&author=P.+Andreauthor=F.+DeGuzmanauthor=H.+Haberstock-Debicauthor=S.+Millsauthor=Y.+Pakauthor=M.+Inagakiauthor=A.+Pandeyauthor=S.+Hollenbachauthor=D.+R.+Phillipsauthor=P.+B.+Conley&title=Thienopyridines%2C+but+not+elinogrel%2C+result+in+off-target+effects+at+the+vessel+wall+that+contribute+to+bleeding&doi=10.1124%2Fjpet.110.178574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding</span></div><div class="casAuthors">Andre, Patrick; DeGuzman, Francis; Haberstock-Debic, Helena; Mills, Scott; Pak, Yvonne; Inagaki, Mayuko; Pandey, Anjali; Hollenbach, Stanley; Phillips, David R.; Conley, Pamela B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clin. studies with clopidogrel or prasugrel show that although increased inhibition of P2Y12 and platelet function improves efficacy, bleeding is also increased.  Other preclin. and clin. studies have suggested a greater therapeutic index (TI) with reversible inhibitors and disproportionate effects of thienopyridines on bleeding at high doses.  We used multiple in vivo (FeCl3-induced arterial thrombosis in mesenteric arteries, blood loss after tail transsection, and platelet deposition and wound closure time in a micropuncture model in mesenteric veins) and ex vivo (light transmittance aggregometry, prothrombin time, and activated partial thromboplastin time) mouse models to (1) compare the TI of clopidogrel, prasugrel, and elinogrel, a reversible, competitive antagonist, with that in P2Y12(-/-) mice and (2) det. whether the bleeding consequences of the thienopyridines are attributed only to the inhibition of P2Y12.  Data indicated greater (elinogrel) and decreased (thienopyridines) TI compared with that in P2Y12(-/-) mice.  The impaired TI assocd. with the thienopyridines was not attributed to non-P2Y12 activities on platelet function or coagulation but was related to a direct effect at the vessel wall (inhibition of vascular tone).  Further anal. showed that the prasugrel off-target effect was dose- and time-dependent and of a reversible nature.  In conclusion, the TI of thienopyridines in the mouse may be decreased by P2Y12-independent off-target effects at the vessel wall, whereas that of elinogrel may be enhanced by the reversible, competitive nature of the antiplatelet agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqg4BcD1er_e7Vg90H21EOLACvtfcHk0lg8M21G663u_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCitbY%253D&md5=b2cd05a85e0988416608e5b2af2ea976</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.178574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.178574%26sid%3Dliteratum%253Aachs%26aulast%3DAndre%26aufirst%3DP.%26aulast%3DDeGuzman%26aufirst%3DF.%26aulast%3DHaberstock-Debic%26aufirst%3DH.%26aulast%3DMills%26aufirst%3DS.%26aulast%3DPak%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DHollenbach%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BR.%26aulast%3DConley%26aufirst%3DP.%2BB.%26atitle%3DThienopyridines%252C%2520but%2520not%2520elinogrel%252C%2520result%2520in%2520off-target%2520effects%2520at%2520the%2520vessel%2520wall%2520that%2520contribute%2520to%2520bleeding%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D22%26epage%3D30%26doi%3D10.1124%2Fjpet.110.178574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Post, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morser, J.</span></span> <span> </span><span class="NLM_article-title">Novel P2Y<sub>12</sub> adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18495218" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=523-532&author=J.+Bryantauthor=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=L.+Kentauthor=S.+Schirmauthor=J.+L.+Tsengauthor=B.+Subramanyamauthor=B.+Buckmanauthor=I.+Islamauthor=S.+Yuanauthor=M.+E.+Sullivanauthor=M.+Sniderauthor=J.+Morser&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28I%29%3A+in+vitro+effects+on+platelets&doi=10.1016%2Fj.thromres.2008.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets</span></div><div class="casAuthors">Bryant, Judi; Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Kent, Lorraine; Schirm, Sabine; Tseng, Jih-Lie; Subramanyam, Babu; Buckman, Brad; Islam, Imadul; Yuan, Shendong; Sullivan, Mark E.; Snider, Mike; Morser, John</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">523-532</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the effects of two novel P2Y12 receptor antagonists, BX 667 and its active metabolite BX 048, on platelets.  BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets.  Both compds. were shown to be reversible inhibitors of platelet aggregation.  BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADP.  The specificity of BX 667 and BX 048 was demonstrated against cell lines expressing P2Y1 and P2Y6 as well as against a panel of receptors and enzymes.  Taken all together these data show that both BX 048 and BX 667 are potent P2Y12 antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpePdQfPdqtrbVg90H21EOLACvtfcHk0lg8M21G663u_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbs%253D&md5=9667b7bdfa878d9cee94486f77c4dd9f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DSchirm%26aufirst%3DS.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DBuckman%26aufirst%3DB.%26aulast%3DIslam%26aufirst%3DI.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DSnider%26aufirst%3DM.%26aulast%3DMorser%26aufirst%3DJ.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528I%2529%253A%2520in%2520vitro%2520effects%2520on%2520platelets%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D523%26epage%3D532%26doi%3D10.1016%2Fj.thromres.2008.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Post, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincelette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergona, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dole, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span> <span> </span><span class="NLM_article-title">Novel P2Y<sub>12</sub> adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18539312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=533-540&author=J.+M.+Postauthor=S.+Alexanderauthor=Y.+X.+Wangauthor=J.+Vinceletteauthor=R.+Vergonaauthor=L.+Kentauthor=J.+Bryantauthor=M.+E.+Sullivanauthor=W.+P.+Doleauthor=J.+Morserauthor=B.+Subramanyam&title=Novel+P2Y12+adenosine+diphosphate+receptor+antagonists+for+inhibition+of+platelet+aggregation+%28II%29%3A+pharmacodynamic+and+pharmacokinetic+characterization&doi=10.1016%2Fj.thromres.2008.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization</span></div><div class="casAuthors">Post, Joseph M.; Alexander, Serene; Wang, Yi-Xin; Vincelette, Jon; Vergona, Ron; Kent, Lorraine; Bryant, Judi; Sullivan, Mark E.; Dole, William P.; Morser, John; Subramanyam, Babu</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-540</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiplatelet drugs are used to prevent aberrant platelet activation in pathophysiol. conditions such as myocardial infarction and ischemic stroke.  The key role that ADP plays in this process has led to the development of antiplatelet drugs that target the P2Y12 receptor.  The aim of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of the novel P2Y12 receptor antagonists, BX 667 and BX 048.  BX 667 blocks ADP-induced platelet aggregation in human, dog and rat blood (IC50 = 97, 317 and 3000 nM resp.).  BX 667 had nominal effects on collagen-induced aggregation and weakly inhibited arachidonic acid-induced aggregation.  BX 667 has an active metabolite, BX 048, that also potently inhibits ADP-induced aggregation (IC50 = 290 nM) in human blood.  BX 667 was shown to have high oral bioavailability in both dog and rat unlike BX 048.  Administration of BX 667 resulted in a rapid and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition was directly proportional to circulating plasma levels.  This report describes the PK/PD properties of BX 667 showing that it has the properties required for a potential antiplatelet therapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjWxENonqg7bVg90H21EOLACvtfcHk0lhaMmFapVUjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChtbg%253D&md5=87826ec634199235a94b2f89553fe806</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPost%26aufirst%3DJ.%2BM.%26aulast%3DAlexander%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DVergona%26aufirst%3DR.%26aulast%3DKent%26aufirst%3DL.%26aulast%3DBryant%26aufirst%3DJ.%26aulast%3DSullivan%26aufirst%3DM.%2BE.%26aulast%3DDole%26aufirst%3DW.%2BP.%26aulast%3DMorser%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DB.%26atitle%3DNovel%2520P2Y12%2520adenosine%2520diphosphate%2520receptor%2520antagonists%2520for%2520inhibition%2520of%2520platelet%2520aggregation%2520%2528II%2529%253A%2520pharmacodynamic%2520and%2520pharmacokinetic%2520characterization%26jtitle%3DThromb.%2520Res.%26date%3D2008%26volume%3D122%26spage%3D533%26epage%3D540%26doi%3D10.1016%2Fj.thromres.2008.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boldron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordes, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tissandie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yvon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badorc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseaux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meneyrol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zech, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossey, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Lignon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herault, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delesque, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-[6-(4-butanoyl-5-methyl-1<i>H</i>-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methyl piperazin-1-yl)-2-oxoethyl]-1<i>H</i>-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y<sub>12</sub> antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7293</span>– <span class="NLM_lpage">7316</span>, <span class="refDoi"> DOI: 10.1021/jm500588w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500588w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7293-7316&author=C.+Boldronauthor=A.+Besseauthor=M.+F.+Bordesauthor=S.+Tissandieauthor=X.+Yvonauthor=B.+Gauauthor=A.+Badorcauthor=T.+Rousseauxauthor=G.+Barreauthor=J.+Meneyrolauthor=G.+Zechauthor=M.+Nazareauthor=V.+Fosseyauthor=A.+M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=C.+Briotauthor=F.+Dolauthor=J.+P.+Heraultauthor=P.+Saviauthor=G.+Lassalleauthor=N.+Delesqueauthor=J.+M.+Herbertauthor=F.+Bono&title=N-%5B6-%284-butanoyl-5-methyl-1H-pyrazol-1-yl%29pyridazin-3-yl%5D-5-chloro-1-%5B2-%284-methyl+piperazin-1-yl%29-2-oxoethyl%5D-1H-indole-3-carboxamide+%28SAR216471%29%2C+a+novel+intravenous+and+oral%2C+reversible%2C+and+directly+acting+P2Y12+antagonist&doi=10.1021%2Fjm500588w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">N-[6-(4-Butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist</span></div><div class="casAuthors">Boldron, Christophe; Besse, Angelina; Bordes, Marie-Francoise; Tissandie, Stephanie; Yvon, Xavier; Gau, Benjamin; Badorc, Alain; Rousseaux, Tristan; Barre, Guillaume; Meneyrol, Jerome; Zech, Gernot; Nazare, Marc; Fossey, Valerie; Pflieger, Anne-Marie; Bonnet-Lignon, Sandrine; Millet, Laurence; Briot, Christophe; Dol, Frederique; Herault, Jean-Pascal; Savi, Pierre; Lassalle, Gilbert; Delesque, Nathalie; Herbert, Jean-Marc; Bono, Francoise</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7293-7316</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the search of a potential backup for clopidogrel, the authors have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists.  Starting from a hit with low micromolar binding activity, the authors report here the main steps of the optimization process leading to the identification of the preclin. candidate SAR216471, I.  It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature.  I displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGUVg5pZdW1rVg90H21EOLACvtfcHk0lhaMmFapVUjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git7fO&md5=b6eeb28566a300c4aadb6575bdd28607</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm500588w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500588w%26sid%3Dliteratum%253Aachs%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DBesse%26aufirst%3DA.%26aulast%3DBordes%26aufirst%3DM.%2BF.%26aulast%3DTissandie%26aufirst%3DS.%26aulast%3DYvon%26aufirst%3DX.%26aulast%3DGau%26aufirst%3DB.%26aulast%3DBadorc%26aufirst%3DA.%26aulast%3DRousseaux%26aufirst%3DT.%26aulast%3DBarre%26aufirst%3DG.%26aulast%3DMeneyrol%26aufirst%3DJ.%26aulast%3DZech%26aufirst%3DG.%26aulast%3DNazare%26aufirst%3DM.%26aulast%3DFossey%26aufirst%3DV.%26aulast%3DPflieger%26aufirst%3DA.%2BM.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DBriot%26aufirst%3DC.%26aulast%3DDol%26aufirst%3DF.%26aulast%3DHerault%26aufirst%3DJ.%2BP.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DDelesque%26aufirst%3DN.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DN-%255B6-%25284-butanoyl-5-methyl-1H-pyrazol-1-yl%2529pyridazin-3-yl%255D-5-chloro-1-%255B2-%25284-methyl%2520piperazin-1-yl%2529-2-oxoethyl%255D-1H-indole-3-carboxamide%2520%2528SAR216471%2529%252C%2520a%2520novel%2520intravenous%2520and%2520oral%252C%2520reversible%252C%2520and%2520directly%2520acting%2520P2Y12%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7293%26epage%3D7316%26doi%3D10.1021%2Fjm500588w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delesque-Touchard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Lignon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, F.</span></span> <span> </span><span class="NLM_article-title">SAR216471, an alternative to the use of currently available P2Y<sub>12</sub> receptor inhibitors?</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2014.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2014.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=25064036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1WjsrzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2014&pages=693-703&author=N.+Delesque-Touchardauthor=A.+M.+Pfliegerauthor=S.+Bonnet-Lignonauthor=L.+Milletauthor=V.+Salelauthor=C.+Boldronauthor=G.+Lassalleauthor=J.+M.+Herbertauthor=P.+Saviauthor=F.+Bono&title=SAR216471%2C+an+alternative+to+the+use+of+currently+available+P2Y12+receptor+inhibitors%3F&doi=10.1016%2Fj.thromres.2014.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?</span></div><div class="casAuthors">Delesque-Touchard, N.; Pflieger, A. M.; Bonnet-Lignon, S.; Millet, L.; Salel, V.; Boldron, C.; Lassalle, G.; Herbert, J. M.; Savi, P.; Bono, F.</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-703</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  P2Y12 antagonism is a key therapeutic strategy in the management and prevention of arterial thrombosis.  The objective of this study was to characterize the pharmacodynamic (PD) and pharmacokinetic (PK) properties of SAR216471, a novel P2Y12 receptor antagonist.  SAR216471 blocks the binding of 2MeSADP to P2Y12 receptors in vitro (IC50 = 17 nM).  This inhibition was shown to be reversible.  It potently antagonized ADP-induced platelet aggregation in human and rat platelet-rich plasma (IC50 = 108 and 62 nM, resp.).  It also inhibited platelet aggregation when blood was exposed to collagen or thromboxane A2.  Its high selectivity was demonstrated against a large panel of receptors, enzymes, and ion channels.  Despite its moderate bioavailability in rats, oral administration of SAR216471 resulted in a fast, potent, and sustained inhibition of platelet aggregation where the extent and duration of platelet inhibition were directly proportional to its circulating plasma levels.  Pre-clin. study of SAR216471 in a rat shunt thrombosis model demonstrated a dose-dependent antithrombotic activity after oral administration (ED50 = 6.7 mg/kg).  By comparison, ED50 values for clopidogrel, prasugrel and ticagrelor were 6.3, 0.35 and 2.6 mg/kg, resp.  Finally, the anti-hemostatic effect of SAR216471 and its competitors was investigated in a rat tail bleeding model, revealing a favorable safety profile of SAR216471.  Together, these findings have established a reliable antiplatelet profile of SAR216471, and support its potential use in clin. practice as an alternative to currently available P2Y12 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKEact9v22yrVg90H21EOLACvtfcHk0lhaMmFapVUjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1WjsrzI&md5=f628876c891ea3f6bcde187c1f2427bc</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2014.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2014.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DDelesque-Touchard%26aufirst%3DN.%26aulast%3DPflieger%26aufirst%3DA.%2BM.%26aulast%3DBonnet-Lignon%26aufirst%3DS.%26aulast%3DMillet%26aufirst%3DL.%26aulast%3DSalel%26aufirst%3DV.%26aulast%3DBoldron%26aufirst%3DC.%26aulast%3DLassalle%26aufirst%3DG.%26aulast%3DHerbert%26aufirst%3DJ.%2BM.%26aulast%3DSavi%26aufirst%3DP.%26aulast%3DBono%26aufirst%3DF.%26atitle%3DSAR216471%252C%2520an%2520alternative%2520to%2520the%2520use%2520of%2520currently%2520available%2520P2Y12%2520receptor%2520inhibitors%253F%26jtitle%3DThromb.%2520Res.%26date%3D2014%26volume%3D134%26spage%3D693%26epage%3D703%26doi%3D10.1016%2Fj.thromres.2014.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atzler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GläNzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C. E.</span></span> <span> </span><span class="NLM_article-title">High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y<sub>12</sub> receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3784</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1021/jm9003297</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9003297" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtlelsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3784-3793&author=Y.+Baqiauthor=K.+Atzlerauthor=M.+K%C3%B6seauthor=M.+Gl%C3%A4Nzelauthor=C.+E.+M%C3%BCller&title=High-affinity%2C+non-nucleotide-derived+competitive+antagonists+of+platelet+P2Y12+receptors&doi=10.1021%2Fjm9003297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity, Non-Nucleotide-Derived Competitive Antagonists of Platelet P2Y12 Receptors</span></div><div class="casAuthors">Baqi, Younis; Atzler, Kerstin; Kose, Meryem; Glanzel, Markus; Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3784-3793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anthraquinone derivs. related to the moderately potent, nonselective P2Y12 receptor antagonist reactive blue 2 were synthesized and optimized with respect to P2Y12 receptor affinity.  These new anthraquinone derivs. were prepd. via copper(0)-catalyzed Ullmann coupling reaction of 1-amino-4-bromoanthraquinone derivs. with anilines in phosphate buffer under microwave irradn.  The most potent compds. I (R1 = SO3Na and CO2H) exhibited Ki values of 24.9 nM and 21.0 nM resp.  1-Amino-2-sulfonato-4-anilinoanthraquinone derivs. appeared to be noncytotoxic, as shown for selected derivs. at two human cell lines (melanoma and astrocytoma).  Compds. I (R1 = SO3Na and CO2H) represent new lead structures for the development of antithrombotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjNFMcZdKXubVg90H21EOLACvtfcHk0li3w8TQiLNZyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtlelsbo%253D&md5=59607a39ed17589cd2c3a36628cbcde7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm9003297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9003297%26sid%3Dliteratum%253Aachs%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DAtzler%26aufirst%3DK.%26aulast%3DK%25C3%25B6se%26aufirst%3DM.%26aulast%3DGl%25C3%25A4Nzel%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DHigh-affinity%252C%2520non-nucleotide-derived%2520competitive%2520antagonists%2520of%2520platelet%2520P2Y12%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3784%26epage%3D3793%26doi%3D10.1021%2Fjm9003297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morena, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glanzel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kugelgen, I.</span></span> <span> </span><span class="NLM_article-title">Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y<sub>12</sub> receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.156687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fjpet.109.156687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19690189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=648-655&author=K.+Hoffmannauthor=Y.+Baqiauthor=M.+S.+Morenaauthor=M.+Glanzelauthor=C.+E.+Mullerauthor=I.+von+Kugelgen&title=Interaction+of+new%2C+very+potent+non-nucleotide+antagonists+with+Arg256+of+the+human+platelet+P2Y12+receptor&doi=10.1124%2Fjpet.109.156687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor</span></div><div class="casAuthors">Hoffmann, Kristina; Baqi, Younis; Morena, Maria Sol; Glaenzel, Markus; Mueller, Christa E.; von Kuegelgen, Ivar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The P2Y12 receptor plays a crucial role in platelet aggregation.  In the present study, we analyzed the properties of non-nucleotide antagonists at the recombinant human P2Y12 receptor and searched for amino acids involved in the mol. interaction.  Receptor function was assessed by measuring the cAMP response element (CRE)-directed luciferase expression in Chinese hamster ovary cells.  The cellular cAMP prodn. was accelerated by forskolin; 2-methylthio-ADP was used to activate the wild-type P2Y12 receptor or mutant constructs.  2-Methylthio-ADP inhibited the CRE-dependent luciferase expression with an IC50 value of approx. 1 nM.  The anthraquinone deriv. reactive blue 2 used at increasing concns. shifted the concn.-response curve of 2-methylthio-ADP to the right in a manner compatible with competitive antagonism (pA2 value, 7.4).  Its analog, 1-amino-4-[4-phenylamino-3-sulfophenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate (PSB-0739), showed a markedly higher antagonistic potency with a pA2 value of 9.8.  In cells expressing the R256A-mutant receptor, the potencies of both reactive blue 2 (apparent pKB, 5.9) and PSB-0739 (apparent pKB, 9.1) were decreased.  The same was true for the pure reactive blue 2 meta- and para-isomers and for the ortho-isomer cibacron blue 3GA.  In contrast, the analog, 1-amino-4-[4-anilino-phenylamino]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate, lacking a sulfonic acid residue at ring D (PSB-0826), showed similar pKB values at wild-type (8.4) and R256A-mutant receptors (8.3).  In summary, the results demonstrate that PSB-0739 is the most potent competitive non-nucleotide antagonist at the human P2Y12 receptor described so far.  The results also indicate that the sulfonic acid residue at ring D is involved in the interaction of antagonists derived from reactive blue 2 with the residue Arg256 of the human P2Y12 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAK7tsHlBv2LVg90H21EOLACvtfcHk0li3w8TQiLNZyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlKnu73F&md5=91c4a53c07bb3087d47fc194dbed13c6</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.156687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.156687%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DMorena%26aufirst%3DM.%2BS.%26aulast%3DGlanzel%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3Dvon%2BKugelgen%26aufirst%3DI.%26atitle%3DInteraction%2520of%2520new%252C%2520very%2520potent%2520non-nucleotide%2520antagonists%2520with%2520Arg256%2520of%2520the%2520human%2520platelet%2520P2Y12%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D648%26epage%3D655%26doi%3D10.1124%2Fjpet.109.156687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3342</span>– <span class="NLM_lpage">3352</span>, <span class="refDoi"> DOI: 10.1021/jm300038c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300038c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC38XktFemtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3342-3352&author=J.+Shanauthor=B.+Zhangauthor=Y.+Zhuauthor=B.+Jiaoauthor=W.+Zhengauthor=X.+Qiauthor=Y.+Gongauthor=F.+Yuanauthor=F.+Lvauthor=H.+Sun&title=Overcoming+clopidogrel+resistance%3A+discovery+of+vicagrel+as+a+highly+potent+and+orally+bioavailable+antiplatelet+agent&doi=10.1021%2Fjm300038c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet Agent</span></div><div class="casAuthors">Shan, Jiaqi; Zhang, Boyu; Zhu, Yaoqiu; Jiao, Bo; Zheng, Weiyi; Qi, Xiaowei; Gong, Yanchun; Yuan, Fang; Lv, Fusheng; Sun, Hongbin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3342-3352</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of optically active 2-hydroxytetrahydrothienopyridine derivs. were designed and synthesized as prodrugs of clopidogrel thiolactone in order to overcome clopidogrel resistance.  The final compds. were evaluated for their inhibitory effect on ADP-induced platelet aggregation in rats.  Compd. 9a was selected for further in vitro and in vivo metab. studies, since its potency was comparable to that of prasugrel and was much higher than that of clopidogrel.  Preliminary pharmacokinetic study results showed that the bioavailability of clopidogrel thiolactone generated from 9a was 6-fold higher than that generated from clopidogrel, implying a much lower clin. ED for 9a in comparison with clopidogrel.  In summary, 9a (vicagrel, I) holds great promise as a more potent and a safer antiplatelet agent that might have the following advantages over clopidogrel: (1) no drug resistance for CYP2C19 poor metabolizers; (2) lower dose-related toxicity due to a much lower ED; (3) faster onset of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjnY3RFwYKpbVg90H21EOLACvtfcHk0lj_gdVBAr366g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktFemtLo%253D&md5=de26cb85b78ffed42eb877f74d1b43b7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm300038c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300038c%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJiao%26aufirst%3DB.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DF.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DOvercoming%2520clopidogrel%2520resistance%253A%2520discovery%2520of%2520vicagrel%2520as%2520a%2520highly%2520potent%2520and%2520orally%2520bioavailable%2520antiplatelet%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3342%26epage%3D3352%26doi%3D10.1021%2Fjm300038c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caroff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, M. A.</span></span> <span> </span><span class="NLM_article-title">4-((R)-2-{[6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl] amino}- 3-phosphonopropionyl) piperazine-1-carboxylic acid butyl ester (ACT-246475) and its prodrug (ACT-281959), a novel P2Y<sub>12</sub> receptor antagonist with a wider therapeutic window in the rat than clopidogrel</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9133</span>– <span class="NLM_lpage">9153</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyktbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9133-9153&author=E.+Caroffauthor=F.+Hublerauthor=E.+Meyerauthor=D.+Rennebergauthor=C.+Gnerreauthor=A.+Treiberauthor=M.+Reyauthor=P.+Hessauthor=B.+Steinerauthor=K.+Hilpertauthor=M.+A.+Riederer&title=4-%28%28R%29-2-%7B%5B6-%28%28S%29-3-methoxypyrrolidin-1-yl%29-2-phenylpyrimidine-4-carbonyl%5D+amino%7D-+3-phosphonopropionyl%29+piperazine-1-carboxylic+acid+butyl+ester+%28ACT-246475%29+and+its+prodrug+%28ACT-281959%29%2C+a+novel+P2Y12+receptor+antagonist+with+a+wider+therapeutic+window+in+the+rat+than+clopidogrel&doi=10.1021%2Facs.jmedchem.5b00933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel</span></div><div class="casAuthors">Caroff, Eva; Hubler, Francis; Meyer, Emmanuel; Renneberg, Dorte; Gnerre, Carmela; Treiber, Alexander; Rey, Markus; Hess, Patrick; Steiner, Beat; Hilpert, Kurt; Riederer, Markus A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9133-9153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent posthoc analyses of several clin. trials with P2Y12 antagonists showed the need for new mols. being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding.  The authors have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y12 antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma.  Herein the authors present the optimization steps that led to the discovery of clin. candidate ACT-246475 I.  The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent mols. of the program.  In addn., low in vivo clearance in rat and dog was achieved for the first time.  Since the bioavailability of I was low in rat and dog, the authors developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug ACT-281959, II.  Compd. I showed efficacy in the rat ferric chloride thrombosis model when administered i.v. as parent or orally as its prodrug 45.  Moreover, I displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroPF59EdlX8LVg90H21EOLACvtfcHk0lj_gdVBAr366g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyktbnI&md5=ee08c3b17c78295e847003159aa5eaed</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00933%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DE.%26aulast%3DHubler%26aufirst%3DF.%26aulast%3DMeyer%26aufirst%3DE.%26aulast%3DRenneberg%26aufirst%3DD.%26aulast%3DGnerre%26aufirst%3DC.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DHilpert%26aufirst%3DK.%26aulast%3DRiederer%26aufirst%3DM.%2BA.%26atitle%3D4-%2528%2528R%2529-2-%257B%255B6-%2528%2528S%2529-3-methoxypyrrolidin-1-yl%2529-2-phenylpyrimidine-4-carbonyl%255D%2520amino%257D-%25203-phosphonopropionyl%2529%2520piperazine-1-carboxylic%2520acid%2520butyl%2520ester%2520%2528ACT-246475%2529%2520and%2520its%2520prodrug%2520%2528ACT-281959%2529%252C%2520a%2520novel%2520P2Y12%2520receptor%2520antagonist%2520with%2520a%2520wider%2520therapeutic%2520window%2520in%2520the%2520rat%2520than%2520clopidogrel%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9133%26epage%3D9153%26doi%3D10.1021%2Facs.jmedchem.5b00933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, S. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer-Fernandes, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savio, L. E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, F. G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho-Silva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C. L. M.</span></span> <span> </span><span class="NLM_article-title">Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y<sub>1</sub> receptors</span>. <i>Vasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.vph.2016.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.vph.2016.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26924460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12gt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=66-72&author=S.+D.+S.+Oliveiraauthor=N.+F.+Oliveiraauthor=J.+R.+Meyer-Fernandesauthor=L.+E.+B.+Savioauthor=F.+G.+I.+Ornelasauthor=Z.+S.+Ferreiraauthor=R.+Coutinho-Silvaauthor=C.+L.+M.+Silva&title=Increased+expression+of+NTPDases+2+and+3+in+mesenteric+endothelial+cells+during+schistosomiasis+favors+leukocyte+adhesion+through+P2Y1+receptors&doi=10.1016%2Fj.vph.2016.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y1 receptors</span></div><div class="casAuthors">Oliveira, Suellen Darc Santos; Oliveira, Nathalia F.; Meyer-Fernandes, Jose R.; Savio, Luiz Eduardo Baggio; Ornelas, Flavia G. I.; Ferreira, Zulma S.; Coutinho-Silva, Robson; Silva, Claudia Lucia Martins</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">66-72</span>CODEN:
                <span class="NLM_cas:coden">VPAHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1537-1891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Schistosomiasis is caused by an intravascular parasite and linked to phenotypic changes in endothelial cells that favor inflammation.  Endothelial cells express P2Y1 receptors (P2Y1R), and their activation by ADP favors leukocyte adhesion to the endothelial monolayer.  We aimed to evaluate the influence of schistosomiasis upon endothelial purinergic signaling-mediated leukocyte adhesion.  Mesenteric endothelial cells and mononuclear cells from control and Schistosoma mansoni-infected mice were used in co-culture.  P2Y1R levels were similar in both groups.  Basal leukocyte adhesion was higher in the infected than in the control group; leukocyte adhesion increased after treatment with the P2Y1R agonist 2-MeSATP in both groups, though it only marginally increased in the infected group.  Pre-incubation with the selective P2Y1R antagonist MRS2179 (0.3 μM) prevented the agonist effect.  However, in the infected group it also reduced the basal leukocyte adhesion, suggesting endothelial cell pre-activation.  The endothelial expressions of NTPDases 2 and 3 were significantly increased in the infected group, increasing extracellular ATP hydrolysis and ADP formation by endothelial cells.  Therefore, mesenteric endothelial cells are primed by schistosomiasis to a pro-inflammatory phenotype characterized by an increased expression of NTPDases 2 and 3, favoring ADP accumulation and mononuclear cell adhesion, possibly contributing to mesenteric inflammation and schistosomiasis morbidity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-atbvubuHSbVg90H21EOLACvtfcHk0lhNxtVb_QHtZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12gt7w%253D&md5=08d524f4c68abfb8532963fbd33079fd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.vph.2016.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vph.2016.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DOliveira%26aufirst%3DS.%2BD.%2BS.%26aulast%3DOliveira%26aufirst%3DN.%2BF.%26aulast%3DMeyer-Fernandes%26aufirst%3DJ.%2BR.%26aulast%3DSavio%26aufirst%3DL.%2BE.%2BB.%26aulast%3DOrnelas%26aufirst%3DF.%2BG.%2BI.%26aulast%3DFerreira%26aufirst%3DZ.%2BS.%26aulast%3DCoutinho-Silva%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DC.%2BL.%2BM.%26atitle%3DIncreased%2520expression%2520of%2520NTPDases%25202%2520and%25203%2520in%2520mesenteric%2520endothelial%2520cells%2520during%2520schistosomiasis%2520favors%2520leukocyte%2520adhesion%2520through%2520P2Y1%2520receptors%26jtitle%3DVasc.%2520Pharmacol.%26date%3D2016%26volume%3D82%26spage%3D66%26epage%3D72%26doi%3D10.1016%2Fj.vph.2016.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span> <span> </span><span class="NLM_article-title">2-Chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y<sub>1</sub> receptor antagonist</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fsj.bjp.0704673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=11959804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlels74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=2004-2010&author=J.+L.+Boyerauthor=M.+Adamsauthor=R.+G.+Raviauthor=K.+A.+Jacobsonauthor=T.+K.+Harden&title=2-Chloro-N6-methyl-%28N%29-methanocarba-2%E2%80%B2-deoxyadenosine-3%E2%80%B2%2C5%E2%80%B2-bisphosphate+is+a+selective+high+affinity+P2Y1+receptor+antagonist&doi=10.1038%2Fsj.bjp.0704673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">2-chloro N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y1 receptor antagonist</span></div><div class="casAuthors">Boyer, Jose L.; Adams, Mary; Ravi, R. Gnana; Jacobson, Kenneth A.; Harden, T. Kendall</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2004-2010</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We reported previously that bisphosphate derivs. of adenosine are antagonists of the P2Y1 receptor and that modification of the ribose in these analogs is tolerated in the P2Y1 receptor binding pharmacophore.  Here we delineate the pharmacol. activity of one such non-nucleotide mol., 2-chloro N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate (MRS2279), in which the ribose is replaced by a cyclopentane ring constrained in the (N)-conformation by a cyclopropane moiety.  MRS2279 antagonized 2MeSADP-stimulated inositol phosphate formation in turkey erythrocyte membranes with competitive kinetics (pKB = 7.75).  High affinity competitive antagonism by MRS2279 was also obsd. at the human P2Y1 receptor (pKB = 8.10) stably expressed in 1321N1 human astrocytoma cells.  Antagonism was specific for the P2Y1 receptor since MRS2279 had no effect on activation of the human P2Y2, P2Y4, P2Y6, or P2Y11 receptors by their cognate agonists.  MRS2279 also did not block the capacity of ADP to act through the Gi/adenylyl cyclase linked P2Y receptor of platelets to inhibit cAMP accumulation.  In contrast, the P2Y1 receptor is known to be obligatory in the process of ADP-induced platelet aggregation, and MRS2279 competitively inhibited ADP-promoted platelet aggregation with an apparent affinity (pKB = 8.05) similar to that obsd. at the human P2Y1 receptor heterologously expressed in 1321N1 cells.  Taken together these results illustrate selective high affinity antagonism of the P2Y1 receptor by a non-nucleotide mol. that should prove useful for pharmacol. delineation of this receptor in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5daZS3WWovrVg90H21EOLACvtfcHk0lhNxtVb_QHtZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlels74%253D&md5=c961b239774ebec55d3c467a1cbbd241</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704673%26sid%3Dliteratum%253Aachs%26aulast%3DBoyer%26aufirst%3DJ.%2BL.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DRavi%26aufirst%3DR.%2BG.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26atitle%3D2-Chloro-N6-methyl-%2528N%2529-methanocarba-2%25E2%2580%25B2-deoxyadenosine-3%25E2%2580%25B2%252C5%25E2%2580%25B2-bisphosphate%2520is%2520a%2520selective%2520high%2520affinity%2520P2Y1%2520receptor%2520antagonist%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D2004%26epage%3D2010%26doi%3D10.1038%2Fsj.bjp.0704673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1<i>H</i>-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2015.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26363870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=343-353&author=S.+Chenauthor=T.+Zhangauthor=J.+Wangauthor=F.+Wangauthor=H.+Niuauthor=C.+Wuauthor=S.+Wang&title=Synthesis+and+evaluation+of+1-hydroxy%2Fmethoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic+acid+derivatives+as+non-purine+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2015.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors</span></div><div class="casAuthors">Chen, Shaolei; Zhang, Tingjian; Wang, Jian; Wang, Fangyang; Niu, Handong; Wu, Chunfu; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">343-353</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Xanthine oxidase is a key enzyme that catalyzes hypoxanthine and xanthine to uric acid, whose overprodn. leads to the gout-causing hyperuricemia.  In this study, a series of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivs. was synthesized and evaluated for their inhibitory potency against xanthine oxidase.  The 1-hydroxyl substituted derivs. showed excellent inhibitory potency with IC50 values ranging from 0.003 μM to 1.2 μM, with compds. I [R = n-Bu] (IC50 = 0.003 μM), I [R = sec-Bu] (IC50 = 0.003 μM), and I [R = iso-Bu] (IC50 = 0.006 μM) manifesting the most potent xanthine oxidase inhibitory potency that were comparable with that of Febuxostat (IC50 = 0.01 μM).  Lineweaver-Burk plot anal. revealed that representative compd. I [R = iso-Bu] acted as a mixed-type inhibitor for xanthine oxidase.  The basis of significant inhibition of xanthine oxidase by compd. I [R = iso-Bu] was rationalized by its mol. docking into the active site of xanthine dehydrogenase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_tKiu3i8ErVg90H21EOLACvtfcHk0lhNxtVb_QHtZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsbjF&md5=c8a19d841a0ec5e515095db8a96b19f9</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%25201-hydroxy%252Fmethoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic%2520acid%2520derivatives%2520as%2520non-purine%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D343%26epage%3D353%26doi%3D10.1016%2Fj.ejmech.2015.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS</span>. <i>J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1113</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.jchromb.2019.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.jchromb.2019.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30901732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1eht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1113&publication_year=2019&pages=77-83&author=D.+Zhangauthor=T.+Yangauthor=J.+Lin&title=A+novel+xanthine+oxidase+inhibitor+WSJ-557+study+on+pharmacokinetics+and+tissue+distribution+in+rats+by+UPLC-MS%2FMS&doi=10.1016%2Fj.jchromb.2019.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A novel xanthine oxidase inhibitor WSJ-557 study on pharmacokinetics and tissue distribution in rats by UPLC-MS/MS</span></div><div class="casAuthors">Zhang, Donghu; Yang, Tian; Lin, Jianyang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-83</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As a novel non-purine xanthine oxidase inhibitor, WSJ-557 is a potential drug for gout.  To det. the WSJ-557 concn. in plasma and various tissues of rats, a fast and sensitive method was first established by the ultra-performance liq. chromatog.-tandem mass spectrometry (UPLC-MS/MS) in this paper.  The liq.-liq. extn. of Et acetate was adopted for the sample prepn., and carbamazepine was taken as the internal std.  In the process of chromatog. sepn., MRM transitions for WSJ-557 and carbamazepine (internal std., IS) were m/z 316.1 → 260.0 and m/z 237.0 → 194.0, correspondingly.  The great linearity of WSJ-557 in all bio-samples was found in the corresponding concn. range (r > 0.99).  The intra- and inter-day precision (RSD%) were below 9.5% in various tissues and plasma, whose accuracy (RE%) was within ±9.2%.  This method was resoundingly employed to the WSJ-557 study on rat pharmacokinetics and tissue distribution after the i.v. administration and oral administration.  The av. abs. bioavailability (F) of WSJ-557 was 6.48%.  The highest distribution level of gastric and intestinal tissues indicated that WSJ-557 was first absorbed in the stomach and intestine.  Moreover, this anal. method provides a significant approach for the further development and investigation of WSJ-557.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCjy6BdV4z1bVg90H21EOLACvtfcHk0lh2ocoPe7q3ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1eht70%253D&md5=8344a518cdc3add4ca3b1033ce2770b0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2019.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2019.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DA%2520novel%2520xanthine%2520oxidase%2520inhibitor%2520WSJ-557%2520study%2520on%2520pharmacokinetics%2520and%2520tissue%2520distribution%2520in%2520rats%2520by%2520UPLC-MS%252FMS%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2019%26volume%3D1113%26spage%3D77%26epage%3D83%26doi%3D10.1016%2Fj.jchromb.2019.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. J.</span></span> <span> </span><span class="NLM_article-title">Compound with Xanthine Oxidase Inhibitory Activity and Salt Thereof, Preparation Method and Usage for the Same</span>. Patent <span class="NLM_patent">WO 2014023104A1</span>, Feb 13, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+J.+Wang&title=Compound+with+Xanthine+Oxidase+Inhibitory+Activity+and+Salt+Thereof%2C+Preparation+Method+and+Usage+for+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BJ.%26atitle%3DCompound%2520with%2520Xanthine%2520Oxidase%2520Inhibitory%2520Activity%2520and%2520Salt%2520Thereof%252C%2520Preparation%2520Method%2520and%2520Usage%2520for%2520the%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aungraheeta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conibear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundell, S. J.</span></span> <span> </span><span class="NLM_article-title">Inverse agonism at the P2Y<sub>12</sub> receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2717</span>– <span class="NLM_lpage">2728</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707844</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1182%2Fblood-2016-03-707844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=27694321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWgsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=2717-2728&author=R.+Aungraheetaauthor=A.+Conibearauthor=M.+Butlerauthor=E.+Kellyauthor=S.+Nylanderauthor=A.+Mumfordauthor=S.+J.+Mundell&title=Inverse+agonism+at+the+P2Y12+receptor+and+ENT1+transporter+blockade+contribute+to+platelet+inhibition+by+ticagrelor&doi=10.1182%2Fblood-2016-03-707844"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor</span></div><div class="casAuthors">Aungraheeta, Riyaad; Conibear, Alexandra; Butler, Mark; Kelly, Eamonn; Nylander, Sven; Mumford, Andrew; Mundell, Stuart J.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2717-2728</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ticagrelor is a potent antagonist of the P2Y12 receptor (P2Y12R) and consequently an inhibitor of platelet activity effective in the treatment of atherothrombosis.  Here, we sought to further characterize its mol. mechanism of action.  Initial studies showed that ticagrelor promoted a greater inhibition of ADP (ADP) -induced Ca2+ release in washed platelets vs other P2Y12R antagonists.  This addnl. effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors.  This contributed to an increase in basal cyclic adenosine monophosphate (cAMP) and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P).  In addn., ticagrelor increased platelet cAMP and VASP-P in the absence of ADP in an adenosine receptor-independent manner.  We hypothesized that this increase originated from a direct effect on basal agonist-independent P2Y12R signaling, and this was validated in 1321N1 cells stably transfected with humanP2Y12R.  In these cells, ticagrelor blocked the constitutive agonist-independent activity of the P2Y12R, limiting basalGi-coupled signaling and thereby increasing cAMP levels.  These data suggest that ticagrelor has the pharmacol. profile of an inverse agonist.  Based on our results showing insurmountable inhibition of ADP-induced Ca2+ release and forskolin-induced cAMP, the mode of antagonism of ticagrelor also appears noncompetitive, at least functionally.  In summary, our studies describe 2 novel modes of action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12Rthat contribute to its effective inhibition of platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE62NVOLgembVg90H21EOLACvtfcHk0lh2ocoPe7q3ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWgsLY%253D&md5=5d3c979c05bb10ad9424f13a661a55fc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707844%26sid%3Dliteratum%253Aachs%26aulast%3DAungraheeta%26aufirst%3DR.%26aulast%3DConibear%26aufirst%3DA.%26aulast%3DButler%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DMumford%26aufirst%3DA.%26aulast%3DMundell%26aufirst%3DS.%2BJ.%26atitle%3DInverse%2520agonism%2520at%2520the%2520P2Y12%2520receptor%2520and%2520ENT1%2520transporter%2520blockade%2520contribute%2520to%2520platelet%2520inhibition%2520by%2520ticagrelor%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D2717%26epage%3D2728%26doi%3D10.1182%2Fblood-2016-03-707844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cattaneo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harden, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Antiaggregatory activity in human platelets of potent antagonists of the P2Y<sub>1</sub> receptor</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1995</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bcp.2004.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=15476670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot12ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=1995-2002&author=M.+Cattaneoauthor=A.+Lecchiauthor=M.+Ohnoauthor=B.+V.+Joshiauthor=P.+Besadaauthor=S.+Tchilibonauthor=R.+Lombardiauthor=N.+Bischofbergerauthor=T.+K.+Hardenauthor=K.+A.+Jacobson&title=Antiaggregatory+activity+in+human+platelets+of+potent+antagonists+of+the+P2Y1+receptor&doi=10.1016%2Fj.bcp.2004.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor</span></div><div class="casAuthors">Cattaneo, Marco; Lecchi, Anna; Ohno, Michihiro; Joshi, Bhalchandra V.; Besada, Pedro; Tchilibon, Susanna; Lombardi, Rossana; Bischofberger, Norbert; Harden, T. Kendall; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1995-2002</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Activation of the P2Y1 nucleotide receptor in platelets by ADP causes changes in shape and aggregation, mediated by activation of phospholipase C (PLC).  Recently, MRS2500 (2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate) was introduced as a highly potent and selective antagonist for this receptor.  We have studied the actions of MRS2500 in human platelets and compared these effects with the effects of two acyclic nucleotide analogs, a bisphosphate MRS2298 and a bisphosphonate deriv. MRS2496, which act as P2Y1 receptor antagonists, although less potently than MRS2500.  Improved synthetic methods for MRS2500 and MRS2496 were devised.  The bisphosphonate is predicted to be more stable in general in biol. systems than phosphate antagonists due to the non-hydrolyzable C-P bond.  MRS2500 inhibited the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM.  MRS2298 and MRS2496 also both inhibited the ADP-induced aggregation of human platelets with IC50 values of 62.8 nM and 1.5 μM, resp.  A similar order of potency was obsd. for the three antagonists in binding to the recombinant human P2Y1 receptor and in inhibition of ADP-induced shape change and ADP-induced rise in intracellular Ca2+.  No substantial antagonism of the pathway linked to the inhibition of cAMP was obsd. for the nucleotide derivs., indicating no interaction of these three P2Y1 receptor antagonists with the proaggregatory P2Y12 receptor, which is also activated by ADP.  Thus, all three of the bisphosphate derivs. are highly selective antagonists of the platelet P2Y1 receptor, and MRS2500 is the most potent such antagonist yet reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQU9krQWJwpbVg90H21EOLACvtfcHk0lh2ocoPe7q3ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot12ntro%253D&md5=23ea4e4a3600f0b2fe89efa651028cb9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DCattaneo%26aufirst%3DM.%26aulast%3DLecchi%26aufirst%3DA.%26aulast%3DOhno%26aufirst%3DM.%26aulast%3DJoshi%26aufirst%3DB.%2BV.%26aulast%3DBesada%26aufirst%3DP.%26aulast%3DTchilibon%26aufirst%3DS.%26aulast%3DLombardi%26aufirst%3DR.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DHarden%26aufirst%3DT.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DAntiaggregatory%2520activity%2520in%2520human%2520platelets%2520of%2520potent%2520antagonists%2520of%2520the%2520P2Y1%2520receptor%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D1995%26epage%3D2002%26doi%3D10.1016%2Fj.bcp.2004.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanachkov, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frelinger, A. L.</span></span> <span> </span><span class="NLM_article-title">Modified diadenosine tetraphosphates with dual specificity for P2Y<sub>1</sub> and P2Y<sub>12</sub> are potent antagonists of ADP-induced platelet activation</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2573</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1111/jth.12035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fjth.12035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=23083103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=2573-2580&author=H.+Changauthor=I.+B.+Yanachkovauthor=E.+J.+Dixauthor=Y.+F.+Liauthor=M.+R.+Barnardauthor=G.+E.+Wrightauthor=A.+D.+Michelsonauthor=A.+L.+Frelinger&title=Modified+diadenosine+tetraphosphates+with+dual+specificity+for+P2Y1+and+P2Y12+are+potent+antagonists+of+ADP-induced+platelet+activation&doi=10.1111%2Fjth.12035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation</span></div><div class="casAuthors">Chang, H.; Yanachkov, I. B.; Dix, E. J.; Li, Y. F.; Barnard, M. R.; Wright, G. E.; Michelson, A. D.; Frelinger, A. L., III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2573-2580</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background: Diadenosine 5',5'"-P1,P4-tetraphosphate (Ap4A), a natural compd. stored in platelet dense granules, inhibits ADP-induced platelet aggregation.  Ap4A inhibits the platelet ADP receptors P2Y1 and P2Y12, is a partial agonist of P2Y12, and is a full agonist of the platelet ATP-gated ion channel P2X1.  Modification of the Ap4A tetraphosphate backbone enhances inhibition of ADP-induced platelet aggregation.  However, the effects of these Ap4A analogs on human platelet P2Y1, P2Y12 and P2X1 are unclear.  Objective: To det. the agonist and antagonist activities of diadenosine tetraphosphate analogs towards P2Y1, P2Y12, and P2X1.  Methods: We synthesized the following Ap4A analogs: P1,P4-dithiotetraphosphate; P2,P3-chloromethylenetetraphosphate; P1-thio-P2,P3-chloromethylenetetraphosphate; and P1,P4-dithio-P2,P3-chloromethylenetetraphosphate.  We then measured the effects of these analogs on: (i) ADP-induced platelet aggregation; (ii) P2Y1-mediated changes in cytosolic Ca2+; (iii) P2Y12-mediated changes in vasodilator-stimulated phosphoprotein phosphorylation; and (iv) P2X1-mediated entry of extracellular Ca2+.  Results: Ap4A analogs with modifications in the phosphate backbone inhibited both P2Y1 and P2Y12, and showed no agonist activity towards these receptors.  The dithio modification increased inhibition of P2Y1, P2Y12, and platelet aggregation, whereas the chloromethylene modification increased inhibition of P2Y12 and platelet aggregation, but decreased P2Y1 inhibition.  Combining the dithio and chloromethylene modifications increased P2Y1 and P2Y12 inhibition.  As compared with Ap4A, each modification decreased agonist activity towards P2X1, and the dual modification completely eliminated P2X1 agonist activity.  Conclusions: As compared with Ap4A, tetraphosphate backbone analogs of Ap4A have diminished activity towards P2X1 but inhibit both P2Y1 and P2Y12 and, with greater potency, inhibit ADP-induced platelet aggregation.  Thus, diadenosine tetraphosphate analogs with dual receptor selectivity may have potential as antiplatelet drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHbETpMYCHXLVg90H21EOLACvtfcHk0lisTGQw5Vz0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFCjtrY%253D&md5=13580b821cc2907fc183d381499da177</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjth.12035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjth.12035%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%26aulast%3DYanachkov%26aufirst%3DI.%2BB.%26aulast%3DDix%26aufirst%3DE.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BF.%26aulast%3DBarnard%26aufirst%3DM.%2BR.%26aulast%3DWright%26aufirst%3DG.%2BE.%26aulast%3DMichelson%26aufirst%3DA.%2BD.%26aulast%3DFrelinger%26aufirst%3DA.%2BL.%26atitle%3DModified%2520diadenosine%2520tetraphosphates%2520with%2520dual%2520specificity%2520for%2520P2Y1%2520and%2520P2Y12%2520are%2520potent%2520antagonists%2520of%2520ADP-induced%2520platelet%2520activation%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2012%26volume%3D10%26spage%3D2573%26epage%3D2580%26doi%3D10.1111%2Fjth.12035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silakari, O.</span></span> <span> </span><span class="NLM_article-title">Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5260</span>– <span class="NLM_lpage">5267</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.07.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.bmc.2017.07.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28789912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1yrs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5260-5267&author=D.+Singhauthor=O.+Silakari&title=Facile+alkylation+of+4-nitrobenzotriazole+and+its+platelet+aggregation+inhibitory+activity&doi=10.1016%2Fj.bmc.2017.07.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity</span></div><div class="casAuthors">Singh, Dhandeep; Silakari, Om</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5260-5267</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors explored the facile alkylation of 4-nitrobenzotriazole under basic conditions and the synthesized derivs. were tested for their potential ADP induced platelet aggregation inhibition activity in comparison with std. drug ticagrelor (selective P2Y12 inhibitor).  The nitro group at 4-position is highly activating toward alkylation reactions (under strong basic conditions) and resulted in formation of degrdn. product like 3-nitrobenzene-1,2-diamine which make isolation of alkyl products very difficult.  The authors optimized the reaction under mild basic condition (potassium carbonate and DMF) which is devoid of any degrdn. product.  This is perhaps the first report of 4-nitrobenzotriazole derivs. possessing platelet aggregation inhibitory activity.  Generally activity increases with increase in length of alkyl chain and 1-alkyl positional isomers were found to be more potent than 2-alkyl isomers.  The benzoyl deriv. was found to be the most potent [compd. 22; (4-Nitro-1H-benzotriazol-1-yl)(phenyl)methanone; IC50 = 0.65±0.10 mM] which may be attributed to electroneg. oxygen atom and arom. ring.  Benzyl derivs. [compd. 20; 1-Benzyl-4-nitro-1H-benzotriazole; IC50 = 0.81±0.08 mM, compd. 21; 2-Benzyl-4-nitro-2H-benzotriazole; IC50 = 0.82±0.19 mM] and sulfonyl deriv. [compd. 23; 1-[(4-Methylphenyl)sulfonyl]-4-nitro-1H-benzotriazole; IC50 = 0.82±0.19 mM] are also found to be highly active.  Furthermore, all compds. possess P2Y12 binding affinity as confirmed by VASP/P2Y12 phosphorylation assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUQufzw-dv7LVg90H21EOLACvtfcHk0lisTGQw5Vz0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1yrs77I&md5=0e72f9746600693c22b3095ccf5a7deb</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.07.045%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSilakari%26aufirst%3DO.%26atitle%3DFacile%2520alkylation%2520of%25204-nitrobenzotriazole%2520and%2520its%2520platelet%2520aggregation%2520inhibitory%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5260%26epage%3D5267%26doi%3D10.1016%2Fj.bmc.2017.07.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bijak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelenberger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziedzic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saluk-Bijak, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of flavonolignans on the P2Y<sub>12</sub> pathway in blood platelets</span>. <i>Molecules.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">374</span>, <span class="refDoi"> DOI: 10.3390/molecules23020374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3390%2Fmolecules23020374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1GqsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=374&author=M.+Bijakauthor=R.+Szelenbergerauthor=A.+Dziedzicauthor=J.+Saluk-Bijak&title=Inhibitory+effect+of+flavonolignans+on+the+P2Y12+pathway+in+blood+platelets&doi=10.3390%2Fmolecules23020374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of Flavonolignans on the P2Y12 pathway in blood platelets</span></div><div class="casAuthors">Bijak, Michal; Szelenberger, Rafal; Dziedzic, Angela; Saluk-Bijak, Joanna</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">374/1-374/10</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">ADP (ADP) is the major platelet agonist, which is important in the shape changes, stability, and growth of the thrombus.  Platelet activation by ADP is assocd. with the G protein-coupled receptors P2Y1 and P2Y12.  The pharmacol. blockade of the P2Y12 receptor significantly reduces the risk of peripheral artery disease, myocardial infarction, ischemic stroke, and vascular death.  Recent studies demonstrated the inhibition of ADP-induced blood platelet activation by three major compds. of the flavonolignans group: silybin, silychristin, and silydianin.  For this reason, the aim of the current work was to verify the effects of silybin, silychristin, and silydianin on ADP-induced physiol. platelets responses, as well as mechanisms of P2Y12-dependent intracellular signal transduction.  We evaluated the effect of tested flavonolignans on ADP-induced blood platelets' aggregation in platelet-rich plasma (PRP) (using light transmission aggregometry), adhesion to fibrinogen (using the static method), and the secretion of PF-4 (using the ELISA method).  Addnl., using the double labeled flow cytometry method, we estd. platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation.  We demonstrated a dose-dependent redn. of blood platelets' ability to perform ADP-induced aggregation, adhere to fibrinogen, and secrete PF-4 in samples treated with flavonolignans.  Addnl., we obsd. that all of the tested flavonolignans were able to increase VASP phosphorylation in blood platelets samples, which is correlated with P2Y12 receptor inhibition.  All of these analyses show that silychristin and silybin have the strongest inhibitory effect on blood platelet activation by ADP, while silydianin also inhibits the ADP pathway, but to a lesser extent.  The results obtained in this study clearly demonstrate that silybin, silychristin, and silydianin have inhibitory properties against the P2Y12 receptor and block ADP-induced blood platelet activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LW1Q82jl_LVg90H21EOLACvtfcHk0lisTGQw5Vz0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1GqsrzP&md5=8fc3ebdb50353a8944be9125f430e033</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23020374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23020374%26sid%3Dliteratum%253Aachs%26aulast%3DBijak%26aufirst%3DM.%26aulast%3DSzelenberger%26aufirst%3DR.%26aulast%3DDziedzic%26aufirst%3DA.%26aulast%3DSaluk-Bijak%26aufirst%3DJ.%26atitle%3DInhibitory%2520effect%2520of%2520flavonolignans%2520on%2520the%2520P2Y12%2520pathway%2520in%2520blood%2520platelets%26jtitle%3DMolecules.%26date%3D2018%26volume%3D23%26spage%3D374%26doi%3D10.3390%2Fmolecules23020374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lortie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudreault, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, J. F.</span></span> <span> </span><span class="NLM_article-title">Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">873</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2008.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2008.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=19128824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvV2nurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=869-873&author=E.+Lortieauthor=F.+Girardauthor=D.+Boudreaultauthor=M.+Ruelauthor=S.+Mansourauthor=N.+Blaisauthor=J.+F.+Hardy&title=Clopidogrel+induces+an+acute+hemostatic+deficit+and+increases+intra+abdominal+bleeding+in+rabbits&doi=10.1016%2Fj.thromres.2008.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits</span></div><div class="casAuthors">Lortie, Elise; Girard, Francois; Boudreault, Daniel; Ruel, Monique; Mansour, Saad; Blais, Normand; Hardy, Jean-Francois</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">869-873</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Clopidogrel, a potent antiplatelet drug, increases hemorrhagic adverse events when its use is continued ≤ 5 days before cardiac surgery but data are lacking in non-cardiac surgery.  We sought to det. the dose of clopidogrel which has a maximal antiplatelet and hemorrhagic effect in a rabbit model of non-cardiac surgery.  Twenty-four rabbits were divided into 3 groups according to the dose of clopidogrel administered (5, 10, and 20 mg.kg- 1).  Baseline measurement of platelet aggregation induced with ADP, platelet reactivity index (PRI) of the VASP-phosphorylation assay and hematol. variables were obtained the day before the expt.  Two hours after clopidogrel administration, the same variables were measured, along with intra abdominal bleeding following standardized hepato-splenic lesions.  Platelet aggregation was inhibited in a dose-dependent manner: 46% with 5 mg.kg- 1 and 93% with 20 mg.kg- 1 of clopidogrel.  PRI was reduced by 61 with 5 mg.kg- 1 of clopidogrel and by 92 and 94% with 10 mg.kg- 1 and 20 mg.kg- 1 resp.  Percentage redn. of platelet aggregation was pos. correlated with the percentage redn. of PRI (r = 0.69; CI95, 0.40 to 0.86).  Bleeding from hepato-splenic lesions was more important in the 10 and 20 mg.kg- 1 groups compared to the 5 mg.kg- 1 group.  Higher doses of clopidogrel are assocd. with a more profound inhibition of platelet aggregation and PRI and increased blood losses following standardized hepato-splenic lesions.  We conclude that our animal model demonstrates clopidogrel's propensity to increase intra abdominal bleeding after standardized hepato-splenic lesions and may help develop blood sparing strategies for patients undergoing surgery while on clopidogrel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ6_41XfEMirVg90H21EOLACvtfcHk0li084ZWPp9cAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvV2nurk%253D&md5=c219c6bfd9095ed9383f23a9deb24cab</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2008.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2008.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DLortie%26aufirst%3DE.%26aulast%3DGirard%26aufirst%3DF.%26aulast%3DBoudreault%26aufirst%3DD.%26aulast%3DRuel%26aufirst%3DM.%26aulast%3DMansour%26aufirst%3DS.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DHardy%26aufirst%3DJ.%2BF.%26atitle%3DClopidogrel%2520induces%2520an%2520acute%2520hemostatic%2520deficit%2520and%2520increases%2520intra%2520abdominal%2520bleeding%2520in%2520rabbits%26jtitle%3DThromb.%2520Res.%26date%3D2009%26volume%3D123%26spage%3D869%26epage%3D873%26doi%3D10.1016%2Fj.thromres.2008.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Söderlund, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asztély, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berggren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelander, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellheim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romlin, B. S.</span></span> <span> </span><span class="NLM_article-title">In vitro anti-platelet potency of ticagrelor in blood samples from infants and children</span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2015.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2015.07.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26210892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FmsV2hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=620-624&author=F.+S%C3%B6derlundauthor=A.-K.+Aszt%C3%A9lyauthor=A.+Jeppssonauthor=S.+Nylanderauthor=A.+Berggrenauthor=K.+Nelanderauthor=A.+Castellheimauthor=B.+S.+Romlin&title=In+vitro+anti-platelet+potency+of+ticagrelor+in+blood+samples+from+infants+and+children&doi=10.1016%2Fj.thromres.2015.07.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro anti-platelet potency of ticagrelor in blood samples from infants and children</span></div><div class="casAuthors">Soderlund Fredrik; Asztely Anna-Karin; Nylander Sven; Berggren Anders; Nelander Karin; Jeppsson Anders; Castellheim Albert; Romlin Birgitta S</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">620-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Ticagrelor, a novel platelet inhibitor acting on the ADP-dependent P2Y12 receptor, is currently approved for treating adults with acute coronary syndrome.  The effect of ticagrelor in children has not been explored.  As a first step, we here evaluate if the in vitro anti-platelet potency of ticagrelor in blood samples from children of different age is different as compared with in blood samples from adults.  MATERIALS AND METHODS:  Blood samples from 36 healthy children grouped by age (0-2 months, n=6; 2-6 months, n=6; 6months-2years, n=6; 2-6 years, n=10; 6-12 years, n=8) and 13 adults were collected for in vitro analysis using vasodilator stimulated phosphoprotein phosphorylation (VASP) assay in whole blood and ADP-induced light transmission aggregometry (LTA) in platelet rich plasma.  Ticagrelor (0.01 - 10μmol/L) was added in vitro and its potency was assessed by calculating the concentration that provided 50% inhibition of the maximum response (IC50).  RESULTS:  The in vitro potency of ticagrelor in blood from adults and in blood from children of any age group were comparable, both when analyzed with LTA and with VASP.  CONCLUSIONS:  These in vitro results are consistent with the hypothesis that ticagrelor would achieve a comparable anti-platelet effect in children of different ages as in adults at equal plasma exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2vWkaw12dnpI8NvIb08rbfW6udTcc2eZIxnc3NDOW37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FmsV2hsg%253D%253D&md5=3cc5492667e0ed0d7c1518c79792f9fa</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2015.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2015.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25B6derlund%26aufirst%3DF.%26aulast%3DAszt%25C3%25A9ly%26aufirst%3DA.-K.%26aulast%3DJeppsson%26aufirst%3DA.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DBerggren%26aufirst%3DA.%26aulast%3DNelander%26aufirst%3DK.%26aulast%3DCastellheim%26aufirst%3DA.%26aulast%3DRomlin%26aufirst%3DB.%2BS.%26atitle%3DIn%2520vitro%2520anti-platelet%2520potency%2520of%2520ticagrelor%2520in%2520blood%2520samples%2520from%2520infants%2520and%2520children%26jtitle%3DThromb.%2520Res.%26date%3D2015%26volume%3D136%26spage%3D620%26epage%3D624%26doi%3D10.1016%2Fj.thromres.2015.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bourguet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulay-moine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulard, M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of ELISA-based VASP assay with whole blood samples from several animal species, and compatibility with various platelet antagonists</span>. <i>BIOCYTEX.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>, <span class="refDoi"> DOI: 10.13140/RG.2.2.10221.69609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.13140%2FRG.2.2.10221.69609" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Bourguetauthor=D.+Boulay-moineauthor=S.+Mietauthor=M.+Moulard&title=Evaluation+of+ELISA-based+VASP+assay+with+whole+blood+samples+from+several+animal+species%2C+and+compatibility+with+various+platelet+antagonists&doi=10.13140%2FRG.2.2.10221.69609"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.13140%2FRG.2.2.10221.69609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.13140%252FRG.2.2.10221.69609%26sid%3Dliteratum%253Aachs%26aulast%3DBourguet%26aufirst%3DN.%26aulast%3DBoulay-moine%26aufirst%3DD.%26aulast%3DMiet%26aufirst%3DS.%26aulast%3DMoulard%26aufirst%3DM.%26atitle%3DEvaluation%2520of%2520ELISA-based%2520VASP%2520assay%2520with%2520whole%2520blood%2520samples%2520from%2520several%2520animal%2520species%252C%2520and%2520compatibility%2520with%2520various%2520platelet%2520antagonists%26jtitle%3DBIOCYTEX.%26date%3D2011%26doi%3D10.13140%2FRG.2.2.10221.69609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span> <i>Glide</i>; <span class="NLM_publisher-name">Schrodinger, LLC</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Glide%3B+Schrodinger%2C+LLC%3A+New+York%2C+NY%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGlide%26pub%3DSchrodinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span> <span> </span><span class="NLM_article-title">Two disparate ligand-binding sites in the human P2Y<sub>1</sub> receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>520</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1038/nature14287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnature14287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=25822790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFekt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=520&publication_year=2015&pages=317-321&author=D.+Zhangauthor=Z.-G.+Gaoauthor=K.+Zhangauthor=E.+Kiselevauthor=S.+Craneauthor=J.+Wangauthor=S.+Paolettaauthor=C.+Yiauthor=L.+Maauthor=W.+Zhangauthor=G.+W.+Hanauthor=H.+Liuauthor=V.+Cherezovauthor=V.+Katritchauthor=H.+Jiangauthor=R.+C.+Stevensauthor=K.+A.+Jacobsonauthor=Q.+Zhaoauthor=B.+Wu&title=Two+disparate+ligand-binding+sites+in+the+human+P2Y1+receptor&doi=10.1038%2Fnature14287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Two disparate ligand-binding sites in the human P2Y1 receptor</span></div><div class="casAuthors">Zhang, Dandan; Gao, Zhan-Guo; Zhang, Kaihua; Kiselev, Evgeny; Crane, Steven; Wang, Jiang; Paoletta, Silvia; Yi, Cuiying; Ma, Limin; Zhang, Wenru; Han, Gye Won; Liu, Hong; Cherezov, Vadim; Katritch, Vsevolod; Jiang, Hualiang; Stevens, Raymond C.; Jacobson, Kenneth A.; Zhao, Qiang; Wu, Beili</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">520</span>
        (<span class="NLM_cas:issue">7547</span>),
    <span class="NLM_cas:pages">317-321</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to ADP, the P2Y1 receptor (P2Y1R) facilitates platelet aggregation, and thus serves as an important antithrombotic drug target.  Here we report the crystal structures of the human P2Y1R in complex with a nucleotide antagonist MRS2500 at 2.7 Å resoln., and with a non-nucleotide antagonist BPTU at 2.2 Å resoln.  The structures reveal two distinct ligand-binding sites, providing at. details of P2Y1R's unique ligand-binding modes.  MRS2500 recognizes a binding site within the seven transmembrane bundle of P2Y1R, which is different in shape and location from the nucleotide binding site in the previously detd. structure of P2Y12R, representative of another P2YR subfamily.  BPTU binds to an allosteric pocket on the external receptor interface with the lipid bilayer, making it the first structurally characterized selective G-protein-coupled receptor (GPCR) ligand located entirely outside of the helical bundle.  These high-resoln. insights into P2Y1R should enable discovery of new orthosteric and allosteric antithrombotic drugs with reduced adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopE4fFTJwyarVg90H21EOLACvtfcHk0lh6jkxGk6e_XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFekt7Y%253D&md5=fb29b394fbf9497f63833c05364460b3</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnature14287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14287%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DCrane%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DYi%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DB.%26atitle%3DTwo%2520disparate%2520ligand-binding%2520sites%2520in%2520the%2520human%2520P2Y1%2520receptor%26jtitle%3DNature%26date%3D2015%26volume%3D520%26spage%3D317%26epage%3D321%26doi%3D10.1038%2Fnature14287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenalti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span> <span> </span><span class="NLM_article-title">Structure of the human P2Y<sub>12</sub> receptor in complex with an antithrombotic drug</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1038/nature13083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1038%2Fnature13083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=24670650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=115-118&author=K.+Zhangauthor=J.+Zhangauthor=Z.+G.+Gaoauthor=D.+Zhangauthor=L.+Zhuauthor=G.+W.+Hanauthor=S.+M.+Mossauthor=S.+Paolettaauthor=E.+Kiselevauthor=W.+Luauthor=G.+Fenaltiauthor=W.+Zhangauthor=C.+E.+Mullerauthor=H.+Yangauthor=H.+Jiangauthor=V.+Cherezovauthor=V.+Katritchauthor=K.+A.+Jacobsonauthor=R.+C.+Stevensauthor=B.+Wuauthor=Q.+Zhao&title=Structure+of+the+human+P2Y12+receptor+in+complex+with+an+antithrombotic+drug&doi=10.1038%2Fnature13083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human P2Y12 receptor in complex with an antithrombotic drug</span></div><div class="casAuthors">Zhang, Kaihua; Zhang, Jin; Gao, Zhan-Guo; Zhang, Dandan; Zhu, Lan; Han, Gye Won; Moss, Steven M.; Paoletta, Silvia; Kiselev, Evgeny; Lu, Weizhen; Fenalti, Gustavo; Zhang, Wenru; Mueller, Christa E.; Yang, Huaiyu; Jiang, Hualiang; Cherezov, Vadim; Katritch, Vsevolod; Jacobson, Kenneth A.; Stevens, Raymond C.; Wu, Beili; Zhao, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7498</span>),
    <span class="NLM_cas:pages">115-118</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2Y receptors (P2YRs), a family of purinergic G-protein-coupled receptors (GPCRs), are activated by extracellular nucleotides.  There are a total of eight distinct functional P2YRs expressed in human, which are subdivided into P2Y1-like receptors and P2Y12-like receptors.  Their ligands are generally charged mols. with relatively low bioavailability and stability in vivo, which limits the authors' understanding of this receptor family.  P2Y12R regulates platelet activation and thrombus formation, and several antithrombotic drugs targeting P2Y12R-including the prodrugs clopidogrel (Plavix) and prasugrel (Effient) that are metabolized and bind covalently, and the nucleoside analog ticagrelor (Brilinta) that acts directly on the receptor-have been approved for the prevention of stroke and myocardial infarction.  However, limitations of these drugs (for example, a very long half-life of clopidogrel action and a characteristic adverse effect profile of ticagrelor) suggest that there is an unfulfilled medical need for developing a new generation of P2Y12R inhibitors.  Here the authors report the 2.6 Å resoln. crystal structure of human P2Y12R in complex with a non-nucleotide reversible antagonist, AZD1283.  The structure reveals a distinct straight conformation of helix V, which sets P2Y12R apart from all other known class A GPCR structures.  With AZD1283 bound, the highly conserved disulfide bridge in GPCRs between helix III and extracellular loop 2 is not obsd. and appears to be dynamic.  Along with the details of the AZD1283-binding site, anal. of the extracellular interface reveals an adjacent ligand-binding region and suggests that both pockets could be required for dinucleotide binding.  The structure provides essential insights for the development of improved P2Y12R ligands and allosteric modulators as drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOY06VN4D76bVg90H21EOLACvtfcHk0lgZUNjI5f6_5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyisrg%253D&md5=539bb91325c547737bc98baf59f3ff26</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature13083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13083%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DMoss%26aufirst%3DS.%2BM.%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DKiselev%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DFenalti%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520P2Y12%2520receptor%2520in%2520complex%2520with%2520an%2520antithrombotic%2520drug%26jtitle%3DNature%26date%3D2014%26volume%3D509%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature13083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span> <i>The PyMOL Molecular Graphics System</i>, version <span class="NLM_edition">1.5.0.3</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular+Graphics+System%2C+version+1.5.0.3%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%2520Graphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paoletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbadin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Kugelgen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelrahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strassburger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baqi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Modeling ligand recognition at the P2Y<sub>12</sub> receptor in light of X-ray structural information</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">737</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1007/s10822-015-9858-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1007%2Fs10822-015-9858-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26194851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=737-756&author=S.+Paolettaauthor=D.+Sabbadinauthor=I.+von+Kugelgenauthor=S.+Hinzauthor=V.+Katritchauthor=K.+Hoffmannauthor=A.+Abdelrahmanauthor=J.+Strassburgerauthor=Y.+Baqiauthor=Q.+Zhaoauthor=R.+C.+Stevensauthor=S.+Moroauthor=C.+E.+Mullerauthor=K.+A.+Jacobson&title=Modeling+ligand+recognition+at+the+P2Y12+receptor+in+light+of+X-ray+structural+information&doi=10.1007%2Fs10822-015-9858-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information</span></div><div class="casAuthors">Paoletta, Silvia; Sabbadin, Davide; von Kugelgen, Ivar; Hinz, Sonja; Katritch, Vsevolod; Hoffmann, Kristina; Abdelrahman, Aliaa; Strassburger, Jens; Baqi, Younis; Zhao, Qiang; Stevens, Raymond C.; Moro, Stefano; Muller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The G protein-coupled P2Y12 receptor (P2Y12R) is an important antithrombotic target and of great interest for pharmaceutical discovery.  Its recently solved, highly divergent crystallog. structures in complex either with nucleotides (full or partial agonist) or with a nonnucleotide antagonist raise the question of which structure is more useful to understand ligand recognition.  Therefore, we performed extensive mol. modeling studies based on these structures and mutagenesis, to predict the binding modes of major classes of P2Y12R ligands previously reported.  Various nucleotide derivs. docked readily to the agonist-bound P2Y12R, but uncharged nucleotide-like antagonist ticagrelor required a hybrid receptor resembling the agonist-bound P2Y12R except for the top portion of TM6.  Supervised mol. dynamics (SuMD) of ticagrelor binding indicated interactions with the extracellular regions of P2Y12R, defining possible meta-binding sites.  Ureas, sulfonylureas, sulfonamides, anthraquinones and glutamic acid piperazines docked readily to the antagonist-bound P2Y12R.  Docking dinucleotides at both agonist- and antagonist-bound structures suggested interactions with two P2Y12R pockets.  Thus, our structure-based approach consistently rationalized the main structure-activity relationships within each ligand class, giving useful information for designing improved ligands.  Graphical Abstr.: [Figure not available: see full text.].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8QHrDrSpB57Vg90H21EOLACvtfcHk0lgZUNjI5f6_5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Sgur7J&md5=f6d2128d8067de9a9e0aed5dd1a375d7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9858-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9858-z%26sid%3Dliteratum%253Aachs%26aulast%3DPaoletta%26aufirst%3DS.%26aulast%3DSabbadin%26aufirst%3DD.%26aulast%3Dvon%2BKugelgen%26aufirst%3DI.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHoffmann%26aufirst%3DK.%26aulast%3DAbdelrahman%26aufirst%3DA.%26aulast%3DStrassburger%26aufirst%3DJ.%26aulast%3DBaqi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMoro%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DModeling%2520ligand%2520recognition%2520at%2520the%2520P2Y12%2520receptor%2520in%2520light%2520of%2520X-ray%2520structural%2520information%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D737%26epage%3D756%26doi%3D10.1007%2Fs10822-015-9858-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knights, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miners, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> drug metabolism using liver microsomes</span>. <i>Curr. Protoc Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1002/cpph.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fcpph.9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2016&pages=1-24&author=K.+M.+Knightsauthor=D.+M.+Stresserauthor=J.+O.+Minersauthor=C.+L.+Crespi&title=In+vitro+drug+metabolism+using+liver+microsomes&doi=10.1002%2Fcpph.9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcpph.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpph.9%26sid%3Dliteratum%253Aachs%26aulast%3DKnights%26aufirst%3DK.%2BM.%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DMiners%26aufirst%3DJ.%2BO.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DIn%2520vitro%2520drug%2520metabolism%2520using%2520liver%2520microsomes%26jtitle%3DCurr.%2520Protoc%2520Pharmacol.%26date%3D2016%26volume%3D74%26spage%3D1%26epage%3D24%26doi%3D10.1002%2Fcpph.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. H.</span></span> <span> </span><span class="NLM_article-title">Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography–tandem mass spectrometry</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1002/bdd.2174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fbdd.2174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30730576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVWjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=101-111&author=H.+J.+Kimauthor=H.+Leeauthor=H.+K.+Jiauthor=T.+Leeauthor=K.+H.+Liu&title=Screening+of+ten+cytochrome+P450+enzyme+activities+with+12+probe+substrates+in+human+liver+microsomes+using+cocktail+incubation+and+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fbdd.2174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Kim, Hyun-Ji; Lee, Hyunyoung; Ji, Hyeon-Kyeong; Lee, Taeho; Liu, Kwang-Hyeon</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">101-111</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">In this study, an assay was designed to evaluate drug interactions with 10 major human cytochrome P 450 (P 450) enzymes incubated in liver microsomes, involving 12 probe substrates with two cocktail incubation sets used in a single liq. chromatog.-tandem mass spectrometry run.  The P 450 substrate compn. in each cocktail set was optimized to minimize solvent effects and mutual drug interactions among substrates as follows: cocktail A was composed of phenacetin for CYP1A2, bupropion for CYP2B6, amodiaquine for CYP2C8, diclofenac for CYP2C9, S-mephenytoin for CYP2C19, and dextromethorphan for CYP2D6; cocktail B was composed of coumarin for CYP2A6, chlorzoxazone for CYP2E1, astemizole for CYP2J2, and midazolam, nifedipine, and testosterone for CYP3A.  Multiple probe substrates were used for CYP3A owing to the multiple substrate-binding sites and substrate-dependent inhibition.  After incubation in human liver microsomes, each incubation mixt. was pooled and all probe metabolites were simultaneously analyzed in a single LC-MS/MS run.  Polarity switching was used to acquire the neg.-ion mode for hydroxychlorzoxazone and pos.-ion mode for the remaining analytes.  The method was validated by comparing inhibition data obtained from incubation of each individual probe substrate alone and with the substrate cocktails.  The half-maximal inhibitory concn. values obtained from the cocktail and individual incubations were well correlated and in agreement with previously reported values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWQt2lI2WtrVg90H21EOLACvtfcHk0lg2TkiNws0xMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVWjsr8%253D&md5=eac65e5423eb84a58a4ad4ff901a527b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2174%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DH.%2BK.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DK.%2BH.%26atitle%3DScreening%2520of%2520ten%2520cytochrome%2520P450%2520enzyme%2520activities%2520with%252012%2520probe%2520substrates%2520in%2520human%2520liver%2520microsomes%2520using%2520cocktail%2520incubation%2520and%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2019%26volume%3D40%26spage%3D101%26epage%3D111%26doi%3D10.1002%2Fbdd.2174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stresser, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broudy, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargill, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandeneau, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erve, J. C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patten, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespi, C. L.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of human cyp3aa in vitro by azamulin and evidence that inhibition is irreversible</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1124/dmd.32.1.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.32.1.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=14709627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFWqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=105-112&author=D.+M.+Stresserauthor=M.+I.+Broudyauthor=T.+Hoauthor=C.+E.+Cargillauthor=A.+P.+Blanchardauthor=R.+Sharmaauthor=A.+A.+Dandeneauauthor=J.+J.+Goodwinauthor=S.+D.+Turnerauthor=J.+C.+L.+Erveauthor=C.+J.+Pattenauthor=S.+S.+Dehalauthor=C.+L.+Crespi&title=Highly+selective+inhibition+of+human+cyp3aa+in+vitro+by+azamulin+and+evidence+that+inhibition+is+irreversible&doi=10.1124%2Fdmd.32.1.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective inhibition of human CYP3A in vitro by azamulin and evidence that inhibition is irreversible</span></div><div class="casAuthors">Stresser, David M.; Broudy, Marc I.; Ho, Thuy; Cargill, Catherine E.; Blanchard, Andrew P.; Sharma, Raman; Dandeneau, Andre A.; Goodwin, Joseph J.; Turner, Stephanie D.; Erve, John C. L.; Patten, Christopher J.; Dehal, Shangara S.; Crespi, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole deriv. of the pleuromutilin class of anti-infectives.  The authors tested the inhibition potency of azamulin toward 18 cytochromes P 450 using human liver microsomes or microsomes from insect cells expressing single isoforms.  In a competitive inhibition model, IC50 values for CYP3A (0.03-0.24 μM) were at least 100-fold lower than all other non-CYP3A enzymes except CYP2J2 (∼50-fold lower).  The IC50 value with heterologously expressed CYP3A4 was 15-fold and 13-fold less than those of CYP3A5 and CYP3A7, resp.  The ref. inhibitor ketoconazole was less selective and exhibited potent inhibition (IC50 values <10 μM) for CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP4F2, and CYP4F12.  Inhibition of CYP3A by azamulin appeared sigmoidal and well behaved with the substrates 7-benzyloxy-4-trifluoromethylcoumarin, testosterone, and midazolam.  Preincubation of 4.8 μM azamulin in the presence of NADPH for 10 min inhibited ∼95% of testosterone 6β-hydroxylase activity compared with preincubation in the absence of NADPH.  Catalytic activities of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were unaffected by similar expts.  Incubation of azamulin with heterologously expressed CYP3A4 yielded a type I binding spectrum with a spectral dissocn. const. of 3.5 μM, whereas no interaction was found with CYP2D6.  Azamulin exhibited good chem. stability when stored in acetonitrile for up to 12 days.  Aq. soly. was found to be >300 μM.  Azamulin represents an important new chem. tool for use in characterizing the contribution of CYP3A to the metab. of xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxpHyX0lmJULVg90H21EOLACvtfcHk0lg2TkiNws0xMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFWqs7o%253D&md5=a6119b5808418a555a9abe3353508be0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.1.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.1.105%26sid%3Dliteratum%253Aachs%26aulast%3DStresser%26aufirst%3DD.%2BM.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DHo%26aufirst%3DT.%26aulast%3DCargill%26aufirst%3DC.%2BE.%26aulast%3DBlanchard%26aufirst%3DA.%2BP.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DDandeneau%26aufirst%3DA.%2BA.%26aulast%3DGoodwin%26aufirst%3DJ.%2BJ.%26aulast%3DTurner%26aufirst%3DS.%2BD.%26aulast%3DErve%26aufirst%3DJ.%2BC.%2BL.%26aulast%3DPatten%26aufirst%3DC.%2BJ.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26aulast%3DCrespi%26aufirst%3DC.%2BL.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520human%2520cyp3aa%2520in%2520vitro%2520by%2520azamulin%2520and%2520evidence%2520that%2520inhibition%2520is%2520irreversible%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D105%26epage%3D112%26doi%3D10.1124%2Fdmd.32.1.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. J.</span></span> <span> </span><span class="NLM_article-title">The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S151660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.2147%2FDDDT.S151660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29343943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1SmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=57-65&author=N.+Chenauthor=X.+Y.+Yangauthor=C.+E.+Guoauthor=X.+N.+Biauthor=J.+H.+Chenauthor=H.+Y.+Chenauthor=H.+P.+Liauthor=H.+Y.+Linauthor=Y.+J.+Zhang&title=The+oral+bioavailability%2C+excretion+and+cytochrome+P450+inhibition+properties+of+epiberberine%3A+an+in+vivo+and+in+vitro+evaluation&doi=10.2147%2FDDDT.S151660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation</span></div><div class="casAuthors">Chen, Ning; Yang, Xiao-yan; Guo, Chang-e; Bi, Xin-ning; Chen, Jian-hua; Chen, Hong-ying; Li, Hong-pin; Lin, Hong-ying; Zhang, Yu-jie</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Epiberberine (EPI) is a novel and potentially effective therapeutic and preventive agent for diabetes and cardiovascular disease.  To evaluate its potential value for drug development, a specific, sensitive and robust high-performance liq. chromatog.-tandem mass spectrometry assay for the detn. of EPI in rat biol. samples was established.  This assay was used to study the pharmacokinetics, bioavailability and excretion of EPI in rats after oral administration.  In addn., a cocktail method was used to compare the inhibition characteristics of EPI on cytochrome P 450 (CYP450) isoforms in human liver microsomes (HLMs) and rat liver microsomes (RLMs).  The results demonstrated that EPI was rapidly absorbed and metabolized after oral administration (10, 54 or 81 mg/kg) in rats, with Tmax of 0.37-0.42 h and T1/2 of 0.49-2.73 h.  The Cmax and area under the curve values for EPI increased proportionally with the dose, and the oral abs. bioavailability was 14.46%.  EPI was excreted mainly in bile and feces, and after its oral administration to rats, EPI was eliminated predominantly by the kidneys.  A comparison of the current half-maximal inhibitory concn. and Ki values revealed that EPI demonstrated an obvious inhibitory effect on CYP2C9 and CYP2D6.  Furthermore, its effect was stronger in HLM than in RLM, more likely to be a result of noncompetitive inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocsnqYGEveF7Vg90H21EOLACvtfcHk0lg2TkiNws0xMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1SmtLw%253D&md5=8944d97a4036c32cf31ea04662325855</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S151660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S151660%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DX.%2BY.%26aulast%3DGuo%26aufirst%3DC.%2BE.%26aulast%3DBi%26aufirst%3DX.%2BN.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DH.%2BP.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26atitle%3DThe%2520oral%2520bioavailability%252C%2520excretion%2520and%2520cytochrome%2520P450%2520inhibition%2520properties%2520of%2520epiberberine%253A%2520an%2520in%2520vivo%2520and%2520in%2520vitro%2520evaluation%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2018%26volume%3D12%26spage%3D57%26epage%3D65%26doi%3D10.2147%2FDDDT.S151660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span> <i>The Hershberger Guideline, Performance-Based Test: OECD guideline
for the testing of chemicals</i>. <span class="NLM_year">2001</span>;  <span class="NLM_volume">601</span>,  <span class="NLM_fpage">858</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+Hershberger+Guideline%2C+Performance-Based+Test%3A+OECD+guideline%0Afor+the+testing+of+chemicals.+2001%3B+601%2C+858."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Hershberger%2520Guideline%252C%2520Performance-Based%2520Test%253A%2520OECD%2520guideline%250Afor%2520the%2520testing%2520of%2520chemicals%26date%3D2001%26volume%3D601%26spage%3D858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, K. M.</span></span> <span> </span><span class="NLM_article-title">Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100(R) and Multiplate (R) whole blood aggregometer <i>in vitro</i>, <i>ex vivo</i> and FeCl<sub>3</sub>-induced thrombosis models <i>in vivo</i></span>. <i>Thromb. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1016/j.thromres.2011.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.thromres.2011.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21420150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFWntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2011&pages=565-570&author=C.+W.+Kimauthor=J.+W.+Yunauthor=I.+H.+Baeauthor=Y.+H.+Parkauthor=Y.+S.+Jeongauthor=J.+W.+Parkauthor=J.+H.+Chungauthor=Y.+H.+Parkauthor=K.+M.+Lim&title=Evaluation+of+anti-platelet+and+anti-thrombotic+effects+of+cilostazol+with+PFA-100%28R%29+and+Multiplate+%28R%29+whole+blood+aggregometer+in+vitro%2C+ex+vivo+and+FeCl3-induced+thrombosis+models+in+vivo&doi=10.1016%2Fj.thromres.2011.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100 and Multiplate whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo</span></div><div class="casAuthors">Kim, Chae-Wook; Yun, Jun-Won; Bae, Il-Hong; Park, Yang-Hui; Jeong, Yeon-Su; Park, Jin-Woo; Chung, Jin-Ho; Park, Young-Ho; Lim, Kyung-Min</div><div class="citationInfo"><span class="NLM_cas:title">Thrombosis Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">565-570</span>CODEN:
                <span class="NLM_cas:coden">THBRAA</span>;
        ISSN:<span class="NLM_cas:issn">0049-3848</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We evaluate the anti-platelet and anti-thrombotic effects of cilostazol using Multiplate and PFA-100 in vitro and ex vivo with freshly isolated rat whole blood and in vivo venous and arterial thrombosis models in the same species, in an effort to assess the sensitivity of the whole blood aggregometer assays without potential issues of species differences.  In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 μM while it showed a highly sensitive and all-or-none type inhibition response from 25 μM in PFA-100.  Interestingly, cilostazol manifested anti-thrombotic effects in vivo at much lower plasma concns. than the effective concns. measured in ex vivo or in vitro aggregation tests using PFA-100 or Multiplate.  In addn., the tail bleeding time measurement demonstrated that rats have lower sensitivity to the anti-platelet effects of cilostazol than mice.  These results suggest that the detailed comparative evaluation of whole blood aggregometer assays with anti-thrombotic effects in vivo should be preceded before the application of these methods for the pharmacodynamic studies of anti-thrombotic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5s_LLoldIy7Vg90H21EOLACvtfcHk0lipE7SbBRLNiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFWntLY%253D&md5=bd2f7369f0aca7ccf58b381976fd37de</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.thromres.2011.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.thromres.2011.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BW.%26aulast%3DYun%26aufirst%3DJ.%2BW.%26aulast%3DBae%26aufirst%3DI.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DJeong%26aufirst%3DY.%2BS.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DChung%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DK.%2BM.%26atitle%3DEvaluation%2520of%2520anti-platelet%2520and%2520anti-thrombotic%2520effects%2520of%2520cilostazol%2520with%2520PFA-100%2528R%2529%2520and%2520Multiplate%2520%2528R%2529%2520whole%2520blood%2520aggregometer%2520in%2520vitro%252C%2520ex%2520vivo%2520and%2520FeCl3-induced%2520thrombosis%2520models%2520in%2520vivo%26jtitle%3DThromb.%2520Res.%26date%3D2011%26volume%3D127%26spage%3D565%26epage%3D570%26doi%3D10.1016%2Fj.thromres.2011.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span> <span> </span><span class="NLM_article-title">Effects of modified Je-Ho-Tang on ferric chloride-induced thrombosis in a rat model and of peripheral circulatory disturbance in a mouse model</span>. <i>Han'guk Eungyong Sangmyong Hwahakhoeji</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">842</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.3839/jksabc.2010.128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.3839%2Fjksabc.2010.128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=842-846&author=S.+K.+Kim&title=Effects+of+modified+Je-Ho-Tang+on+ferric+chloride-induced+thrombosis+in+a+rat+model+and+of+peripheral+circulatory+disturbance+in+a+mouse+model&doi=10.3839%2Fjksabc.2010.128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.3839%2Fjksabc.2010.128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3839%252Fjksabc.2010.128%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BK.%26atitle%3DEffects%2520of%2520modified%2520Je-Ho-Tang%2520on%2520ferric%2520chloride-induced%2520thrombosis%2520in%2520a%2520rat%2520model%2520and%2520of%2520peripheral%2520circulatory%2520disturbance%2520in%2520a%2520mouse%2520model%26jtitle%3DHan%2527guk%2520Eungyong%2520Sangmyong%2520Hwahakhoeji%26date%3D2010%26volume%3D53%26spage%3D842%26epage%3D846%26doi%3D10.3839%2Fjksabc.2010.128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hechler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazenave, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangin, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gachet, C.</span></span> <span> </span><span class="NLM_article-title">Mechanisms underlying FeCl<sub>3</sub>-induced arterial thrombosis</span>. <i>J. Thromb. Haemostasis</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1111/j.1538-7836.2011.04218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1111%2Fj.1538-7836.2011.04218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=21261806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1egu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=779-789&author=A.+Ecklyauthor=B.+Hechlerauthor=M.+Freundauthor=M.+Zerrauthor=J.+P.+Cazenaveauthor=F.+Lanzaauthor=P.+H.+Manginauthor=C.+Gachet&title=Mechanisms+underlying+FeCl3-induced+arterial+thrombosis&doi=10.1111%2Fj.1538-7836.2011.04218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms underlying FeCl3-induced arterial thrombosis</span></div><div class="casAuthors">Eckly, A.; Hechler, B.; Freund, M.; Zerr, M.; Cazenave, J.-P.; Lanza, F.; Mangin, P. H.; Gachet, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thrombosis and Haemostasis</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779-789</span>CODEN:
                <span class="NLM_cas:coden">JTHOA5</span>;
        ISSN:<span class="NLM_cas:issn">1538-7933</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The FeCl3-induced vascular injury model is widely used to study thrombogenesis in vivo, but the processes leading to vascular injury and thrombosis are poorly defined.  The aim of our study was to better characterize the mechanisms of FeCl3-induced vascular injury and thrombus formation, in order to evaluate the pathophysiol. relevance of this model.  FeCl3 was applied at different concns. (from 7.5% to 20%) and for different time periods (up to 5 min) to mouse carotid or mesenteric arteries.  Under all the conditions tested, ultrastructural anal. revealed that FeCl3 diffused through the vessel wall, resulting in endothelial ceil denudation without exposure of the inner layers.  Hence, only the basement membrane components were exposed to circulating blood cells and might have contributed to thrombus formation.  Shortly after FeCl3 application, numerous ferric ion-filled spherical bodies appeared on the endothelial cells.  Interestingly, platelets could adhere to these spheres and form aggregates.  Immunogold labeling revealed important amts. of tissue factor at their surface, suggesting that these spheres may play a role in thrombin generation.  In vitro expts. indicated that FeCl3 altered the ability of adhesive proteins, including collagen, fibrinogen and von Willebrand factor, to support platelet adhesion.  Finally, real-time intravital microscopy showed no protection against thrombosis in GPVI-immunodepleted and β1 -/- mice, suggesting that GPVI and β1 integrins, known to be involved in initial platelet adhesion and activation, do not play a crit. role in FeCl3-induced thrombus formation.  This model should be used cautiously, in particular to study the earliest stage of thrombus formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJr5Ut17tn7Vg90H21EOLACvtfcHk0lipE7SbBRLNiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1egu7k%253D&md5=6ad7142cce2152f9b3a90dda1e66680b</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1111%2Fj.1538-7836.2011.04218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1538-7836.2011.04218.x%26sid%3Dliteratum%253Aachs%26aulast%3DEckly%26aufirst%3DA.%26aulast%3DHechler%26aufirst%3DB.%26aulast%3DFreund%26aufirst%3DM.%26aulast%3DZerr%26aufirst%3DM.%26aulast%3DCazenave%26aufirst%3DJ.%2BP.%26aulast%3DLanza%26aufirst%3DF.%26aulast%3DMangin%26aufirst%3DP.%2BH.%26aulast%3DGachet%26aufirst%3DC.%26atitle%3DMechanisms%2520underlying%2520FeCl3-induced%2520arterial%2520thrombosis%26jtitle%3DJ.%2520Thromb.%2520Haemostasis%26date%3D2011%26volume%3D9%26spage%3D779%26epage%3D789%26doi%3D10.1111%2Fj.1538-7836.2011.04218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, T. D.</span></span> <span> </span><span class="NLM_article-title">96-well plate-based aggregometry</span>. <i>Platelets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1080/09537104.2018.1445838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F09537104.2018.1445838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=29543546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslamtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=650-655&author=M.+V.+Chanauthor=P.+C.+Armstrongauthor=T.+D.+Warner&title=96-well+plate-based+aggregometry&doi=10.1080%2F09537104.2018.1445838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A 96-well plate-based aggregometry</span></div><div class="casAuthors">Chan, Melissa V.; Armstrong, Paul C.; Warner, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Platelets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">PLTEEF</span>;
        ISSN:<span class="NLM_cas:issn">0953-7104</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  While there are many bench and bedside tests to assess platelet reactivity, ex vivo light transmission aggregometry (LTA) remains the gold std.  LTA, however, is expensive, time-consuming and requires dedicated equipment and staff, making it impractical in many situations.  In addn., there is significant variability between data generated at different testing sites meaning that tests often need to be repeated if a patient is transferred to the care of a different hospital.  As such, there is clearly an unmet need for standardization of platelet testing.  Using the principles of LTA, aggregometry can be conducted in 96-well plates with readings being made in a std. plate reader.  This approach allows for the assessment of multiple concns. of agonists, since the vol. of platelets required for each test is significantly lower than for LTA.  Furthermore, the lyophilization of a set panel of agonists to a 96-well plate to produce a stable assay substrate allows the prodn. of portable, standardized plates that can be used to generate reproducible tests at multiple sites.  In this review, we will discuss the methods and uses of 96-well plate aggregometry for both research and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxUOBsH2ipg7Vg90H21EOLACvtfcHk0lipE7SbBRLNiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslamtbo%253D&md5=b366c6d06e85ffd89bb79d1e3785d6f6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1080%2F09537104.2018.1445838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09537104.2018.1445838%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DM.%2BV.%26aulast%3DArmstrong%26aufirst%3DP.%2BC.%26aulast%3DWarner%26aufirst%3DT.%2BD.%26atitle%3D96-well%2520plate-based%2520aggregometry%26jtitle%3DPlatelets%26date%3D2018%26volume%3D29%26spage%3D650%26epage%3D655%26doi%3D10.1080%2F09537104.2018.1445838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Megías, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedroche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yust, M. d. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alaiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girón-Calle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millán, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vioque, J.</span></span> <span> </span><span class="NLM_article-title">Stability of sunflower protein hydrolysates in simulated gastric and intestinal fluids and Caco-2 cell extracts</span>. <i>LWT - Food Science and Technology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1016/j.lwt.2009.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.lwt.2009.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2009&pages=1496-1500&author=C.+Meg%C3%ADasauthor=J.+Pedrocheauthor=M.+d.+M.+Yustauthor=M.+Alaizauthor=J.+Gir%C3%B3n-Calleauthor=F.+Mill%C3%A1nauthor=J.+Vioque&title=Stability+of+sunflower+protein+hydrolysates+in+simulated+gastric+and+intestinal+fluids+and+Caco-2+cell+extracts&doi=10.1016%2Fj.lwt.2009.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Stability of sunflower protein hydrolysates in simulated gastric and intestinal fluids and Caco-2 cell extracts</span></div><div class="casAuthors">Megias, Cristina; Pedroche, Justo; Yust, Maria del Mar; Alaiz, Manuel; Giron-Calle, Julio; Millan, Francisco; Vioque, Javier</div><div class="citationInfo"><span class="NLM_cas:title">LWT--Food Science and Technology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1496-1500</span>CODEN:
                <span class="NLM_cas:coden">LSTWB3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The in vitro stability of bioactive properties in sunflower protein hydrolyzates and purified peptides was studied by using simulated gastric fluid, simulated intestinal fluid, and Caco-2 cells exts.  Protein hydrolyzates that inhibit the angiotensin converting enzyme and copper chelating peptides produced by hydrolysis with the microbial protease alcalase were partially resistant to incubation with simulated gastric and intestinal fluids.  These hydrolyzates and others produced by hydrolysis using pepsin plus pancreatin were also partially resistant to incubation with Caco-2 cells exts.  In addn., the ACE inhibitory peptide FVNPQAGS that is generated by extensive hydrolysis using pepsin and pancreatin, was found to be resistant to hydrolysis by Caco-2 cells exts.  These results suggest that stability in the digestive tract should not be a problem for the bioavailability of these bioactive peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSI5pwRfCrs7Vg90H21EOLACvtfcHk0li0Hc3nNggUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFajurY%253D&md5=f065438320b19d3339384eb7a723ed03</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2Fj.lwt.2009.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lwt.2009.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DMeg%25C3%25ADas%26aufirst%3DC.%26aulast%3DPedroche%26aufirst%3DJ.%26aulast%3DYust%26aufirst%3DM.%2Bd.%2BM.%26aulast%3DAlaiz%26aufirst%3DM.%26aulast%3DGir%25C3%25B3n-Calle%26aufirst%3DJ.%26aulast%3DMill%25C3%25A1n%26aufirst%3DF.%26aulast%3DVioque%26aufirst%3DJ.%26atitle%3DStability%2520of%2520sunflower%2520protein%2520hydrolysates%2520in%2520simulated%2520gastric%2520and%2520intestinal%2520fluids%2520and%2520Caco-2%2520cell%2520extracts%26jtitle%3DLWT%2520-%2520Food%2520Science%2520and%2520Technology%26date%3D2009%26volume%3D42%26spage%3D1496%26epage%3D1500%26doi%3D10.1016%2Fj.lwt.2009.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konotop, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafiah, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, M. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.02.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2017.02.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28258034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Ojsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=240-247&author=A.+B.+Petersenauthor=N.+S.+Andersenauthor=G.+Konotopauthor=N.+H.+Hanafiahauthor=M.+S.+Raabauthor=A.+Kramerauthor=M.+H.+Clausen&title=Synthesis+and+formulation+studies+of+griseofulvin+analogues+with+improved+solubility+and+metabolic+stability&doi=10.1016%2Fj.ejmech.2017.02.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability</span></div><div class="casAuthors">Petersen, Asger B.; Andersen, Nikolaj S.; Konotop, Gleb; Hanafiah, Nur Hafzan Md.; Raab, Marc S.; Kramer, Alwin; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">240-247</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Griseofulvin I (R = Me) is an important antifungal agent that has recently received attention due to its antiproliferative activity in mammalian cancer cells.  Comprehensive SAR studies have led to the identification of 2'-benzyloxy griseofulvin I (R = CH2Ph) (II), a more potent analog with low micromolar anticancer potency in vitro.  Analog II was also shown to retard tumor growth through inhibition of centrosomal clustering in murine xenograft models of colon cancer and multiple myeloma.  However, similar to griseofulvin, compd. II exhibited poor metabolic stability and aq. soly.  In order to improve the poor pharmacokinetic properties, 11 griseofulvin analogs were synthesized and evaluated for biol. activity and physiol. stabilities including SGF, plasma, and metabolic stability.  Finally, the most promising compds. were investigated in respect to thermodn. soly. and formulation studies.  The 2'-benzylamine analog I (R = NHCH2Ph) (III) proved to be the most promising compd. with low μM in vitro anticancer potency, a 200-fold increase in PBS soly. over compd. II, and with improved metabolic stability.  Furthermore, this analog proved compatible with formulations suitable for both oral and i.v. administration.  Finally, 2'-benzylamine analog III was confirmed to induce G2/M cell cycle arrest in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6VVdH4LbX6LVg90H21EOLACvtfcHk0li0Hc3nNggUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Ojsbc%253D&md5=e60d91f73ddad3fc2bd14318220647bd</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.02.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.02.055%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DA.%2BB.%26aulast%3DAndersen%26aufirst%3DN.%2BS.%26aulast%3DKonotop%26aufirst%3DG.%26aulast%3DHanafiah%26aufirst%3DN.%2BH.%26aulast%3DRaab%26aufirst%3DM.%2BS.%26aulast%3DKramer%26aufirst%3DA.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DSynthesis%2520and%2520formulation%2520studies%2520of%2520griseofulvin%2520analogues%2520with%2520improved%2520solubility%2520and%2520metabolic%2520stability%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D130%26spage%3D240%26epage%3D247%26doi%3D10.1016%2Fj.ejmech.2017.02.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konsoula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+vitro+plasma+stability%2C+permeability+and+solubility+of+mercaptoacetamide+histone+deacetylase+inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0li0Hc3nNggUTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520plasma%2520stability%252C%2520permeability%2520and%2520solubility%2520of%2520mercaptoacetamide%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent muscarinic M<sub>3</sub> receptor antagonists with proper plasma stability by structural recombination of marketed M<sub>3</sub> antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1182</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fcmdc.201700189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=28741876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1WnsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1173-1182&author=Z.+Xiangauthor=J.+Liuauthor=H.+Sunauthor=X.+Wen&title=Discovery+of+novel+potent+muscarinic+M3+receptor+antagonists+with+proper+plasma+stability+by+structural+recombination+of+marketed+M3+antagonists&doi=10.1002%2Fcmdc.201700189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists</span></div><div class="casAuthors">Xiang, Zuojuan; Liu, Jun; Sun, Hongbin; Wen, Xiaoan</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The marketed long-acting M3 antagonists for treatment of chronic obstructive pulmonary disease have inappropriate plasma stability (either overstable or excessively unstable), which causes substantial systemic exposure or poor patient compliance.  To discover novel M3 antagonists with proper plasma stability, the authors synthesized and biol. evaluated a series of chiral quaternary ammonium salts of pyrrolidinol esters, which were designed by structural recombination of the marketed M3 antagonists.  As a result, two novel potent M3 antagonists, (R/S)-3-[2-hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromides ( (R)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide: Ki = 0.16 nM, IC50=0.38 nM, t1/2=9.34 min;(S)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide: Ki = 0.32 nM, IC50=1.01 nM, t1/2=19.2 min) with proper plasma stability were identified, which (particularly(R)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-1,1-dimethylpyrrolidinium bromide) hold great promise as clin. drug candidates to overcome the drawbacks caused by the inappropriate stability of the currently marketed M3 antagonists.  In addn., structure-activity relation studies revealed that the R configuration of the pyrrolidinyl C3 atom was clearly better than the S configuration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_UQZ9hNnXgbVg90H21EOLACvtfcHk0lhpQTmzRwN_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1WnsrbF&md5=fa9d4bc1e809975fc978f13c31fa21f5</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700189%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520muscarinic%2520M3%2520receptor%2520antagonists%2520with%2520proper%2520plasma%2520stability%2520by%2520structural%2520recombination%2520of%2520marketed%2520M3%2520antagonists%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1173%26epage%3D1182%26doi%3D10.1002%2Fcmdc.201700189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">607</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.014100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.106.014100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=17237157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVOntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2007&pages=607-613&author=G.+Linauthor=J.+Tangauthor=X.+Q.+Liuauthor=Y.+Jiangauthor=J.+Zheng&title=Deacetylclivorine%3A+a+gender-selective+metabolite+of+clivorine+formed+in+female+Sprague-Dawley+rat+liver+microsomes&doi=10.1124%2Fdmd.106.014100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Deacetylclivorine: a gender-selective metabolite of clivorine formed in female Sprague-Dawley rat liver microsomes</span></div><div class="casAuthors">Lin, Ge; Tang, Jun; Liu, Xiao Quan; Jiang, Yan; Zheng, Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-613</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Clivorine, a naturally occurring pyrrolizidine alkaloid, causes liver toxicity via its metabolic activation to generate toxic metabolite (pyrrolic ester).  Female Sprague-Dawley (SD) rats are reported to be less susceptible to clivorine intoxication than male SD rats.  However, the biochem. mechanism causing such gender difference is largely unknown.  The present study investigated hepatic microsomal metab. of clivorine in female rats to delineate the mechanism of the gender difference.  Two pathways, which directly metabolize clivorine, were obsd.  First, the metabolic activation to produce the toxic pyrrolic ester followed by formations of bound pyrroles, dehydroretronecine, 7-glutathionyldehydroretronecine, and clivoric acid were found in female rats, and CYP3A1/2 isoenzymes were identified to catalyze the metabolic activation.  Compared with male rats (∼21%), the metabolic activation in female rats was significantly lower (∼4%) possibly because of significantly lower CYP3A1/2 levels expressed in female rats.  Second, a direct hydrolysis to generate the novel female rat-specific metabolite deacetylclivorine was shown as the predominant pathway (∼16% clivorine metab.) in female rat liver microsomes and was detd. to be mediated by microsomal hydrolase A.  Furthermore, when the metabolic activation was completely inhibited by ketoconazole, the amt. of deacetylclivorine formed in a 1-h incubation significantly increased from 19.44 ± 3.00 to 54.87 ± 9.30 nmol/mg protein, suggesting that the two pathways compete with each other.  Therefore, the lower susceptibility of female SD rats to clivorine intoxication is suggested to be caused by the significantly higher extent of the direct hydrolysis and a lower degree of the metabolic activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj3E9gSwN7m7Vg90H21EOLACvtfcHk0lhpQTmzRwN_Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVOntL0%253D&md5=eb5d9b18b16200a68c5982ea5ae52725</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.014100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.014100%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DDeacetylclivorine%253A%2520a%2520gender-selective%2520metabolite%2520of%2520clivorine%2520formed%2520in%2520female%2520Sprague-Dawley%2520rat%2520liver%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2007%26volume%3D35%26spage%3D607%26epage%3D613%26doi%3D10.1124%2Fdmd.106.014100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span> <span> </span><span class="NLM_article-title">Identification of epoxide-derived metabolite(s) of benzbromarone</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">607</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.066803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1124%2Fdmd.115.066803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=26792818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A280%3ADC%252BC28nivVCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=607-615&author=K.+Wangauthor=H.+Wangauthor=Y.+Pengauthor=J.+Zheng&title=Identification+of+epoxide-derived+metabolite%28s%29+of+benzbromarone&doi=10.1124%2Fdmd.115.066803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Epoxide-Derived Metabolite(s) of Benzbromarone</span></div><div class="casAuthors">Wang Kai; Wang Hui; Peng Ying; Zheng Jiang</div><div class="citationInfo"><span class="NLM_cas:title">Drug metabolism and disposition: the biological fate of chemicals</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">607-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Benzbromarone (BBR) is a benzofuran derivative that has been quite useful for the treatment of gout; however, it was withdrawn from European markets in 2003 because of reported serious incidents of drug-induced liver injury.  BBR-induced hepatotoxicity has been suggested to be associated with the formation of a quinone intermediate.  The present study reported epoxide-derived intermediate(s) of BBR.  An N-acetylcysteine (NAC) conjugate derived from epoxide metabolite(s) was detected in both microsomal incubations of BBR and urine samples of mice treated with BBR.  The NAC conjugate was identified as 6-NAC BBR.  Ketoconazole suppressed the bioactivation of BBR to the epoxide intermediate(s), and the CYP3A subfamily was the primary enzyme responsible for the formation of the epoxide(s).  The present study provided new information on metabolic activation of BBR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTewHRhiyuvaOWhZTslLrfffW6udTcc2eaxwZCdUM6rMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nivVCnsg%253D%253D&md5=b1854ab5e77d14aa084f243674150221</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.066803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.066803%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520epoxide-derived%2520metabolite%2528s%2529%2520of%2520benzbromarone%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D607%26epage%3D615%26doi%3D10.1124%2Fdmd.115.066803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chhonker, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleightholm, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murry, D. J.</span></span> <span> </span><span class="NLM_article-title">Bioanalytical method development and validation of moxidectin in plasma by LC-MS/MS: Application to in vitro metabolism</span>. <i>Biomed. Chromatogr.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">e4389</span>, <span class="refDoi"> DOI: 10.1002/bmc.4389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1002%2Fbmc.4389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30238696" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=e4389&author=Y.+S.+Chhonkerauthor=R.+L.+Sleightholmauthor=D.+J.+Murry&title=Bioanalytical+method+development+and+validation+of+moxidectin+in+plasma+by+LC-MS%2FMS%3A+Application+to+in+vitro+metabolism&doi=10.1002%2Fbmc.4389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fbmc.4389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbmc.4389%26sid%3Dliteratum%253Aachs%26aulast%3DChhonker%26aufirst%3DY.%2BS.%26aulast%3DSleightholm%26aufirst%3DR.%2BL.%26aulast%3DMurry%26aufirst%3DD.%2BJ.%26atitle%3DBioanalytical%2520method%2520development%2520and%2520validation%2520of%2520moxidectin%2520in%2520plasma%2520by%2520LC-MS%252FMS%253A%2520Application%2520to%2520in%2520vitro%2520metabolism%26jtitle%3DBiomed.%2520Chromatogr.%26date%3D2019%26volume%3D33%26spage%3De4389%26doi%3D10.1002%2Fbmc.4389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, H. H.</span></span> <span> </span><span class="NLM_article-title">Determination of microsome and hepatocyte scaling factors for <i>in vitro</i>/<i>in vivo</i> extrapolation in the rat and dog</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1386</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1080/00498250802491662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1080%2F00498250802491662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=18988082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlens7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2008&pages=1386-1398&author=R.+Smithauthor=R.+D.+Jonesauthor=P.+G.+Ballardauthor=H.+H.+Griffiths&title=Determination+of+microsome+and+hepatocyte+scaling+factors+for+in+vitro%2Fin+vivo+extrapolation+in+the+rat+and+dog&doi=10.1080%2F00498250802491662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog</span></div><div class="casAuthors">Smith, R.; Jones, R. D. O.; Ballard, P. G.; Griffiths, H. H.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1386-1398</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">In vivo clearance predictions from in vitro assays require scaling factors to relate the concns. of hepatocytes or microsomal protein to the intact liver.  The aims were to measure the variability in scaling factors for Wistar rat and beagle dog for which the literature is particularly scarce and det. any sex differences.  Scaling factors were detd. by comparing the cytochrome P 450 (P 450) content in hepatocytes or microsomes against the P 450 content of fresh liver homogenate.  The use of fresh homogenate is recommended as freezing can increase contamination and affect the P 450 assay.  Meangeo hepatic microsomal concns. in Wistar rats were 61 mg/g liver (95% confidence interval (CI); 47-75 mg/g liver) and in beagle dogs 55 mg/g liver (95% CI = 48-62 mg/g liver).  Meangeo hepatocellularity was 163 × 106 cells/g liver for Wistar rats (95% CI = 127-199 × 106 cells/g liver) and 169 × 106 cells/g liver (95% CI = 131-207 × 106 cells/g liver) for beagle dogs.  The data generated in this study indicate a consistency in scaling factors between rat and dog.  No sex differences were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUaQwY_CMkBbVg90H21EOLACvtfcHk0ljc5VJwSeSHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlens7vM&md5=67f11c3d42fd45eda1787bd1f9f3e045</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1080%2F00498250802491662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498250802491662%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DR.%2BD.%26aulast%3DBallard%26aufirst%3DP.%2BG.%26aulast%3DGriffiths%26aufirst%3DH.%2BH.%26atitle%3DDetermination%2520of%2520microsome%2520and%2520hepatocyte%2520scaling%2520factors%2520for%2520in%2520vitro%252Fin%2520vivo%2520extrapolation%2520in%2520the%2520rat%2520and%2520dog%26jtitle%3DXenobiotica%26date%3D2008%26volume%3D38%26spage%3D1386%26epage%3D1398%26doi%3D10.1080%2F00498250802491662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Cunha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winokur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span> <span> </span><span class="NLM_article-title">Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2019.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.jpba.2019.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=30981954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1CktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2019&pages=111-117&author=T.+Bachauthor=S.+Baeauthor=R.+D%E2%80%99Cunhaauthor=P.+Winokurauthor=G.+An&title=Development+and+validation+of+a+simple%2C+fast%2C+and+sensitive+LC%2FMS%2FMS+method+for+the+quantification+of+oxfendazole+in+human+plasma+and+its+application+to+clinical+pharmacokinetic+study&doi=10.1016%2Fj.jpba.2019.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study</span></div><div class="casAuthors">Bach, Thanh; Bae, SoHyun; D'Cunha, Ronilda; Winokur, Patricia; An, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111-117</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The most popular std. treatments for soil transmitted helminths in humans including mebendazole, albendazole, levamisole, and pyrantel pamoate, show greatly variable efficacy against different species of parasites and have unfavorable pharmacokinetic characteristics, such as short half-life.  The transition of oxfendazole, a potent broad-spectrum anthelmintic with long half-life, from veterinary medicine to human use has been considered as a promising approach.  However, anal. methods for the quant. detection of oxfendazole in human matrix are very limited and lack sensitivity.  In this study, we have developed a high-performance liq. chromatog.-tandem mass spectrometry (LC/MS/MS) method for the quantification of oxfendazole in human plasma using albendazole as an internal std.  The established method was fully validated with lower limit of quantitation (LLOQ) of 0.5 ng/mL and linearity in the range of 0.5-1000 ng/mL; intra-day and inter-day accuracies ranged from 2.6 to 9.5% for 3 quality control levels (1.5 ng/mL, 75 ng/mL, and 750 ng/mL) and LLOQ; intra-day and inter-day precision was ≤13.6% for quality controls and ≤15.1% for LLOQ; matrix factor and extn. recovery were consistent with coeff. of variation of less than 15.0%.  Other parameters including matrix selectivity, injection carryover, reinjection reproducibility, hemolysis effect, interference of analyte with internal std., diln. integrity, freeze/thaw stability, whole blood stability, and stock soln. stability were also validated and met the acceptance criteria.  The assay was successfully applied to quantify oxfendazole plasma concn. in healthy adult volunteers after the administration of multiple oral doses of oxfendazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqMUvHjkcf6bVg90H21EOLACvtfcHk0ljc5VJwSeSHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1CktLw%253D&md5=3f3d8f717de606ca435e1886f0074ff9</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2019.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2019.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DBach%26aufirst%3DT.%26aulast%3DBae%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Cunha%26aufirst%3DR.%26aulast%3DWinokur%26aufirst%3DP.%26aulast%3DAn%26aufirst%3DG.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520simple%252C%2520fast%252C%2520and%2520sensitive%2520LC%252FMS%252FMS%2520method%2520for%2520the%2520quantification%2520of%2520oxfendazole%2520in%2520human%2520plasma%2520and%2520its%2520application%2520to%2520clinical%2520pharmacokinetic%2520study%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2019%26volume%3D171%26spage%3D111%26epage%3D117%26doi%3D10.1016%2Fj.jpba.2019.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano) phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111558</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2019.07.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31369933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsV2jurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111558&author=Q.+Maoauthor=X.+Daiauthor=G.+Xuauthor=Y.+Suauthor=B.+Zhangauthor=D.+Liuauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+2-%284-alkoxy-3-cyano%29+phenyl-6-oxo-1%2C6-dihydropyrimidine-5-carboxylic+acid+derivatives+as+novel+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2019.07.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors</span></div><div class="casAuthors">Mao, Qing; Dai, Xiwen; Xu, Gaoyang; Su, Yu; Zhang, Bing; Liu, Dan; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111558pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-(4-alkoxy-3-cyano)phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivs. I [R = O, NH; R1 = i-Pr, allyl, Bn, etc.; R2 = H, Me] was synthesized as novel xanthine oxidase (XO) inhibitors.  These compds. exhibited remarkable in vitro XO inhibitory potency with IC50 values ranging from 0.0181 μM to 0.5677 μM.  Specifically, compds. I [R = NH; R1 = (CH2)2CH(CH3)2, 2-methylallyl], with IC50 values of 0.0240 μM and 0.0181 μM, resp., emerged as the most potent XO inhibitors and their potencies were comparable to that of febuxostat.  Structure-activity relationship anal. revealed that the Me group at 4-position of pyrimidine ring could damage the potency and the XO inhibitory potency was maintained when carbonyl group was changed to an imino group.  Lineweaver-Burk plot anal. revealed that the representative compd. I [R = NH; R1 = (CH2)2CH(CH3)2] acted as a mixed-type inhibitor.  A potassium oxonate induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of compd. I [R = NH; R1 = (CH2)2CH(CH3)2] and the results showed that compd. I [R = NH; R1 = (CH2)2CH(CH3)2] (5 mg/kg) was able to significantly lower the serum uric acid level.  Furthermore, in acute oral toxicity study, no sign of toxicity was obsd. when the mice were administered with a single 2000 mg/kg oral dose of compd. I [R = NH; R1 = (CH2)2CH(CH3)2].  These results suggested that compd. I [R = NH; R1 = (CH2)2CH(CH3)2] was a potent and promising uric acid-lowing agent for the treatment of hyperuricemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCwRnSfm0CarVg90H21EOLACvtfcHk0ljc5VJwSeSHww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsV2jurvF&md5=f31a2b4edf5bcbbb98ecc0d01d2628fb</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.061%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25202-%25284-alkoxy-3-cyano%2529%2520phenyl-6-oxo-1%252C6-dihydropyrimidine-5-carboxylic%2520acid%2520derivatives%2520as%2520novel%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111558%26doi%3D10.1016%2Fj.ejmech.2019.07.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1<i>H</i>-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">111559</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2019.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=31376568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2019&pages=111559&author=B.+Zhangauthor=X.+Daiauthor=Z.+Baoauthor=Q.+Maoauthor=Y.+Duanauthor=Y.+Yangauthor=S.+Wang&title=Targeting+the+subpocket+in+xanthine+oxidase%3A+Design%2C+synthesis%2C+and+biological+evaluation+of+2-%5B4-alkoxy-3-%281H-tetrazol-1-yl%29+phenyl%5D-6-oxo-1%2C6-dihydropyrimidine-5-carboxylic+acid+derivatives&doi=10.1016%2Fj.ejmech.2019.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives</span></div><div class="casAuthors">Zhang, Bing; Dai, Xiwen; Bao, Ziyang; Mao, Qing; Duan, Yulin; Yang, Yuwei; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111559</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 2-[4-alkoxy-3-(1H-tetrazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivs. I (R =H, Me, Bn, etc.) with a tetrazole group targeting subpocket of the xanthine oxidase active site were designed, synthesized and they were further evaluated for their inhibitory potency against xanthine oxidase in vitro.  All the tested compds. exhibited an apparent xanthine oxidase inhibitory potency, with IC50 values ranging from 0.0288μM to 0.629μM and the structure-activity relationship results revealed that the hydrophobic group at the 4'-position was indispensable for the inhibitory potency in vitro against xanthine oxidase.  Compd. I (R = 3-chlorobenzyl) emerged as the most potent xanthine oxidase inhibitor, with an IC50 value of 0.0288μM, which was comparable to febuxostat (IC50 = 0.0236μM) and a Lineweaver-Burk plot revealed of this compd. acted as a mixed-type inhibitor for xanthine oxidase.  Mol. modeling studies were performed to gain insights into the binding mode of this compd. with xanthine oxidase which suggested that the tetrazole group of the Ph unit was accommodated in the subpocket, as expected.  A potassium oxonate-induced hyperuricemia model in rats was chosen to further confirm the hypouricemic effect of the above compd. and the result demonstrated that it could effectively reduce serum uric acid levels at an oral dose of 5 mg/kg, acute oral toxicity study in mice indicated that it was nontoxic and tolerated at a dose up to 2000 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriD45HSf08k7Vg90H21EOLACvtfcHk0ligZ2QvopK7-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFWmtL3J&md5=933c7ce340b133a645f853c5ea12fd48</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DZ.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520subpocket%2520in%2520xanthine%2520oxidase%253A%2520Design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-%255B4-alkoxy-3-%25281H-tetrazol-1-yl%2529%2520phenyl%255D-6-oxo-1%252C6-dihydropyrimidine-5-carboxylic%2520acid%2520derivatives%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D181%26spage%3D111559%26doi%3D10.1016%2Fj.ejmech.2019.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1<i>H</i>-indole-3-carbonitriles as novel xanthine oxidase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112077</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=10.1016%2Fj.ejmech.2020.112077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=32014678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112077&author=J.+Gaoauthor=X.+Liuauthor=B.+Zhangauthor=Q.+Maoauthor=Z.+Zhangauthor=Q.+Zouauthor=X.+Daiauthor=S.+Wang&title=Design%2C+synthesis+and+biological+evaluation+of+1-alkyl-5%2F6-%285-oxo-4%2C5-dihydro-1%2C2%2C4-oxadiazol-3-yl%29-1H-indole-3-carbonitriles+as+novel+xanthine+oxidase+inhibitors&doi=10.1016%2Fj.ejmech.2020.112077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors</span></div><div class="casAuthors">Gao, Jun; Liu, Xuegui; Zhang, Bing; Mao, Qing; Zhang, Zhuo; Zou, Qian; Dai, Xiwen; Wang, Shaojie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112077pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Xanthine oxidase (XO) has emerged as an important target for the treatment of hyperuricemia and gout.  In this study, to obtain novel nonpurine XO inhibitors, a series of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles I (R = H, iso-Bu, cyclopentyl, benzyl, etc.; R1 = R2 = H, 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) was designed using a bioisosteric replacement strategy and synthesized through a five-step procedure with good yields.  Thereafter, the in vitro XO inhibitory potencies of these compds. were evaluated by spectrophotometry, showing inhibitory profiles in the micromolar/submicromolar range.  Particularly, compd. I (R = cyclopentyl; R1 = 5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) (A) emerged as the strongest XO inhibitor, with an IC50 value of 0.36μM, which was approx. 21-fold more potent than the pos. control allopurinol.  Addnl., the structure-activity relationships revealed that the 5-oxo-4,5-dihydro-1,2,4-oxadiazole moiety linked at the 5-position of the indole scaffold was more preferable than the 6-position for the XO inhibitory potency.  Enzyme kinetic studies indicated that compd. A acted as a mixed-type XO inhibitor.  Moreover, mol. modeling studies were performed on compd. A to gain insights into its binding modes with XO.  The results showed that the 5-oxo-4,5-dihydro-1,2,4-oxadiazole moiety could interact with Arg880 and Thr1010 in the innermost part of the active pocket through hydrogen bonds, while the cyano group could form hydrogen bonds with Asn768 and Lys771 in the subpocket.  Furthermore, the in vivo hypouricemic effect of compd. I (R = cyclopentyl) was further investigated in a hyperuricemia rat model induced by potassium oxonate.  The results suggested that compd. I (R = cyclopentyl) could effectively reduce serum uric acid levels at an oral dose of 10 mg/kg.  Therefore, compd. I (R = cyclopentyl) could be a promising lead compd. for the treatment of hyperuricemia and gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp9xCCOk7_kbVg90H21EOLACvtfcHk0ligZ2QvopK7-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOgtrs%253D&md5=c5f3c2deb1cc0249eff200dcae09eae0</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112077%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DDai%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201-alkyl-5%252F6-%25285-oxo-4%252C5-dihydro-1%252C2%252C4-oxadiazol-3-yl%2529-1H-indole-3-carbonitriles%2520as%2520novel%2520xanthine%2520oxidase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112077%26doi%3D10.1016%2Fj.ejmech.2020.112077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuser, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalloum, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherukupalli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4790</span>– <span class="NLM_lpage">4810</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnt12ru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4790-4810&author=L.+Sunauthor=A.+Dickauthor=M.+E.+Meuserauthor=T.+Huangauthor=W.+A.+Zalloumauthor=C.+H.+Chenauthor=S.+Cherukupalliauthor=S.+Xuauthor=X.+Dingauthor=P.+Gaoauthor=D.+Kangauthor=E.+De+Clercqauthor=C.+Pannecouqueauthor=S.+Cocklinauthor=K.+H.+Leeauthor=X.+Liuauthor=P.+Zhan&title=Design%2C+synthesis%2C+and+mechanism+study+of+benzenesulfonamide-containing+phenylalanine+derivatives+as+novel+HIV-1+capsid+inhibitors+with+improved+antiviral+activities&doi=10.1021%2Facs.jmedchem.0c00015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities</span></div><div class="casAuthors">Sun, Lin; Dick, Alexej; Meuser, Megan E.; Huang, Tianguang; Zalloum, Waleed A.; Chen, Chin-Ho; Cherukupalli, Srinivasulu; Xu, Shujing; Ding, Xiao; Gao, Ping; Kang, Dongwei; De Clercq, Erik; Pannecouque, Christophe; Cocklin, Simon; Lee, Kuo-Hsiung; Liu, Xinyong; Zhan, Peng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4790-4810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 CA protein has gained remarkable attention as a promising therapeutic target for the development of new antivirals, due to its pivotal roles in HIV-1 replication (structural and regulatory).  Herein, we report the design and synthesis of three series of benzenesulfonamide-contg. phenylalanine derivs. obtained by further structural modifications of PF-74 to aid in the discovery of more potent and drug-like HIV-1 CA inhibitors.  Structure-activity relationship studies of these compds. led to the identification of new phenylalanine derivs. with a piperazinone moiety, represented by compd. (I), which exhibited anti-HIV-1NL4-3 activity 5.78-fold better than PF-74.  Interestingly, I also showed anti-HIV-2ROD activity (EC50 = 31 nΜ), with almost 120 times increased potency over PF-74.  However, due to the higher significance of HIV-1 as compared to HIV-2 for the human population, this manuscript focused on the mechanism of action of our compds. in the context of HIV-1.  SPR studies on representative compds. confirmed CA as the binding target.  The action stage detn. assay demonstrated that these inhibitors exhibited antiviral activities with a dual-stage inhibition profile.  The early-stage inhibitory activity of compd. I was 6.25 times more potent as compared to PF-74, but appears to work via accelerating capsid core assembly rather than stabilization.  However, the mechanism by which they exert their antiviral activity in the late-stage appears to be the same as PF-74 with less infectious HIV-1 virions are produced in their presence as judged p24 content studies.  MD simulations provided the key rationale for the promising antiviral potency of I.  Addnl., I exhibited modest increase in HLM and human plasma metabolic stabilities as compared to PF-74, as well as moderately improved pharmacokinetic profile, favorable oral bioavailability, and no acute toxicity.  These studies provide insights and serves as a starting point for subsequent medicinal chem. efforts in optimizing these promising HIV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwKdnsc-Iy-LVg90H21EOLACvtfcHk0ligZ2QvopK7-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnt12ru7s%253D&md5=77a89a34489fc04cbe4c29b5bdb4b396</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00015%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DA.%26aulast%3DMeuser%26aufirst%3DM.%2BE.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DZalloum%26aufirst%3DW.%2BA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DCherukupalli%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520mechanism%2520study%2520of%2520benzenesulfonamide-containing%2520phenylalanine%2520derivatives%2520as%2520novel%2520HIV-1%2520capsid%2520inhibitors%2520with%2520improved%2520antiviral%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4790%26epage%3D4810%26doi%3D10.1021%2Facs.jmedchem.0c00015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XNW','PDB','4XNW'); return false;">PDB: 4XNW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4NTJ','PDB','4NTJ'); return false;">PDB: 4NTJ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01524">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33382"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01524?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01524</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Worksheet of molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_001.xlsx">XLSX</a>)</p></li><li><p class="inline">Figures of HPLC spectra, <sup>1</sup>H and <sup>13</sup>C NMR spectra, HRMS spectra, and MS spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_001.xlsx">jm0c01524_si_001.xlsx (12.12 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01524/suppl_file/jm0c01524_si_002.pdf">jm0c01524_si_002.pdf (6.89 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01524&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01524" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01524" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998d967d55d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
